



NEW EUROPEAN PATENT SPECIFICATION

After opposition procedure

(45) Date of publication and mention
of the opposition decision:
01.06.2016 Bulletin 2016/22

(45) Mention of the grant of the patent:
23.11.2011 Bulletin 2011/47

(21) Application number: **02762148.1**

(22) Date of filing: **17.04.2002**

(51) Int Cl.:

C12N 15/00 ^(2006.01) **C12P 21/06** ^(2006.01)
C12N 15/09 ^(2006.01) **C12N 15/63** ^(2006.01)
C12N 15/70 ^(2006.01) **C12N 15/74** ^(2006.01)
C12P 21/04 ^(2006.01) **C12Q 3/00** ^(2006.01)
C12Q 1/70 ^(2006.01) **G01N 33/53** ^(2006.01)

(86) International application number:
PCT/US2002/012405

(87) International publication number:
WO 2002/083872 (24.10.2002 Gazette 2002/43)

(54) **NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES**

NEUE VERFAHREN ZUM AUFBAU VON PRÄSENTIERTEN UND/ODER EXPRIMIERTEN MITGLIEDERN EINER WEITLÄUFIGEN FAMILIE VON PEPTIDEN, POLYPEPTIDEN ODER PROTEINEN UMFASSENDEN BIBLIOTHEKEN SOWIE DIE NEUEN BIBLIOTHEKEN

NOUVEAUX PROCEDES DE CONSTRUCTION DE BIBLIOTHEQUES COMPRENANT DES MEMBRES VISUALISES ET/OU EXPRIMES DE DIVERSES FAMILLES DE PEPTIDES, POLYPEPTIDES ET PROTEINES ET NOUVELLES BIBLIOTHEQUES OBTENUES

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **17.04.2001 US 837306**
24.10.2001 US 516
25.10.2001 US 45674

(43) Date of publication of application:
28.09.2005 Bulletin 2005/39

(73) Proprietor: **Dyax Corp.**
Burlington, MA 01803 (US)

(72) Inventors:
• **LADNER, Robert C.**
Ijamsville, MD 21754 (US)
• **COHEN, Edward H.**
Belmont, MA 02478 (US)
• **NASTRI, Horacio G.**
Needham, MA 02492 (US)
• **ROOKEY, Kristin L.**
Revere, MA 02151 (US)
• **HOET, René**
6226 CZ Maastricht (NL)
• **HOOGENBOOM, Hendricus R.J.M.**
6214 AE Maastricht (NL)

(74) Representative: **Wichmann, Hendrik**
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München (DE)

(56) References cited:
DE-A1- 19 624 562 US-A- 5 223 409
US-A- 5 380 833 US-A- 5 688 666
US-A- 5 798 208 US-A- 5 846 765
US-A- 5 858 671 US-A- 5 969 108

- **DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, September 1996 (1996-09), pages 169-179, XP004070292 ISSN: 1380-2933**
- **ARDEN B: "Conserved motifs in T-cell receptor CDR1 and CDR2: implications for ligand and CD8 co-receptor binding" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 10, no. 1, February 1998 (1998-02), pages 74-81, XP004313624 ISSN: 0952-7915**

- **HOOGENBOOM H R ET AL: "By-passing Immunisation - Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 227, 1992, pages 381-388, XP002974448 ISSN: 0022-2836**
- **DE HAARD H J ET AL: "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM,, US, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18218-18230, XP002128301 ISSN: 0021-9258**
- **TOMLINSON I M ET AL: "THE REPERTOIRE OF HUMAN GERMLINE VH SEQUENCES REVEALS ABOUT FIFTY GROUPS OF VH SEGMENTS WITH DIFFERENT HYPERVARIABLE LOOPS" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 227, 1992, pages 776-798, XP000990787 ISSN: 0022-2836**
- **BARBAS S M ET AL: "HUMAN AUTOANTIBODY RECOGNITION OF DNA" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 92, March 1995 (1995-03), pages 2529-2533, XP002927212 ISSN: 0027-8424**

Description

[0001] This application is a continuation-in-part of United States provisional application 60/198,069, filed April 17, 2000, a continuation-in-part of United States patent application 09/837,306, filed on April 17, 2001, a continuation-in-part of PCT application PCT/US01/12454, filed on April 17, 2001, a continuation-in-part of United States application 10/000,516, filed on October 24, 2001 and a continuation-in-part of United States application 10/045,674, filed on October 25, 2001.

[0002] The present invention relates to the embodiments characterized in the claims.

[0003] Thus, it relates to a method for producing a population or library of immunoglobulin genes that comprises the steps of:

- (i) introducing synthetic diversity into at least one of VH CDR1 or VH CDR2 of those genes; and
- (ii) combining the diversity from step (i) with VH CDR3 natural diversity captured from the VH CDR3 region of immunoglobulin genes from B cells.

[0004] The present invention also relates to a library comprising a collection of genetic packages that display a member of a diverse family of antibodies and that collectively display at least a portion of the family, the antibodies being encoded by DNA sequences comprising sequences each encoding

- a) a VH CDR1 having an amino acid sequence according to the formula -X1-Y-X2-M-X3-, wherein X1, X2, and X3 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y, provided in a human 3-23 framework;
- b) a VH CDR2 having an amino acid sequence according to the formula X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G-, wherein X4 and X5 are independently selected from the group consisting of Y, R, W, V, G, and S, X6 is selected from the group consisting of P and S, and X7 and X8 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y, provided in a human 3-23 framework; and
- (c) a sequence encoding a natural VH CDR3, wherein said VH CDR3 is a VH CDR3 captured from the VH CDR3 region of an immunoglobulin gene from a B cell; as defined in the claims.

[0005] In a preferred embodiment, the genetic packages are filamentous phage or phagemids.

[0006] The present disclosure further relates to vectors for displaying and/or expressing a diverse family of peptides, polypeptides or proteins.

[0007] The present disclosure further relates to methods of screening the libraries of the invention and to the peptides, polypeptides and proteins identified by such screening.

BACKGROUND OF THE INVENTION

[0008] It is now common practice in the art to prepare libraries of genetic packages that display, express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to antibodies. Often, they are Fabs or single chain antibodies.

[0009] In general, the DNAs that encode members of the families to be displayed and/or expressed must be amplified before they are cloned and used to display and/or express the desired member. Such amplification typically makes use of forward and backward primers.

[0010] Such primers can be complementary to sequences native to the DNA to be amplified or complementary to oligonucleotides attached at the 5' or 3' ends of that DNA. Primers that are complementary to sequences native to the DNA to be amplified are disadvantaged in that they bias the members of the families to be displayed. Only those members that contain a sequence in the native DNA that is substantially complementary to the primer will be amplified. Those that do not will be absent from the family. For those members that are amplified, any diversity within the primer region will be suppressed.

[0011] For example, in European patent 368,684 B1, the primer that is used is at the 5' end of the V_H region of an antibody gene. It anneals to a sequence region in the native DNA that is said to be "sufficiently well conserved" within a single species. Such primer will bias the members amplified to those having this "conserved" region. Any diversity within this region is extinguished.

[0012] It is generally accepted that human antibody genes arise through a process that involves a combinatorial selection of V and J or V, D, and J followed by somatic mutations. Although most diversity occurs in the Complementary Determining Regions (CDRs), diversity also occurs in the more conserved Framework Regions (FRs) and at least some of this diversity confers or enhances specific binding to antigens (Ag). As a consequence, libraries should contain as

much of the CDR and FR diversity as possible.

[0013] To clone the amplified DNAs of the peptides, polypeptides or proteins that they encode for display on a genetic package and/or for expression, the DNAs must be cleaved to produce appropriate ends for ligation to a vector. Such cleavage is generally effected using restriction endonuclease recognition sites carried on the primers. When the primers are at the 5' end of DNA produced from reverse transcription of RNA, such restriction leaves deleterious 5' untranslated regions in the amplified DNA. These regions interfere with expression of the cloned genes and thus the display of the peptides, polypeptides and proteins coded for by them.

SUMMARY OF THE INVENTION

[0014] It is an object of this invention to provide a method for producing a population or library of immunoglobulin genes that comprises the steps of:

- (i) introducing synthetic diversity into at least one of VH CDR1 or VH CDR2 of those genes; and
- (ii) combining the diversity from step (i) with VH CDR3 natural diversity captured from the VH CDR3 region of immunoglobulin genes from B cells.

[0015] These methods are not biased toward DNAs that contain native sequences that are complementary to the primers used for amplification. They also enable any sequences that may be deleterious to expression to be removed from the amplified DNA before cloning and displaying and/or expressing.

[0016] Additional objects of the invention are reflected in claims 2 to 13. Each of these claims is specifically incorporated by reference in this specification.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017]

FIG. 1 is a schematic of various methods that may be employed to amplify VH genes without using primers specific for VH sequences.

FIG. 2 is a schematic of various methods that may be employed to amplify VL genes without using primers specific for VL sequences.

FIG. 3 is a schematic of RACE amplification of antibody heavy and light chains.

FIG. 4 depicts gel analysis of amplification products obtained after the primary PCR reaction from 4 different patient samples.

FIG. 5 depicts gel analysis of cleaved kappa DNA from Example 2.

FIG. 6 depicts gel analysis of extender-cleaved kappa DNA from Example 2.

FIG. 7 depicts gel analysis of the PCR product from the extender-kappa amplification from Example 2.

FIG. 8 depicts gel analysis of purified PCR product from the extender-kappa amplification from Example 2.

FIG. 9 depicts gel analysis of cleaved and ligated kappa light chains from Example 2.

FIG. 10 is a schematic of the design for CDR1 and CDR2 synthetic diversity.

FIG. 11 is a schematic of the cloning schedule for construction of the heavy chain repertoire.

FIG. 12 is a schematic of the cleavage and ligation of the antibody light chain.

FIG. 13 depicts gel analysis of cleaved and ligated lambda light chains from Example 4.

FIG. 14 is a schematic of the cleavage and ligation of the antibody heavy chain.

FIG. 15 depicts gel analysis of cleaved and ligated lambda light chains from Example 5.

FIG. 16 is a schematic of a phage display vector.

FIG. 17 is a schematic of a Fab cassette.

FIG. 18 is a schematic of a process for incorporating fixed FR1 residues in an antibody lambda sequence.

FIG. 19 is a schematic of a process for incorporating fixed FR1 residues in an antibody kappa sequence.

FIG. 20 is a schematic of a process for incorporating fixed FR1 residues in an antibody heavy chain sequence.

TERMS

[0018] In this application, the following terms and abbreviations are used:

Sense strand	The upper strand of ds DNA as usually written. In the sense strand, 5'-ATG-3' codes for Met.
--------------	--

EP 1 578 903 B2

	Antisense strand	The lower strand of ds DNA as usually written. In the antisense strand, 3'-TAC-5' would correspond to a Met codon in the sense strand.
5	Forward primer	A "forward" primer is complementary to a part of the sense strand and primes for synthesis of a new antisense-strand molecule. "Forward primer" and "lower-strand primer" are equivalent.
10	Backward primer	A "backward" primer is complementary to a part of the antisense strand and primes for synthesis of a new sense-strand molecule. "Backward primer" and "top-strand primer" are equivalent.
15	Bases	Bases are specified either by their position in a vector or gene as their position within a gene by codon and base. For example, "89.1" is the first base of codon 89, 89.2 is the second base of codon 89.
	Sv	Streptavidin
	Ap	Ampicillin
20	<i>ap^R</i>	A gene conferring ampicillin resistance.
	RERS	Restriction endonuclease recognition site
25	RE	Restriction endonuclease - cleaves preferentially at RERS
	URE	Universal restriction endonuclease
30	Functionally complementary	Two sequences are sufficiently complementary so as to anneal under the chosen conditions.
	AA	Amino acid
	PCR	Polymerization chain reaction
35	GLGs	Germline genes
40	Ab	Antibody: an immunoglobulin. The term also covers any protein having a binding domain which is homologous to an immunoglobulin binding domain. A few examples of antibodies within this definition are, <i>inter alia</i> , immunoglobulin isotypes and the Fab, F(ab ¹) ₂ , scfv, Fv, dAb and Fd fragments.
	Fab	Two chain molecule comprising an Ab light chain and part of a heavy-chain.
45	scFv	A single-chain Ab comprising either VH::linker::VL or VL::linker::VH
	w.t.	Wild type
	HC	Heavy chain
50	LC	Light chain
	VK	A variable domain of a Kappa light chain.
55	VH	A variable domain of a heavy chain.
	VL	A variable domain of a lambda light chain.

[0019] In this application when it is said that nucleic acids are cleaved solely at the cleavage site of a restriction

endonuclease, it should be understood that minor cleavage may occur at random, e.g., at nonspecific sites other than the specific cleavage site that is characteristic of the restriction endonuclease. The skilled worker will recognize that such nonspecific, random cleavage is the usual occurrence. Accordingly, "solely at the cleavage site" of a restriction endonuclease means that cleavage occurs preferentially at the site characteristic of that endonuclease.

[0020] As used in this application and claims, the term "cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide" includes cleavage sites formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, cleavage sites in the double-stranded portion of the partially double-stranded oligonucleotide, and cleavage sites introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination.

[0021] In the two methods of this invention for preparing single-stranded nucleic acid sequences, the first of those cleavage sites is preferred. In the methods of this invention for capturing diversity and cloning a family of diverse nucleic acid sequences, the latter two cleavage sites are preferred.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] The nucleic acid sequences that are useful in the methods of this invention, *i.e.*, those that encode at least in part the individual peptides, polypeptides and proteins displayed, or expressed in or comprising the libraries of this invention, may be native, synthetic or a combination thereof. They may be mRNA, DNA or cDNA. The nucleic acids encode antibodies. Preferably, they encode Fabs.

[0023] The nucleic acids useful in this invention may be naturally diverse, synthetic diversity may be introduced into those naturally diverse members, or the diversity may be entirely synthetic. For example, synthetic diversity can be introduced into one or more CDRs of antibody genes. Preferably, it is introduced into CDR1 and CDR2 of immunoglobulins. Natural diversity is captured in the CDR3 regions of the immunoglobulin genes of this invention from B cells. Thus, the nucleic acids of this invention comprise a population of immunoglobulin genes that comprise synthetic diversity in at least one, and more preferably both of the CDR1 and CDR2 and diversity in CDR3 captured from B cells.

[0024] Synthetic diversity may be created, for example, through the use of TRIM technology (U.S. 5,869,644). TRIM technology allows control over exactly which amino-acid types are allowed at variegated positions and in what proportions. In TRIM technology, codons to be diversified are synthesized using mixtures of trinucleotides. This allows any set of amino acid types to be included in any proportion.

[0025] Another alternative that may be used to generate diversified DNA is mixed oligonucleotide synthesis. With TRIM technology, one could allow Ala and Trp. With mixed oligonucleotide synthesis, a mixture that included Ala and Trp would also necessarily include Ser and Gly. The amino-acid types allowed at the variegated positions are picked with reference to the structure of antibodies, or other peptides, polypeptides or proteins of the family, the observed diversity in germline genes, the observed somatic mutations frequently observed, and the desired areas and types of variegation.

[0026] The nucleic acid sequences for at least one CDR or other region of the peptides, polypeptides or proteins of the family are cDNAs produced by reverse transcription from mRNA. More preferably, the mRNAs are obtained from peripheral blood cells, bone marrow cells, spleen cells or lymph node cells (such as B-lymphocytes or plasma cells) that express members of naturally diverse sets of related genes. The mRNAs encode a diverse family of antibodies. Most preferably, the mRNAs are obtained from patients suffering from at least one autoimmune disorder or cancer. Preferably, mRNAs containing a high diversity of autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, antiphospholipid syndrome and vasculitis are used.

[0027] In a preferred embodiment of this invention, the cDNAs are produced from the mRNAs using reverse transcription. In this preferred embodiment, the mRNAs are separated from the cell and degraded using standard methods, such that only the full length (*i.e.*, capped) mRNAs remain. The cap is then removed and reverse transcription used to produce the cDNAs.

[0028] The reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, *e.g.*, HJ de Haard et al., *Journal of Biological Chemistry*, 274(26):18218-30 (1999). In the preferred embodiment of this invention where the mRNAs encode antibodies, primers that are complementary to the constant regions of antibody genes may be used. Those primers are useful because they do not generate bias toward subclasses of antibodies. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes). Alternatively, sequences complementary to the primer may be attached to the termini of the antisense strand.

[0029] In one preferred embodiment of this invention, the reverse transcriptase primer may be biotinylated, thus allowing the cDNA product to be immobilized on streptavidin (Sv) beads. Immobilization can also be effected using a primer labeled at the 5' end with one of a) free amine group, b) thiol, c) carboxylic acid, or d) another group not found in DNA that can react to form a strong bond to a known partner on an insoluble medium. If, for example, a free amine (preferably primary amine) is provided at the 5' end of a DNA primer, this amine can be reacted with carboxylic acid groups on a polymer bead using standard amide-forming chemistry. If such preferred immobilization is used during

reverse transcription, the top strand RNA is degraded using well-known enzymes, such as a combination of RNaseH and RNaseA, either before or after immobilization.

[0030] The nucleic acid sequences useful in the methods of this invention are generally amplified before being used to display and/or express the antibodies that they encode. Prior to amplification, the single-stranded DNAs may be cleaved using either of the methods described before. Alternatively, the single-stranded DNAs may be amplified and then cleaved using one of those methods.

[0031] Any of the well known methods for amplifying nucleic acid sequences may be used for such amplification. Methods that maximize, and do not bias, diversity are preferred. The nucleic acid sequences are derived from antibody genes, the present invention preferably utilizes primers in the constant regions of the heavy and light chain genes and primers to a synthetic sequence that are attached at the 5' end of the sense strand. Priming at such synthetic sequence avoids the use of sequences within the variable regions of the antibody genes. Those variable region priming sites generate bias against V genes that are either of rare subclasses or that have been mutated at the priming sites. This bias is partly due to suppression of diversity within the primer region and partly due to lack of priming when many mutations are present in the region complementary to the primer. The methods disclosed in this invention have the advantage of not biasing the population of amplified antibody genes for particular V gene types.

[0032] The synthetic sequences may be attached to the 5' end of the DNA strand by various methods well known for ligating DNA sequences together. RT CapExtension is one preferred method.

[0033] In RT CapExtension (derived from Smart PCR^(TM)), a short overlap (5'...GGG-3' in the upper-strand primer (USP-GGG) complements 3'-CCC....5' in the lower strand) and reverse transcriptases are used so that the reverse complement of the upper-strand primer is attached to the lower strand.

[0034] FIGs. 1 and 2 show schematics to amplify VH and VL genes using RT CapExtension. FIG. 1 shows a schematic of the amplification of VH genes. FIG. 1, Panel A shows a primer specific to the poly-dT region of the 3' UTR priming synthesis of the first, lower strand. Primers that bind in the constant region are also suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. Panel E shows immobilized double-stranded (ds) cDNA obtained by using a 5'-biotinylated top-strand primer.

[0035] FIG. 2 shows a similar schematic for amplification of VL genes. FIG. 2, Panel A shows a primer specific to the constant region at or near the 3' end priming synthesis of the first, lower strand. Primers that bind in the poly-dT region are also suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. The bottom-strand primer also contains a useful restriction endonuclease site, such as Ascl. Panel E shows immobilized ds cDNA obtained by using a 5'-biotinylated top-strand primer.

[0036] In FIGs. 1 and 2, each V gene consists of a 5' untranslated region (UTR) and a secretion signal, followed by the variable region, followed by a constant region, followed by a 3' untranslated region (which typically ends in poly-A). An initial primer for reverse transcription may be complementary to the constant region or to the poly A segment of the 3'-UTR. For human heavy-chain genes, a primer of 15 T is preferred. Reverse transcriptases attach several C residues to the 3' end of the newly synthesized DNA. RT CapExtension exploits this feature. The reverse transcription reaction is first run with only a lower-strand primer. After about 1 hour, a primer ending in GGG (USP-GGG) and more RTase are added. This causes the lower-strand cDNA to be extended by the reverse complement of the USP-GGG up to the final GGG. Using one primer identical to part of the attached synthetic sequence and a second primer complementary to a region of known sequence at the 3' end of the sense strand, all the V genes are amplified irrespective of their V gene subclass.

[0037] In another preferred embodiment, synthetic sequences may be added by Rapid Amplification of cDNA Ends (RACE) (see Frohman, M.A., Dush, M.K., & Martin, G.R. (1988) Proc. Natl. Acad. Sci. USA (85): 8998-9002).

[0038] FIG. 1 shows a schematic of RACE amplification of antibody heavy and light chains. First, mRNA is selected by treating total or poly(A⁺) RNA with calf intestinal phosphatase (CIP) to remove the 5'-phosphate from all molecules that have them such as ribosomal RNA, fragmented mRNA, tRNA and genomic DNA. Full length mRNA (containing a protective 7-methyl cap structure) is unaffected. The RNA is then treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure from full length mRNAs leaving a 5'-monophosphate group. Next, a synthetic RNA adaptor is ligated to the RNA population, only molecules which have a 5-phosphate (uncapped, full length mRNAs) will accept the adaptor. Reverse transcriptase reactions using an oligodT primer, and nested PCR (using one adaptor primer (located in the 5' synthetic adaptor) and one primer for the gene) are then used to amplify the desired transcript.

[0039] In a preferred embodiment of this invention, the upper strand or lower strand primer may be also biotinylated or labeled at the 5' end with one of a) free amino group, b) thiol, c) carboxylic acid and d) another group not found in DNA that can react to form a strong bond to a known partner as an insoluble medium. These can then be used to immobilize the labeled strand after amplification. The immobilized DNA can be either single or double-stranded.

[0040] After amplification (using e.g., RT CapExtension or RACE), the DNAs of this invention are rendered single-stranded. For example, the strands can be separated by using a biotinylated primer, capturing the biotinylated product on streptavidin beads, denaturing the DNA, and washing away the complementary strand. Depending on which end of the captured DNA is wanted, one will choose to immobilize either the upper (sense) strand or the lower (antisense) strand.

[0041] To prepare the single-stranded amplified DNAs for cloning into genetic packages so as to effect display of, or for expression of, the peptides, polypeptides or proteins encoded, at least in part, by those DNAs, they must be manipulated to provide ends suitable for cloning and display and/or expression. In particular, any 5' untranslated regions and mammalian signal sequences must be removed and replaced, in frame, by a suitable signal sequence that functions in the display or expression host. Additionally, parts of the variable domains (in antibody genes) may be removed and replaced by synthetic segments containing synthetic diversity. The diversity of other gene families may likewise be expanded with synthetic diversity.

[0042] According to the methods of this disclosure, there are two ways to manipulate the single-stranded DNAs for display and/or expression. The first method comprises the steps of:

- (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

[0043] In this first method, short oligonucleotides are annealed to the single-stranded DNA so that restriction endonuclease recognition sites formed within the now locally double-stranded regions of the DNA can be cleaved. In particular, a recognition site that occurs at the same position in a substantial fraction of the single-stranded DNAs is identical.

[0044] For antibody genes, this can be done using a catalog of germline sequences. See, e.g., "<http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html>." Updates can be obtained from this site under the heading "Amino acid and nucleotide sequence alignments." For other families, similar comparisons exist and may be used to select appropriate regions for cleavage and to maintain diversity.

[0045] For example, Table 1 depicts the DNA sequences of the FR3 regions of the 51 known human VH germline genes. In this region, the genes contain restriction endonuclease recognition sites shown in Table 2. Restriction endonucleases that cleave a large fraction of germline genes at the same site are preferred over endonucleases that cut at a variety of sites. Furthermore, it is preferred that there be only one site for the restriction endonucleases within the region to which the short oligonucleotide binds on the single-stranded DNA, e.g., about 10 bases on either side of the restriction endonuclease recognition site.

[0046] An enzyme that cleaves downstream in FR3 is also more preferable because it captures fewer mutations in the framework. This may be advantageous in some cases. However, it is well known that framework mutations exist and confer and enhance antibody binding. The present invention, by choice of appropriate restriction site, allows all or part of FR3 diversity to be captured. Hence, the method also allows extensive diversity to be captured.

[0047] Finally, in the methods of this invention restriction endonucleases that are active between about 37°C and about 75°C are used. Preferably, restriction endonucleases that are active between about 45°C and about 75°C may be used. More preferably, enzymes that are active above 50°C, and most preferably active about 55°C, are used. Such temperatures maintain the nucleic acid sequence to be cleaved in substantially single-stranded form.

[0048] Enzymes shown in Table 2 that cut many of the heavy chain FR3 germline genes at a single position include: *MaeIII* (24@4), *Tsp45I* (21@4), *HphI* (44@5), *BsaI* (23@65), *AluI* (23@47), *BlnI* (21@48), *DdeI* (29@58), *BglII* (10@61), *MslI* (44@72), *BsiEI* (23@74), *EaeI* (23@74), *EagI* (23@74), *HaeIII* (25@75), *Bst4CI* (51@86), *HpyCH4III* (51@86), *HinfI* (38@2), *MlyI* (18@2), *PleI* (18@2), *MnlI* (31@67), *HpyCH4V* (21@44), *BsmAI* (16@11), *Bpml* (19@12), *XmnI* (12@30), and *SacI* (11@51). (The notation used means, for example, that *BsmAI* cuts 16 of the FR3 germline genes with a restriction endonuclease recognition site beginning at base 11 of FR3.)

[0049] For cleavage of human heavy chains in FR3, the preferred restriction endonucleases are: *Bst4CI* (or *Taal* or

HpyCH4III), *BlpI*, *HpyCH4V*, and *MslI*. Because ACNGT (the restriction endonuclease recognition site for *Bst4CI*, *Taal*, and *HpyCH4III*) is found at a consistent site in all the human FR3 germline genes, one of those enzymes is the most preferred for capture of heavy chain CDR3 diversity. *BlpI* and *HpyCH4V* are complementary. *BlpI* cuts most members of the VH1 and VH4 families while *HpyCH4V* cuts most members of the VH3, VH5, VH6, and VH7 families. Neither enzyme cuts VH2s, but this is a very small family, containing only three members. Thus, these enzymes may also be used in preferred embodiments of the methods of this invention.

[0050] The restriction endonucleases *HpyCH4III*, *Bst4CI*, and *Taal* all recognize 5'-ACnGT-3' and cut upper strand DNA after n and lower strand DNA before the base complementary to n. This is the most preferred restriction endonuclease recognition site for this method on human heavy chains because it is found in all germline genes. Furthermore, the restriction endonuclease recognition region (ACnGT) matches the second and third bases of a tyrosine codon (tay) and the following cysteine codon (tgy) as shown in Table 3. These codons are highly conserved, especially the cysteine in mature antibody genes.

[0051] Table 4 E shows the distinct oligonucleotides of length 22 (except the last one which is of length 20) bases. Table 5 C shows the analysis of 1617 actual heavy chain antibody genes. Of these, 1511 have the site and match one of the candidate oligonucleotides to within 4 mismatches. Eight oligonucleotides account for most of the matches and are given in Table 4 F.1. The 8 oligonucleotides are very similar so that it is likely that satisfactory cleavage will be achieved with only one oligonucleotide (such as H43.77.97.1-02#1) by adjusting temperature, pH, salinity, and the like. One or two oligonucleotides may likewise suffice whenever the germline gene sequences differ very little and especially if they differ very little close to the restriction endonuclease recognition region to be cleaved. Table 5 D shows a repeat analysis of 1617 actual heavy chain antibody genes using only the 8 chosen oligonucleotides. This shows that 1463 of the sequences match at least one of the oligonucleotides to within 4 mismatches and have the site as expected. Only 7 sequences have a second *HpyCH4III* restriction endonuclease recognition region in this region.

[0052] Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human heavy chains. Cleavage in FR1 allows capture of the entire CDR diversity of the heavy chain.

[0053] The germline genes for human heavy chain FR1 are shown in Table 6. Table 7 shows the restriction endonuclease recognition sites found in human germline genes FR1s. The preferred sites are *BsgI*(GTGCAG;39@4), *BsoFI*(GCngc; 43@6, 11@9, 2@3, 1@12), *TseI*(Gcwg; 43@6, 11@9, 2@3, 1@12), *MspA1I*(CMGckg; 46@7, 2@1), *PvuII*(CAGctg; 46@7, 2@1), *AluI*(AGct; 48@82@2), *DdeI*(Ctnag; 22@52, 9@48), *HphI*(tcacc; 22@80), *BssKI*(Nccngg; 35@39, 2@40), *BsaI*(Ccnngg; 32@40, 2@41), *BstNI*(CCwgg; 33@40), *ScrFI*(CCngg; 35@40, 2@41), *EcoO109I*(RGgnccy; 22@46, 11@43), *Sau96I*(Ggncc;23@47, 11@44), *Avall*(Ggwcc; 23@47, 4@44), *PpuMI*(RGgwccy; 22@46, 4@43), *BsmFI*(gtccc; 20@48), *HinfI*(Gantc; 34@16, 21@56, 21@77), *TfiI*(21@77), *MlyI*(GAGTC; 34@16), *MlyI*(gactc; 21@56), and *AlwNI*(CAGnnnctg; 22@68). The more preferred sites are *MspAI* and *PvuII*. *MspAI* and *PvuII* have 46 sites at 7-12 and 2 at 1-6. To avoid cleavage at both sites, oligonucleotides are used that do not fully cover the site at 1-6. Thus, the DNA will not be cleaved at that site. We have shown that DNA that extends 3, 4, or 5 bases beyond a *PvuII*-site can be cleaved efficiently.

[0054] Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human kappa light chains. Table 8 shows the human kappa FR1 germline genes and Table 9 shows restriction endonuclease recognition sites that are found in a substantial number of human kappa FR1 germline genes at consistent locations. Of the restriction endonuclease recognition sites listed, *BsmAI* and *PfIFI* are the most preferred enzymes. *BsmAI* sites are found at base 18 in 35 of 40 germline genes. *PfIFI* sites are found in 35 of 40 germline genes at base 12.

[0055] Another example of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of the human lambda light chain. Table 10 shows the 31 known human lambda FR1 germline gene sequences. Table 11 shows restriction endonuclease recognition sites found in human lambda FR1 germline genes. *HinfI* and *DdeI* are the most preferred restriction endonucleases for cutting human lambda chains in FR1.

[0056] After the appropriate site or sites for cleavage are chosen, one or more short oligonucleotides are prepared so as to functionally complement, alone or in combination, the chosen recognition site. The oligonucleotides also include sequences that flank the recognition site in the majority of the amplified genes. This flanking region allows the sequence to anneal to the single-stranded DNA sufficiently to allow cleavage by the restriction endonuclease specific for the site chosen.

[0057] The actual length and sequence of the oligonucleotide depends on the recognition site and the conditions to be used for contacting and cleavage. The length must be sufficient so that the oligonucleotide is functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location.

[0058] Typically, the oligonucleotides of this preferred method of the invention are about 17 to about 30 nucleotides in length. Below about 17 bases, annealing is too weak and above 30 bases there can be a loss of specificity. A preferred length is 18 to 24 bases.

[0059] Oligonucleotides of this length need not be identical complements of the germline genes. Rather, a few mismatches taken may be tolerated. Preferably, however, no more than 1-3 mismatches are allowed. Such mismatches do

not adversely affect annealing of the oligonucleotide to the single-stranded DNA. Hence, the two DNAs are said to be functionally complementary.

[0060] The second method to manipulate the single-stranded DNAs of this invention for display and/or expression comprises the steps of:

- (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and
- (ii) cleaving the nucleic acid solely at the cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

[0061] As explained above, the cleavage site may be formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, the cleavage site may be carried in the double-stranded portion of the partially double-stranded oligonucleotide, or the cleavage site may be introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination. In this embodiment, the first is preferred. And, the restriction endonuclease recognition site may be located in either the double-stranded portion of the oligonucleotide or introduced by the amplification primer, which is complementary to that double-stranded region, as used to amplify the combination.

[0062] Preferably, the restriction endonuclease site is that of a Type II-S restriction endonuclease, whose cleavage site is located at a known distance from its recognition site.

[0063] This second method, preferably, employs Universal Restriction Endonucleases ("URE"). UREs are partially double-stranded oligonucleotides. The single-stranded portion or overlap of the URE consists of a DNA adapter that is functionally complementary to the sequence to be cleaved in the single-stranded DNA. The double-stranded portion consists of a restriction endonuclease recognition site, preferably type II-S.

[0064] The URE method of this invention is specific and precise and can tolerate some (e.g., 1-3) mismatches in the complementary regions, *i.e.*, it is functionally complementary to that region. Further, conditions under which the URE is used can be adjusted so that most of the genes that are amplified can be cut, reducing bias in the library produced from those genes.

[0065] The sequence of the single-stranded DNA adapter or overlap portion of the URE typically consists of about 14-22 bases. However, longer or shorter adapters may be used. The size depends on the ability of the adapter to associate with its functional complement in the single-stranded DNA and the temperature used for contacting the URE and the single-stranded DNA at the temperature used for cleaving the DNA with the restriction enzyme. The adapter must be functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that the cleavage may occur at the chosen temperature and at the desired location. We prefer single-stranded or overlap portions of 14-17 bases in length, and more preferably 18-20 bases in length.

[0066] The site chosen for cleavage using the URE is preferably one that is substantially conserved in the family of amplified DNAs. As compared to the first cleavage method of this invention, these sites do not need to be endonuclease recognition sites. However, like the first method, the sites chosen can be synthetic rather than existing in the native DNA. Such sites may be chosen by references to the sequences of known antibodies or other families of genes. For example, the sequences of many germline genes are reported at <http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html>. For example, one preferred site occurs near the end of FR3 – codon 89 through the second base of codon 93. CDR3 begins at codon 95.

[0067] The sequences of 79 human heavy-chain genes are also available at <http://www.ncbi.nlm.nih.gov/entre2/nucleotide.html>. This site can be used to identify appropriate sequences for URE cleavage according to the methods of this invention. See, e.g., Table 12B.

[0068] Most preferably, one or more sequences are identified using these sites or other available sequence information. These sequences together are present in a substantial fraction of the amplified DNAs. For example, multiple sequences could be used to allow for known diversity in germline genes or for frequent somatic mutations. Synthetic degenerate sequences could also be used. Preferably, a sequence(s) that occurs in at least 65% of genes examined with no more than 2-3 mismatches is chosen

[0069] URE single-stranded adapters or overlaps are then made to be complementary to the chosen regions. Conditions for using the UREs are determined empirically. These conditions should allow cleavage of DNA that contains the functionally complementary sequences with no more than 2 or 3 mismatches but that do not allow cleavage of DNA

lacking such sequences.

[0070] As described above, the double-stranded portion of the URE includes an endonuclease recognition site, preferably a Type II-S recognition site. Any enzyme that is active at a temperature necessary to maintain the single-stranded DNA substantially in that form and to allow the single-stranded DNA adapter portion of the URE to anneal long enough to the single-stranded DNA to permit cleavage at the desired site may be used.

[0071] The preferred Type II-S enzymes for use in the URE methods of this invention provide asymmetrical cleavage of the single-stranded DNA. Among these are the enzymes listed in Table 13. The most preferred Type II-S enzyme is FokI.

[0072] When the preferred FokI containing URE is used, several conditions are preferably used to effect cleavage:

1) Excess of the URE over target DNA should be present to activate the enzyme. URE present only in equimolar amounts to the target DNA would yield poor cleavage of ssDNA because the amount of active enzyme available would be limiting.

2) An activator may be used to activate part of the FokI enzyme to dimerize without causing cleavage. Examples of appropriate activators are shown in Table 14.

3) The cleavage reaction is performed at a temperature between 45°-75°C, preferably above 50°C and most preferably above 55°C.

[0073] The UREs used in the prior art contained a 14-base single-stranded segment, a 10-base stem (containing a FokI site), followed by the palindrome of the 10-base stem. While such UREs may be used in the methods of this invention, the preferred UREs of this invention also include a segment of three to eight bases (a loop) between the FokI restriction endonuclease recognition site containing segments. In the preferred embodiment, the stem (containing the FokI site) and its palindrome are also longer than 10 bases. Preferably, they are 10-14 bases in length. Examples of these "lollipop" URE adapters are shown in Table 15.

[0074] One example of using a URE to cleave an single-stranded DNA involves the FR3 region of human heavy chain. Table 16 shows an analysis of 840 full-length mature human heavy chains with the URE recognition sequences shown. The vast majority (718/840=0.85) will be recognized with 2 or fewer mismatches using five UREs (VHS881-1.1, VHS881-1.2, VHS881-2.1, VHS881-4.1, and VHS881-9.1). Each has a 20-base adaptor sequence to complement the germline gene, a ten-base stem segment containing a FokI site, a five base loop, and the reverse complement of the first stem segment. Annealing those adapters, alone or in combination, to single-stranded antisense heavy chain DNA and treating with FokI in the presence of, e.g., the activator FOKIact, will lead to cleavage of the antisense strand at the position indicated.

[0075] Another example of using a URE(s) to cleave a single-stranded DNA involves the FR1 region of the human Kappa light chains. Table 17 shows an analysis of 182 full-length human kappa chains for matching by the four 19-base probe sequences shown. Ninety-six percent of the sequences match one of the probes with 2 or fewer mismatches. The URE adapters shown in Table 17 are for cleavage of the sense strand of kappa chains. Thus, the adaptor sequences are the reverse complement of the germline gene sequences. The URE consists of a ten-base stem, a five base loop, the reverse complement of the stem and the complementation sequence. The loop shown here is TTGTT, but other sequences could be used. Its function is to interrupt the palindrome of the stems so that formation of a lollipop monomer is favored over dimerization. Table 17 also shows where the sense strand is cleaved.

[0076] Another example of using a URE to cleave a single-stranded DNA involves the human lambda light chain. Table 18 shows analysis of 128 human lambda light chains for matching the four 19-base probes shown. With three or fewer mismatches, 88 of 128 (69%) of the chains match one of the probes. Table 18 also shows URE adapters corresponding to these probes. Annealing these adapters to upper-strand ssDNA of lambda chains and treatment with FokI in the presence of FOKIact at a temperature at or above 45°C will lead to specific and precise cleavage of the chains.

[0077] The conditions under which the short oligonucleotide sequences of the first method and the UREs of the second method are contacted with the single-stranded DNAs may be empirically determined. The conditions must be such that the single-stranded DNA remains in substantially single-stranded form. More particularly, the conditions must be such that the single-stranded DNA does not form loops that may interfere with its association with the oligonucleotide sequence or the URE or that may themselves provide sites for cleavage by the chosen restriction endonuclease.

[0078] The effectiveness and specificity of short oligonucleotides (first method) and UREs (second method) can be adjusted by controlling the concentrations of the URE adapters/oligonucleotides and substrate DNA, the temperature, the pH, the concentration of metal ions, the ionic strength, the concentration of chaotropes (such as urea and formamide), the concentration of the restriction endonuclease (e.g., FokI), and the time of the digestion. These conditions can be optimized with synthetic oligonucleotides having: 1) target germline gene sequences, 2) mutated target gene sequences, or 3) somewhat related non-target sequences. The goal is to cleave most of the target sequences and minimal amounts of non-targets.

[0079] In accordance with this invention, the single-stranded DNA is maintained in substantially that form using a temperature between about 37°C and about 75°C. Preferably, a temperature between about 45°C and about 75°C is

used. More preferably, a temperature between 50°C and 60°C, most preferably between 55°C and 60°C, is used. These temperatures are employed both when contacting the DNA with the oligonucleotide or URE and when cleaving the DNA using the method of this invention, as defined in the claims.

[0080] The two cleavage methods of this disclosure have several advantages. The first method allows the individual members of the family of single-stranded DNAs to be cleaved preferentially at one substantially conserved endonuclease recognition site. The method also does not require an endonuclease recognition site to be built into the reverse transcription or amplification primers. Any native or synthetic site in the family can be used.

[0081] The second method has both of these advantages. In addition, the preferred URE method allows the single-stranded DNAs to be cleaved at positions where no endonuclease recognition site naturally occurs or has been synthetically constructed.

[0082] Most importantly, both cleavage methods permit the use of 5' and 3' primers so as to maximize diversity and then cleavage to remove unwanted or deleterious sequences before cloning, display and/or expression.

[0083] After cleavage of the amplified DNAs using one of the methods of this invention, the DNA is prepared for cloning, display and/or expression. This is done by using a partially duplexed synthetic DNA adapter, whose terminal sequence is based on the specific cleavage site at which the amplified DNA has been cleaved.

[0084] The synthetic DNA is designed such that when it is ligated to the cleaved single-stranded DNA in proper reading frame so that the desired antibody can be displayed on the surface of the genetic package and/or expressed. Preferably, the double-stranded portion of the adapter comprises the sequence of several codons that encode the amino acid sequence characteristic of the family of peptides, polypeptides or proteins up to the cleavage site. For human heavy chains, the amino acids of the 3-23 framework are preferably used to provide the sequences required for expression of the cleaved DNA.

[0085] Preferably, the double-stranded portion of the adapter is about 12 to 100 bases in length. More preferably, about 20 to 100 bases are used. The double-stranded region of the adapter also preferably contains at least one endonuclease recognition site useful for cloning the DNA into a suitable display and/or expression vector (or a recipient vector used to archive the diversity). This endonuclease restriction site may be native to the germline gene sequences used to extend the DNA sequence. It may be also constructed using degenerate sequences to the native germline gene sequences. Or, it may be wholly synthetic.

[0086] The single-stranded portion of the adapter is complementary to the region of the cleavage in the single-stranded DNA. The overlap can be from about 2 bases up to about 15 bases. The longer the overlap, the more efficient the ligation is likely to be. A preferred length for the overlap is 7 to 10. This allows some mismatches in the region so that diversity in this region may be captured.

[0087] The single-stranded region or overlap of the partially duplexed adapter is advantageous because it allows DNA cleaved at the chosen site, but not other fragments to be captured. Such fragments would contaminate the library with genes encoding sequences that will not fold into proper antibodies and are likely to be non-specifically sticky.

[0088] One illustration of the use of a partially duplexed adaptor in the methods of this invention involves ligating such adaptor to a human FR3 region that has been cleaved, as described above, at 5'-ACnGT-3' using HpyCH4III, Bst4CI or Taal.

[0089] Table 4 F.2 shows the bottom strand of the double-stranded portion of the adaptor for ligation to the cleaved bottom-strand DNA. Since the HpyCH4III-Site is so far to the right (as shown in Table 3), a sequence that includes the AflII-site as well as the XbaI site can be added. This bottom strand portion of the partially-duplexed adaptor, H43.XAExt, incorporates both XbaI and AflII-sites. The top strand of the double-stranded portion of the adaptor has neither site (due to planned mismatches in the segments opposite the XbaI and AflII-Sites of H43.XAExt), but will anneal very tightly to H43.XAExt. H43AExt contains only the AflII-site and is to be used with the top strands H43.ABr1 and H43.ABr2 (which have intentional alterations to destroy the AflII-site).

[0090] After ligation, the desired, captured DNA can be PCR amplified again, if desired, using in the preferred embodiment a primer to the downstream constant region of the antibody gene and a primer to part of the double-stranded region of the adapter. The primers may also carry restriction endonuclease sites for use in cloning the amplified DNA.

[0091] After ligation, and perhaps amplification, of the partially double-stranded adapter to the single-stranded amplified DNA, the composite DNA is cleaved at chosen 5' and 3' endonuclease recognition sites.

[0092] The cleavage sites useful for cloning depend on the phage or phagemid or other vectors into which the cassette will be inserted and the available sites in the antibody genes. Table 19 provides restriction endonuclease data for 75 human light chains. Table 20 shows corresponding data for 79 human heavy chains. In each Table, the endonucleases are ordered by increasing frequency of cutting. In these Tables, Nch is the number of chains cut by the enzyme and Ns is the number of sites (some chains have more than one site).

[0093] From this analysis, SfiI, NotI, AflII, ApaLI, and Ascl are very suitable. SfiI and NotI are preferably used in pCES1 to insert the heavy-chain display segment. ApaLI and Ascl are preferably used in pCES1 to insert the light-chain display segment.

[0094] BstEII-sites occur in 97% of germ-line JH genes. In rearranged V genes, only 54/79 (68%) of heavy-chain

genes contain a *Bst*EII-Site and 7/61 of these contain two sites. Thus, 47/79 (59%) contain a single *Bst*EII-Site. An alternative to using *Bst*EII is to cleave via UREs at the end of JH and ligate to a synthetic oligonucleotide that encodes part of CH1.

[0095] One example of preparing a family of DNA sequences using the methods of this invention involves capturing human CDR 3 diversity. As described above, mRNAs from various autoimmune patients are reverse transcribed into lower strand cDNA. After the top strand RNA is degraded, the lower strand is immobilized and a short oligonucleotide used to cleave the cDNA upstream of CDR3. A partially duplexed synthetic DNA adapter is then annealed to the DNA and the DNA is amplified using a primer to the adapter and a primer to the constant region (after FR4). The DNA is then cleaved using *Bst*EII (in FR4) and a restriction endonuclease appropriate to the partially double-stranded adapter (e.g., *Xba*I and *Afl*III (in FR3)). The DNA is then ligated into a synthetic VH skeleton such as 3-23.

[0096] One example of preparing a single-stranded DNA that was cleaved using the URE method involves the human Kappa chain. The cleavage site in the sense strand of this chain is depicted in Table 17. The oligonucleotide kapextURE is annealed to the oligonucleotides (kaBR01UR, kaBR02UR, kaBR03UR, and kaBR04UR) to form a partially duplex DNA. This DNA is then ligated to the cleaved soluble kappa chains. The ligation product is then amplified using primers kapextUREPCR and CKForeAsc (which inserts a *Asc*I site after the end of C kappa). This product is then cleaved with *Apa*LI and *Asc*I and ligated to similarly cut recipient vector.

[0097] Another example involves the cleavage of lambda light chains, illustrated in Table 18. After cleavage, an extender (ON_LamEx133) and four bridge oligonucleotides (ON_LamB1-133, ON_LamB2-133, ON_LamB3-133, and ON_LamB4-133) are annealed to form a partially duplex DNA. That DNA is ligated to the cleaved lambda-chain sense strands. After ligation, the DNA is amplified with ON_Lam133PCR and a forward primer specific to the lambda constant domain, such as CL2ForeAsc or CL7ForeAsc (Table 130).

[0098] In human heavy chains, one can cleave almost all genes in FR4 (downstream, i.e., toward the 3' end of the sense strand, of CDR3) at a *Bst*EII-Site that occurs at a constant position in a very large fraction of human heavy-chain V genes. One then needs a site in FR3, if only CDR3 diversity is to be captured, in FR2, if CDR2 and CDR3 diversity is wanted, or in FR1, if all the CDR diversity is wanted. These sites are preferably inserted as part of the partially double-stranded adaptor.

[0099] The present disclosure also relates to recipient vectors (e.g., for display and/or expression) having sites that allow cloning of either light or heavy chains. Such vectors are well known and widely used in the art. A preferred phage display vector in accordance with this invention is phage MALIA3. This displays in gene III. The sequence of the phage MALIA3 is shown in Table 21A (annotated) and Table 21B (condensed).

[0100] The DNA encoding the selected regions of the light or heavy chains can be transferred to the vectors using endonucleases that cut either light or heavy chains only very rarely. For example, light chains may be captured with *Apa*LI and *Asc*I. Heavy-chain genes are preferably cloned into a recipient vector having *Sfi*I, *Nco*I, *Xba*I, *Afl*III, *Bst*EII, *Apa*I, and *Not*I sites. The light chains are preferably moved into the library as *Apa*LI-*Asc*I fragments. The heavy chains are preferably moved into the library as *Sfi*I-*Not*I fragments.

[0101] Most preferably, the display is had on the surface of a derivative of M13 phage. The most preferred vector contains all the genes of M13, an antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family of genes, as cassettes. The preferred vector is stable against rearrangement under the growth conditions used to amplify phage.

[0102] In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a phagemid vector (e.g., pCES1) that displays and/or expresses the peptide, polypeptide or protein. Such vectors may also be used to store the diversity for subsequent display and/or expression using other vectors or phage.

[0103] In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a yeast vector.

[0104] In another embodiment, the mode of display may be through a short linker to anchor domains -- one possible anchor comprising the final portion of M13 III ("IIIstump") and a second possible anchor being the full length III mature protein.

[0105] The IIIstump fragment contains enough of M13 III to assemble into phage but not the domains involved in mediating infectivity. Because the w.t. III proteins are present the phage is unlikely to delete the antibody genes and phage that do delete these segments receive only a very small growth advantage. For each of the anchor domains, the DNA encodes the w.t. AA sequence, but differs from the w.t. DNA sequence to a very high extent. This will greatly reduce the potential for homologous recombination between the anchor and the w.t. gene that is also present (see Example 6).

[0106] Most preferably, the present invention uses a complete phage carrying an antibiotic-resistance gene (such as an ampicillin-resistance gene) and the display cassette. Because the w.t. *iii* and possibly *viii* genes are present, the w.t. proteins are also present. The display cassette is transcribed from a regulatable promoter (e.g., P_{LacZ}). Use of a regulatable promoter allows control of the ratio of the fusion display gene to the corresponding w.t. coat protein. This ratio determines the average number of copies of the display fusion per phage (or phagemid) particle.

[0107] In another embodiment of the methods of this invention, the phage or phagemid can display and/or express proteins other than Fab, by replacing the Fab portions indicated above, with other protein genes.

[0108] Various hosts can be used the display and/or expression aspect of this invention. Such hosts are well known in the art. In the preferred embodiment, where Fabs are being displayed and/or expressed, the preferred host should grow at 30°C and be RecA⁻ (to reduce unwanted genetic recombination) and EndA⁻ (to make recovery of RF DNA easier). It is also preferred that the host strain be easily transformed by electroporation.

[0109] XL1-Blue MRF⁺ satisfies most of these preferences, but does not grow well at 30°C. XL1-Blue MRF⁺ does grow slowly at 38°C and thus is an acceptable host. TG-1 is also an acceptable host although it is RecA⁺ and EndA⁺. XL1-Blue MRF⁺ is more preferred for the intermediate host used to accumulate diversity prior to final construction of the library.

[0110] After display and/or expression, the libraries of this invention may be screened using well known and conventionally used techniques. The selected peptides, polypeptides or proteins may then be used to treat disease. Generally, the peptides, polypeptides or proteins for use in therapy or in pharmaceutical compositions are produced by isolating the DNA encoding the desired peptide, polypeptide or protein from the member of the library selected. That DNA is then used in conventional methods to produce the peptide, polypeptides or protein it encodes in appropriate host cells, preferably mammalian host cells, e.g., CHO cells. After isolation, the peptide, polypeptide or protein is used alone or with pharmaceutically acceptable compositions in therapy to treat disease.

EXAMPLES

Example 1: RACE amplification of heavy and light chain antibody repertoires from autoimmune patients.

[0111] Total RNA was isolated from individual blood samples (50 ml) of 11 patients using a RNeasy kit (QIAGEN/BioLabs), as described by the manufacturer. The patients were diagnosed as follows:

1. SLE and phospholipid syndrome
2. limited systemic sclerosis
3. SLE and Sjogren syndrome
4. Limited Systemic sclerosis
5. Rheumatoid Arthritis with active vasculitis
6. Limited systemic sclerosis and Sjogren Syndrome
7. Rheumatoid Arthritis and (not active) vasculitis
8. SLE and Sjogren syndrome
9. SLE
10. SLE and (active) glomerulonephritis
11. Polyarthritis/ Raynauds Phenomen

From these 11 samples of total RNA, Poly-A⁺ RNA was isolated using Promega PolyATtract® mRNA Isolation kit (Promega).

[0112] 250 ng of each poly-A⁺ RNA sample was used to amplify antibody heavy and light chains with the GeneRacer™ kit (Invitrogen cat no. L1500-01). A schematic overview of the RACE procedure is shown in FIG. 3.

[0113] Using the general protocol of the GeneRacer™ kit, an RNA adaptor was ligated to the 5' end of all mRNAs. Next, a reverse transcriptase reaction was performed in the presence of oligo(dT15) specific primer under conditions described by the manufacturer in the GeneRacer™ kit.

[0114] 1/5 of the cDNA from the reverse transcriptase reaction was used in a 20 µl PCR reaction. For amplification of the heavy chain IgM repertoire, a forward primer based on the CH1 chain of IgM [HuCmFOR] and a backward primer based on the ligated synthetic adaptor sequence [5'A] were used. (See Table 22)

[0115] For amplification of the kappa and lambda light chains, a forward primer that contains the 3' coding-end of the cDNA [HuCkFor and HuCLFor2+HuCLfor7] and a backward primer based on the ligated synthetic adapter sequence [5'A] was used (See Table 22). Specific amplification products after 30 cycles of primary PCR were obtained.

[0116] FIG. 4 shows the amplification products obtained after the primary PCR reaction from 4 different patient samples. 8 µl primary PCR product from 4 different patients was analyzed on a agarose gel [labeled 1,2, 3 and 4]. For the heavy chain, a product of approximately 950 nt is obtained while for the kappa and lambda light chains the product is approximately 850 nt. M1-2 are molecular weight markers.

[0117] PCR products were also analyzed by DNA sequencing [10 clones from the lambda, kappa or heavy chain repertoires]. All sequenced antibody genes recovered contained the full coding sequence as well as the 5' leader sequence and the V gene diversity was the expected diversity (compared to literature data).

[0118] 50 ng of all samples from all 11 individual amplified samples were mixed for heavy, lambda light or kappa light chains and used in secondary PCR reactions.

[0119] In all secondary PCRs approximately 1 ng template DNA from the primary PCR mixture was used in multiple 50 µl PCR reactions [25 cycles].

[0120] For the heavy chain, a nested biotinylated forward primer [HuCm-Nested] was used, and a nested 5' end backward primer located in the synthetic adapter-sequence [5'NA] was used. The 5' end lower-strand of the heavy chain was biotinylated.

[0121] For the light chains, a 5' end biotinylated nested primer in the synthetic adapter was used [5'NA] in combination with a 3' end primer in the constant region of Ckappa and Clambda, extended with a sequence coding for the Ascl restriction site [kappa: HuCkForAscl, Lambda: HuCL2-FOR-ASC + HuCL7-FOR-ASC]. [5' end Top strand DNA was biotinylated]. After gel-analysis the secondary PCR products were pooled and purified with Promega Wizzard PCR cleanup.

[0122] Approximately 25 µg biotinylated heavy chain, lambda and kappa light chain DNA was isolated from the 11 patients.

Example 2: Capturing kappa chains with BsmAI.

[0123] A repertoire of human-kappa chain mRNAs was prepared using the RACE method of Example 1 from a collection of patients having various autoimmune diseases.

[0124] This Example followed the protocol of Example 1. Approximately 2 micrograms (µg) of human kappa-chain (Igkappa) gene RACE material with biotin attached to 5' end of upper strand was immobilized as in Example 1 on 200 microliters (µL) of SeraDyn magnetic beads. The lower strand was removed by washing the DNA with 2 aliquots 200 µL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 200 µL of 10 mM Tris (pH 7.5) 100 mM NaCl. The short oligonucleotides shown in Table 23 were added in 40 fold molar excess in 100 µL of NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9) to the dry beads. The mixture was incubated at 95°C for 5 minutes then cooled down to 55°C over 30 minutes. Excess oligonucleotide was washed away with 2 washes of NEB buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9). Ten units of BsmAI (NEB) were added in NEB buffer 3 and incubated for 1 h at 55°C. The cleaved downstream DNA was collected and purified over a Qiagen PCR purification column (FIGs. 5 and 6).

[0125] FIG. 5 shows an analysis of digested kappa single-stranded DNA. Approximately 151.5 pmol of adapter was annealed to 3.79 pmol of immobilized kappa single-stranded DNA followed by digestion with 15 U of *BsmAI*. The supernatant containing the desired DNA was removed and analyzed by 5% polyacrylamide gel along with the remaining beads which contained uncleaved full length kappa DNA. 189 pmol of cleaved single-stranded DNA was purified for further analysis. Five percent of the original full length ssDNA remained on the beads.

[0126] FIG. 6 shows an analysis of the extender - cleaved kappa ligation. 180 pmol of pre-annealed bridge/extender was ligated to 1.8 pmol of *BsmAI* digested single-stranded DNA. The ligated DNA was purified by Qiagen PCR purification column and analyzed on a 5% polyacrylamide gel. Results indicated that the ligation of extender to single-stranded DNA was 95% efficient.

[0127] A partially double-stranded adaptor was prepared using the oligonucleotide shown in Table 23. The adaptor was added to the single-stranded DNA in 100 fold molar excess along with 1000 units of T4 DNA ligase and incubated overnight at 16°C. The excess oligonucleotide was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using the primers kapPCRT1 and kapfor shown in Table 23 for 10 cycles with the program shown in Table 24. The soluble PCR product was run on a gel and showed a band of approximately 700 n, as expected (FIGs. 7 and 8). The DNA was cleaved with enzymes *ApaI* and *Ascl*, gel purified, and ligated to similarly cleaved vector pCES1.

[0128] FIG. 7 shows an analysis of the PCR product from the extender-kappa amplification. Ligated extender-kappa single-stranded DNA was amplified with primers specific to the extender and to the constant region of the light chain. Two different template concentrations, 10 ng versus 50 ng, were used as template and 13 cycles were used to generate approximately 1.5 µg of dsDNA as shown by 0.8% agarose gel analysis.

[0129] FIG. 8 shows an analysis of the purified PCR product from the extender-kappa amplification. Approximately 5 µg of PCR amplified extender-kappa double-stranded DNA was run out on a 0.8% agarose gel, cut out, and extracted with a GFX gel purification column. By gel analysis, 3.5 µg of double-stranded DNA was prepared.

[0130] The assay for capturing kappa chains with BsmA1 was repeated and produced similar results. FIG 9A shows the DNA after it was cleaved and collected and purified over a Qiagen PCR purification column. FIG. 9B shows the partially double-stranded adaptor ligated to the single-stranded DNA. This ligated material was then amplified (FIG. 9C). The gel showed a band of approximately 700 n.

[0131] Table 25 shows the DNA sequence of a kappa light chain captured by this procedure. Table 26 shows a second sequence captured by this procedure. The closest bridge sequence was complementary to the sequence 5'-agccacc-3', but the sequence captured reads 5'-Tgccacc-3', showing that some mismatch in the overlapped region is tolerated.

Example 3: Construction of Synthetic CDR1 and CDR2 Diversity in V-3-23 VH Framework.

[0132] Synthetic diversity in Complementary Determinant Region (CDR) 1 and 2 was created in the 3-23 VH framework in a two step process: first, a vector containing the 3-23 VH framework was constructed; and then, a synthetic CDR 1 and 2 was assembled and cloned into this vector.

[0133] For construction of the 3-23 VH framework, 8 oligonucleotides and two PCR primers (long oligonucleotides - TOPFR1A, BOTFR1B, BOTFR2, BOTFR3, F06, BOTFR4, ON-vgC1, and ON-vgC2 and primers - SFPRMET and BOT-PCRPRIM, shown in Table 27) that overlap were designed based on the Genbank sequence of 3-23 VH framework region. The design incorporated at least one useful restriction site in each framework region, as shown in Table 27. In Table 27, the segments that were synthesized are shown as bold, the overlapping regions are underscored, and the PCR priming regions at each end are underscored.

[0134] A mixture of these 8 oligos was combined at a final concentration of 2.5uM in a 20ul PCR reaction. The PCR mixture contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*[™] DNA Polymerase, 1U Qiagen HotStart Taq DNA Polymerase, and 1X Qiagen PCR buffer. The PCR program consisted of 10 cycles of 94_C for 30s, 55_C for 30s, and 72_C for 30s.

[0135] The assembled 3-23 VH DNA sequence was then amplified, using 2.5ul of a 10-fold dilution from the initial PCR in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*[™] DNA Polymerase, 1U Qiagen HotStart Taq DNA Polymerase, 1X Qiagen PCR Buffer and 2 outside primers (SFPRMET and BOTPCRPRIM) at a concentration of 1uM. The PCR program consisted of 23 cycles at 94_C for 30s, 55_C for 30s, and 72_C for 60s. The 3-23 VH DNA sequence was digested and cloned into pCES1 (phagemid vector) using the *Sfi*I and *Bst*EII restriction endonuclease sites. All restriction enzymes mentioned herein were supplied by New England Biolabs, Beverly, MA and used as per the manufacturer's instructions.

[0136] Stuffer sequences (shown in Table 28 and Table 29) were introduced into pCES1 to replace CDR1/CDR2 sequences (900 bases between *Bsp*EI and *Xba*I RE sites) and CDR3 sequences (358 bases between *Afl*II and *Bst*EII) prior to cloning the CDR1/CDR2 diversity. This new vector was termed pCES5 and its sequence is given in Table 29.

[0137] Having stuffers in place of the CDRs avoids the risk that a parental sequence would be over-represented in the library. The stuffer sequences are fragments from the penicillase gene of *E. coli*. The CDR1-2 stuffer contains restriction sites for *Bgl*II, *Bsu*36I, *Bcl*I, *Xcm*I, *Mlu*I, *Pvu*II, *Hpa*I, and *Hinc*II, the underscored sites being unique within the vector pCES5. The stuffer that replaces CDR3 contains the unique restriction endonuclease site *Rsr*II.

[0138] A schematic representation of the design for CDR1 and CDR2 synthetic diversity is shown FIG. 10. The design was based on the presence of mutations in DP47/3-23 and related germline genes. Diversity was designed to be introduced at the positions within CDR1 and CDR2 indicated by the numbers in FIG. 10. The diversity at each position was chosen to be one of the three following schemes: 1 = ADEFGHIKLMNPQRSTUVWXYZ; 2 = YRWVGS; 3 = PS, in which letters encode equimolar mixes of the indicated amino acids.

[0139] For the construction of the CDR1 and CDR2 diversity, 4 overlapping oligonucleotides (ON-vgC1, ON_Br12, ON_CD2Xba, and ON-vgC2, shown in Table 27 and Table 30) encoding CDR1/2, plus flanking regions, were designed. A mixture of these 4 oligos was combined at a final concentration of 2.5uM in a 40ul PCR reaction. Two of the 4 oligos contained variegated sequences positioned at the CDR1 and the CDR2. The PCR mixture contained 200uM dNTPs, 2.5U Pwo DNA Polymerase (Roche), and 1X Pwo PCR buffer with 2mM MgSO₄. The PCR program consisted of 10 cycles at 94_C for 30s, 60_C for 30s, and 72_C for 60s. This assembled CDR1/2 DNA sequence was amplified, using 2.5ul of the mixture in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5U Pwo DNA Polymerase, 1X Pwo PCR Buffer with 2mM MgSO₄ and 2 outside primers at a concentration of 1uM. The PCR program consisted of 10 cycles at 94_C for 30s, 60_C for 30s, and 72_C for 60s. These variegated sequences were digested and cloned into the 3-23 VH framework in place of the CDR1/2 stuffer.

[0140] We obtained approximately 7 X 10⁷ independent transformants. CDR3 diversity either from donor populations or from synthetic DNA can be cloned into the vector containing synthetic CDR1 and CDR 2 diversity.

[0141] A schematic representation of this procedure is shown in FIG. 11. A sequence encoding the FR-regions of the human V3-23 gene segment and CDR regions with synthetic diversity was made by oligonucleotide assembly and cloning via *Bsp*E1 and *Xba*I sites into a vector that complements the FR1 and FR3 regions. Into this library of synthetic VH segments, the complementary VH-CDR3 sequence (top right) was cloned via *Xba*I and *Bst*EII sites. The resulting cloned CH genes contain a combination of designed synthetic diversity and natural diversity (see FIG. 11).

Example 4: Cleavage and ligation of the lambda light chains with HinfI.

[0142] A schematic of the cleavage and ligation of antibody light chains is shown in FIGs. 12A and 12B. Approximately 2 ug of biotinylated human Lambda DNA prepared as described in Example 1 was immobilized on 200 ul Seradyn magnetic beads. The lower strand was removed by incubation of the DNA with 200 ul of 0.1 M NaOH (pH=13) for 3 minutes, the supernatant was removed and an additional washing of 30 seconds with 200 ul of 0.1 M NaOH was

performed. Supernatant was removed and the beads were neutralized with 200 μ l of 10 mM Tris (pH=7.5), 100 mM NaCl. 2 additional washes with 200 μ l NEB2 buffer 2, containing 10 mM Tris (pH=7.9), 50 mM NaCl, 10 mM MgCl₂ and 1 mM dithiothreitol, were performed. After immobilization, the amount of ssDNA was estimated on a 5% PAGE-UREA gel.

[0143] About 0.8 μ g ssDNA was recovered and incubated in 100 μ l NEB2 buffer 2 containing 80 molar fold excess of an equimolar mix of ON_Lam1aB7, ON_Lam2aB7, ON_Lam3lB7 and ON_Lam3rB7 [each oligo in 20 fold molar excess] (see Table 31).

[0144] The mixture was incubated at 95° C for 5 minutes and then slowly cooled down to 50° C over a period of 30 minutes. Excess of oligonucleotide was washed away with 2 washes of 200 μ l of NEB buffer 2. 4 U/ μ g of *Hinf I* was added and incubated for 1 hour at 50° C. Beads were mixed every 10 minutes.

[0145] After incubation the sample was purified over a Qiagen PCR purification column and was subsequently analysed on a 5% PAGE-urea gel (see FIG. 13A, cleavage was more than 70% efficient).

[0146] A schematic of the ligation of the cleaved light chains is shown in FIG. 12B. A mix of bridge/extender pairs was prepared from the Brg/Ext oligo's listed in Table 31 (total molar excess 100 fold) in 1000 U of T4 DNA Ligase (NEB) and incubated overnight at 16° C. After ligation of the DNA, the excess oligonucleotide was removed with a Qiagen PCR purification column and ligation was checked on a Urea-PAGE gel (see FIG. 13B; ligation was more than 95% efficient).

[0147] Multiple PCRs were performed containing 10 ng of the ligated material in an 50 μ l PCR reaction using 25 pMol ON lamPlePCR and 25 pmol of an equimolar mix of Hu-CL2Ascl/HuCL7Ascl primer (see Example 1).

[0148] PCR was performed at 60° C for 15 cycles using Pfu polymerase. About 1 μ g of dsDNA was recovered per PCR (see FIG. 13C) and cleaved with *ApaL1* and *Ascl* for cloning the lambda light chains in pCES2.

Example 5: Capture of human heavy-chain CDR3 population.

[0149] A schematic of the cleavage and ligation of antibody light chains is shown in FIGs. 14A and 14B.

[0150] Approximately 3 μ g of human heavy-chain (IgM) gene RACE material with biotin attached to 5'-end of lower strand was immobilized on 300 μ l of Seradyn magnetic beads. The upper strand was removed by washing the DNA with 2 aliquots 300 μ l of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 300 μ l of 10 mM Tris (pH 7.5) 100 mM NaCl. The REadaptors (oligonucleotides used to make single-stranded DNA locally double-stranded) shown in Table 32 were added in 30 fold molar excess in 200 μ l of NEB buffer 4 (50 mM Potassium Acetate, 20 mM Tris-Acetate, 10 mM Magnesium Acetate, 1 mM dithiothreitol pH 7.9) to the dry beads. The REadaptors were incubated with the single-stranded DNA at 80° C for 5 minutes then cooled down to 55° C over 30 minutes. Excess REadaptors were washed away with 2 washes of NEB buffer 4. Fifteen units of HpyCH4III (NEB) were added in NEB buffer 4 and incubated for 1 hour at 55° C. The cleaved downstream DNA remaining on the beads was removed from the beads using a Qiagen Nucleotide removal column (see FIG. 15).

[0151] The Bridge/Extender pairs shown in Table 33 were added in 25 molar excess along with 1200 units of T4 DNA ligase and incubated overnight at 16° C. Excess Bridge/Extender was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using primers H43.XAExtPCR2 and Hucumnest shown in Table 34 for 10 cycles with the program shown in Table 35.

[0152] The soluble PCR product was run on a gel and showed a band of approximately 500 n, as expected (see FIG. 15B). The DNA was cleaved with enzymes *SfiI* and *NotI*, gel purified, and ligated to similarly cleaved vector PCES1.

Example 6: Description of Phage Display Vector CJRA05, a member of the library built in vector DY3F7.

[0153] Table 36 contains an annotated DNA sequence of a member of the library, CJRA05, see FIG. 16. Table 36 is to be read as follows: on each line everything that follows an exclamation mark "!" is a comment. All occurrences of A, C, G, and T before "!" are the DNA sequence. Case is used only to show that certain bases constitute special features, such as restriction sites, ribosome binding sites, and the like, which are labeled below the DNA. CJRA05 is a derivative of phage DY3F7, obtained by cloning an *ApaL1* to *NotI* fragment into these sites in DY3F31. DY3F31 is like DY3F7 except that the light chain and heavy chain genes have been replaced by "stuffer" DNA that does not code for any antibody. DY3F7 contains an antibody that binds streptavidin, but did not come from the present library.

[0154] The phage genes start with gene ii and continue with genes x, v, vii, ix, viii, iii, vi, i, and iv. Gene iii has been slightly modified in that eight codons have been inserted between the signal sequence and the mature protein and the final amino acids of the signal sequence have been altered. This allows restriction enzyme recognition sites *EagI* and *XbaI* to be present. Following gene iv is the phage origin of replication (ori). After ori is bla which confers resistance to ampicillin (ApR). The phage genes and bla are transcribed in the same sense.

[0155] After bla, is the Fab cassette (illustrated in FIG. 17) comprising:

- a) PlacZ promoter,
- b) A first Ribosome Binding Site (RBS1),

- c) The signal sequence form M13 iii,
- d) An *ApaI* RERS,
- e) A light chain (a kappa L20::JK1 shortened by one codon at the V-J boundary in this case),
- f) An *AscI* RERS,
- g) A second Ribosome Binding Site (RBS2),
- h) A signal sequence, preferably PelB, which contains,
- i) An *SfiI* RERS,
- j) A synthetic 3-23 V region with diversity in CDR1 and CDR2,
- k) A captured CDR3,
- l) A partially synthetic J region (FR4 after *BstEII*),
- m) CH1,
- n) A *NotI* RERS,
- o) A His6 tag,
- p) A cMyc tag,
- q) An amber codon,
- r) An anchor DNA that encodes the same amino-acid sequence as codons 273 to 424 of M13 iii (as shown in Table 37).
- s) Two stop codons,
- t) An *AvrII* RERS, and
- u) A trp terminator.

[0156] The anchor (item r) encodes the same amino-acid sequence as do codons 273 to 424 of M13 iii but the DNA is approximately as different as possible from the wild-type DNA sequence. In Table 36, the III' stump runs from base 8997 to base 9455. Below the DNA, as comments, are the differences with wild-type iii for the comparable codons with "IW.T" at the ends of these lines. Note that Met and Trp have only a single codon and must be left as is. These AA types are rare. Ser codons can be changed at all three base, while Leu and Arg codons can be changed at two.

[0157] In most cases, one base change can be introduced per codon. This has three advantages: 1) recombination with the wild-type gene carried elsewhere on the phage is less likely, 2) new restriction sites can be introduced, facilitating construction; and 3) sequencing primers that bind in only one of the two regions can be designed.

[0158] The fragment of M13 III shown in CJRA05 is the preferred length for the anchor segment. Alternative longer or shorter anchor segments defined by reference to whole mature III protein may also be utilized.

[0159] The sequence of M13 III consists of the following elements: Signal Sequence::Domain 1 (D1)::Linker 1 (L1)::Domain 2 (D2)::Linker 2 (L2)::Domain 3 (D3)::Transmembrane Segment (TM)::Intracellular anchor (IC) (see Table 38).

[0160] The pIII anchor (also known as trpIII) preferably consists of D2::L2::D3::TM::IC. Another embodiment for the pIII anchor consists of D2':L2::D3::TM::IC (where D2' comprises the last 21 residues of D2 with the first 109 residues deleted). A further embodiment of the pIII anchor consists of D2'(C>S)::L2::D3::TM::IC (where D2'(C>S) is D2' with the single C converted to S), and d) D3::TM::IC.

[0161] Table 38 shows a gene fragment comprising the *NotI* site, His6 tag, cMyc tag, an amber codon, a recombinant enterokinase cleavage site, and the whole of mature M13 III protein. The DNA used to encode this sequence is intentionally very different from the DNA of wild-type gene iii as shown by the lines denoted "W.T." containing the w.t. bases where these differ from this gene. III is divided into domains denoted "domain 1" "linker 1" "domain 2", "linker 2", "domain 3", "transmembrane segment", and "intracellular anchor".

[0162] Alternative preferred anchor segments (defined by reference to the sequence of Table 38) include:

codons 1-29 joined to codons 104-435, deleting domain 1 and retaining linker 1 to the end;

codons 1-38 joined to codons 104-435, deleting domain 1 and retaining the rEK cleavage site plus linker 1 to the end from III;

codons 1-29 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end;

codons 1-38 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end and the rEK cleavage site;

codons 1-29 joined to codons 236-435 and changing codon 240 to Ser (e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end; and

codons 1-38 joined to codons 236-435 and changing codon 240 to Ser (e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end and the rEK cleavage site.

[0163] The constructs would most readily be made by methods similar to those of Wang and Wilkinson (Biotechniques 2001: 31(4)722-724) in which PCR is used to copy the vector except the part to be deleted and matching restriction sites are introduced or retained at either end of the part to be kept. Table 39 shows the oligonucleotides to be used in deleting

parts of the III anchor segment. The DNA shown in Table 38 has an *NheI* site before the DINDDRMA recombinant enterokinase cleavage site (rEKCS). If *NheI* is used in the deletion process with this DNA, the rEKCS site would be lost. This site could be quite useful in cleaving Fabs from the phage and might facilitate capture of very high-affinity antibodies. One could mutagenize this sequence so that the *NheI* site would follow the rEKCS site, an Ala Ser amino-acid sequence is already present. Alternatively, one could use *SphI* for the deletions. This would involve a slight change in amino acid sequence but would be of no consequence.

Example 7 : Selection of antigen binders from an enriched library of human antibodies using phage vector DY3F31.

[0164] In this example the human antibody library used is described in de Haard et al., (Journal of Biological Chemistry, 274 (26): 18218-30 (1999). This library, consisting of a large non-immune human Fab phagemid library, was first enriched on antigen, either on streptavidin or on phenyl-oxazolone (phOx). The methods for this are well known in the art. Two preselected Fab libraries, the first one selected once on immobilized phOx-BSA (R1-ox) and the second one selected twice on streptavidin (R2-strep), were chosen for recloning.

[0165] These enriched repertoires of phage antibodies, in which only a very low percentage have binding activity to the antigen used in selection, were confirmed by screening clones in an ELISA for antigen binding. The selected Fab genes were transferred from the phagemid vector of this library to the DY3F31 vector via *ApaI* 1-*NotI* restriction sites.

[0166] DNA from the DY3F31 phage vector was pretreated with ATP dependent DNase to remove chromosomal DNA and then digested with *ApaI* 1 and *NotI*.

An extra digestion with *AscI* was performed in between to prevent self-ligation of the vector. The *ApaI* 1/*NotI* Fab fragment from the preselected libraries was subsequently ligated to the vector DNA and transformed into competent XL1-blue MRF' cells.

[0167] Libraries were made using vector:insert ratios of 1:2 for phOx-library and 1:3 for STREP library, and using 100 ng ligated DNA per 50 μ l of electroporation-competent cells (electroporation conditions : one shock of 1700 V, 1 hour recovery of cells in rich SOC medium, plating on ampicillin-containing agar plates).

[0168] This transformation resulted in a library size of 1.6×10^6 for R1-ox in DY3F31 and 2.1×10^6 for R2-strep in DY3F31. Sixteen colonies from each library were screened for insert, and all showed the correct size insert (± 1400 bp) (for both libraries).

[0169] Phage was prepared from these Fab libraries as follows. A representative sample of the library was inoculated in medium with ampicillin and glucose, and at OD 0.5, the medium exchanged for ampicillin and 1 mM IPTG. After overnight growth at 37 °C, phage was harvested from the supernatant by PEG-NaCl precipitation. Phage was used for selection on antigen. R1-ox was selected on phOx-BSA coated by passive adsorption onto immunotubes and R2-strep on streptavidin coated paramagnetic beads (DynaI, Norway), in procedures described in de Haard et. al. and Marks et. al., Journal of Molecular Biology, 222(3): 581-97 (1991). Phage titers and enrichments are given in Table 40.

[0170] Clones from these selected libraries, dubbed R2-ox and R3-strep respectively, were screened for binding to their antigens in ELISA. 44 clones from each selection were picked randomly and screened as phage or soluble Fab for binding in ELISA. For the libraries in DY3F31, clones were first grown in 2TY-2% glucose-50 μ g/ml AMP to an OD600 of approximately 0.5, and then grown overnight in 2TY-50 μ g/ml AMP +/- 1mM IPTG. Induction with IPTG may result in the production of both phage-Fab and soluble Fab. Therefore the (same) clones were also grown without IPTG. Table 41 shows the results of an ELISA screening of the resulting supernatant, either for the detection of phage particles with antigen binding (Anti-M13 HRP = anti-phage antibody), or for the detection of human Fabs, be it on phage or as soluble fragments, either with using the anti-myc antibody 9E10 which detects the myc-tag that every Fab carries at the C-terminal end of the heavy chain followed by a HRP-labeled rabbit-anti-Mouse serum (column 9E10/RAM-HRP), or with anti-light chain reagent followed by a HRP-labeled goat-anti-rabbit antiserum(anti-CK/CL Gar-HRP).

[0171] The results shows that in both cases antigen-binders are identified in the library, with as Fabs on phage or with the anti-Fab reagents (Table 41). IPTG induction yields an increase in the number of positives. Also it can be seen that for the phOx-clones, the phage ELISA yields more positives than the soluble Fab ELISA, most likely due to the avid binding of phage. Twenty four of the ELISA-positive clones were screened using PCR of the Fab-insert from the vector, followed by digestion with *BstNI*. This yielded 17 different patterns for the phOx-binding Fab's in 23 samples that were correctly analyzed, and 6 out of 24 for the streptavidin binding clones. Thus, the data from the selection and screening from this pre-enriched non-immune Fab library show that the DY3F31 vector is suitable for display and selection of Fab fragments, and provides both soluble Fab and Fab on phage for screening experiments after selection.

Example 8: Selection of Phage-antibody libraries on streptavidin magnetic beads.

[0172] The following example describes a selection in which one first depletes a sample of the library of binders to streptavidin and optionally of binders to a non-target (*i.e.*, a molecule other than the target that one does not want the

selected Fab to bind). It is hypothesized that one has a molecule, termed a "competitive ligand", which binds the target and that an antibody which binds at the same site would be especially useful.

[0173] For this procedure Streptavidin Magnetic Beads (Dyna) were blocked once with blocking solution (2% Marvel Milk, PBS (pH 7.4), 0.01% Tween-20 ("2%MPBST")) for 60 minutes at room temperature and then washed five times with 2%MPBST. 450 μ L of beads were blocked for each depletion and subsequent selection set.

[0174] Per selection, 6.25 μ L of biotinylated depletion target (1 mg/mL stock in PBST) was added to 0.250 mL of washed, blocked beads (from step 1). The target was allowed to bind overnight, with tumbling, at 4°C. The next day, the beads are washed 5 times with PBST.

[0175] Per selection, 0.010 mL of biotinylated target antigen (1 mg/mL stock in PBST) was added to 0.100 mL of blocked and washed beads (from step 1). The antigen was allowed to bind overnight, with tumbling, at 4°C. The next day, the beads were washed 5 times with PBST.

[0176] In round 1, 2×10^{12} up to 10^{13} plaque forming units (pfu) per selection were blocked against non-specific binding by adding to 0.500 mL of 2%MPBS (=2%MPBST without Tween) for 1 hr at RT (tumble). In later rounds, 1011 pfu per selection were blocked as done in round 1.

[0177] Each phage pool was incubated with 50 μ L of depletion target beads (final wash supernatant removed just before use) on a Labquake rotator for 10 min at room temperature. After incubation, the phage supernatant was removed and incubated with another 50 μ L of depletion target beads. This was repeated 3 more times using depletion target beads and twice using blocked streptavidin beads for a total of 7 rounds of depletion, so each phage pool required 350 μ L of depletion beads.

[0178] A small sample of each depleted library pool was taken for titering. Each library pool was added to 0.100 mL of target beads (final wash supernatant was removed just before use) and allowed to incubate for 2 hours at room temperature (tumble).

[0179] Beads were then washed as rapidly as possible (e.g., 3 minutes total) with 5 X 0.500 mL PBST and then 2X with PBS. Phage still bound to beads after the washing were eluted once with 0.250 mL of competitive ligand ($\sim 1 \mu\text{M}$) in PBST for 1 hour at room temperature on a Labquake rotator. The eluate was removed, mixed with 0.500 mL Minimal A salts solution and saved. For a second selection, 0.500 mL 100 mM TEA was used for elution for 10 min at RT, then neutralized in a mix of 0.250 mL of 1 M Tris, pH 7.4 + 0.500 mL Min A salts.

[0180] After the first selection elution, the beads can be eluted again with 0.300 mL of non-biotinylated target (1 mg/mL) for 1 hr at RT on a Labquake rotator. Eluted phage are added to 0.450 mL Minimal A salts.

[0181] Three eluates (competitor from 1st selection, target from 1st selection and neutralized TEA elution from 2nd selection) were kept separate and a small aliquot taken from each for titering. 0.500 mL Minimal A salts were added to the remaining bead aliquots after competitor and target elution and after TEA elution. Take a small aliquot from each was taken for titrating.

[0182] Each elution and each set of eluted beads was mixed with 2X YT and an aliquot (e.g., 1 mL with 1×10^{10} mL) of XL1-Blue MRF' E. coli cells (or other F' cell line) which had been chilled on ice after having been grown to mid-logarithmic phase, starved and concentrated (see procedure below - "Mid-Log prep of XL-1 blue MRF' cells for infection").

[0183] After approximately 30 minutes at room temperature, the phage/cell mixtures were spread onto Bio-Assay Dishes (243 X 243 X 18 mm, Nalge Nunc) containing 2XYT, 1mM IPTG agar. The plates were incubated overnight at 30°C. The next day, each amplified phage culture was harvested from its respective plate. The plate was flooded with 35 mL TBS or LB, and cells were scraped from the plate. The resuspended cells were transferred to a centrifuge bottle. An additional 20 mL TBS or LB was used to remove any cells from the plate and pooled with the cells in the centrifuge bottle. The cells were centrifuged out, and phage in the supernatant was recovered by PEG precipitation. Over the next day, the amplified phage preps were titered.

[0184] In the first round, two selections yielded five amplified eluates. These amplified eluates were panned for 2-3 more additional rounds of selection using $\sim 1 \times 10^{12}$ input phage/round. For each additional round, the depletion and target beads were prepared the night before the round was initiated.

[0185] For the elution steps in subsequent rounds, all elutions up to the elution step from which the amplified elution came from were done, and the previous elutions were treated as washes. For the bead infection amplified phage, for example, the competitive ligand and target elutions were done and then tossed as washes (see below). Then the beads were used to infect E. coli. Two pools, therefore, yielded a total of 5 final elutions at the end of the selection.

1st selection set

[0186]

A. Ligand amplified elution: elute w/ ligand for 1 hr, keep as elution

B. Target amplified elution: elute w/ ligand for 1 hr, toss as wash elute w/ target for 1 hr, keep as elution

C. Bead infect. amp. elution: elute w/ ligand for 1 hr, toss as wash elute w/ target for 1 hr, toss as wash elute w/ cell infection, keep as elution

2nd selection set

[0187]

A. TEA amplified elution; elute w/ TEA 10min, keep as elution

B. Bead infect. amp. elution; elute w/ TEA 10min, toss as wash elute w/ cell infection, keep as elution

Mid-log prep of XL1 blue MRF' cells for infection (based on Barbas et al. Phage Display manual procedure)

[0188] Culture XL1 blue MRF' in NZCYM (12.5 mg/mL tet) at 37°C and 250 rpm overnight. Started a 500 mL culture in 2 liter flask by diluting cells 1/50 in NZCYM/tet (10 mL overnight culture added) and incubated at 37°C at 250 rpm until OD600 of 0.45 (1.5-2 hrs) was reached. Shaking was reduced to 100 rpm for 10 min. When OD600 reached between 0.55-0.65, cells were transferred to 2 x 250 mL centrifuge bottles, centrifuged at 600 g for 15 min at 4°C. Supernatant was poured off. Residual liquid was removed with a pipette.

[0189] The pellets were gently resuspended (not pipetting up and down) in the original volume of 1 X Minimal A salts at room temp. The resuspended cells were transferred back into 2-liter flask, shaken at 100 rpm for 45 min at 37°C. This process was performed in order to starve the cells and restore pili. The cells were transferred to 2 x 250 mL centrifuge bottles, and centrifuged as earlier.

[0190] The cells were gently resuspended in ice cold Minimal A salts (5 mL per 500 mL original culture). The cells were put on ice for use in infections as soon as possible.

[0191] The phage eluates were brought up to 7.5 mL with 2XYT medium and 2.5 mL of cells were added. Beads were brought up to 3 mL with 2XYT and 1 mL of cells were added. Incubated at 37°C for 30 min. The cells were plated on 2XYT, 1 mM IPTG agar large NUNC plates and incubated for 18 hr at 30°C.

Example 9: Incorporation of synthetic region in FR1/3 region.

[0192] Described below are examples for incorporating of fixed residues in antibody sequences for light chain kappa and lambda genes, and for heavy chains. The experimental conditions and oligonucleotides used for the examples below have been described in previous examples (e.g., Examples 3 & 4).

[0193] The process for incorporating fixed FR1 residues in an antibody lambda sequence consists of 3 steps (see FIG. 18): (1) annealing of single-stranded DNA material encoding VL genes to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 5-7 of the FR1 of the lambda genes (indicated with X..X; within the lambda genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VL gene. In this process the first few residues of all lambda genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr). After the PCR, the lambda genes can be cloned using the indicated restriction site for ApaLI.

[0194] The process for incorporating fixed FR1 residues in an antibody kappa sequence (FIG. 19) consists of 3 steps : (1) annealing of single-stranded DNA material encoding VK genes to a partially complementary oligonucleotide mix (indicated with Ext and Bri), to anneal in this example to the region encoding residues 8-10 of the FR1 of the kappa genes (indicated with X..X; within the kappa genes the overlap may sometimes not be perfect) ; (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VK gene. In this process the first few (8) residues of all kappa genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr.). After the PCR, the kappa genes can be cloned using the indicated restriction site for ApaLI.

[0195] The process of incorporating fixed FR3 residues in a antibody heavy chain sequence (FIG. 20) consists of 3 steps : (1) annealing of single-stranded DNA material encoding part of the VH genes (for example encoding FR3, CDR3 and FR4 regions) to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 92-94 (within the FR3 region) of VH genes (indicated with X..X; within the VH genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VH gene (such as in the FR4 region). In this process certain residues of all VH genes will be encoded by the sequences present in the oligonucleotides used here, in particular from PCRpr (for residues 70-73), or from Ext/Bridge oligonucleotides (residues 74-91). After the PCR, the partial VH genes can be cloned using the indicated restriction site for *XbaI*.

Table 1: Human GLG FR3 sequences

! VH1

5 ! 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
 agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac atg

! 81 82 82a 82b 82c 83 84 85 86 87 88 89 90 91 92
 gag ctg agc agg ctg aga tct gac gac acg gcc gtg tat tac tgt

10 ! 93 94 95
 gcg aga ga ! 1-02# 1
 aga gtc acc att acc agg gac aca tcc gcg agc aca gcc tac atg
 gag ctg agc agc ctg aga tct gaa gac acg gct gtg tat tac tgt

15 gcg aga ga ! 1-03# 2
 aga gtc acc atg acc agg aac acc tcc ata agc aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gcg aga gg ! 1-08# 3

20 aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac atg
 gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt
 gcg aga ga ! 1-18# 4

25 aga gtc acc atg acc gag gac aca tct aca gac aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gca aca ga ! 1-24# 5

30 aga gtc acc att acc agg gac agg tct atg agc aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac aca gcc atg tat tac tgt
 gca aga ta ! 1-45# 6

35 aga gtc acc atg acc agg gac acg tcc acg agc aca gtc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gcg aga ga ! 1-46# 7

aga gtc acc att acc agg gac atg tcc aca agc aca gcc tac atg
 gag ctg agc agc ctg aga tcc gag gac acg gcc gtg tat tac tgt
 gcg gca ga ! 1-58# 8

40 aga gtc acg att acc gcg gac gaa tcc acg agc aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gcg aga ga ! 1-69# 9

45 aga gtc acg att acc gcg gac aaa tcc acg agc aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gcg aga ga ! 1-e# 10

50 aga gtc acc ata acc gcg gac acg tct aca gac aca gcc tac atg
 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
 gca aca ga ! 1-f# 11

55

! VH2

agg ctc acc atc acc aag gac acc tcc aaa aac cag gtg gtc ctt
 aca atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
 5 gca cac aga c! 2-05# 12
 agg ctc acc atc tcc aag gac acc tcc aaa agc cag gtg gtc ctt
 acc atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
 10 gca cgg ata c! 2-26# 13
 agg ctc acc atc tcc aag gac acc tcc aaa aac cag gtg gtc ctt
 aca atg acc aac atg gac cct gtg gac aca gcc acg tat tac tgt
 gca cgg ata c! 2-70# 14

! VH3

cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
 caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3-07# 15
 20 cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
 caa atg aac agt ctg aga gct gag gac acg gcc ttg tat tac tgt
 gca aaa gat a! 3-09#16
 cga ttc acc atc tcc agg gac aac gcc aag aac tca ctg tat ctg
 25 caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
 gcg aga ga ! 3-11# 17
 cga ttc acc atc tcc aga gaa aat gcc aag aac tcc ttg tat ctt
 caa atg aac agc ctg aga gcc ggg gac acg gct gtg tat tac tgt
 30 gca aga ga ! 3-13# 18
 aga ttc acc atc tca aga gat gat tca aaa aac acg ctg tat ctg
 caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
 acc aca ga ! 3-15# 19
 35 cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
 caa atg aac agt ctg aga gcc gag gac acg gcc ttg tat cac tgt
 gcg aga ga ! 3-20# 20
 40 cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
 caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3-21# 21
 cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 45 caa atg aac agc ctg aga gcc gag gac acg gcc gta tat tac tgt
 gcg aaa ga ! 3-23# 22
 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
 50 gcg aaa ga ! 3-30# 23
 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3303# 24
 55

EP 1 578 903 B2

cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
 gcg aaa ga ! 3305# 25
 5 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3-33# 26
 10 cga ttc acc atc tcc aga gac aac agc aaa aac tcc ctg tat ctg
 caa atg aac agt ctg aga act gag gac acc gcc ttg tat tac tgt
 gca aaa gat a! 3-43#27
 cga ttc acc atc tcc aga gac aat gcc aag aac tca ctg tat ctg
 15 caa atg aac agc ctg aga gac gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3-48# 28
 aga ttc acc atc tca aga gat ggt tcc aaa agc atc gcc tat ctg
 caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
 20 act aga ga ! 3-49# 29
 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
 caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
 gcg aga ga ! 3-53# 30
 25 aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
 caa atg ggc agc ctg aga gct gag gac atg gct gtg tat tac tgt
 gcg aga ga ! 3-64# 31
 aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
 30 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
 gcg aga ga ! 3-66# 32
 aga ttc acc atc tca aga gat gat tca aag aac tca ctg tat ctg
 caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
 35 gct aga ga ! 3-72# 33
 agg ttc acc atc tcc aga gat gat tca aag aac acg gcg tat ctg
 caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
 40 act aga ca ! 3-73# 34
 cga ttc acc atc tcc aga gac aac gcc aag aac acg ctg tat ctg
 caa atg aac agt ctg aga gcc gag gac acg gct gtg tat tac tgt
 gca aga ga ! 3-74# 35
 45 aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg cat ctt
 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
 aag aaa ga ! 3-d# 36
 ! VH4
 50 cga gtc acc ata tca gta gac aag tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
 gcg aga ga ! 4-04# 37
 55 cga gtc acc atg tca gta gac acg tcc aag aac cag ttc tcc ctg

EP 1 578 903 B2

aag ctg agc tct gtg acc gcc gtg gac acg gcc gtg tat tac tgt
 gcg aga aa ! 4-28# 38
 5 cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
 aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
 gcg aga ga ! 4301# 39
 cga gtc acc ata tca gta gac agg tcc aag aac cag ttc tcc ctg
 10 aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
 gcc aga ga ! 4302# 40
 cga gtt acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg act gcc gca gac acg gcc gtg tat tac tgt
 15 gcc aga ga ! 4304# 41
 cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
 aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
 gcg aga ga ! 4-31# 42
 20 cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg acc gcc gcg gac acg gct gtg tat tac tgt
 gcg aga ga ! 4-34# 43
 cga gtc acc ata tcc gta gac acg tcc aag aac cag ttc tcc ctg
 25 aag ctg agc tct gtg acc gcc gca gac acg gct gtg tat tac tgt
 gcg aga ca ! 4-39# 44
 cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
 30 gcg aga ga ! 4-59# 45
 cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
 gcg aga ga ! 4-61# 46
 35 cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
 aag ctg agc tct gtg acc gcc gca gac acg gcc gtg tat tac tgt
 gcg aga ga ! 4-b# 47
 40 ! VH5
 cag gtc acc atc tca gcc gac aag tcc atc agc acc gcc tac ctg
 cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
 gcg aga ca ! 5-51# 48
 45 cac gtc acc atc tca gct gac aag tcc atc agc act gcc tac ctg
 cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
 gcg aga ! 5-a# 49
 ! VH6
 50 cga ata acc atc aac cca gac aca tcc aag aac cag ttc tcc ctg
 cag ctg aac tct gtg act ccc gag gac acg gct gtg tat tac tgt
 gca aga ga ! 6-1# 50
 ! VH7
 55

EP 1 578 903 B2

cgg ttt gtc ttc tcc ttg gac acc tct gtc agc acg gca tat ctg
cag atc tgc agc cta aag gct gag gac act gcc gtg tat tac tgt
gcg aga ga ! 74.1# 51

Table 2: Enzymes that either cut 15 or more human GLGs or have 5+-base recognition in FR3

Typical entry:

REname Recognition

#sites

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

BstEII Ggtnacc

2

1: 3

48: 3

There are 2 hits at base#

3

MaeIII gtnac

36

1: 4

2: 4

3: 4

4: 4

5: 4

6: 4

7: 4

8: 4

9: 4

10: 4

11: 4

37: 4

37: 58

38: 4

38: 58

39: 4

39: 58

40: 4

40: 58

41: 4

41: 58

42: 4

42: 58

43: 4

43: 58

44: 4

44: 58

45: 4

45: 58

46: 4

46: 58

47: 4

47: 58

48: 4

49: 4

50: 58

There are 24 hits at base# 4

Tsp45I gt sac

33

1: 4

2: 4

3: 4

4: 4

5: 4

6: 4

7: 4

8: 4

9: 4

10: 4

11: 4

37: 4

37: 58

38: 4

38: 58

39: 58

40: 4

40: 58

41: 58

42: 58

43: 4

43: 58

44: 4

44: 58

45: 4

45: 58

46: 4

46: 58

47: 4

47: 58

48: 4

49: 4

50: 58

There are 21 hits at base# 4

HphI tcacc

45

1: 5

2: 5

3: 5

4: 5

5: 5

6: 5

7: 5

8: 5

11: 5

12: 5

12: 11

13: 5

14: 5

15: 5

16: 5

17: 5

18: 5

19: 5

20: 5

21: 5

22: 5

23: 5

24: 5

25: 5

26: 5

27: 5

28: 5

29: 5

30: 5

31: 5

32: 5

33: 5

34: 5

35: 5

36: 5

37: 5

38: 5

40: 5

43: 5

44: 5

45: 5

46: 5

47: 5

48: 5

49: 5

There are 44 hits at base# 5

NlaIII CATG

26

1: 9

1: 42

2: 42

3: 9

3: 42

4: 9

4: 42

5: 9

5: 42

6: 42

6: 78

7: 9

7: 42

8: 21

8: 92

9: 42

10: 42

11: 42

12: 57

13: 48

13: 57

14: 57

31: 72

38: 9

48: 78

49: 78

There are 11 hits at base# 42

There are 1 hits at base# 48 Could cause raggedness.

BsaJI Ccngg

37

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

1: 14	2: 14	5: 14	6: 14	7: 14	8: 14
8: 65	9: 14	10: 14	11: 14	12: 14	13: 14
14: 14	15: 65	17: 14	17: 65	18: 65	19: 65
20: 65	21: 65	22: 65	26: 65	29: 65	30: 65
33: 65	34: 65	35: 65	37: 65	38: 65	39: 65
40: 65	42: 65	43: 65	48: 65	49: 65	50: 65
51: 14					

There are 23 hits at base# 65

There are 14 hits at base# 14

Alul AGct

42

1: 47	2: 47	3: 47	4: 47	5: 47	6: 47
7: 47	8: 47	9: 47	10: 47	11: 47	16: 63
23: 63	24: 63	25: 63	31: 63	32: 63	36: 63
37: 47	37: 52	38: 47	38: 52	39: 47	39: 52
40: 47	40: 52	41: 47	41: 52	42: 47	42: 52
43: 47	43: 52	44: 47	44: 52	45: 47	45: 52
46: 47	46: 52	47: 47	47: 52	49: 15	50: 47

There are 23 hits at base# 47

There are 11 hits at base# 52 Only 5 bases from 47

Blnl GCtnagc

21

1: 48	2: 48	3: 48	5: 48	6: 48	7: 48
8: 48	9: 48	10: 48	11: 48	37: 48	38: 48
39: 48	40: 48	41: 48	42: 48	43: 48	44: 48
45: 48	46: 48	47: 48			

There are 21 hits at base# 48

Mwol GCNNNNNnngc

19

1: 48	2: 28	19: 36	22: 36	23: 36	24: 36
25: 36	26: 36	35: 36	37: 67	39: 67	40: 67
41: 67	42: 67	43: 67	44: 67	45: 67	46: 67
47: 67					

There are 10 hits at base# 67

There are 7 hits at base# 36

Ddel Ctnag

71

1: 49	1: 58	2: 49	2: 58	3: 49	3: 58
3: 65	4: 49	4: 58	5: 49	5: 58	5: 65
6: 49	6: 58	6: 65	7: 49	7: 58	7: 65
8: 49	8: 58	9: 49	9: 58	9: 65	10: 49
10: 58	10: 65	11: 49	11: 58	11: 65	15: 58
16: 58	16: 65	17: 58	18: 58	20: 58	21: 58
22: 58	23: 58	23: 65	24: 58	24: 65	25: 58
25: 65	26: 58	27: 58	27: 65	28: 58	30: 58

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

5						
	31: 58	31: 65	32: 58	32: 65	35: 58	36: 58
	36: 65	37: 49	38: 49	39: 26	39: 49	40: 49
	41: 49	42: 26	42: 49	43: 49	44: 49	45: 49
10	46: 49	47: 49	48: 12	49 12	51: 65	

There are 29 hits at base# 58

There are 22 hits at base# 49 Only nine base from 58

There are 16 hits at base# 65 Only seven bases from 58

15	BglII Agatct			11		
	1: 61	2: 61	3: 61	4: 61	5: 61	6: 61
	7: 61	9: 61	10: 61	11: 61	51: 47	

There are 10 hits at base# 61

20	BstYI Rgatcy			12		
	1: 61	2: 61	3: 61	4: 61	5: 61	6: 61
	7: 61	8: 61	9: 61	10: 61	11: 61	51: 47

There are 11 hits at base# 61

25	Hpy188I TCNga			17		
	1: 64	2: 64	3: 64	4: 64	5: 64	6: 64
	7: 64	8: 64	9: 64	10: 64	11: 64	16: 57
	20: 57	27: 57	35: 57	48: 67	49: 67	

There are 11 hits at base# 64

There are 4 hits at base# 57

There are 2 hits at base# 67 Could be ragged.

35	MslI CAYNNnnRTG			44		
	1: 72	2: 72	3: 72	4: 72	5: 72	6: 72
	7: 72	8: 72	9: 72	10: 72	11: 72	15: 72
	17: 72	18: 72	19: 72	21: 72	23: 72	24: 72
	25: 72	26: 72	28: 72	29: 72	30: 72	31: 72
40	32: 72	33: 72	34: 72	35: 72	36: 72	37: 72
	38: 72	39: 72	40: 72	41: 72	42: 72	43: 72
	44: 72	45: 72	46: 72	47: 72	48: 72	49: 72
	50: 72	51: 72				

There are 44 hits at base# 72

45	BsiEI CGRYcg			23		
	1: 74	3: 74	4: 74	5: 74	7: 74	8: 74
	9: 74	10: 74	11: 74	17: 74	22: 74	30: 74
50	33: 74	34: 74	37: 74	38: 74	39: 74	40: 74
	41: 74	42: 74	45: 74	46: 74	47: 74	

There are 23 hits at base# 74

55	EaeI Yggccr			23		
	1: 74	3: 74	4: 74	5: 74	7: 74	8: 74
	9: 74	10: 74	11: 74	17: 74	22: 74	30: 74
	33: 74	34: 74	37: 74	38: 74	39: 74	40: 74

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

5

41: 74 42: 74 45: 74 46: 74 47: 74

There are 23 hits at base# 74

10

EagI Cggccg

23

1: 74 3: 74 4: 74 5: 74 7: 74 8: 74
9: 74 10: 74 11: 74 17: 74 22: 74 30: 74
33: 74 34: 74 37: 74 38: 74 39: 74 40: 74
41: 74 42: 74 45: 74 46: 74 47: 74

15

There are 23 hits at base# 74

HaeIII GGcc

27

1: 75 3: 75 4: 75 5: 75 7: 75 8: 75
9: 75 10: 75 11: 75 16: 75 17: 75 20: 75
22: 75 30: 75 33: 75 34: 75 37: 75 38: 75
39: 75 40: 75 41: 75 42: 75 45: 75 46: 75
47: 75 48: 63 49: 63

20

There are 25 hits at base# 75

25

Bst4CI ACNgt 65°C 63 Sites There is a third isoschismer

1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
50: 86 51: 0 51: 86

30

35

There are 51 hits at base# 86 All the other sites are well away

40

HpyCH4III ACNgt

63

1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
50: 86 51: 0 51: 86

45

50

There are 51 hits at base# 86

Hinfi Gantc

43

2: 2 3: 2 4: 2 5: 2 6: 2 7: 2
8: 2 9: 2 9: 22 10: 2 11: 2 15: 2
16: 2 17: 2 18: 2 19: 2 19: 22 20: 2

55

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

5	GLGid#:base#	GLGid#:base#	GLGid#:base#	GLGid#:base#	GLGid#:base#	GLGid#:base#
	21: 2	23: 2	24: 2	25: 2	26: 2	27: 2
	28: 2	29: 2	30: 2	31: 2	32: 2	33: 2
	33: 22	34: 22	35: 2	36: 2	37: 2	38: 2
10	40: 2	43: 2	44: 2	45: 2	46: 2	47: 2
	50: 60					
	There are 38 hits at base# 2					
	MlyI GAGTCNNNNNn					
15				18		
	2: 2	3: 2	4: 2	5: 2	6: 2	7: 2
	8: 2	9: 2	10: 2	11: 2	37: 2	38: 2
	40: 2	43: 2	44: 2	45: 2	46: 2	47: 2
	There are 18 hits at base# 2					
20	PleI gagtc					
				18		
	2: 2	3: 2	4: 2	5: 2	6: 2	7: 2
	8: 2	9: 2	10: 2	11: 2	37: 2	38: 2
	40: 2	43: 2	44: 2	45: 2	46: 2	47: 2
25	There are 18 hits at base# 2					
	AclI Cgc					
				24		
	2: 26	9: 14	10: 14	11: 14	27: 74	37: 62
	37: 65	38: 62	39: 65	40: 62	40: 65	41: 65
30	42: 65	43: 62	43: 65	44: 62	44: 65	45: 62
	46: 62	47: 62	47: 65	48: 35	48: 74	49: 74
	There are 8 hits at base# 62					
	There are 8 hits at base# 65					
35	There are 3 hits at base# 14					
	There are 3 hits at base# 74					
	There are 1 hits at base# 26					
	There are 1 hits at base# 35					
40	-"- Gcgg					
				11		
	8: 91	9: 16	10: 16	11: 16	37: 67	39: 67
	40: 67	42: 67	43: 67	45: 67	46: 67	
	There are 7 hits at base# 67					
	There are 3 hits at base# 16					
45	There are 1 hits at base# 91					
	BsiHKA I GWGCWc					
				20		
	2: 30	4: 30	6: 30	7: 30	9: 30	10: 30
	12: 89	13: 89	14: 89	37: 51	38: 51	39: 51
	40: 51	41: 51	42: 51	43: 51	44: 51	45: 51
50	46: 51	47: 51				
	There are 11 hits at base# 51					
	Bsp1286I GDGCHc					
55				20		
	2: 30	4: 30	6: 30	7: 30	9: 30	10: 30
	12: 89	13: 89	14: 89	37: 51	38: 51	39: 51
	40: 51	41: 51	42: 51	43: 51	44: 51	45: 51

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

5	GLGid#:base#	GLGid#:base#	GLGid#:base#.....
	46: 51	47: 51	
	There are 11 hits at base# 51		
10	HgiAI GWGCWc		20
	2: 30	4: 30	6: 30 7: 30 9: 30 10: 30
	12: 89	13: 89	14: 89 37: 51 38: 51 39: 51
	40: 51	41: 51	42: 51 43: 51 44: 51 45: 51
	46: 51	47: 51	
15	There are 11 hits at base# 51		
	BsoFI GCngc		26
	2: 53	3: 53	5: 53 6: 53 7: 53 8: 53
	8: 91	9: 53	10: 53 11: 53 31: 53 36: 36
20	37: 64	39: 64	40: 64 41: 64 42: 64 43: 64
	44: 64	45: 64	46: 64 47: 64 48: 53 49: 53
	50: 45	51: 53	
	There are 13 hits at base# 53		
25	There are 10 hits at base# 64		
	TseI GcwgC		17
	2: 53	3: 53	5: 53 6: 53 7: 53 8: 53
	9: 53	10: 53	11: 53 31: 53 36: 36 45: 64
30	46: 64	48: 53	49: 53 50: 45 51: 53
	There are 13 hits at base# 53		
	MnII gagg		34
	3: 67	3: 95	4: 51 5: 16 5: 67 6: 67
35	7: 67	8: 67	9: 67 10: 67 11: 67 15: 67
	16: 67	17: 67	19: 67 20: 67 21: 67 22: 67
	23: 67	24: 67	25: 67 26: 67 27: 67 28: 67
	29: 67	30: 67	31: 67 32: 67 33: 67 34: 67
	35: 67	36: 67	50: 67 51: 67
40	There are 31 hits at base# 67		
	HpyCH4V TGca		34
	5: 90	6: 90	11: 90 12: 90 13: 90 14: 90
45	15: 44	16: 44	16: 90 17: 44 18: 90 19: 44
	20: 44	21: 44	22: 44 23: 44 24: 44 25: 44
	26: 44	27: 44	27: 90 28: 44 29: 44 33: 44
	34: 44	35: 44	35: 90 36: 38 48: 44 49: 44
	50: 44	50: 90	51: 44 51: 52
50	There are 21 hits at base# 44		
	There are 1 hits at base# 52		
	AccI GTmkac		13 5-base recognition
55	7: 37	11: 24	37: 16 38: 16 39: 16 40: 16
	41: 16	42: 16	43: 16 44: 16 45: 16 96: 16
	47: 16		
	There are 11 hits at base# 16		

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

5

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

SacII CCGCgg

8

6-base recognition

9: 14

10: 14

11: 14

37: 65

39: 65

40: 65

42: 65

43: 65

10

There are 5 hits at base# 65

There are 3 hits at base# 14

TfiI Gawtc

24

15

9: 22

15: 2

16: 2

17: 2

18: 2

19: 2

19: 22

20: 2

21: 2

23: 2

24: 2

25: 2

26: 2

27: 2

28: 2

29: 2

30: 2

31: 2

32: 2

33: 2

33: 22

34: 22

35: 2

36: 2

20

There are 20 hits at base# 2

BsmAI Nnnnnngagac

19

15: 11

16: 11

20: 11

21: 11

22: 11

23: 11

24: 11

25: 11

26: 11

27: 11

28: 11

28: 56

30: 11

31: 11

32: 11

35: 11

36: 11

44: 87

25

48: 87

There are 16 hits at base# 11

BpmI ctccag

19

30

15: 12

16: 12

17: 12

18: 12

20: 12

21: 12

22: 12

23: 12

24: 12

25: 12

26: 12

27: 12

28: 12

30: 12

31: 12

32: 12

34: 12

35: 12

36: 12

There are 19 hits at base# 12

35

XmnI GAANNnttc

12

37: 30

38: 30

39: 30

40: 30

41: 30

42: 30

43: 30

44: 30

45: 30

46: 30

47: 30

50: 30

There are 12 hits at base# 30

40

BsrI NCcagt

12

37: 32

38: 32

39: 32

40: 32

41: 32

42: 32

43: 32

44: 32

45: 32

46: 32

47: 32

50: 32

45

There are 12 hits at base# 32

BanII GRGCYc

11

37: 51

38: 51

39: 51

40: 51

41: 51

42: 51

43: 51

44: 51

45: 51

46: 51

47: 51

50

There are 11 hits at base# 51

EclI36I GAGctc

11

37: 51

38: 51

39: 51

40: 51

41: 51

42: 51

43: 51

44: 51

45: 51

46: 51

47: 51

55

There are 11 hits at base# 51

SacI GAGCTc

11

EP 1 578 903 B2

(continued)

Typical entry:

REname Recognition

#sites

5

GLGid#:base#

GLGid#:base#

GLGid#:base#.....

37: 51

38: 51

39: 51

40: 51

41: 51

42: 51

43: 51

44: 51

45: 51

46: 51

47: 51

There are 11 hits at base# 51

10

15

20

25

30

35

40

45

50

55

Table 3: Synthetic 3-23 FR3 of human heavy chains showing positions of possible cleavage sites

```

5      ! Sites engineered into the synthetic gene are shown in upper case
      DNA
      ! with the RE name between vertical bars (as in | XbaI |).
      ! RERSs frequently found in GLGs are shown below the synthetic
10     sequence
      ! with the name to the right (as in gtn ac=MaeIII(24), indicating
      that
      ! 24 of the 51 GLGs contain the site).
15     !
      !
      !
      in
      !
20     synthetic 3-23)
                                     |---FR3---
                                     89  90 (codon #
                                     R   F
                                     |cgc|ttc|  6
                                     |cgn|tty|
                                     |agr|
25     !
                                     ga ntc =
HinfI(38)
      !
                                     ga gtc =
PleI(18)
      !
30     !
                                     ga wtc =
TfiI(20)
      !
                                     gtn ac =
MaeIII(24)
      !
35     !
                                     gts ac =
Tsp45I(21)
      !
                                     tc acc =
HphI(44)
      !
40     !
      ! -----FR3-----
      !
      !   91  92  93  94  95  96  97  98  99 100 101 102 103 104 105
      !   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M
45     !   |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|  51
      !allowed|acn|ath|tcn|cgn|gay|aay|tcn|aar|aay|acn|ttr|tay|ttr|car|atg|
      !
      !           |agy|agr|           |agy|           |ctn|   |ctn|
      !           |   ga|gac = BsmAI(16)           ag ct =
50     AluI(23)
      !
      !           c|tcc ag = BpmI(19)           g ctn agc =
      BlnI(21)

```

EP 1 578 903 B2

```

!           |           |           g aan nnn ttc = XmnI(12)
!           | XbaI   |           tg ca = HpyCH4V(21)
!
5  !  ---FR3----->|
!      106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!      N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   K
!      |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 96
10 !allowed|aay|tcn|ttr|cgn|gcn|gar|gay|acn|gcn|gtn|tay|tay|tgy|gcn|aar|
!      |agy|ctn|agr|           |           |
!           |           | cc nng g = BsaJI(23)          ac ngt = Bst4CI(51)
!           |           | aga tct = BglII(10)          |          ac ngt = HpyCH4III(51)
15 !           |           | Rga tcY = BstYI(11)          |          ac ngt = TaaI(51)
!           |           |           c ayn nnn rtc = MslI(44)
!           |           |           cg ryc g = BsiEI(23)
!           |           |           yg gcc r = EaeI(23)
20 !           |           |           cg gcc g = EagI(23)
!           |           |           lg gcc = HaeIII(25)
!           |           |           gag g = MnlI(31)|
!           |AflIII|           | PstI |
25
30
35
40
45
50
55

```

Table 4: REdaptors, Extenders, and Bridges used for Cleavage and Capture of Human Heavy Chains in FR3.

A: HpyCH4V Probes of actual human HC genes

!HpyCH4V in FR3 of human HC, bases 35-56; only those with TGca site TGca;10,

RE recognition:tgca of length 4 is expected at

10

1	6-1	agttctccctgcagctgaactc
2	3-11,3-07,3-21,3-72,3-48	cactgtatctgcaaatgaacag
3	3-09,3-43,3-20	ccctgtatctgcaaatgaacag
4	5-51	ccgcctacctgcagtggagcag
5	3-15,3-30,3-30.5,3-30.3,3-74,3-23,3-33	cgctgtatctgcaaatgaacag
6	7-4.1	cggcatatctgcagatctgcag
7	3-73	cggcgtatctgcaaatgaacag
8	5-a	ctgcctacctgcagtggagcag
9	3-49	tcgcctatctgcaaatgaacag

B: HpyCH4V REdaptors, Extenders, and Bridges

B.1 REdaptors

! Cutting HC lower strand:

! TmKeller for 100 mM NaCl, zero formamide

! Edaptors for cleavage

		T_m^W	T_m^K
(ON_HCFR36-1)	5'-agttctcccTGCAgctgaactc-3'	68.0	64.5
(ON_HCFR36-1A)	5'-ttctcccTGCAgctgaactc-3'	62.0	62.5
(ON_HCFR36-1B)	5'-ttctcccTGCAgctgaac-3'	56.0	59.9
(ON_HCFR33-15)	5'-cgctgtatcTGCAaatgaacag-3'	64.0	60.8
(ON_HCFR33-15A)	5'-ctgtatcTGCAaatgaacag-3'	56.0	56.3
(ON_HCFR33-15B)	5'-ctgtatcTGCAaatgaac-3'	50.0	53.1
(ON_HCFR33-11)	5'-cactgtatcTGCAaatgaacag-3'	62.0	58.9
(ON_HCFR35-51)	5'-ccgcctaccTGCAgtggagcag-3'	74.0	70.1

!

B.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

! XbaI...

!D323* cgCttcacTaag tcT_aga gac aaC tcT aag aaT acT ctC taC

! scab..... designed gene 3-23 gene.....

!

! HpyCH4V
 ! AflIII...
 ! Ttg caG atg aac agc TtA agG . . .
 !
 !

B.3 Extender and Bridges

! Extender (bottom strand):

! (ON_HCHpyEx01) 5'-cAagTAgAgAgTATTcTTAgAgTTgTcTcTAgAcTTAgTgAAgcg-3'

! ON_HCHpyEx01 is the reverse complement of

! 5'-cgCttcacTaag tcT aga gac aaC tcT aag aaT acT ctC taC Ttg -3'

! Bridges (top strand, 9-base overlap):
 !

(ON_HCHpyBr016-1) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
 aaT acT ctC taC Ttg CAgctgaac-3' {3'-term C is
 blocked}

! 3-15 et al. + 3-11

(ON_HCHpyBr023-15) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
 aaT acT ctC taC Ttg CAaatgaac-3' {3'-term C is
 blocked}

!

! 5-51

(ON_HCHpyBr045-51) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
 aaT acT ctC taC Ttg CAgtgagac-3' {3'-term C is
 blocked}

!

! PCR primer (top strand)

!

(ON_HCHpyPCR) 5'-cgCttcacTaag tcT aga gac-3'

!

C: BspI Probes from human HC GLGs

1 1-58,1-03,1-08,1-69,1-24,1-45,1-46,1-f,1-e
 acatggaGCTGAGCagcctgag

2 1-02
 acatggaGCTGAGCaggctgag

3 1-18
 acatggagctgaggagcctgag
 4 5-51,5-a
 5 acctgcagtggagcagcctgaa
 5 3-15,3-73,3-49,3-72
 atctgcaaataaacagcctgaa
 6 3303,3-33,3-07,3-11,3-30,3-21,3-23,3305,3-48
 10 atctgcaaataaacagcctgag
 7 3-20,3-74,3-09,3-43
 atctgcaaataaacagtctgag
 8 74.1
 15 atctgcagatctgcagcctaaa
 9 3-66,3-13,3-53,3-d
 atcttcaaataaacagcctgag
 10 3-64
 20 atcttcaaataagggcagcctgag
 11 4301,4-28,4302,4-04,4304,4-31,4-34,4-39,4-59,4-61,4-b
 ccctgaaGCTGAGCtctgtgac
 12 6-1
 25 ccctgcagctgaactctgtgac
 13 2-70,2-05
 tccttacaatgaccaacatgga
 14 2-26
 30 tccttaccatgaccaacatgga

D: BlpI REaptors, Extenders, and Bridges

D.1 REaptors

		T_m^H	T_m^K
35	(BlpF3HC1-58) 5'-ac atg gaG CTG AGC agc ctg ag-3'	70	66.
			4
	(BlpF3HC6-1) 5'-cc ctg aag ctg agc tct gtg ac-3'	70	66.
			4
40	! BlpF3HC6-1 matches 4-30.1, not 6-1.		

D.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

45 !
 BlpI
 50 ! XbaI...

55

!D323* cgCttcacTaag TCT AGA gac aaC tcT aag aaT acT ctC taC Ttg
caG atg aac

!

!

AflIII...

!

agC TTA AGG

D.3 Extender and Bridges

! Bridges

(BlpF3Br1) 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-
taC Ttg caG Ctg a|GC agc ctg-3'

(BlpF3Br2) 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-
taC Ttg caG Ctg a|gc tct gtg-3'

!

| lower strand is cut here

! Extender

(BlpF3Ext) 5'-TcAgcTgcAAgTAcAAAgTATTTTAcTgTTATcTcTAgA_cTgAgTgAAgcg-
3'

! BlpF3Ext is the reverse complement of:

! 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG taC Ttg caG
Ctg a-3'

!

(BlpF3PCR) 5'-cgCttcacTcag tcT aga gaT aaC-3'

E: *Hpy*CH4III Distinct GLG sequences surrounding site, bases 77-98

1 102#1,118#4,146#7,169#9,1e#10,311#17,353#30,404#37,4301
ccgtgtattactgtgcgagaga

2 103#2,307#15,321#21,3303#24,333#26,348#28,364#31,366#32
ctgtgtattactgtgcgagaga

3 108#3
ccgtgtattactgtgcgagagg

4 124#5,1f#11
ccgtgtattactgtgcaacaga

5 145#6
ccatgtattactgtgcaagata

6 158#8
ccgtgtattactgtgcggcaga

7 205#12
ccacatattactgtgcacacag

8 226#13
ccacatattactgtgcacggat

	9	270#14
	ccacgtattactgtgcacggat	
	10	309#16, 343#27
5	ccttggtattactgtgcaaaaga	
	11	313#18, 374#35, 61#50
	ctgtgtattactgtgcaagaga	
	12	315#19
	ccgtgtattactgtaccacaga	
10	13	320#20
	ccttggtatcactgtgagagaga	
	14	323#22
	ccgtatattactgtgcaaaaga	
15	15	330#23, 3305#25
	ctgtgtattactgtgcaaaaga	
	16	349#29
	ccgtgtattactgtactagaga	
	17	372#33
20	ccgtgtattactgtgctagaga	
	18	373#34
	ccgtgtattactgtactagaca	
	19	3d#36
	ctgtgtattactgtgaaaga	
25	20	428#38
	ccgtgtattactgtgcaaaa	
	21	4302#40, 4304#41
	ccgtgtattactgtgccagaga	
	22	439#44
30	ctgtgtattactgtgcaagaca	
	23	551#48
	ccatgtattactgtgcaagaca	
	24	5a#49
35	ccatgtattactgtgcaagaga	

F: HpyCH4III REaptors, Extenders, and Bridges
F.1 REaptors

! ONs for cleavage of HC(lower) in FR3(bases 77-97)

! For cleavage with HpyCH4III, Bst4CI, or TaaI

! cleavage is in lower chain before base 88.

! 77 788 888 888 889 999 999 9

! 78 901 234 567 890 123 456 7

 T_m^H T_m^K

(H43.77.97.1-02#1)	5'-cc gtg tat tAC TGT gcg aga g-3'	6462.6
(H43.77.97.1-03#2)	5'-c ₁₂ gtg tat tAC TGT gcg aga g-3'	6260.6
(H43.77.97.108#3)	5'-cc gtg tat tAC TGT gcg aga g-3'	6462.6
(H43.77.97.323#22)	5'-cc g ₁₂ at tat tac tgt gcg a ₁₂ a g-3'	6058.7
(H43.77.97.330#23)	5'-c ₁₂ gtg tat tac tgt gcg a ₁₂ a g-3'	6058.7

(H43.77.97.439#44) 5'-c¹gtg tat tac tgt gcg aga ²-3' 6260.6
 (H43.77.97.551#48) 5'-cc³atg tat tac tgt gcg aga ⁴-3' 6260.6
 (H43.77.97.5a#49) 5'-cc⁵atg tat tAC TGT gcg aga ⁶-3' 5858.3

F.2 Extender and Bridges

! XbaI and AflII sites in bridges are bunged

(H43.XABr1) 5'-ggtgtagtga-

|TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|agC|TTt|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat tgt gcg aga-3'

(H43.XABr2) 5'-ggtgtagtga-

|TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|agC|TTt|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat tgt gcg aaa-3'

(H43.XAExt) 5'-ATAgTAgAcT gcAgTgTccT cAgcccTTAA gcTgTTcATc
 TgcAAgTAgA-

gAgTATTcTT AgAgTTgTcT cTAgATcAcT AcAcc-3'

!H43.XAExt is the reverse complement of

! 5'-ggtgtagtga-

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! |aac|agC|TTA|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat -3'

(H43.XAPCR) 5'-ggtgtagtga |TCT|AGA|gac|aac-3'

! XbaI and AflII sites in bridges are bunged

(H43.ABr1) 5'-ggtgtagtga-

|aac|agC|TTt|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat tgt gcg aga-3'

(H43.ABr2) 5'-ggtgtagtga-

|aac|agC|TTt|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat tgt gcg aaa-3'

(H43.AExt) 5'-ATAgTAgAcTgcAgTgTccTcAgcccTTAAgcTgTTTcAcTAcAcc-3'

!(H43.AExt) is the reverse complement of 5'-ggtgtagtga-

! |aac|agC|TTA|AGg|gct|gaq|gac|aCT|GCA|Gtc|tac|tat -3'

(H43.APCR) 5'-ggtgtagtga |aac|agC|TTA|AGg|gct|g-3'

Table 5: Analysis of frequency of matching REaptors in actual V genes

A: HpyCH4V in HC at bases 35-56

Number of mismatches..... Number																	
Id	Ntot	0	1	2	3	4	5	6	7	8	9	10	Cut	Id	Probe		
1	510	5	11	274	92	61	25	22	11	1	3	5	443	6-1	agttctcccTGCAGctgaactc		
2	192	54	42	32	24	15	2	3	10	3	1	6	167	3-11	cactgtatcTGCaaatgaacag		
3	58	19	7	17	6	5	1	0	1	0	2	0	54	3-09	ccctgtatcTGCaaatgaacag		
4	267	42	33	9	8	8	82	43	22	8	11	1	100	5-51	ccgcctaccTGCAGtgaggcag		
5	250	111	59	41	24	7	5	1	0	0	2	0	242	3-15	cgctgtatcTGCaaatgaacag		
6	7	0	2	0	1	0	0	0	0	0	4	0	3	7-4.1	cggcatatcTGCAGatctgcag		
7	7	0	2	2	0	0	2	1	0	0	0	0	4	3-73	cggcgtatcTGCaaatgaacag		
8	26	10	4	1	3	1	2	1	3	1	0	0	19	5-a	ctgcctaccTGCAGtgaggcag		
9	21	8	2	3	1	6	1	0	0	0	0	0	20	3-49	tcgcctatcTGCaaatgaacag		
1338		249	162	379	149	103	120	71	47	13	23	12	1052				
		249	411	790	939	1162	1280	1316									
		1042 1233 1293 1338															

Id	Probe	dotted probe
6-1	agttctcccTGCAGctgaactc	agttctcccTGCAGctgaactc
3-11	cactgtatcTGCaaatgaacag	cac.g.at.....aa.....ag
3-09	ccctgtatcTGCaaatgaacag	ccc.g.at.....aa.....ag

5-51 ccgcctaccTGCAgtggagcag ccgc..a.....tg..g.ag
 3-15 cgctgtatcTGCAaatgaacag c.c.g.at.....aa.....ag
 7-4.1 cggcatatcTGCAgatctgcag c.gca.at.....a.ctg.ag
 3-73 cggcgtatcTGCAaatgaacag c.gcg.at.....aa.....ag
 5-a ctgcctaccTGCAgtggagcag ctgc..a.....tg..g.ag
 3-49 tcgcctatcTGCAaatgaacag tcgc..at.....aa.....ag

Seqs with the expected RE site only.....1004

(Counts only cases with 4 or fewer mismatches)

Seqs with only an unexpected site..... 0

Seqs with both expected and unexpected.... 48

(Counts only cases with 4 or fewer mismatches)

Seqs with no sites..... 0

B: Bipl in HC

	Id	Ntot	0	1	2	3	4	5	6	7	8	Ncut	Name
1	133	73	16	11	13	6	9	1	4	0	119	1-58	acatggaGCTGAGCagcctgag
2	14	11	1	0	0	0	0	1	0	1	12	1-02	acatggagctgagcaggctgag
3	34	17	8	2	6	1	0	0	0	0	0	1-18	acatggagctgagcaggcctgag
4	120	50	32	16	10	9	1	1	1	0	2	5-51	acctgcagtggagcagcctgaa
5	55	13	11	10	17	3	1	0	0	0	0	3-15	atctgcaaatgaacagcctgaa

[illegible]

Name	Full sequence	Dot mode
1-58	acatggaGCTGAGCagcctgag	acatggaGCTGAGCagcctgag
1-02	acatggagctgagcaggctgag	g.....
1-18	acatggagctgaggagcctgag	g.....
5-51	acctgcagtgaggagcctgaa	..C..C..tg.....a
3-15	atctgcaaatgaacagcctgaa	.tc..C.aa....a.....a
3-30.3	atctgcaaatgaacagcctgag	.tc..C.aa....a.....
3-20	atctgcaaatgaacagtctgag	.tc..C.aa....a...t.....
7-4.1	atctgcagatctgcagcctaaa	.tc..C..a.ct.....a.a
3-66	atcttcaaatgaacagcctgag	.tc.tc.aa....a.....
3-64	atcttcaaatggcagcctgag	.tc.tc.aa..g.....
4-30.1	ccctgaagctgagctctgtgac	c.c..a.....tctg...c
6-1	ccctgcagctgaactctgtgac	c.c..C.....a.tctg...c
2-70	tccttacaatgaccaacacatgga	t.c.tacaa...c..a.a..ga
2-26	tccttaccatgaccaacacatgga	t.c.tacca...c..a.a..ga

Seqs with the expected RE site only..... 597 (counting sequences with 4 or fewer mismatches)

Seqs with only an unexpected site..... 2

Seqs with both expected and unexpected.... 2

Seqs with no sites..... 686

5
10
15
20
25
30
35
40
45
50
55

C: HpyCH4III, Bst4CI, or Taal in HC

In scoring whether the RE site of interest is present, only ONs that have 4 or fewer mismatches are counted.

Number of sequences..... 1617

5
10
15
20
25
30
35
40
45
50
55

Id	Ntot	0	1	2	3	4	5	6	7	8	Ncut	acnqt	acnqt
1	244	78	92	43	18	10	1	2	0	0	241	102#1,1	ccgtgtattACTGtgcgagaga
2	457	69	150	115	66	34	11	8	3	1	434	103#2,3	ctgtgtattactgtgcgagaga
3	173	52	45	36	22	14	3	0	0	1	169	108#3	ccgtgtattactgtgcgagagg
4	16	0	3	2	2	1	6	0	1	1	8	124#5,1	ccgtgtattactgtgcaacaga
5	4	0	0	1	0	1	1	0	1	0	2	145#6	ccatgtattactgtgcaagata
6	15	1	0	1	0	6	4	1	1	1	8	158#8	ccgtgtattactgtgcggcaga
7	23	4	8	5	2	2	1	1	0	0	21	205#12	ccacatattactgtgcacacag
8	9	1	1	1	0	3	2	1	0	0	6	226#13	ccacatattactgtgcacggat
9	7	1	3	1	1	0	0	1	0	0	6	270#14	ccacgtattactgtgcacggat
10	23	7	3	5	5	2	1	0	0	0	22	309#16,	ccttgtattactgtgcaaaaga
11	35	5	10	7	6	3	3	0	1	0	31	313#18,	ctgtgtattactgtgcaagaga
12	18	2	3	2	2	6	1	0	2	0	15	315#19	ccgtgtattactgtaccacaga
13	3	1	2	0	0	0	0	0	0	0	3	320#20	ccttgtatcactgtgcgagaga
14	117	29	23	28	22	8	4	2	1	0	110	323#22	ccgtatattactgtgcgaaga
15	75	21	25	13	9	1	4	2	0	0	69	330#23,	ctgtgtattactgtgcgaaga
16	14	2	2	2	3	0	3	1	1	0	9	349#29	ccgtgtattactgtgactagaga
17	2	0	0	1	0	0	1	0	0	0	1	372#33	ccgtgtattactgtgctagaga
18	1	0	0	1	0	0	0	0	0	0	1	373#34	ccgtgtattactgtgactagaca
19	2	0	0	0	0	0	0	0	0	2	0	3d#36	ctgtgtattactgtgaagaaga
20	34	4	9	9	4	5	3	0	0	0	31	428#38	ccgtgtattactgtgcgagaaa
21	17	5	4	2	2	3	1	0	0	0	16	4302#40	ccgtgtattactgtgccagaga
22	75	15	17	24	7	10	1	1	0	0	73	439#44	ctgtgtattactgtgcgagaca
23	40	14	15	4	5	1	0	1	0	0	39	551#48	ccatgtattactgtgcgagaca
24	213	26	56	60	42	20	7	2	0	0	204	5a#49	ccatgtattactgtgcgagaAA

5

10

15

20

25

30

35

40

45

50

55

Group	337	471	363	218	130	58	23	11	6
Cumulative	337	808	1171	1389	1519	1577	1600	1611	1617
Seqs with the expected RE site only.....	1511								
Seqs with only an unexpected site.....	0								
Seqs with both expected and unexpected....	8								
Seqs with no sites.....	0								

Table 5D:

5	Analysis repeated using only 8 best REaptors																	
	Id	Ntot	0	1	2	3	4	5	6	7	8+							
	1	301	78	101	54	32	16	9	10	1	0	281	102#1					
	ccgtgtattactgtgcgagaga																	
10	2	493	69	155	125	73	37	14	11	3	6	459	103#2					
	ctgtgtattactgtgcgagaga																	
	3	189	52	45	38	23	18	5	4	1	3	176	108#3					
	ccgtgtattactgtgcgagagg																	
15	4	127	29	23	28	24	10	6	5	2	0	114	323#22					
	ccgtatattactgtgcgaaaga																	
	5	78	21	25	14	11	1	4	2	0	0	72	330#23					
20	ctgtgtattactgtgcgaaaga 6 79 15 17 25 8 11 1 2 0 0 76																	
	439#44 ctgtgtattactgtgcgagaca																	
	7	43	14	15	5	5	3	0	1	0	0	42	551#48					
	ccatgtattactgtgcgagaca																	
25	8	307	26	63	72	51	38	24	14	13	6	250	5a#49					
	ccatgtattactgtgcgaga																	
	1	102#1	ccgtgtattactgtgcgagaga								ccgtgtattactgtgcgagaga							
	2	103#2	ctgtgtattactgtgcgagaga								.t.....							
30	3	108#3	ccgtgtattactgtgcgagagg								g							
	4	323#22	ccgtatattactgtgcgaaaga								a.....a...							
	5	330#23	ctgtgtattactgtgcgaaaga								.t.....a...							
	6	439#44	ctgtgtattactgtgcgagaca								.t.....c.							
35	7	551#48	ccatgtattactgtgcgagaca								..a.....c.							
	8	5a#49	ccatgtattactgtgcgagaAA								..a.....AA							
Seqs with the expected RE site only.....1463 / 1617																		
40	Seqs with only an unexpected site..... 0																	
	Seqs with both expected and unexpected.... 7																	
	Seqs with no sites..... 0																	

Table 6: Human HC GLG FR1 Sequences

VH Exon - Nucleotide sequence alignment

VH1

1-02	CAG GTG CAG CTG GTG CAG TCT GGG GCT GAG GTG AAG CCT GGG GCC TCA GTG AAG GTC
	TCC TGC AAG GCT TCT GGA TAC ACC TTC ACC
1-03	cag gtC cag ctT gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT
	tcc tgc aag gct tct gga tac acc ttc acT
1-08	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gct tct gga tac acc ttc acc
1-18	cag gtT cag ctg gtg cag tct gga gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gct tct ggT tac acc ttT acc
1-24	cag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gTt tCg gga. tac acc Ctc acT
1-45	cag Atg cag ctg gtg cag tct ggg gct gag gtg aag aag Act ggg Tcc tca gtg aag gtT
	tcc tgc aag gct tCg gga tac acc ttc acc
1-46	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT
	tcc tgc aag gcA tct gga tac acc ttc acc
1-58	caA Atg cag ctg gtg cag tct ggg Cct gag gtg aag aag cct ggg Acc tca gtg aag gtc
	tcc tgc aag gct tct gga tTc acc ttT acT
1-69	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tCg gtg aag gtc
	tcc tgc aag gct tct gga GGc acc ttc aGc
1-e	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tCg gtg aag gtc
	tcc tgc aag gct tct gga GGc acc ttc aGc
1-f	Gag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gCT Aca gtg aaA Atc
	tcc tgc aag gTt tct gga tac acc ttc acc
VH2	
2-05	CAG ATC ACC TTG AAG GAG TCT GGT CCT ACG CTG GTG AAA CCC ACA CAG ACC CTC ACG CTG
	ACC TGC ACC TTC TCT TCT GGG TTC TCA CTC AGC
2-26	cag Gtc acc ttg aag gag tct ggt cct GTg ctg gtg aaa ccc aca Gag acc ctc acg ctg
	acc tgc acc Gtc tct tct ggg ttc tca ctc agc

5
10
15
20
25
30
35
40
45
50
55

(continued)

VH2
2-70
cag Gtc acc ttg aag gag tct ggt cct Gcg ctg gtg aaa ccc aca cag acc ctc aca ctg
acc tgc acc ttc tct ggg ttc tca ctc agc

VH3
3-07
GAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC CAG CCT GGG GGG TCC CTG AGA CTC
TCC TGT GCA GCC TCT GGA TTC ACC TTT AGT

3-09
gaA gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggc Agg tcc ctg aga ctc
tcc tat qca acc tct qaa ttc acc ttt GAt

3-11
Cag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc Aag cct gGA ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-13
gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-15
gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA Aag cct ggg ggg tcc ctT aga ctc
tcc tgt gca gcc tct gga ttc acT ttC agt

3-20
gag gtg cag ctg gtg gag tct ggg gga ggt Gtg gtA cGg cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttt GAt

3-21
gag gtg cag ctg gtg gag tct ggg gga ggc Ctg gtc Aag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-23
gag gtg cag ctg Ttg gag tct ggg gga ggc Ttg gtA cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttt agC

3-30
Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-30.3
Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-30.5
Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

3-33
Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttC agt

(continued)

VH3

3-43

gaA gtg cag ctg gtg gag tct ggg gga gTc Gtg gtA cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttt GAt

3-48

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttc agt

3-49

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag ccA ggg Cgg tcc ctg aga ctc
tcc tgt Aca gcT tct gga ttc acc ttt Ggt

3-53

gag gtg cag ctg gtg gag Act gga gga ggc ttg Atc cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct ggG ttc acc GtC agt

3-64

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttc agt

3-66

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc GtC agt

3-72

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct gga ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttc agt

3-73

gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aAa ctc
tcc tgt gca gcc tct ggG ttc acc ttc agt

3-74

gag gtg cag ctg gtg gag tcc ggg gga ggc tTA gtT cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc ttc agt

3-d

gag gtg cag ctg gtg gag tct Cgg gga gTc ttg gtA cag cct ggg ggg tcc ctg aga ctc
tcc tgt gca gcc tct gga ttc acc GtC agt

VH4

4-04

CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GGG ACC CTG TCC CTC
ACC TGC GCT GTC TCT GGT GGC TCC ATC AGC

4-28

cag gtg cag ctg cag gag tct ggc cca gga ctg gtg aag cct tct gAC acc ctg tcc ctc
acc tgc gct gtc tct ggt TAc tcc atc agc

4-30.1

cag gtg cag ctg cag gag tct ggc cca gga ctg gtg aag cct tca CAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc atc agc

4-30.2

cag Ctg cag ctg cag gag tcc ggc Tca gga ctg gtg aag cct tca CAg acc ctg tcc ctc
acc tgc gct gtc tct ggt ggc tcc atc agc

5
10
15
20
25
30
35
40
45
50
55

(continued)

VH4
4-30.4
cag gtg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tca CAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc atc agc
4-31
cag gtg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tca CAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc atc agc
4-34
cag gtg cag ctA cag Cag tGg ggc Gca gga ctg Ttg aag cct tcg gAg acc ctg tcc ctc
acc tgc gct gtc tAt ggt ggG tcc Ttc agT
4-39
cag Ctg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc atc agc
4-59
cag gtg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc atc agT
4-61
cag gtg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
acc tgc Act gtc tct ggt ggc tcc Gtc agc
4-b
cag gtg cag ctg cag gag ctg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
acc tgc gct gtc tct ggt TAc tcc atc agc
VH5
5-51
GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG AAG ATC
TCC TGT AAG GGT TCT GGA TAC AGC TTT ACC
5-a
gaA gtg cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag tct ctg agg atc
tcc tgt aag ggt tct gga tac agc ttt acc
VH6
6-1
CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC TCA CTC
ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT
VH7
7-4.1
CAG GTG CAG CTG GTG CAA TCT GGG TCT GAG TTG AAG AAG CCT GGG GCC TCA GTG AAG GTT
TCC TGC AAG GCT TCT GGA TAC ACC TTC ACT

Table 7: RERS sites in Human HC GLG FR1s where there are at least 20 GLGs cut

BsgI GTGCAG		71 (cuts 16/14 bases to right)				
5	1: 4	1: 13	2: 13	3: 4	3: 13	4: 13
	6: 13	7: 4	7: 13	8: 13	9: 4	9: 13
	10: 4	10: 13	15: 4	15: 65	16: 4	16: 65
	17: 4	17: 65	18: 4	18: 65	19: 4	19: 65
	20: 4	20: 65	21: 4	21: 65	22: 4	22: 65
10	23: 4	23: 65	24: 4	24: 65	25: 4	25: 65
	26: 4	26: 65	27: 4	27: 65	28: 4	28: 65
	29: 4	30: 4	30: 65	31: 4	31: 65	32: 4
	32: 65	33: 4	33: 65	34: 4	34: 65	35: 4
	35: 65	36: 4	36: 65	37: 4	38: 4	39: 4
15	41: 4	42: 4	43: 4	45: 4	46: 4	47: 4
	48: 4	48: 13	49: 4	49: 13	51: 4	
There are 39 hits at base# 4						
There are 21 hits at base# 65						
20	—"— ctgcac			9		
	12: 63	13: 63	14: 63	39: 63	41: 63	42: 63
	44: 63	45: 63	46: 63			
BbvI GCAGC		65				
25	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
30	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67
	36: 6	36: 67	37: 6	38: 6	39: 6	40: 6
	41: 6	42: 6	43: 6	44: 6	45: 6	46: 6
35	47: 6	48: 6	49: 6	50: 12	51: 6	
There are 43 hits at base# 6 Bolded sites very near sites listed below						
There are 21 hits at base# 67						
40	-"- gctgc			13		
	37: 9	38: 9	39: 9	40: 3	40: 9	41: 9
	42: 9	44: 3	44: 9	45: 9	46: 9	47: 9
	50: 9					
There are 11 hits at base# 9						
45	BsoFI GCngc	78				
	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
50	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
55	33: 6	33: 67	39: 6	34: 67	35: 6	35: 67
	36: 6	36: 67	37: 6	37: 9	38: 6	38: 9
	39: 6	39: 9	40: 3	40: 6	40: 9	41: 6

EP 1 578 903 B2

(continued)

	41: 9	42: 6	42: 9	43: 6	44: 3	44: 6
5	44: 9	45: 6	45: 9	46: 6	46: 9	47: 6
	47: 9	48: 6	49: 6	50: 9	50: 12	51: 6

There are 43 hits at base# 6 These often occur together.

There are 11 hits at base# 9

There are 2 hits at base# 3

There are 21 hits at base# 67

	Tsel Gcwg		78			
	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
15	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
20	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67
	36: 6	36: 67	37: 6	37: 9	38: 6	38: 9
	39: 6	39: 9	40: 3	40: 6	40: 9	41: 6
25	41: 9	42: 6	42: 9	43: 6	44: 3	44: 6
	44: 9	45: 6	45: 9	46: 6	46: 9	47: 6
	47: 9	48: 6	49: 6	50: 9	50: 12	51: 6

There are 43 hits at base# 6 Often together.

There are 11 hits at base# 9

There are 2 hits at base# 3

There are 1 hits at base# 12

There are 21 hits at base# 67

	MspAll CMGckg		48			
	1: 7	3: 7	4: 7	5: 7	6: 7	7: 7
	8: 7	9: 7	10: 7	11: 7	15: 7	16: 7
40	17: 7	18: 7	19: 7	20: 7	21: 7	22: 7
	23: 7	24: 7	25: 7	26: 7	27: 7	28: 7
	29: 7	30: 7	31: 7	32: 7	33: 7	34: 7
	35: 7	36: 7	37: 7	38: 7	39: 7	40: 1
45	40: 7	41: 7	42: 7	44: 1	44: 7	45: 7
	46: 7	47: 7	48: 7	49: 7	50: 7	51: 7

There are 46 hits at base# 7

PvuII CAGctg

48

	1: 7	3: 7	4: 7	5: 7	6: 7	7: 7
50	8: 7	9: 7	10: 7	11: 7	15: 7	16: 7
	17: 7	18: 7	19: 7	20: 7	21: 7	22: 7
	23: 7	24: 7	25: 7	26: 7	27: 7	28: 7
	29: 7	30: 7	31: 7	32: 7	33: 7	34: 7
55	35: 7	36: 7	37: 7	38: 7	39: 7	40: 1
	40: 7	41: 7	42: 7	44: 1	44: 7	45: 7
	46: 7	47: 7	48: 7	49: 7	50: 7	51: 7

EP 1 578 903 B2

(continued)

There are 46 hits at base# 7

There are 2 hits at base# 1

5

Alul AGct

54

10

15

1: 8	2: 8	3: 8	4: 8	4: 24	5: 8
6: 8	7: 8	8: 8	9: 8	10: 8	11: 8
15: 8	16: 8	17: 8	18: 8	19: 8	20: 8
21: 8	22: 8	23: 8	24: 8	25: 8	26: 8
27: 8	28: 8	29: 8	29: 69	30: 8	31: 8
32: 8	33: 8	34: 8	35: 8	36: 8	37: 8
38: 8	39: 8	40: 2	40: 8	41: 8	42: 8
43: 8	44: 2	44: 8	45: 8	46: 8	47: 8
48: 8	48: 82	49: 8	49: 82	50: 8	51: 8

There are 48 hits at base# 8

There are 2 hits at base# 2

20

Ddel Ctnag

48

25

30

1: 26	1: 48	2: 26	2: 48	3: 26	3: 48
4: 26	4: 48	5: 26	5: 48	6: 26	6: 48
7: 26	7: 48	8: 26	8: 48	9: 26	10: 26
11: 26	12: 85	13: 85	14: 85	15: 52	16: 52
17: 52	18: 52	19: 52	20: 52	21: 52	22: 52
23: 52	24: 52	25: 52	26: 52	27: 52	28: 52
29: 52	30: 52	31: 52	32: 52	33: 52	35: 30
35: 52	36: 52	40: 24	49: 52	51: 26	51: 48

There are 22 hits at base# 52 52 and 48 never together.

There are 9 hits at base# 48

There are 12 hits at base# 26 26 and 24 never together.

35

HphI tcacc

42

40

1: 86	3: 86	6: 86	7: 86	8: 80	11: 86
12: 5	13: 5	14: 5	15: 80	16: 80	17: 80
18: 80	20: 80	21: 80	22: 80	23: 80	24: 80
25: 80	26: 80	27: 80	28: 80	29: 80	30: 80
31: 80	32: 80	33: 80	34: 80	35: 80	36: 80
37: 59	38: 59	39: 59	40: 59	41: 59	42: 59
43: 59	44: 59	45: 59	46: 59	47: 59	50: 59

There are 22 hits at base# 80 80 and 86 never together

45

There are 5 hits at base# 86

There are 12 hits at base# 59

50

BssKI Nccngg

50

55

1: 39	2: 39	3: 39	4: 39	5: 39	7: 39
8: 39	9: 39	10: 39	11: 39	15: 39	16: 39
17: 39	18: 39	19: 39	20: 39	21: 29	21: 39
22: 39	23: 39	24: 39	25: 39	26: 39	27: 39
28: 39	29: 39	30: 39	31: 39	32: 39	33: 39
34: 39	35: 19	35: 39	36: 39	37: 24	38: 24
39: 24	41: 24	42: 24	44: 24	45: 24	46: 24
47: 24	48: 39	48: 40	49: 39	49: 40	50: 24

EP 1 578 903 B2

(continued)

50: 73 51: 39

There are 35 hits at base# 39 39 and 40 together twice.

5 There are 2 hits at base# 40

	BsaJI Ccngg		47		
	1: 40	2: 40	3: 40	4: 40	5: 40
10	8: 40	9: 40	9: 47	10: 40	10: 47
	15: 40	18: 40	19: 40	20: 40	21: 40
	23: 40	24: 40	25: 40	26: 40	27: 40
	29: 40	30: 40	31: 40	32: 40	34: 40
	35: 40	36: 40	37: 24	38: 24	39: 24
15	42: 24	44: 24	45: 24	46: 24	47: 24
	48: 41	49: 40	49: 41	50: 74	51: 40

There are 32 hits at base# 40 40 and 41 together twice

There are 2 hits at base# 41

20 **There are 9 hits at base# 24**

There are 2 hits at base# 47

	BstNI CCwgg		44		
25	PspGI ccwgg				
	ScrFI(\$M.HpaII) CCwgg				
	1: 40	2: 40	3: 40	4: 40	5: 40
	8: 40	9: 40	10: 40	11: 40	15: 40
	17: 40	18: 40	19: 40	20: 40	21: 30
30	22: 40	23: 40	24: 40	25: 40	26: 40
	28: 40	29: 40	30: 40	31: 40	32: 40
	34: 40	35: 40	36: 40	37: 25	38: 25
	41: 25	42: 25	44: 25	95: 25	46: 25
35	50: 25	51: 40			

There are 33 hits at base# 40

	ScrFI CCngg		50		
	1: 40	2: 40	3: 40	4: 40	5: 40
40	8: 40	9: 40	10: 40	11: 40	15: 40
	17: 40	18: 40	19: 40	20: 40	21: 30
	22: 40	23: 40	24: 40	25: 40	26: 40
	28: 40	29: 40	30: 40	31: 40	32: 40
	34: 40	35: 20	35: 40	36: 40	37: 25
45	39: 25	41: 25	42: 25	44: 25	45: 25
	47: 25	48: 40	48: 41	49: 90	49: 41
	50: 74	51: 40			

There are 35 hits at base# 40

50 **There are 2 hits at base# 41**

	Eco0109I RGgncyy		34		
	1: 43	2: 43	3: 43	4: 43	5: 43
	7: 43	8: 43	9: 43	10: 43	15: 46
55	17: 46	18: 46	19: 46	20: 46	21: 46
	23: 46	24: 46	25: 46	26: 46	27: 46
	30: 46	31: 46	32: 46	33: 46	39: 46
					35: 46

EP 1 578 903 B2

(continued)

36: 46 37: 46 43: 79 51: 43

There are 22 hits at base# 46 46 and 43 never together

5 There are 11 hits at base# 43

NlaIV GGNncc

71

1: 43 2: 43 3: 43 4: 43 5: 43 6: 43

7: 43 8: 43 9: 43 9: 79 10: 43 10: 79

15: 46 15: 47 16: 47 17: 46 17: 47 18: 46

10 18: 47 19: 46 19: 47 20: 46 20: 47 21: 46

21: 47 22: 46 22: 47 23: 47 24: 47 25: 47

26: 47 27: 46 27: 47 28: 46 28: 47 29: 47

15 30: 46 30: 47 31: 46 31: 47 32: 46 32: 47

33: 46 33: 47 34: 46 34: 47 35: 46 35: 47

36: 46 36: 47 37: 21 37: 46 37: 47 37: 79

38: 21 39: 21 39: 79 40: 79 41: 21 41: 79

20 42: 21 42: 79 43: 79 44: 21 44: 79 45: 21

45: 79 46: 21 46: 79 47: 21 51: 43

There are 23 hits at base# 47 46 & 47 often together

There are 17 hits at base# 46 There are 11 hits at base# 43

25 Sau96I Ggncc

70

1: 44 2: 3 2: 44 3: 44 4: 44 5: 3 5: 44 6: 44

7: 44 8: 22 8: 44 9: 44 10: 44 11: 3 12: 22 13: 22

14: 22 15: 33 15: 47 16: 47 17: 47 18: 47 19: 47 20: 47

21: 47 22: 47 23: 33 23: 47 24: 33 24: 47 25: 33 25: 47

30 26: 33 26: 47 27: 47 28: 47 29: 47 30: 47 31: 33 31: 47

32: 33 32: 47 33: 33 33: 47 34: 33 34: 47 35: 47 36: 47

37: 21 37: 22 37: 47 38: 21 38: 22 39: 21 39: 22 41: 21

41: 22 42: 21 42: 22 43: 80 44: 21 44: 22 45: 21 45: 22

35 46: 21 46: 22 47: 21 47: 22 50: 22 51: 44

There are 23 hits at base# 47 These do not occur together.

There are 11 hits at base# 44

There are 14 hits at base# 22 These do occur together.

There are 9 hits at base# 21

40

BsmAI GTCTCNnnnn

22

1: 58 3: 58 4: 58 5: 58 8: 58 9: 58

10: 58 13: 70 36: 18 37: 70 38: 70 39: 70

45 40: 70 41: 70 42: 70 44: 70 45: 70 46: 70

47: 70 48: 48 49: 48 50: 85

There are 11 hits at base# 70

50 -"- Nnnnnngagac

27

13: 40 15: 48 16: 48 17: 48 18: 48 20: 48

21: 48 22: 48 23: 48 24: 48 25: 48 26: 48

27: 48 28: 48 29: 48 30: 10 30: 48 31: 48

32: 48 33: 48 35: 48 36: 48 43: 40 44: 40

55 45: 40 46: 40 47: 40

There are 20 hits at base# 48

EP 1 578 903 B2

(continued)

Avall Ggwcc

44

Sau96I(\$M.HaeIII) Ggwcc

44

5	2: 3	5: 3	6: 44	8: 44	9: 44	10: 44
	11: 3	12: 22	13: 22	14: 22	15: 33	15: 47
	16: 47	17: 47	18: 47	19: 47	20: 47	21: 47
	22: 47	23: 33	23: 47	24: 33	29: 47	25: 33
	25: 47	26: 33	26: 47	27: 47	28: 47	29: 47
10	30: 47	31: 33	31: 47	32: 33	32: 47	33: 33
	33: 47	34: 33	34: 47	35: 47	36: 47	37: 47
	43: 80	50: 22				

There are 23 hits at base# 47 44 & 47 never together

15 There are 4 hits at base# 44

PpuMI RGgwccy

27

	6: 43	8: 43	9: 43	10: 43	15: 46	16: 46
	17: 46	18: 46	19: 46	20: 46	21: 46	22: 46
20	23: 46	24: 46	25: 46	26: 46	27: 46	28: 46
	30: 46	31: 46	32: 46	33: 46	34: 46	35: 46
	36: 46	37: 46	43: 79			

There are 22 hits at base# 46 43 and 46 never occur together.

25 There are 4 hits at base# 43

BsmFI GG GAC

3

	8: 43	37: 46	50: 77			
30	15: 48	16: 48	17: 48	1: 0	1: 0	20: 48
	21: 48	22: 48	23: 48	29: 48	25: 48	26: 48
	27: 48	28: 48	29: 48	30: 48	31: 48	32: 48
	33: 48	34: 48	35: 48	36: 48	37: 54	38: 54
35	39: 54	40: 54	41: 54	42: 54	43: 54	44: 54
	45: 54	46: 54	47: 54			

There are 20 hits at base# 48

There are 11 hits at base# 54

Hinfl Gantc

80

40	8: 77	12: 16	13: 16	14: 16	15: 16	15: 56
	15: 77	16: 16	16: 56	16: 77	17: 16	17: 56
	17: 77	18: 16	18: 56	18: 77	19: 16	19: 56
	19: 77	20: 16	20: 56	20: 77	21: 16	21: 56
45	21: 77	22: 16	22: 56	22: 77	23: 16	23: 56
	23: 77	24: 16	24: 56	24: 77	25: 16	25: 56
	25: 77	26: 16	26: 56	26: 77	27: 16	27: 26
	27: 56	27: 77	28: 16	28: 56	28: 77	29: 16
50	29: 56	29: 77	30: 56	31: 16	31: 56	31: 77
	32: 16	32: 56	32: 77	33: 16	33: 56	33: 77
	34: 16	35: 16	35: 56	35: 77	36: 16	36: 26
	36: 56	36: 77	37: 16	38: 16	39: 16	40: 16
55	41: 16	42: 16	44: 16	45: 16	46: 16	47: 16
	48: 46	49: 46				

There are 34 hits at base# 16

EP 1 578 903 B2

(continued)

Tfil Gawtc

21

	8: 77	15: 77	16: 77	17: 77	18: 77	19: 77
5	20: 77	21: 77	22: 77	23: 77	24: 77	25: 77
	26: 77	27: 77	28: 77	29: 77	31: 77	32: 77
	33: 77	35: 77	36: 77			

There are 21 hits at base# 77

10

MlyI GAGTC

38

	12: 16	13: 16	14: 16	15: 16	16: 16	17: 16
	18: 16	19: 16	20: 16	21: 16	22: 16	23: 16
	24: 16	25: 16	26: 16	27: 16	27: 26	28: 16
15	29: 16	31: 16	32: 16	33: 16	34: 16	35: 16
	36: 16	36: 26	37: 16	38: 16	39: 16	40: 16
	41: 16	42: 16	44: 16	45: 16	46: 16	47: 16
	48: 46	49: 46				

There are 34 hits at base# 16

20

-"- GACTC

21

	15: 56	16: 56	17: 56	18: 56	19: 56	20: 56
	21: 56	22: 56	23: 56	24: 56	25: 56	26: 56
25	27: 56	28: 56	29: 56	30: 56	31: 56	32: 56
	33: 56	35: 56	36: 56			

There are 21 hits at base# 56

30

PleI gagtc

38

	12: 16	13: 16	14: 16	15: 16	16: 16	17: 16
	18: 16	19: 16	20: 16	21: 16	22: 16	23: 16
	24: 16	25: 16	26: 16	27: 16	27: 26	28: 16
	29: 16	31: 16	32: 16	33: 16	34: 16	35: 16
35	36: 16	36: 26	37: 16	38: 16	39: 16	40: 16
	41: 16	42: 16	44: 16	45: 16	46: 16	47: 16
	48: 46	49: 46				

There are 34 hits at base# 16

40

-"- gactc

21

	15: 56	16: 56	17: 56	18: 56	19: 56	20: 56
	21: 56	22: 56	23: 56	24: 56	25: 56	26: 56
	27: 56	28: 56	29: 56	30: 56	31: 56	32: 56
	33: 56	35: 56	36: 56			

There are 21 hits at base# 56

45

AlwNI CAGNNNctg

26

	15: 68	16: 68	17: 68	18: 68	19: 68	20: 68
	21: 68	22: 68	23: 68	24: 68	25: 68	26: 68
	27: 68	28: 68	29: 68	30: 68	31: 68	32: 68
50	33: 68	34: 68	35: 68	36: 68	39: 46	40: 46
	41: 46	42: 46				

There are 22 hits at base# 68

55

Table 8: Kappa FR1 GLGs

	!	1	2	3	4	5	6	7	8	9	10	11	12	
5		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
	!	13	14	15	16	17	18	19	20	21	22	23		
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O12
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
10		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O2
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O18
15		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O8
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
20		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A20
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A30
		AAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	GCC	ATG	TCT	
25		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L14
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L1
30		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L15
		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L4
35		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L18
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCC	GTG	TCT	
40		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L5
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCT	GTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L19
45		GAC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TTC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L8
		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TTC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L23
50		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	TTC	TCT	
		GCA	TCT	ACA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L9

EP 1 578 903 B2

	GTC ATC TGG ATG ACC CAG TCT CCA TCC TTA CTC TCT	
	GCA TCT ACA GGA GAC AGA GTC ACC ATC AGT TGT !	L24
5	GCC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L11
	GAC ATC CAG ATG ACC CAG TCT CCT TCC ACC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L12
10	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O11
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
15	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O1
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A17
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
20	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A1
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A18
25	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A2
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
30	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A19
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A3
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC TCA CCT	
35	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A23
	GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A27
40	GAA ATT GTG TTG ACG CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A11
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
45	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L2
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L16
	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	
50	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L6
	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	

55

EP 1 578 903 B2

	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L20
	GAA ATT GTA ATG ACA CAG TCT CCA GCC ACC CTG TCT	
5	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L25
	GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT	
	GTG TCT CTG GGC GAG AGG GCC ACC ATC AAC TGC !	B3
	GAA ACG ACA CTC ACG CAG TCT CCA GCA TTC ATG TCA	
10	GCG ACT CCA GGA GAC AAA GTC AAC ATC TCC TGC !	B2
	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A26
15	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A10
	GAT GTT GTG ATG ACA CAG TCT CCA GCT TTC CTC TCT	
20	GTG ACT CCA GGG GAG AAA GTC ACC ATC ACC TGC !	A14
25		
30		
35		
40		
45		
50		
55		

Table 9 RERS sites found in Human Kappa FR1 GLGs

	MslI	FokI --> <-- -->	PflP1	BsrI	BsmAI	MnlI	HpyCH 4V
VKI							
O12 1-69	3	3 23	12 49	15	18 47	26	36
O2 101-169	103	103 123	112 149	115	118 147	126	136
O18 201-269	203	203 223	212 249	215	218 247	226	236
O8 301-369	303	303 323	312 349	315	318 347	326	336
A20 401-469	403	403 423	412 449	415	418 447	426	436
A30 501-569	503	503 523	512 549	515	518 547	526	536
L14 601-669	603	603	612 649	615	618 647	-	636
L1 701-769	703	703 723	712 749	715	718 747	726	736
L15 801-869	803	803 823	812 849	815	818 847	826	836
L4 901-969	-	903 923	912 949	906 915	918 947	926	936
L18 1001-1069	-	1003	1012 1049	1006 1015	1018 1047	1026	1036
L5 1101-1169	1103	-	1112 1149	1115	1118 1147	-	1136
L19 1201-1269	1203	1203	1212 1249	1215	1218 1247	-	1236
L8 1301-1369	-	1303 1323	1312 1349	1306 1315	1318 1347	-	1336
L23 1401-1469	1403	1403 1408	1412 1449	1415	1418 1447	-	1436
L9 1501-1569	1503	1503 1508 1523	1512 1549	1515	1518 1547	1526	1536

	MslI	FokI --> <-- -->	PflFI	BsrI	BsmAI	MnlI	HpyCH 4V
L24 1601-1669	1603	1608 1623	1612 1649	1615	1618 1647	-	1636
L11 1701-1769	1703	1703 1723	1712 1749	1715	1718 1747	1726	1736
L12 1801-1869	1803	1803	1812 1849	1815	1818 1847	-	1836
VKII							
O11 1901-1969	-	-	-	-	-	1956	-
O1 2001-2069	-	-	-	-	-	2056	-
A17 2101-2169	-	-	2112	-	2118	2156	-
A1 2201-2269	-	-	2212	-	2218	2256	-
A18 2301-2369	-	-	-	-	-	2356	-
A2 2401-2469	-	-	-	-	-	2456	-
A19 2501-2569	-	-	2512	-	2518	2556	-
A3 2601-2669	-	-	2612	-	2618	2656	-
A23 2701-2769	-	-	-	-	-	2729 2756	-
VKIII							
A27 2801-2869	-	-	2812	-	2818 2839	2860	-
A11 2901-2969	-	-	2912	-	2918 2939	2960	-
L2 3001-3069	-	-	3012	-	3018 3039	3060	-
L16 3101-3169	-	-	3112	-	3118 3139	3160	-

	MslI	FokI --> <-- --> .	PstFI	BsrI	BsmAI	MnlI	HpyCH 4V
L6 3201-3269	-	-	3212	-	3218 3239	3260	-
L20 3301-3369	-	-	3312	-	3318 3339	3360	-
L25 3401-3469	-	-	3412	-	3418 3439	3460	-
VKIV							
B3 3501-3569	3503	-	3512	3515	3518 3539	3551<	-
VKV							
B2 3601-3669	-	-	3649	-	3618 3647		-
VKVI							
A26 3701-3769	-	-	3712	-	3718		-
A10 3801-3869	-	-	3812	-	3818		-
A14 3901-3969	-	-	3912	-	3918	3930>	-

Table 9 RERS sites found in Human Kappa FR1 GLGs, continued

	SfaNI	SfcI	Hinfi	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
VK1							
O12 1-69	37	41	53	53	55	56	-
O2 101-169	137	141	153	153	155	156	-
O18 201-269	237	241	253	253	255	256	-
O8 301-369	337	341	353	353	355	356	-
A20 401-469	437	441	453	453	455	456	-
A30 501-569	537	541	553	553	555	556	-
L14 601-669	637	641	653	653	655	656	-
L1 701-769	737	741	753	753	755	756	-
L15 801-869	837	841	853	853	855	856	-
L4 901-969	937	941	953	953	955	956	-
L18 1001-1069	1037	1041	1053	1053	1055	1056	-
L5 1101-1169	1137	1141	1153	1153	1155	1156	-
L19 1201-1269	1237	1241	1253	1253	1255	1256	-
L8 1301-1369	1337	1341	1353	1353	1355	1356	-
L23 1401-1469	1437	1441	1453	1453	1455	1456	1406
L9 1501-1569	1537	1541	1553	1553	1555	1556	1506

	SfaNI	SfiI	HinfI	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
L24 1601-1669	1637	1641	1653	1653	1655	1656	
L11 1701-1769	1737	1741	1753	1753	1755	1756	
L12 1801-1869	1837	1841	1853	1853	1855	1856	
VKII							
O11 1901-1969	-	-	1918	1918	1937	1938	1952
O1 2001-2069	-	-	2018	2018	2037	2038	2052
A17 2101-2169	-	-	2112	2112	2137	2138	2152
A1 2201-2269	-	-	2212	2212	2237	2238	2252
A18 2301-2369	-	-	2318	2318	2337	2338	2352
A2 2401-2469	-	-	2418	2418	2437	2438	2452
A19 2501-2569	-	-	2512	2512	2537	2538	2552
A3 2601-2669	-	-	2612	2612	2637	2638	2652
A23 2701-2769	-	-	2718	2718	2737	2731* 2738*	-
VKIII							
A27 2801-2869	-	-	-	-			-
A11 2901-2969	-	-	-	-			-
L2 3001-3069	-	-	-	-			-

	SfaNI	SfiI	HinII	MlyI --> --> --> <-- --> --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
L16 3101-3169	-	-	-	-			-
L6 3201-3269	-	-	-	-			-
L20 3301-3369	-	-	-	-			-
L25 3401-3469	-	-	-	-			-
VKIV							
B3 3501-3569	-	-	3525	3525			-
VKV							
B2 3601-3669	-	-	3639	3639			-
VKVI							
A26 3701-3769	-	-	3712 3739	3712 3739	3737 3755	3756 3762	-
A10 3801-3869	-	-	3812 3839	3812 3839	3837 3855	3856 3862	-
A14 3901-3969	-	-	3939	3939	3937 3955	3956 3962	-

Table 9 RERS sites found in Human Kappa FR1, continued

	BsaJI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> --> <-- --> --> -->	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
VK1						
O12 1-69	.	.	.	.	.	.
O2 101-169	.	.	.	.	.	.
O18 201-269	.	.	.	.	.	.
O8 301-369	.	.	.	.	.	.
A20 401-469	.	.	.	.	.	.
A30 501-569	.	.	.	.	.	.
L14 601-669	.	.	.	.	.	.
L1 701-769	.	.	.	.	.	.
L15 801-869	.	.	.	.	.	.
L4 901-969	.	.	.	.	.	.
L18 1001-1069	.	.	.	.	.	.
L5 1101-1169	.	.	.	.	.	.
L19 1201-1269	.	.	.	.	.	.
L8 1301-1369	.	.	.	.	.	.
L23 1401-1469	.	.	.	.	.	.

	BsaJI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
L9 1501-1569	-	-	-	-	-	-
L24 1601-1669	-	-	-	-	-	-
L11 1701-1769	-	-	-	-	-	-
L12 1801-1869	-	-	-	-	-	-
VKII						
O11 1901-1969	1942	1943	1944	1951	1954	-
O1 2001-2069	2042	2043	2044	2051	2054	-
A17 2101-2169	2142	-	-	2151	2154	-
A1 2201-2269	2242	-	-	2251	2254	-
A18 2301-2369	2342	2343	-	2351	2354	-
A2 2401-2469	2442	2443	-	2451	2454	-
A19 2501-2569	2542	2543	2544	2551	2554	-
A3 2601-2669	2642	2643	2644	2651	2654	-
A23 2701-2769	2742	-	-	2751	2754	-
VKIII						
A27 2801-2869	2843	2822 2843	2820 2841	-	-	2803
A11 2901-2969	2943	2943	2920 2941	-	-	2903

	BsaJI xx29 xx42 xx43	BssKI (NsdNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <-- --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
L2 3001-3069	3043	3043	3041	-	-	-
L16 3101-3169	3143	3143	3120 3141	-	-	-
L6 3201-3269	3243	3243	3220 3241	-	-	3203
L20 3301-3369	3343	3343	3320 3341	-	-	3303
L25 3401-3469	3443	3443	3420 3441	-	-	3403
VKIV						
B3 3501-3569	3529	3530	3520	-	3554	
VKV						
B2 3601-3669		3643	3620 3641	-	-	
VKV1						
A26 3701-3769		-	3720	-	-	3703
A10 3801-3869		-	3820	-	-	3803
A14 3901-3969	3943	3943	3920 3941	-	-	-

Table 10 Lambda FR1 GLG sequences

! VL1

5 CAG TCT GTG CTG ACT CAG CCA CCC TCG GTG TCT GAA
 GCC CCC AGG CAG AGG GTC ACC ATC TCC TGT ! 1a
 cag tct gtg ctg acG cag ccG ccc tCA gtg tct gGG
 gcc ccA Ggg cag agg gtc acc atc tcc tgC ! 1e
 10 cag tct gtg ctg act cag cca ccc tCA gCg tct gGG
 Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1c
 cag tct gtg ctg act cag cca ccc tCA gCg tct gGG
 15 Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1g
 cag tct gtg Ttg acG cag ccG ccc tCA gtg tct gCG
 gcc ccA GgA cag aAg gtc acc atc tcc tgC ! 1b

! VL2

20 CAG TCT GCC CTG ACT CAG CCT CCC TCC GCG TCC GGG
 TCT CCT GGA CAG TCA GTC ACC ATC TCC TGC ! 2c
 cag tct gcc ctg act cag cct cGc tCA gTg tcc ggg
 25 tct cct gga cag tca gtc acc atc tcc tgc! 2e
 cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
 tct cct gga cag tcG Atc acc atc tcc tgc ! 2a2
 30 cag tct gcc ctg act cag cct ccc tcc gTg tcc ggg
 tct cct gga cag tca gtc acc atc tcc tgc ! 2d
 cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
 35 tct cct gga cag tcG Atc acc atc tcc tgc ! 2b2

! VL3

40 TCC TAT GAG CTG ACT CAG CCA CCC TCA GTG TCC GTG
 TCC CCA GGA CAG ACA GCC AGC ATC ACC TGC! 3r
 tcc tat gag ctg act cag cca cTc tca gtg tCA gtg
 Gcc cTG gga cag acG gcc agG atT acc tgT ! 3j
 tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
 45 tcc cca gga caA acG gcc agG atc acc tgc! 3p
 tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
 tcc cTa gga cag aTG gcc agG atc acc tgc ! 3a
 50 tcT tCt gag ctg act cag GAC ccT GcT gtg tcT gtg
 Gcc TTG gga cag aca gTc agG atc acA tgc ! 3l

55

EP 1 578 903 B2

5 tcc tat gTg ctg act cag cca ccc tca gtg tcA gtg
 Gcc cca gga Aag acG gcc agG atT acc tgT ! 3h
 tcc tat gag ctg acA cag cTa ccc tcG gtg tcA gtg
 tcc cca gga cag aca gcc agG atc acc tgc ! 3e
 tcc tat gag ctg aTG cag cca ccc tcG gtg tcA gtg
 tcc cca gga cag acG gcc agG atc acc tgc ! 3m
 10 tcc tat gag ctg acA cag cca Tcc tca gtg tcA gtg
 tcT ccG gga cag aca gcc agG atc acc tgc ! V2-19

VL4

15 CTG CCT GTG CTG ACT CAG CCC CCG TCT GCA TCT GCC
 TTG CTG GGA GCC TCG ATC AAG CTC ACC TGC ! 4c
 cAg cct gtg ctg act caA TcA TcC tct gcC tct gcT
 20 tCC ctg gga Tcc tcg Gtc aag ctc acc tgc ! 4a
 cAg cTt gtg ctg act caA TcG ccC tct gcC tct gcc
 tCC ctg gga gcc tcg Gtc aag ctc acc tgc ! 4b

! VL5

25 CAG CCT GTG CTG ACT CAG CCA CCT TCC TCC TCC GCA
 TCT CCT GGA GAA TCC GCC AGA CTC ACC TGC ! 5e
 cag Gct gtg ctg act cag ccG Gct tcc CTc tcT gca
 30 tct cct gga gCa tcA gcc agT ctc acc tgc ! 5c
 cag cct gtg ctg act cag cca Tct tcc CAT tcT gca
 tct Tct gga gCa tcA gTc aga ctc acc tgc ! 5b

! VL6

35 AAT TTT ATG CTG ACT CAG CCC CAC TCT GTG TCG GAG
 TCT CCG GGG AAG ACG GTA ACC ATC TCC TGC ! 6a

! VL7

40 CAG ACT GTG GTG ACT CAG GAG CCC TCA CTG ACT GTG
 TCC CCA GGA GGG ACA GTC ACT CTC ACC TGT ! 7a
 cag Gct gtg gtg act cag gag ccc tca ctg act gtg
 45 tcc cca gga ggg aca gtc act ctc acc tgt ! 7b

! VL8

50 CAG ACT GTG GTG ACC CAG GAG CCA TCG TTC TCA GTG
 TCC CCT GGA GGG ACA GTC ACA CTC ACT TGT ! 8a

55

EP 1 578 903 B2

! VL9

CAG CCT GTG CTG ACT CAG CCA CCT TCT GCA TCA GCC
TCC CTG GGA GCC TCG GTC ACA CTC ACC TGC ! 9a

! VL10

CAG GCA GGG CTG ACT CAG CCA CCC TCG GTG TCC AAG
GGC TTG AGA CAG ACC GCC ACA CTC ACC TGC ! 10a

Table 11 RERSs found in human lambda FR1 GLGs

! There are 31 lambda GLGs

MlyI NnnnnnGACTC 25
1: 6 3: 6 9: 6 6: 6 7: 6 8: 6
9: 6 10: 6 11: 6 12: 6 15: 6 16: 6
20: 6 21: 6 22: 6 23: 6 23: 50 24: 6
25: 6 25: 50 26: 6 27: 6 28: 6 30: 6
31: 6

There are 23 hits at base# 6

-"- GAGTCNNNNNn 1
26: 34

MwoI GCNNNNNnngc 20
1: 9 2: 9 3: 9 4: 9 11: 9 11: 56
12: 9 13: 9 14: 9 16: 9 17: 9 18: 9
19: 9 20: 9 23: 9 24: 9 25: 9 26: 9
30: 9 31: 9

There are 19 hits at base# 9

HinfI Gantc 27
1: 12 3: 12 4: 12 6: 12 7: 12 8: 12
9: 12 10: 12 11: 12 12: 12 15: 12 16: 12
20: 12 21: 12 22: 12 23: 12 23: 46 23: 56
24: 12 25: 12 25: 56 26: 12 26: 34 27: 12
28: 12 30: 12 31: 12

There are 23 hits at base# 12

PleI gactc 25
1: 12 3: 12 4: 12 6: 12 7: 12 8: 12
9: 12 10: 12 11: 12 12: 12 15: 12 16: 12
20: 12 21: 12 22: 12 23: 12 23: 56 24: 12
25: 12 25: 56 26: 12 27: 12 28: 12 30: 12
31: 12

There are 23 hits at base# 12

-"- gagtc 1
26: 34

DdeI Ctnag 32
1: 14 2: 24 3: 14 3: 24 4: 14 4: 24
5: 24 6: 14 7: 14 7: 24 8: 14 9: 14
10: 14 11: 14 11: 24 12: 14 12: 24 15: 5
15: 14 16: 14 16: 24 19: 24 20: 14 23: 14

EP 1 578 903 B2

(continued)

24: 14 25: 14 26: 14 27: 14 28: 14 29: 30
30: 14 31: 14

5 There are 21 hits at base# 14

BsaJI Ccnngg

38

1: 23	1: 40	2: 39	2: 40	3: 39	3: 40
4: 39	4: 40	5: 39	11: 39	12: 38	12: 39
13: 23	13: 39	14: 23	14: 39	15: 38	16: 39
17: 23	17: 39	18: 23	18: 39	21: 38	21: 39
21: 47	22: 38	22: 39	22: 47	26: 40	27: 39
28: 39	29: 14	29: 39	30: 38	30: 39	30: 47
31: 23	31: 32				

There are 17 hits at base# 39

There are 5 hits at base# 38

There are 5 hits at base# 40 Makes cleavage ragged.

MnII cctc

35

1: 23	2: 23	3: 23	4: 23	5: 23	6: 19
6: 23	7: 19	8: 23	9: 19	9: 23	10: 23
11: 23	13: 23	14: 23	16: 23	17: 23	18: 23
19: 23	20: 47	21: 23	21: 29	21: 47	22: 23
22: 29	22: 35	22: 47	23: 26	23: 29	24: 27
27: 23	28: 23	30: 35	30: 47	31: 23	

There are 21 hits at base# 23

There are 3 hits at base# 19

There are 3 hits at base# 29

There are 1 hits at base# 26

There are 1 hits at base# 27 These could make cleavage ragged.

-"- gagg

7

1: 48 2: 48 3: 48 4: 48 27: 44 28: 44
29: 44

BssKI Nccngg

39

1: 40	2: 39	3: 39	3: 40	4: 39	4: 40
5: 39	6: 31	6: 39	7: 31	7: 39	8: 39
9: 31	9: 39	10: 39	11: 39	12: 38	12: 52
13: 39	13: 52	14: 52	16: 39	16: 52	17: 39
17: 52	18: 39	18: 52	19: 39	19: 52	21: 38
22: 38	23: 39	24: 39	26: 39	27: 39	28: 39
29: 14	29: 39	30: 38			

There are 21 hits at base# 39

There are 4 hits at base# 38

There are 3 hits at base# 31

There are 3 hits at base# 40 Ragged

BstNI CCwgg

30

1: 91	2: 40	5: 40	6: 40	7: 40	8: 40
9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

EP 1 578 903 B2

(continued)

There are 17 hits at base# 40

There are 7 hits at base# 53

There are 4 hits at base# 39

There are 1 hits at base# 41 Ragged

PspGI ccwgg

30

1: 41	2: 40	5: 40	6: 40	7: 40	8: 40
9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

There are 17 hits at base# 40

There are 7 hits at base# 53

There are 4 hits at base# 39

There are 1 hits at base# 41

ScrFI CCngg

39

1: 41	2: 40	3: 40	3: 41	4: 40	4: 41
5: 40	6: 32	6: 40	7: 32	7: 40	8: 40
9: 32	9: 40	10: 40	11: 40	12: 39	12: 53
13: 40	13: 53	14: 53	16: 40	16: 53	17: 40
17: 53	18: 40	18: 53	19: 40	19: 53	21: 39
22: 39	23: 40	29: 40	26: 40	27: 40	28: 40
29: 15	29: 40	30: 39			

There are 21 hits at base# 40

There are 4 hits at base# 39

There are 3 hits at base# 41

MaeIII gtnac

16

1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
7: 52	9: 52	26: 52	27: 10	27: 52	28: 10
28: 52	29: 10	29: 52	30: 52		

There are 13 hits at base# 52

Tsp45I gtsac

15

1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
7: 52	9: 52	27: 10	27: 52	28: 10	28: 52
29: 10	29: 52	30: 52			

There are 12 hits at base# 52

HphI tcacc

26

1: 53	2: 53	3: 53	4: 53	5: 53	6: 53
7: 53	8: 53	9: 53	10: 53	11: 59	13: 59
14: 59	17: 59	18: 59	19: 59	20: 59	21: 59
22: 59	23: 59	24: 59	25: 59	27: 59	28: 59
30: 59	31: 59				

There are 16 hits at base# 59

There are 10 hits at base# 53

BspMI ACCTGCNNNNn

14

11: 61	13: 61	14: 61	17: 61	18: 61	19: 61
--------	--------	--------	--------	--------	--------

EP 1 578 903 B2

(continued)

20: 61 21: 61 22: 61 23: 61 24: 61 25: 61
30: 61 31: 61

There are 14 hits at base# 61 Goes into CDR1

Table 12: Matches to URE FR3 adapters in 79 human HC.

A. List of Heavy-chains genes sampled

AF008566	AF103367	HSA235674	HSU94417	S83240
AF035043	AF103368	HSA235673	HSU94418	SABVH369
AF103026	AF103369	HSA240559	HSU96389	SADEIGVH
af103033	AF103370	HSCB201	HSU96391	SAH2IGVH
AF103061	af103371	HSIGGVHC	HSU96392	SDA3IGVH
Af103072	AF103372	HSU44791	HSU96395	SIGVHTTD
af103078	AF158381	HSU44793	HSZ93849	SUK4IGVH
AF103099	E05213	HSU82771	HSZ93850	
AF103102	E05886	HSU82949	HSZ93851	
AF103103	E05887	HSU82950	HSZ93853	
AF103174	HSA235661	HSU82952	HSZ93855	
AF103186	HSA235664	HSU82961	HSZ93857	
af103187	HSA235660	HSU86522	HSZ93860	
AF103195	HSA235659	HSU86523	HSZ93863	
af103277	HSA235678	HSU92452	MCOMFRAA	
af103286	HSA235677	HSU94412	MCOMFRVA	
AF103309	HSA235676	HSU94415	S82745	
af103393	HSA235675	HSU94416	S82764	

Table 12B. Testing all distinct GLGs from bases 89.1 to 93.2 of the heavy variable domain

Id	Nb	0	1	2	3	4	Seq		SEQ ID NO:
1	38	15	11	10	0	2	Seq1	gtgtattactgtgc	25
2	19	7	6	4	2	0	Seq2	gtAtattactgtgc	26
3	1	0	0	1	0	0	Seq3	gtgtattactgtAA	27
4	7	1	5	1	0	0	Seq4	gtgtattactgtAc	28
5	0	0	0	0	0	0	Seq5	Ttgtattactgtgc	29
6	0	0	0	0	0	0	Seq6	TtgtatCactgtgc	30
7	3	1	0	1	1	0	Seq7	ACAtattactgtgc	31
8	2	0	2	0	0	0	Seq8	ACgtattactgtgc	32
9	9	2	2	4	1	0	Seq9	ATgtattactgtgc	33
Group		26	26	21	4	2			
Cumulative		26	52	73	77	79			

Table 12C Most important URE recognition seqs in FR3 Heavy

1	VHSzy1	GTGtattactgtgc	(ON_SHC103)	(SEQ ID NO:25)
2	VHSzy2	GTAtattactgtgc	(ON_SHC323)	(SEQ ID NO:26)
3	VHSzy4	GTGtattactgtac	(ON_SHC349)	(SEQ ID NO:28)
4	VHSzy9	ATGtattactgtgc	(ON_SHC5a)	(SEQ ID NO:33)

Table 12D, testing 79 human HC V genes with four probes

Number of sequences

79

Number of bases

29143

		Number of mismatches									
	Id	Best	0	1	2	3	4	5			
	1	39	15	11	10	1	2	0	Seq1	gtgtattactgtgc	(SEQ ID NO:25)
	2	22	7	6	5	3	0	1	Seq2	gtAtattactgtgc	(SEQ ID NO:26)
	3	7	1	5	1	0	0	0	Seq4	gtgtattactgtAc	(SEQ ID NO:28)
	4	11	2	4	4	1	0	0	Seq9	ATgtattactgtgc	(SEQ ID NO:33)
Group			25	26	20	5	2				
Cumulative			25	51	71	76	78				

[0196] One sequence has five mismatches with sequences 2, 4, and 9; it is scored as best for 2.

[0197] Id is the number of the adapter.

[0198] Best is the number of sequence for which the identified adapter was the best available.

[0199] The rest of the table shows how well the sequences match the adapters. For example, there are 10 sequences that match VHSzy1(Id=1) with 2 mismatches and are worse for all other adapters. In this sample, 90% come within 2 bases of one of the four adapters.

Table 13

The following list of enzymes was taken from <http://rebase.neb.com/cqi-bin/asymmlist>.

I have removed the enzymes that a) cut within the recognition, b) cut on both sides of the recognition, or c) have fewer than 2 bases between recognition and closest cut site.

REBASE Enzymes

04/13/2001

Type II restriction enzymes with asymmetric recognition sequences:

Enzymes	Recognition Sequence	Isoschizomers	Suppliers
AarI	CACCTGCNNNNN^NNNN_	-	y
AceII	CAGCTCNNNNNNNN^NNNN_	-	-
Bbr7I	GAAGACNNNNNNNN^NNNN_	-	-
BbvI	GCAGCNNNNNNNN^NNNN_		y
BbvII	GAAGACNN^NNNN_		
Bce83I	CTTGAGNNNNNNNNNNNNNN^ -		-
BceAI	ACGGCNNNNNNNNNNNN^NN_	-	y
Bcefl	ACGGCNNNNNNNNNNNN^N_	-	-
BciVI	GTATCCNNNNN_N^	Bful	y
BfiI	ACTGGGNNNN_N^	Bmrl	y
BinI	GGATCNNNN^N_		
BscAI	GCATCNNNN^NN_	-	-
BseRI	GAGGAGNNNNNNNN^NN^	-	y
BsmFI	GGGACNNNNNNNNNN^NNNN_	BspLU11III	y
BspMI.	ACCTGCNNNN^NNNN_	Acc36I	y
Ecil	GGCGGANNNNNNNNNN^NN^	-	y
Eco57I	CTGAAGNNNNNNNNNNNNNN^	BspKT5I	y
FauI	CCCGCNNNN^NN_	BstFZ438I	y
FokI	GGATGNNNNNNNNNN^NNNN_	BstPZ418I	y
GsuI	CTGGAGNNNNNNNNNNNNNN^	-	y
HgaI	GACGCNNNNN^NNNNN_	-	y

(continued)

Type II restriction enzymes with asymmetric recognition sequences:

	HphI	GGTGANNNNNNN_N^	AsuHPI	y
5	MboII	GAAGANNNNNNN_N^	-	y
	MlyI	GAGTCNNNNN^	SchI	y
	MmeI	TCCRACNNNNNNNNNNNNNNNNNN_NN^	-	-
	MnII	CCTCNNNNNN_N^	-	y
10	PleI	GAGTCNNNN^N_	PpsI	y
	RleAI	CCCACANNNNNNNNN_NNN^	-	-
	SfaNI	GCATCNNNNN^NNNN_	BspST5I	y
	SspD5I	GGTGANNNNNNN^	-	-
	Sth132I	CCCGNNNN^NNNN_	-	-
15	StsI	GGATGNNNNNNNNNN^NNNN_	-	-
	TaqII	GACCGANNNNNNNNN_NN^, CACCCANNNNNNNNN_NN^	-	-
	Tth111II	CAARCANNNNNNNNN_NN^	-	-
20	UbaPI	CGAACG	-	-
The notation is ^ means cut the upper strand and _ means cut the lower strand. If the upper and lower strand are cut at the same place, then only ^ appears.				

Table 14
(FOKlact)

5'-cAATcggTg TtGTT cAcgATgTg-3'

(VHex881) 5'-AATAGTAGAc TgcAgTgTcc TcAgccCTTA AgcTgTtCAT cTgcAAgTAG-
AgAgTATTct TAGAgTTgTc TcTAGAcTTA gTgAAgcg-3'

! note that VHex881 is the reverse complement of the ON below

! [RC] 5'-cgCttcacTaag-

! Scab.....

! Synthetic 3-23 as in Table 206

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! XbaI...

! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'

! AflII...

(VHBA881) 5'-cgCttcacTaag-

|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt gcg ag-3'

(VHBB881) 5'-cgCttcacTaag-

|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt Acg ag-3'

(VH881PCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac -3'

Table 15: Use of *FokI* as "Universal Restriction Enzyme"

FokI - for dsDNA, | represents sites of cleavage

sites of cleavage
 5'-cacGGATGtg--nnnnnnnn|nnnnnnn-3' (SEQ ID NO:15)
 3'-gtgCCTACac--nnnnnnnnnn|nnn-5' (SEQ ID NO:16)
 RECOG
 NITion of *FokI*

Case I

5'-...gtg|tatt-actgtgc..Substrate....-3' (SEQ ID NO:17)
 3'-cac-ataa|tgacacg-
 gtGTAGGcac\
 5'- caCATCCgtg/(SEQ ID NO:18)

Case II

5'-...gtgtatt|agac-tgc..Substrate....-3' (SEQ ID NO:19)
 -cacataa-tctg|acg-5'
 /gtgCCTACac
 \cacGGATGtg-3' (SEQ ID NO:20)

Case III (Case I rotated 180 degrees)

/gtgCCTACac-5'
 \cacGGATGtg-
 gtgtctt|acag-tcc-3' Adapter (SEQ ID NO:21)
 3'-...cacagaa-tgtc|agg..substrate....-5' (SEQ ID NO:22)

Case IV (Case II rotated 180 degrees)

3'- gtGTAGGcac\ (SEQ ID NO:23)
 -caCATCCgtg/
 5'-gag|tctc-actgagc
 Substrate 3'-...ctc-agag|tgactcg...-5' (SEQ ID NO:24)

Improved *FokI* adapters

FokI - for dsDNA, | represents sites of cleavage

Case I

Stem 11, loop 5, stem 11, recognition 17

5'-...catgtg|tatt-actgtgc..Substrate....-3'
 3'-gtacac-ataa|tgacacg-
 gtGTAGGcacG T
 5'- caCATCCgtgc C
 TTJ

Case II
Stem 10, loop 5, stem 10, recognition 18

```

5          5'-...gtgtatt|agac-tgctgcc..Substrate....-3'
           rT1      |cacataa-tctg|acgacgg-5'
           T  gtgCCTACac
           C   cacGGATGtg-3'
           |T1|

```

Case III (Case I rotated 180 degrees)
Stem 11, loop 5, stem 11, recognition 20

```

10          rT1
           T  TgtgCCTACac-5'
           G  AcacGGATGtg-
           |T1|
15          |gtgtctt|acag-tccattctg-3' Adapter
           3'-...cacagaa-tgtc|aggtaagac..substrate....-5'

```

Case IV (Case II rotated 180 degrees)
Stem 11, loop 4, stem 11, recognition 17

```

20          3'- gtGTAGGcacc T
           |caCATCCgtgg T
           5'-atcgag|tctc-actgagc
Substrate 3'-...tagctc-agag|tgactcg...-5'

```

25 **BseRI**

```

           | sites of cleavage
           5'-cacGAGGAGnnnnnnnnnn|nnnnn-3'
           3'-gtgctcctcnnnnnnnnn|nnnnnn-5'
           RECOG
30          NITion of BseRI

```

Stem 11, loop 5, stem 11, recognition 19

```

35          3'-.....gaacat|cg-ttaagccagta.....5'
           rT-T1      |cttgta-gc|aattcggtcac-3'
           C  GCTGAGGAGTC-
           T   cgactcctcag-5' An adapter for BseRI to cleave the substrate above.
           |T1|

```

Table 16 Human heavy chains bases 88.1 to 94.2

Number of sequences..... 840

Id	Ntot	Number of Mismatches.....							Name	Sequence.....	Dot form.....
		0	1	2	3	4	5	6			
1	364	152	97	76	26	7	4	2	0	VHS881-1.1	gctgtgtattactgtgcgag
2	265	150	60	33	13	5	4	0	0	VHS881-1.2	gccgtgtattactgtgcgag
3	96	14	34	16	10	5	7	9	1	VHS881-2.1	gccgtatattactgtgcgag
4	20	0	3	4	9	2	2	0	0	VHS881-4.1	gccgtgtattactgtgcgag
5	95	25	36	18	11	2	2	0	1	VHS881-9.1	gccatgtattactgtgcgag
840	341	230	147	69	21	19	11	11	2		
	341	571	718	787	808	827	838	840			

88 89 90 91 92 93 94 95 Codon number as in Table 195

Recognition..... Stem..... Loop. Stem.....

(VHS881-1.1) 5'-gctgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'(VHS881-1.2) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'(VHS881-2.1) 5'-gccgtatat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'(VHS881-4.1) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'(VHS881-9.1) 5'-gccatgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

| site of substrate cleavage

(FOKlact) 5'-cAcATccgTg TTgTT cAcgATgTg-3'

(VHEx881) 5'-AATAgTAgAc TgcAgTgTcc TcAgcccTTA AgTgTTcAT cTgcAagTAg-

AgAgTATTcT TAgAgTTgTc TcTAGAcTTA gTgAagc-3'

! note that VHEx881 is the reverse complement of the ON below

! [RC] 5'-cgCttcacTaag-

! Scab.....

! Synthetic 3-23 as in Table 206

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! XbaI...

! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'

5
10
15
20
25
30
35
40
45
50
55

! AflII...
(VHBA881) 5'-cgCttcacTaag-
|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|tgg|cag|atg|-
|aac|agc|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt gcg ag-3'
(VHBB881) 5'-cgCttcacTaag-
|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|tgg|cag|atg|-
|aac|agc|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt Acg ag-3'
(VH881PCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac-3'

Table 17: Kappa, bases 12-30

ID	Ntot	0	1	2	3	4	5	6	Name	Sequence.....	Dot Form.....
1	84	40	21	20	1	2	0	0	SK12O12	gaccaggtctccatctcc	gaccaggtctccatctcc
2	32	19	3	6	2	1	0	1	SK12A17	gactcagttctccatctcc	..t.....ct....
3	26	17	8	1	0	0	0	0	SK12A27	gacgcagttccaggcacc	..g.....gg.a..
4	40	21	18	1	0	0	0	0	SK12A11	gacgcagttctccaggcacc	..g.....g.a..
182	97	50	28	3	3	0	1				
97	147	175	178	181	181	182					
URE adapters:											
Stem..... Loop. Stem..... Recognition.....											
(SzKB1230-O12)	5'-cAcATccgTg	TTgTT	cAcgATgTg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg
[RC]	5'-gaccagttctccatctcc	cAcATccgTg	AAcAA	cAcgATgTg-3'							
Recognition..... Stem..... loop. Stem.....											
FokI. FokI.											
Stem..... Loop. Stem..... Recognition.....											
(SzKB1230-A17)	5'-cAcATccgTg	TTgTT	cAcgATgTg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg
[RC]	5'-gactcagttctccatctcc	cAcATccgTg	AAcAA	cAcgATgTg-3'							
Recognition..... Stem..... loop. Stem.....											
FokI. FokI.											
Stem..... Loop. Stem..... Recognition.....											
(SzKB1230-A27)	5'-cAcATccgTg	TTgTT	cAcgATgTg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg
[RC]	5'-gacgcagttccaggcacc	cAcATccgTg	AAcAA	cAcgATgTg-3'							
Recognition..... Stem..... loop. Stem.....											
FokI. FokI.											
Stem..... Loop. Stem..... Recognition.....											
(SzKB1230-A11)	5'-cAcATccgTg	TTgTT	cAcgATgTg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg	ggAgATg
[RC]	5'-gacgcagttccaggcacc	cAcATccgTg	AAcAA	cAcgATgTg-3'							
Recognition..... Stem..... loop. Stem.....											

FokI. FokI.

What happens in the upper strand:

(SzKB1230-O12*) 5'-gac cca gtc | tcc a-tc ctc c-3'
| Site of cleavage in substrate

(SzKB1230-A17*) 5'-gac tca gtc | tcc a-ct ctc c-3'

(SzKB1230-A27*) 5'-gac gca gtc | tcc a-gg cac c-3'

(SzKB1230-A11*) 5'-gac gca gtc | tcc a-gc cac c-3'

(kapextURE) 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg-3' !sense strand
Scab.....ApaLI.

(kapextUREPCR) 5'-ccTctactctTgTcAcAgTg-3'
Scab.....

(kaBR01UR) 5'-ggAggATggA cTggATgTcT TgTgcAcTgT gAcAAGAgTA gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-tc ctc c-3' ON above is R.C. of this one
(kaBR02UR) 5'-ggAggATggA cTggATgTcT TgTgcAcTgT gAcAAGAgTA gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-ct ctc c-3' ON above is R.C. of this one
(kaBR03UR) 5'-ggTgcTggA cTggATgTcT TgTgcAcTgT gAcAAGAgTA gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gg cac c-3' ON above is R.C. of this one
(kaBR04UR) 5'-ggTgcTggA cTggATgTcT TgTgcAcTgT gAcAAGAgTA gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gc cac c-3' ON above is R.C. of this one
Scab.....ApaLI.

Table 18 Lambda URE adapters bases 13.3 to 19.3

Number of sequences..... 128									
Number of mismatches.....									
Id	Ntot	0	1	2	3	4	5	6	7 8 Name Sequence..... Dot form.....
1	58	45	7	1	0	0	2	2	1 VL133-2a2 gtctctggacagtcgac gtctctggacagtcgac
2	16	10	1	0	1	0	1	1	0 2 VL133-3l ggcttgggacagacagtc .g.cttg.....a.ag..
3	17	6	0	0	4	1	1	5	0 VL133-2c gtctctggacagtcgacag..
4	37	3	0	10	4	4	3	7	4 2 VL133-1c ggccccaggagaggggc .g.c.a..g...ag.g..
1	128	64	8	11	5	8	5	11	11 5
1	64	72	83	88	96	101	112	123	128
Stem..... loop. Stem..... Recognition.....									
(VL133-2a2) 5'-cAcATccgTg TTgTT cAcggATgTg gATcgAcTgTccAaggAgAc-3'									
[RC] 5'-gtctctggacagtcgac cAcATccgTg AACAA cAcggATgTg-3'									
Recognition..... Stem..... Loop. Stem.....									
Stem..... loop. Stem..... Recognition.....									
(VL133-3l) 5'-cAcATccgTg TTgTT cAcggATgTg gAcTgTcTgTcccAaggcc-3'									
[RC] 5'-ggcttgggacagacagtc cAcATccgTg AACAA cAcggATgTg-3'									
Recognition..... Stem..... Loop. Stem.....									
Stem..... loop. Stem..... Recognition.....									
(VL133-2c) 5'-cAcATccgTg TTgTT cAcggATgTg gAcTgAcTgTccAaggAgAc-3'									
[RC] 5'-gtctctggacagtcgac cAcATccgTg AACAA cAcggATgTg-3'									
Recognition..... Stem..... Loop. Stem.....									
Stem..... loop. Stem..... Recognition.....									
(VL133-1c) 5'-cAcATccgTg TTgTT cAcggATgTg gAcTcTgcccTggggcc-3'									
[RC] 5'-ggccccaggagaggggc cAcATccgTg AACAA cAcggATgTg-3'									

What happens in the top strand:

```

5      | site of cleavage in the upper strand
(VL133-2a2*) 5'-g tct cct g|ga cag tcg atc
!
(VL133-3l*) 5'-g gcc ttg g|ga cag aca gtc
!
(VL133-2c*) 5'-g tct cct g|ga cag tca gtc
10    !
(VL133-1c*) 5'-g gcc cca g|gg cag agg gtc
!
! The following Extenders and Bridges all encode the AA sequence of 2a2 for codons 1-15
!
15    1
(ON_LamEx133) 5'-ccTcTgAcTgAgT gcA cAg -
!
!      2 3 4 5 6 7 8 9 10 11 12
!      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!      13 14 15
20    !      tcC ccG g! 2a2
!      1
(ON_LamB1-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!      2 3 4 5 6 7 8 9 10 11 12
25    !      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!      13 14 15
!      tcC ccG g ga cag tcg at-3'! 2a2 N.B. the actual seq is the
30    !      reverse complement of the
!      one shown.
!
(ON_LamB2-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!      2 3 4 5 6 7 8 9 10 11 12
35    !      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!      13 14 15
!      tcC ccG g ga cag aca gt-3'! 3l N.B. the actual seq is the
40    !      reverse complement of the
!      one shown.
!
(ON_LamB3-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!      2 3 4 5 6 7 8 9 10 11 12
45    !      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!      13 14 15
!      tcC ccG g ga cag tca gt -3'! 2c N.B. the actual seq is the
50    !      reverse complement of the
!      one shown.
!
! (ON_LamB4-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -

```

55

!
 !
 2 3 4 5 6 7 8 9 10 11 12
 AGt gCt TtA acC caA ccG gCt AGT gTt AGC ggT-s
 !
 5 !
 13 14 15
 tcC ccG g gg cag agg gt-3' ! 1c **N.B.** the actual seq is the
 ! reverse complement of the
 ! one shown.
 !
 10 (ON_Lam133PCR) 5'-ccTcTgAcTgAgT **gcA cAg** AGt gc-3'

Table 19: Cleavage of 75 human light chains.

	Enzyme	Recognition*	Nch	Ns	Planned location of site
15	AfeI	AGCgct	0	0	
	AflII	Cttaag	0	0	HC FR3
	AgeI	Accggt	0	0	
	AscI	GGcgcgcc	0	0	After LC
20	BglII	Agatct	0	0	
	BsiWI	Cgtacg	0	0	
	BspDI	ATcgat	0	0	
	BssHII	GcgcgC	0	0	
	BstBI	TTcgaa	0	0	
25	DrallI	CACNNNgtg	0	0	
	EagI	Cggccg	0	0	
	FseI	GGCCGGcc	0	0	
	FspI	TGCgca	0	0	
30	HpaI	GTTaac	0	0	
	MfeI	Caattg	0	0	HC FR1
	MluI	AcgCGT	0	0	
	NcoI	Ccatgg	0	0	Heavy chain signal
	NheI	Gctagc	0	0	HC/anchor linker
35	NotI	GCggccgc	0	0	In linker after HC
	NruI	TCGcga	0	0	
	PacI	TTAATtaa	0	0	
	PmeI	GTTTaaac	0	0	
40	PmlI	CACgtg	0	0	
	PvuI	CGATcg	0	0	
	SacII	CCGCgg	0	0	
	Sall	Gtcgac	0	0	
	SfiI	GGCCNNNNnggcc	0	0	Heavy Chain signal
45	SgfI	GCGATcgC	0	0	
	SnaBI	TACgta	0	0	
	StuI	AGGcct	0	0	
	XbaI	Tctaga	0	0	HC FR3
50	AatII	GACGTc	1	1	
	AclI	AAcggt	1	1	
	Asel	ATtaat	1	1	
	BsmI	GAATGCN	1	1	
	BspEI	Tccgga	1	1	HC FR1
55	BstXI	CCANNNNNntgg	1	1	HC FR2
	DrdI	GACNNNNnngtc	1	1	
	HindIII	Aagctt	1	1	

EP 1 578 903 B2

(continued)

	Enzyme	Recognition*	Nch	Ns	Planned location of site
	PciI	Acatgt	1	1	
5	SapI	gaagagc	1	1	
	Scal	AGTact	1	1	
	SexAI	Accwgg	1	1	
	SpeI	Actagt	1	1	
10	TliI	Ctcgag	1	1	
	XhoI	Ctcgag	1	1	
	BcgI	cgannnnntgc	2	2	
	BlnI	GCtnagc	2	2	
	BssSI	Ctcgtg	2	2	
15	BstAPI	GCANNNNntgc	2	2	
	EspI	GCtnagc	2	2	
	KasI	Ggcgcc	2	2	
	PfiMI	CCANNNNntgg	2	2	
	XmnI	GAANNnttc	2	2	
20	ApaLI	Gtgcac	3	3	LC signal seq
	NaeI	GCCggc	3	3	
	NgoMI	Gccggc	3	3	
	PvuII	CAGctg	3	3	
25	RsrII	CGgwccg	3	3	
	BsrBI	GAGcgg	4	4	
	BsrDI	GCAATGNNn	4	4	
	BstZ17I	GTAtac	4	4	
	EcoRI	Gaattc	4	4	
30	SphI	GCATGc	4	4	
	SspI	AATatt	4	4	
	AccI	GTmkac	5	5	
	BclI	Tgatca	5	5	
35	BsmBI	Nnnnnngagacg	5	5	
	BsrGI	Tgtaca	5	5	
	DraI	TTTaaa	6	6	
	NdeI	CAtatg	6	6	HC FR4
	Swal	ATTTaaat	6	6	
40	BamHI	Ggatcc	7	7	
	SacI	GAGCTc	7	7	
	BciVI	GTATCCNNNNNN	8	8	
	BsaBI	GATNNnnatc	8	8	
45	NsiI	ATGCA	8	8	
	Bsp120I	Gggccc	9	9	CH1
	Apal	GGGCCc	9	9	CH1
	PspOoMI	Gggccc	9	9	
	BspHI	Tcatga	9	11	
50	EcoRV	GATatc	9	9	
	AhdI	GACNNNnngtc	11	11	
	BbsI	GAAGAC	11	14	
	PsiI	TTAtaa	12	12	
55	BsaI	GGTCTCnNNnn	13	15	
	XmaI	Cccggg	13	14	
	AvaI	Cycgrg	14	16	
	BglI	GCCNNNNnggc	14	17	

EP 1 578 903 B2

(continued)

	Enzyme	Recognition*	Nch	Ns	Planned location of site
5	AlwNI	CAGNNNctg	16	16	
	BspMI	ACCTGC	17	19	
	XcmI	CCANNNNNnnntgg	17	26	
	BstEII	Ggtnacc	19	22	HC FR4
10	Sse8387I	CCTGCAgg	20	20	
	AvrII	Cctagg	22	22	
	HincII	GTYrac	22	22	
	BsgI	GTGCAG	27	29	
15	MscI	TGGcca	30	34	
	BseRI	NNnnnnnnnnctcctc	32	35	
	Bsu36I	CCtnagg	35	37	
	PstI	CTGCAg	35	40	
20	Ecil	nnnnnnnnntccgcc	38	40	
	PpuMI	RGgwccy	41	50	
	StyI	Ccwwgg	44	73	
	Eco0109I	RGgnccy	46	70	
25	Acc65I	Ggtacc	50	51	
	KpnI	GGTACc	50	51	
	BpmI	ctccag	53	82	
	Avall	Ggwcc	71	124	

* cleavage occurs in the top strand after the last upper-case base. For REs that cut palindromic sequences, the lower strand is cut at the symmetrical site.

Table 20: Cleavage of 79 human heavy chains

	Enzyme	Recognition	Nch	Ns	Planned location of site
35	AfeI	AGCgct	0	0	
	AfIII	Cttaag	0	0	HC FR3
	AscI	GGcgcgcc	0	0	After LC
	BsiWI	Cgtacg	0	0	
40	BspDI	ATcgat	0	0	
	BssHII	Gcgcg	0	0	
	FseI	GGCCGGcc	0	0	
	HpaI	GTTaac	0	0	
45	NheI	Gctagc	0	0	HC Linker
	NotI	GCggccgc	0	0	In linker, HC/anchor
	NruI	TCGcga	0	0	
	NsiI	ATGCAat	0	0	
50	PacI	TTAATtaa	0	0	
	PciI	Acatgt	0	0	
	PmeI	GTTTaaac	0	0	
	PvuI	CGATcg	0	0	
55	RsrII	CGgwccg	0	0	
	SapI	gaagagc	0	0	
	SfiI	GGCCNNNNnggcc	0	0	HC signal seq
	SgfI	GCGATcg	0	0	
55	Swal	ATTTaaat	0	0	
	AclI	AAcgtt	1	1	
	AgeI	Accggt	1	1	

EP 1 578 903 B2

(continued)

	Enzyme	Recognition	Nch	Ns	Planned location of site
5	AseI	ATtaat	1	1	
	AvrII	Cctagg	1	1	
	BsmI	GAATGCN	1	1	
	BsrBI	GAGcgg	1	1	
	BsrDI	GCAATGNNn	1	1	
10	DraI	TTTaaa	1	1	
	FspI	TGCgca	1	1	
	HindIII	Aagctt	1	1	
	MfeI	Caattg	1	1	HC FR1
	NaeI	GCCggc	1	1	
15	NgoMI	Gccggc	1	1	
	SpeI	Actagt	1	1	
	Acc65I	Ggtacc	2	2	
	BstBI	TTcgaa	2	2	
20	KpnI	GGTACc	2	2	
	MluI	AcgCGT	2	2	
	NcoI	Ccatgg	2	2	In HC signal seq
	NdeI	CAtatg	2	2	HC FR4
	PmlI	CACgtg	2	2	
25	XcmI	CCANNNNNnnnntgg	2	2	
	BcgI	cgannnnnnntgc	3	3	
	BclI	Tgatca	3	3	
	BglI	GCCNNNNnggc	3	3	
30	BsaBI	GATNNnnatc	3	3	
	BsrGI	Tgtaca	3	3	
	SnaBI	TACgta	3	3	
	Sse8387I	CCTGCAgg	3	3	
	ApaLI	Gtgcac	4	4	LC Signal/FR1
35	BspHI	Tcatga	4	4	
	BssSI	Ctcgtg	4	4	
	PsiI	TTAtaa	4	5	
	SphI	GCATGc	4	4	
40	AhdI	GACNNNNngtc	5	5	
	BspEI	Tccgga	5	5	HC FR1
	MscI	TGGcca	5	5	
	SacI	GAGCTc	5	5	
	SalI	AGTact	5	5	
45	SexAI	Accwgtt	5	6	
	SspI	AATatt	5	5	
	TliI	Ctcgag	5	5	
	XhoI	Ctcgag	5	5	
	BbsI	GAAGAC	7	8	
50	BstAPI	GCANNNNntgc	7	8	
	BstZ17I	GTAtac	7	7	
	EcoRV	GATatc	7	7	
	EcoRI	Gaatc	8	8	
55	BlpI	GCtnagc	9	9	
	Bsu36I	CCtnagg	9	9	
	DraIII	CACNNNgtg	9	9	
	EspI	GCtnagc	9	9	

EP 1 578 903 B2

(continued)

	Enzyme	Recognition	Nch	Ns	Planned location of site
	StuI	AGGcct	9	13	
5	XbaI	Tctaga	9	9	HC FR3
	Bsp120I	Gggccc	10	11	CH1
	ApaI	GGGCCc	10	11	CH1
	PspOoMI	Gggccc	10	11	
10	BciVI	GTATCCNNNNNN	11	11	
	Sall	Gtcgac	11	12	
	DrdI	GACNNNNnngtc	12	12	
	KasI	Gcgccc	12	12	
	XmaI	Cccggg	12	14	
15	BglII	Agatct	14	14	
	HincII	GTyrac	16	18	
	BamHI	Ggatcc	17	17	
	PfiMI	CCANNNNntgg	17	18	
20	BsmBI	Nnnnnngagacg	18	21	
	BstXI	CCANNNNNntgg	18	19	HC FR2
	XmnI	GAANNnnttc	18	18	
	SacII	CCGCgg	19	19	
	PstI	CTGCAg	20	24	
25	PvuII	CAGctg	20	22	
	AvaI	Cycgrg	21	24	
	EagI	Cggccg	21	22	
	AatII	GACGTc	22	22	
	BspMI	ACCTGC	27	33	
30	AccI	GTmkac	30	43	
	StyI	Ccwwgg	36	49	
	AlwNI	CAGNNNctg	38	44	
	BsaI	GGTCTCNnnnn	38	44	
35	PpuMI	RGgwccy	43	46	
	BsgI	GTGCAG	44	54	
	BseRI	NNnnnnnnnnctcctc	48	60	
	EcI	nnnnnnnnntccgcc	52	57	
	BstEII	Ggtnacc	54	61	HC Fr4, 47/79 have one
40	EcoO109I	RGgnccy	54	86	
	BpmI	ctccag	60	121	
	Avall	Ggwcc	71	140	

45

50

55

Table 21: MALIA3, annotated

! MALIA3 9532 bases

```

-----
5  ! 1 aat gct act act att agt aga att gat gcc acc ttt tca gct cgc gcc
    ! gene ii continued
    49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta
    97 tct aat ggt caa act aaa tct act cgt tgc cag aat tgg gaa tca act
    145 gtt aca tgg aat gaa act tcc aga cac cgt act tta gtt gca tat tta
    193 aaa cat gtt gag cta cag cac cag att cag caa tta agc tct aag cca
    241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc tct
10  289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa gct
    337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt
    385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac
    433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa gca
    481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg gac
15  ! RBS?..... Start gene x, ii continues
    529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct
    577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta aac
    625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg
    673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg
    721 atg aat ctt tct acc tgt aat aat gtt gtt ccg tta gtt cgt ttt att
20  769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt
    817 ctt aaa atc gca TAA
    ! End X & II
    832 ggtaattca ca
    !
    ! M1 E5 Q10 T15
25  843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt
    ! Start gene V
    !
    ! S17 S20 P25 E30
    891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cag ctt
30  !
    ! V35 E40 V45
    939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att act
    !
    ! D50 A55 L60
    987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cat
35  ! BsrGI...
    ! L65 V70 S75 R80
    1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gac cgt
    !
    ! P85 K87 end of V
    1083 ctg cgc ctc gtt ccg gct aag TAA C
40  !
    1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg
    ! Start gene VII
    !
    1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc
45  !
    ! VII and IX overlap.
    ! ..... S2 V3 L4 V5 S10
    1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tct ttc gcc tct ttc gtt
    ! End VII
    ! |start IX
50  ! L13 W15 G20 T25 E29
    1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta atg gaa

```

55

```

!
! 1293 act tcc tc
!
! .... stop of IX, IX and VIII overlap by four bases
5 1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc
! Start signal sequence of viii.
!
! 1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg
! mature VIII --->
10 1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg
1445 tgg gcg atg gtt gtt gtc att
1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
1499 aaa ttc acc tcg aaa gca ! 1515
! ..... -35 ..
!
! 1517 agc tga taaaccgat acaattaaag gctccttttg
15 ..... -10 ...
!
! 1552 gagccttttt ttttGGAGAt ttt ! S.D. underlined
!
! <----- III signal sequence ----->
20 ! M K K L L F A I P L V
1575 caac GTG aaa aaa tta tta ttc gca att cct tta gtt ! 1611
!
! V P F Y S H S A Q
1612 gtt cct ttc tat tct cac aGT gcA Cag tCT
! ApaLI...
25 !
1642 GTC GTG ACG CAG CCG CCC TCA GTG TCT GGG GCC CCA GGG CAG
AGG GTC ACC ATC TCC TGC ACT GGG AGC AGC TCC AAC ATC GGG GCA
! BstEII...
1729 GGT TAT GAT GTA CAC TGG TAC CAG CAG CTT CCA GGA ACA GCC CCC AAA
30 1777 CTC CTC ATC TAT GGT AAC AGC AAT CGG CCC TCA GGG GTC CCT GAC CGA
1825 TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC ACT
1870 GGG CTC CAG GCT GAG GAT GAG GCT GAT TAT
1900 TAC TGC CAG TCC TAT GAC AGC AGC CTG AGT
1930 GGC CTT TAT GTC TTC GGA ACT GGG ACC AAG GTC ACC GTC
! BstEII...
35 1969 CTA GGT CAG CCC AAG GCC AAC CCC ACT GTC ACT
2002 CTG TTC CCG CCC TCC TCT GAG GAG CTC CAA GCC AAC AAG GCC ACA CTA
2050 GTG TGT CTG ATC AGT GAC TTC TAC CCG GGA GCT GTG ACA GTG GCC TGG
2098 AAG GCA GAT AGC AGC CCC GTC AAG GCG GGA GTG GAG ACC ACC ACA CCC
2146 TCC AAA CAA AGC AAC AAC AAG TAC GCG GCC AGC AGC TAT CTG AGC CTG
40 2194 ACG CCT GAG CAG TGG AAG TCC CAC AGA AGC TAC AGC TGC CAG GTC ACG
2242 CAT GAA GGG AGC ACC GTG GAG AAG ACA GTG GCC CCT ACA GAA TGT TCA
2290 TAA TAA ACCG CCTCCACCGG GCGCGCCAAT TCTATTTC AA GGAGACAGTC ATA
! AscI.....
!
! PelB signal----->
45 ! M K Y L L P T A A A G L L L L
2343 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
!
! 16 17 18 19 20 21 22
! A A Q P A M A
! 2388 gcG GCC cag ccG GCC atq gcc
50 ! SfiI.....
! NgoMI... (1/2)
! NcoI.....
55

```



```

5      2409      FR1(DP47/V3-23)-----
                23 24 25 26 27 28 29 30
                E  V  Q  L  L  E  S  G
                gaa|gtt|CAA|TTG|tta|gag|tct|ggc|
                | MfeI |
!
!
!
10     2433      -----FR1-----
                31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
                G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A
                |ggc|ggt|ctt|ggt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|
!
!
!
15     2478      -----FR1----->|...CDR1.....|---FR2-----
                46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
                A  S  G  F  T  F  S  S  Y  A  M  S  W  V  R
                |gct|TCC|GGA|ttc|act|ttc|tct|tCG|TAC|Gct|atg|tct|tgg|ggt|cgC|
                | BspEI |                | BsiWI |                |BstXI.
!
!
!
20     2523      -----FR2----->|...CDR2.....
                61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
                Q  A  P  G  K  G  L  E  W  V  S  A  I  S  G
                |CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|ggt|tct|gct|atc|tct|ggt|
                ...BstXI |
!
!
!
25     2568      .....CDR2.....|---FR3---
                76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
                S  G  G  S  T  Y  Y  A  D  S  V  K  G  R  F
                |tct|ggt|ggc|agt|act|tac|tat|gct|gac|tcc|ggt|aaa|ggt|cgc|ttc|
!
!
!
30     2613      -----FR3-----
                91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
                T  I  S  R  D  N  S  K  N  T  L  Y  L  Q  M
                |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|
                | XbaI |
!
!
!
35     2658      ---FR3----->|
                106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
                N  S  L  R  A  E  D  T  A  V  Y  Y  C  A  K
                |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|
                |AflII |                | PstI |
!
!
!
40     2703      .....CDR3.....|---FR4-----
                121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
                D  Y  E  G  T  G  Y  A  F  D  I  W  G  Q  G
                |gac|tat|gaa|ggt|act|ggt|tat|gct|ttc|gaC|ATA|TGg|ggt|caa|ggt|
                | NdeI |(1/4)
!
!
!
45     2748      -----FR4----->|
                136 137 138 139 140 141 142
                T  M  V  T  V  S  S
                |act|atG|GTC|ACC|gtc|tct|agt
                | BstEII |
!
!
!
50     From BstEII onwards, pV323 is same as pCES1, except as noted.
        BstEII sites may occur in light chains; not likely to be unique in final
        vector.

```

EP 1 578 903 B2

```

!
!               143 144 145 146 147 148 149 150 151 152
!               A   S   T   K   G   P   S   V   F   P
5 2769          gcc tcc acc aaG GGC CCa tCG GTC TTC ccc
!               Bsp120I.           BbsI...(2/2)
!               ApaI....
!
!       153 154 155 156 157 158 159 160 161 162 163 164 165 166 167
!       L   A   P   S   S   K   S   T   S   G   G   T   A   A   L
10 2799 ctg gca ccC TCC TCc aag agc acc tct ggg ggc aca gcg gcc ctg
!               BseRI...(2/2)
!
!       168 169 170 171 172 173 174 175 176 177 178 179 180 181 182
!       G   C   L   V   K   D   Y   F   P   E   P   V   T   V   S
15 2844 ggc tgc ctg GTC AAG GAC TAC TTC CCc gaA CCG GTg acg gtg tCG
!               AgeI....
!
!       183 184 185 186 187 188 189 190 191 192 193 194 195 196 197
!       W   N   S   G   A   L   T   S   G   V   H   T   F   P   A
20 2889 tgg aac tca GGC GCC ctg acc agc ggc gtc cac acc ttc ccg gct
!               KasI...(1/4)
!
!       198 199 200 201 202 203 204 205 206 207 208 209 210 211 212
!       V   L   Q   S   S   G   L   Y   S   L   S   S   V   V   T
25 2934 gtc cta cag tCt agc GGa ctc tac tcc ctc agc agc gta gtg acc
!               (Bsu36I...) (knocked out)
!
!       213 214 215 216 217 218 219 220 221 222 223 224 225 226 227
!       V   P   S   S   S   L   G   T   Q   T   Y   I   C   N   V
30 2979 gtg ccC tCt tct agc tTG Ggc acc cag acc tac atc tgc aac gtg
!               (BstXI.....)N.B. destruction of BstXI & BpmI sites.
!
!       228 229 230 231 232 233 234 235 236 237 238 239 240 241 242
!       N   H   K   P   S   N   T   K   V   D   K   K   V   E   P
35 3024 aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc
!
!       243 244 245
!       K   S   C   A   A   A   H   H   H   H   H   H   S   A
35 3069 aaa tct tgt GCG GCC GcT cat cac cac cat cat cac tct gct
!               NotI.....
!
!       E   Q   K   L   I   S   E   E   D   L   N   G   A   A
40 3111 gaa caa aaa ctc atc tca gaa gag gat ctg aat ggt gcc gca
!
!       D   I   N   D   D   R   M       A   S   G   A
35 3153 GAT ATC aac gat gat cgt atg   gct AGC ggc gcc
!       rEK cleavage site.....   NheI...   KasI...
!       EcoRV..
45
! Domain 1 -----
!       A   E   T   V   E   S   C   L   A
35 3183   gct gaa act gtt gaa agt tgt tta gca
!
!       K   P   H   T   E   I   S   F
50 3210 aaa ccc cat aca gaa aat tca ttt
!
!       T   N   V   W   K   D   D   K   T
3234 aCT AAC GTC TGG AAA GAC GAC AAA Act

```

```

!
!   L   D   R   Y   A   N   Y   E   G   C   L   W   N   A   T   G   V
3261 tta gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCt aca ggc gtt
!                                     BsmI_____
5
!   V   V   C   T   G   D   E   T   Q   C   Y   G   T   W   V   P   I
3312 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att
!
!   G   L   A   I   P   E   N
10 3363 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
!   E   G   G   G   S   E   G   G   G   S
3384 gag ggt ggt ggc tct gag ggt ggc ggt tct
!
15 !   E   G   G   G   S   E   G   G   G   T
3414 gag ggt ggc ggt tct gag ggt ggc ggt act
!
!   Domain 2 -----
3444 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac
20 3495 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct
3546 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat
!                                     BseRI___
3597 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act
3645 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct
3693 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA
!                                     AlwNI
25 3741 GAC TGc gct ttc cat tct ggc ttt aat gaa gat cca ttc gtt tgt gaa
!   AlwNI
3789 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
!
3834 ggc ggc ggc tct
30 ! start L2 -----
3846 ggt ggt ggt tct
3858 ggt ggc ggc tct
3870 gag ggt ggt ggc tct gag ggt ggc ggt tct
3900 gag ggt ggc ggc tct gag gga ggc ggt tcc
3930 ggt ggt ggc tct ggt ! end L2
35
!   Domain 3 -----
!   S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
3945 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct
!
!   M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
40 3993 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc
!
!   K   L   D   S   V   A   T   D   Y   G   A   A   I   D   G   F
4041 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc
!
!   I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
45 4089 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat
!
!   F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
4137 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat
!
50 !   S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
4185 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa

```

```

!
!   S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
4233 tcg gtt gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa
!
5  !   F   S   I   D   C   D   K   I   N   L   F   R
4281 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
!                                     End Domain 3
!
!   G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F140
10 4317 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt
!   start transmembrane segment
!
!   S   T   F   A   N   I   L
15 4365 tct acg ttt gct aac ata ctg
!
!   R   N   K   E   S
16 4386 cgt aat aag gag tct TAA ! stop of iii
!   Intracellular anchor.
!
!   M1  P2  V   L  L5   G   I   P   L  L10  L   R   F   L  G15
20 4404 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt
!   Start VI
!
4451 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag
4499 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt att
4547 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct
25 4595 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct
4643 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct att
4691 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat
!
!   M1  A2  V3       F5               L10           G13
30 4739 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!   end VI   Start gene I
!
!   14  15  16  17  18  19  20  21  22  23  24  25  26  27  28
!   K   T   L   V   S   V   G   K   I   Q   D   K   I   V   A
4785 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!   29  30  31  32  33  34  35  36  37  38  39  40  41  42  43
!   G   C   K   I   A   T   N   L   D   L   R   L   Q   N   L
35 4830 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!   44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
!   P   Q   V   G   R   F   A   K   T   P   R   V   L   R   I
40 4875 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!   59  60  61  62  63  64  65  66  67  68  69  70  71  72  73
!   P   D   K   P   S   I   S   D   L   L   A   I   G   R   G
45 4920 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
!
!   74  75  76  77  78  79  80  81  82  83  84  85  86  87  88
!   N   D   S   Y   D   E   N   K   N   G   L   L   V   L   D
4965 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
!   89  90  91  92  93  94  95  96  97  98  99 100 101 102 103
50 5010 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!

```

EP 1 578 903 B2

```

!      104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
!      R   Q   P   I   I   D   W   F   L   H   A   R   K   L   G
5055   aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga
!
!      119 120 121 122 123 124 125 126 127 128 129 130 131 132 133
!      W   D   I   I   F   L   V   Q   D   L   S   I   V   D   K
5100   tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa
!
!      134 135 136 137 138 139 140 141 142 143 144 145 146 147 148
!      Q   A   R   S   A   L   A   E   H   V   V   Y   C   R   R
10    5145   cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt
!
!      149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
!      L   D   R   I   T   L   P   F   V   G   T   L   Y   S   L
15    5190   ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt
!
!      164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
!      I   T   G   S   K   M   P   L   P   K   L   H   V   G   V
20    5235   att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt
!
!      179 180 181 182 183 184 185 186 187 188 189 190 191 192 193
!      V   K   Y   G   D   S   Q   L   S   P   T   V   E   R   W
25    5280   gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg
!
!      194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
!      L   Y   T   G   K   N   L   Y   N   A   Y   D   T   K   Q
30    5325   ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag
!
!      209 210 211 212 213 214 215 216 217 218 219 220 221 222 223
!      A   F   S   S   N   Y   D   S   G   V   Y   S   Y   L   T
35    5370   gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg
!
!      224 225 226 227 228 229 230 231 232 233 234 235 236 237 238
!      P   Y   L   S   H   G   R   Y   F   K   P   L   N   L   G
40    5415   cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt
!
!      239 240 241 242 243 244 245 246 247 248 249 250 251 252 253
!      Q   K   M   K   L   T   K   I   Y   L   K   K   F   S   R
45    5460   cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc
!
!      254 255 256 257 258 259 260 261 262 263 264 265 266 267 268
!      V   L   C   L   A   I   G   F   A   S   A   F   T   Y   S
50    5505   gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt
!
!      269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
!      Y   I   T   Q   P   K   P   E   V   K   K   V   V   S   Q
55    5550   tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct cag
!
!      284 285 286 287 288 289 290 291 292 293 294 295 296 297 298
!      T   Y   D   F   D   K   F   T   I   D   S   S   Q   R   L
60    5595   acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt
!
!      299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
!      N   L   S   Y   R   Y   V   F   K   D   S   K   G   K   L
55    5640   aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA
!                                     PacI

```

```

!       314 315 316 317 318 319 320 321 322 323 324 325 326 327 328
!       I   N   S   D   D   L   Q   K   Q   G   Y   S   L   T   Y

5685 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat
5   PacI
!
!       329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
!       i   I   D   L   C   T   V   S   I   K   K   G   N   S   N   E
!       iv                                     M1 K
10 5730 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
!                                     Start IV
!
!       344 345 346 347 348 349
!       i   I   V   K   C   N   .End of I
!       iv   L3 L   N5 V   I7 N   F V10
15 5775 att gtt aaa tgt aat TAA T TTT GTT
! IV continued.....
5800 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg
5848 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca
5896 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta
20 5944 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct
5992 gtt tta cgt gct aat aat ttt gat atg gtt ggt tca att cct tcc ata
6040 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca
6088 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt
6136 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat
6184 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag
6232 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat
25 6280 cta tta gtt gtt TCT gca cct aaa gat att tta gat aac ctt cct caa
!       ApaLI removed
6328 ttc ctt tct act gtt gat ttg cca act gac cag ata ttg att gag ggt
6376 ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct
6424 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc
30 6472 ctc acc tct gtt tta tct tct gct ggt ggt tgc ttc ggt att ttt aat
6520 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat
6568 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag
6616 ggt tct atc tct gtT GGC CAG aat gtc cct ttt att act ggt cgt gtg
!       MscI
6664 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt
35 6712 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc
6760 ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct
6808 tct act cag gca agt gat gtt att act aat caa aga agt att gct aca
6856 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act
6904 gat tat aaa aac act tct caa gat tct ggc gta ccg ttc ctg tct aaa
6952 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tcc aac gag
40 7000 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg
7048 TAG cggcgcatt
!       End IV
7060 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc
7120 gcccgcctcct ttcgctttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca
!       NgoMI
45 7180 agctctaaat cgggggctcc ctttaggggtt ccgatttagt gctttacggc acctcgacct
7240 caaaaaactt gatttggttg atggttCACG TAGTGggcca tcgccctgat agacggtttt
!       DraIII
7300 tcgccctttG ACGTTGGAGT Ccagttctt taatagtgga ctcttggtcc aaactggaac
!       DrdI
50 7360 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga
7420 accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa
7480 ctctctcagg gccaggcggg gaagggaat CAGCTGttgc cCGTCTCact ggtgaaaaga
!       PvuII. BsmBI.
7540 aaaaccaccc tGGATCC AAGCTT
!       BamHI HindIII (1/2)
55

```

```

!               Insert carrying bla gene
7563   gcagggtg gcacttttctg gggaaatgtg cgcggaaccc
7600   ctatttgttt atttttctaa atacattcaa atatGTATCC gctcatgaga caataaccct
!               BciVI
5   7660   gataaatgct tcaataatat tgaaaaAGGA AGAgT
!               RBS.?...
!               Start bla gene
7695   ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt
7746   tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct
10  7797   gaa gat cag ttg ggC gCA CGA Gtg ggt tac atc gaa ctg gat ctc aac agc
!               BssSI...
!               ApaLI removed
7848   ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc
7899   act ttt aaa gtt ctg cta tgt cat aca cta tta tcc cgt att gac gcc ggg
7950   caa gaG CAA CTC GGT CGc cgg gcg cgg tat tct cag aat gac ttg gtt gAG
15  !               BcgI
8001   TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa
!               ScaI
8052   tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt
8103   ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg cac aac atg
!               PvuI
20  8154   ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc
8205   ata cca aac gac gag cgt gac acc acg atg cct gta gca atg cca aca acg
8256   tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa
!               FspI....
!
25  8307   tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tgc
8358   GCC ctt ccG Gct ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt
!               BglI
8409   gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt
!               BsaI
8460   atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa cga aat
!               AhdI
30  8511   aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt
!               stop
8560   cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa
8620   ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt
8680   cgttccactg tacgtaagac cccc
8704   AAGCTT GTCGAC tgaa tggcgaatgg cgctttgcct
35  !               HindIII SalI..
!               (2/2) HincII
8740   ggtttccggc accagaagcg gtgccgaaa gctggctgga gtgcgatctt
!
8790   CCTGAGG
!               Bsu36I
40  8797   ccgat actgtcgtcg tcccctcaaa ctggcagatg
8832   cacggttacg atgcgcccac ctacaccaac gtaacctatc ccattacggt caatccgccc
8892   tttgttccca cggagaatcc gacgggttgt tactcgctca catttaatgt tgatgaaagc
8952   tggctacagg aaggccagac gcgaattatt tttgatggcg ttcctattgg ttaaaaaatg
9012   agctgattta acaaaaattht aacgcgaatt ttaacaaaat attaacgttt acaATTTAAA
!               SwaI...
45  9072   Tatttgctta tacaatcttc ctgtttttgg ggctttttctg attatcaacc GGGGTACat
!               RBS?
9131   ATG att gac atg cta gtt tta cga tta ccg ttc atc gat tct ctt gtt tgc
!               Start gene II
9182   tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata
50  !               BglII...
9233   gct acc ctc tcc ggc atg aat tta tca gct aga acg gtt gaa tat cat att

9284   gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct tta cct
9335   aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt
55  9386   tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat
9437   aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt
9488   aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt ! 9532
! gene II continues

```

Table 21B: Sequence of MALIA3, condensed

LOCUS	MALIA3	9532	CIRCULAR
ORIGIN			
5	1	AATGCTACTA	CTATTAGTAG
	61	ATAGCTAAAC	AGGTTATTGA
	121	CGTTCGCAGA	ATTGGGAATC
	181	GTTGCATATT	TAAAACATGT
	241	TCCGCAAAAA	TGACCTCTTA
	361	TCTTTTCGGG	TTCCTCTTAA
10	421	CAGGGTAAAG	ACCTGATTTT
	481	TTTGAGGGGG	ATTCAATGAA
	541	AAACATTTTA	CTATTACCCC
	601	GGTTTTTATC	GTCGTCTGGT
	661	AATTCCTTTT	GGCGTTATGT
	721	ATGAATCTTT	CTACCTGTAA
15	781	TCTTCCCAAC	GTCCTGACTG
	841	CAATGATTAA	AGTTGAAATT
	901	CTCGTCAGGG	CAAGCCTTAT
	961	AATATCCGGT	TCTTGTCAAG
	1021	TGTACACCGT	TCATCTGTCC
20	1081	GTCTGCGCCT	CGTTCCGGCT
	1141	CAGGCGATGA	TACAAATCTC
	1201	CAAAGATGAG	TGTTTTAGTG
	1261	GTGGCATTAC	GTATTTTACC
	1321	CAAAGCCTCT	GTAGCCGTTG
	1381	CGATCCCGCA	AAAGCGGCCT
25	1441	TGCGTGGGCG	ATGGTTGTTG
	1501	ATTCACCTCG	AAAGCAAGCT
	1561	TTTTTGGAGA	TTTTCAACGT
	1621	TATTCTCACA	GTGCACAGTC
	1681	CAGAGGGTCA	CCATCTCCTG
	1741	CACTGGTACC	AGCAGCTTCC
30	1801	CGGCCCTCAG	GGGTCCCTGA
	1861	GCCATCACTG	GGCTCCAGGC
	1921	AGCCTGAGTG	GCCTTTATGT
	1981	AAGGCCAACC	CCACTGTCAC
	2041	GCCACACTAG	TGTGTCTGAT
	2101	GCAGATAGCA	GCCCCGTCAA
35	2161	AACAAGTACG	CGGCCAGCAG
	2221	AGCTACAGCT	GCCAGGTCAC
	2281	GAATGTTTAT	AATAAACCGC
	2341	TAATGAAATA	CCTATTGCCT
	2401	CCATGGCCGA	AGTTCAATTG
	2461	TACGTCTTTC	TTGCGCTGCT
40	2521	GCCAAGCTCC	TGGTAAAGGT
	2581	CTTACTATGC	TGACTCCGTT
	2641	CTCTCTACTT	GCAGATGAAC
	2701	AAGACTATGA	AGGTACTGGT
	2761	TCTCTAGTGC	CTCCACCAAG
	2821	CCTCTGGGGG	CACAGCGGCC
45	2881	CGGTGTCTGT	GAACCTCAGG
	2941	AGTCTAGCGG	ACTCTACTCC
	3001	CCCAGACCTA	CATCTGCAAC
	3061	TTGAGCCCAA	ATCTTGTGCG
	3121	TCATCTCAGA	AGAGGATCTG
	3181	CCGCTGAAAC	TGTTGAAAGT
50	3241	TCTGGAAAGA	CGACAAAAC
			TTAGATCGTT
			ACGCTAATA
			TGAGGGTTGT
			CTGTGGAATG

3301	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	TGGGTTCCCTA
3361	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	TCTGAGGGTG
3421	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	ATTCCGGGCT
3481	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	AACCCCGCTA
5 3541	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	CAGAATAATA
3601	GGTTCGGAAA	TAGGCAGGGG	GCATTAACCTG	TTTATACGGG	CACTGTTACT	CAAGGCACTG
3661	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	TATGACGCTT
3721	ACTGGAACGG	TAAATTGAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	GATCCATTCTG
3781	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	GCTGGCGGCG
3841	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	GGCGGTTCTG
10 3901	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	GATTTTGATT
3961	ATGAAAAGAT	GGCAAACGCT	ATAAAGGGG	CTATGACCGA	AAATGCCGAT	GAAAACGCGC
4021	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTGCTAC	TGATTACGGT	GCTGCTATCG
4081	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	GGTGATTTTG
4141	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	TTAATGAATA
4201	ATTTCCGTC	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	TTTGTCTTTA
15 4261	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	TTCCGTGGTG
4321	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	TTTGCTAACA
4381	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	TATTATTGCG
4441	TTTCCTCGGT	TTCTTTCTGG	TAACCTTGTT	CGGCTATCTG	CTTACTTTTC	TTAAAAAGGG
4501	CTTCGGTAAG	ATAGCTATTG	CTATTTTCATT	GTTTCTTGCT	CTTATTATTG	GGCTTAACCTC
4561	AATTCTTGTTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	TTGTTACAGGG
20 4621	TGTTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	TCTCTGTAAA
4681	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	ATTGGGATAA
4741	ATAATATGGC	TGTTTTATTTT	GTAAGTGGCA	AATTAGGCTC	TGGAAAGACG	CTCGTTAGCG
4801	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	CTTGATTTAA
4861	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAC	GCCTCGCGTT	CTTAGAATAC
4921	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	TCCTACGATG
25 4981	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	ACCCGTTCTT
5041	GGAAATGATA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	AAATTAGGAT
5101	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	CGTTCTGCAT
5161	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	TTTGTGCGTA
5221	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	GTTGGCGTTG
5281	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	ACTGGTAAGA
30 5341	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	TCCGGTGTTT
5401	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	AATTTAGGTC
5461	AGAAGATGAA	ATTAACATAA	ATATATTTGA	AAAAGTTTTC	TCGCGTTCTT	TGTCTTGCGA
5521	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	GAGGTTAAAA
5581	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACAT	TGACTCTTCT	CAGCGTCTTA
5641	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	AGCGACGATT
35 5701	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	ATTAAAAAAG
5761	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	TGTTTCATCA
5821	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	TGTAAGTTGG
5881	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	TACTGTTACT
5941	GTATATTTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	TGTTTACGTT
6001	GCTAATAATT	TTGATATGTT	TGGTTCAATT	CCTTCCATAA	TTGAGAAGTA	TAATCCAAAC
40 6061	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	TGATAATTCC
6121	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	TTTTAAATTT
6181	AATAACGTTT	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAG	GTCTAATACT
6241	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	TTCTGCACCT
6301	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	AACTGACCAG
45 6361	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	TTTTTCATTT
6421	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	CCTCACCTCT
6481	GTTTTATCTT	CTGCTGGTGG	TTCGTTCCGG	ATTTTAAATG	GCGATGTTTT	AGGGCTATCA
6541	GTTGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	TATTCCTACG
6601	CTTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	TACTGGTCGT
6661	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTTCTA	CGATTGAGCG	TCAAATGTAA
50 6721	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	TCTGGATATT

6781	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	TACTAATCAA
6841	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	CGGTGGCCTC
6901	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	AATCCCTTTA
5 6961	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	ATACGTGCTC
7021	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	GTGTGGTGGT
7081	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	TCGCTTTCTT
7141	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTC	GCTCTAAATC	GGGGGCTCCC
7201	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	ATTTGGGTGA
7261	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	CGTTGGAGTC
10 7321	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	CTATCTCGGG
7381	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTTCGG	CCACCATCAA	ACAGGATTTT
7441	CGCCTGCTGG	GGCAAACCG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	CCAGGCGGTG
7501	AAGGGCAATC	AGCTGTTGCC	CGTCTCACTG	GTGAAAAGAA	AAACCACCTT	GGATCCAAGC
7561	TTGCAGGTGG	CACTTTTTCG	GGAAATGTGC	GCGGAACCCC	TATTTGTTTA	TTTTTCTAAA
7621	TACATTCAAA	TATGTATCCG	CTCATGAGAC	AATAACCCCTG	ATAAATGCCT	CAATAATATT
15 7681	GAAAAAGGAA	GAGTATGAGT	ATTCAACATT	TCCGTGTCGC	CCTTATTCCC	TTTTTTGCGG
7741	CATTTTGCCT	TCCTGTTTTT	GCTCACCCAG	AAACGCTGGT	GAAAGTAAAA	GATGCTGAAG
7801	ATCAGTTGGG	CGCACGAGTG	GGTTACATCG	AACTGGATCT	CAACAGCGGT	AAGATCCTTG
7861	AGAGTTTTTC	CCCCGAAGAA	CGTTTTCCAA	TAGTAGACAC	TTTAAAGTT	TTGTGATGTC
7921	ATACACTATT	ATCCCGTATT	GACGCCGGGC	AAGAGCAACT	CGGTCGCCGG	GCGCGGTATT
7981	CTCAGAATGA	CTTGGTTGAG	TACTCACCAG	TCACAGAAAA	GCATCTTACG	GATGGCATGA
20 8041	CAGTAAGAGA	ATTATGCAGT	GCTGCCATAA	CCATGAGTGA	TAACACTGCG	GCCAACCTTAC
8101	TTCTGACAAC	GATCGGAGGA	CCGAAGGAGC	TAACCGCTTT	TTTGACACAAC	ATGGGGGATC
8161	ATGTAACCTG	CCTTGATCGT	TGGGAACCGG	AGCTGAATGA	AGCCATACCA	AACGACGAGC
8221	GTGACACCAC	GATGCCTGTA	GCAATGCCAA	CAACGTTGCG	CAAACTATTA	ACTGGCGAAC
8281	TACTTACTCT	AGCTTCCCGG	CAACAATTAA	TAGACTGGAT	GGAGGCGGAT	AAAGTTGCAG
8341	GACCACTTCT	GCGCTCGGCC	CTTCCGGCTG	GCTGGTTTAT	TGCTGATAAA	TCTGGAGCCG
25 8401	GTGAGCGTGG	GTCTCGCGGT	ATCATTGCAG	CACTGGGGCC	AGATGGTAAG	CCCTCCCGTA
8461	TCGTAGTTAT	CTACACGACG	GGGAGTCAGG	CAACTATGGA	TGAACGAAAT	AGACAGATCG
8521	CTGAGATAGG	TGCCTCACTG	ATTAAGCATT	GGTAACTGTC	AGACCAAGTT	TACTCATATA
8581	TACTTTAGAT	TGATTTAAAA	CTTCATTTTT	AATTTAAAAAG	GATCTAGGTG	AAGATCCTTT
8641	TTGATAATCT	CATGACCAAA	ATCCCTTAAC	GTGAGTTTTT	GTTCCACTGT	ACGTAAGACC
8701	CCCAAGCTTG	TCGACTGAAT	GGCGAATGGC	GCTTTGCCTG	GTTTCCGGCA	CCAGAAGCGG
30 8761	TGCCGGAAAG	CTGGCTGGAG	TGCGATCTTC	CTGAGGCCGA	TACTGTCGTC	GTCCCTCAA
8821	ACTGGCAGAT	GCACGGTTAC	GATGCGCCCA	TCTACACCAA	CGTAACCTAT	CCCATTACGG
8881	TCAATCCGCC	GTTTGTTCCC	ACGGAGAATC	CGACGGGTTG	TTACTCGCTC	ACATTTAATG
8941	TTGATGAAAG	CTGGCTACAG	GAGGCCCAGA	CGCGAATTAT	TTTTGATGGC	GTTCTATTG
9001	GTAAAAAAT	GAGCTGATTT	AACAAAAATT	TAACGCGAAT	TTTAACAAAA	TATTAACGTT
9061	TACAATTTAA	ATATTTGCTT	ATACAATCTT	CCTGTTTTTG	GGGCTTTTCT	GATTATCAAC
35 9121	CGGGGTACAT	ATGATTGACA	TGCTAGTTTT	ACGATTACCG	TTCATCGATT	CTCTTGTTTG
9181	CTCCAGACTC	TCAGGCAATG	ACCTGATAGC	CTTTGTAGAT	CTCTCAAAAA	TAGCTACCCT
9241	CTCCGGCATG	AATTTATCAG	CTAGAACGGT	TGAATATCAT	ATTGATGGTG	ATTTGACTGT
9301	CTCCGGCCTT	TCTCACCTTT	TTGAATCTTT	ACCTACACAT	TACTCAGGCA	TTGCATTTAA
9361	AATATATGAG	GGTTCTAAAA	ATTTTTATCC	TTGCGTTGAA	ATAAAGGCTT	CTCCCGCAAA
9421	AGTATTACAG	GGTCATAATG	TTTTTGGTAC	AACCGATTTA	GCTTTATGCT	CTGAGGCTTT
40 9481	ATTGCTTAAT	TTTGCTAATT	CTTTGCCTTG	CCTGTATGAT	TTATTGGATG	TT

Table 22: Primers used in RACE amplification:

Heavy chain	
HuCμ-FOR (1st PCR)	5'-TGG AAG AGG CAC GTT CTT TTC TTT-3'
HuCμ-Nested (2nd PCR)	5' CTT TTC TTT GTT GCC GTT GGG GTG-3'
Kappa light chain	
HuκFor (1st PCR)	5'-ACA CTC TCC CCT GTT GAA GCT CTT-3'
HuκForAscI(2nd PCR)	5'-ACC GCC TCC ACC GGG CGC GCC TTA TTA ACA CTC TCC CCT GTT GAA GCT CTT-3'
Lambda light chain	
HuλmbdaFor (1st PCR)	
HuCL2-FOR	5'-TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL7-FOR	5'-AGA GCA TTC TGC AGG GGC CAC TG-3'
HuλmbdaForAscI (2nd PCR)	
HuCL2-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GCC TTA TTA TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL7-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GCC TTA TTA AGA GCA TTC TGC AGG GGC CAC TG-3'
GeneRacer 5' Primers provided with the kit (Invitrogen)	
5'A 1st PCR	5'CGACTGGAGCACACGAGGACACTGA 3'
5'NA 2nd pCR	5'GGACACTGACATGGACTGAAGGAGTA-3'

Table 23: ONs used in Capture of kappa light chains using CJ method and *BsmAI*
All ONs are written 5' to 3'.

REdapters (6)

ON_20SK15012	gggAggATggAgAcTgggTc
ON_20SK15L12	gggAAGATggAgAcTgggTc
ON_20SK15A17	gggAgAgTggAgAcTgAgTc
ON_20SK15A27	gggTgccTggAgAcTgcgTc
ON_20SK15A11	gggTggcTggAgAcTgcgTc
ON_20SK15B3	gggAgTcTggAgAcTgggTc

Bridges (6)

kapbri1012	gggAggATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbri1L12	gggAAGATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbri1A17	gggAgAgTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbri1A27	gggTgccTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbri1A11	gggTggcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbri1B3	gggAgTcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg

Extender (5' biotinylated)

kapextl bio	ccTcTgTcAcAgTgcAcAAgAcATccAgATgAcccAgTcTcc
-------------	--

Primers

kaPCRtl	ccTcTgTcAcAgTgcAcAAgAc
kapfor	5'-aca ctc tcc cct gtt gaa gct ctt-3'

Table 24: PCR program for amplification of kappa DNA

95°C	5 minutes
95°C	15 seconds
65°C	30 seconds
72°C	1 minute
72°C	7 minutes
4°C	hold

Reagents (100 ul reaction) :

Template	50 ng
10x turbo PCR buffer	1x
turbo Pfu	4U
dNTPs	200 µM each
kaPCRtl	300 nM
kapfor	300 nM

Table 25: h3401-h2 captured Via CJ with BsmAI

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! S A Q D I Q M T Q S P A T L S
 aGTGCA Caa gac atc cag atg acc cag tct cca gcc acc ctg tct
 ! ApaLI... a gcc acc ! L25,L6,L20,L2,L16,A11
 ! Extender.....Bridge...

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
 ! V S P G E R A T L S C R A S Q
 gtg tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
 ! S V S N N L A W Y Q Q K P G Q
 agt gtt agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
 ! V P R L L I Y G A S T R A T D
 gtt ccc agg ctc ctc atc tat ggt gca tcc acc agg gcc act gat

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
 ! I P A R F S G S G S G T D F T
 atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc act

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
 ! L T I S R L E P E D F A V Y Y
 ctc acc atc agc aga ctg gag cct gaa gat ttt gca gtg tat tac

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
 ! C Q R Y G S S P G W T F G Q G
 tgt cag cgg tat ggt agc tca ccg ggg tgg acg ttc ggc caa ggg

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
 ! T K V E I K R T V A A P S V F
 acc aag gtg gaa atc aaa cga act gtg gct gca cca tct gtc ttc

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
 ! I F P P S D E Q L K S G T A S
 atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
 ! V V C L L N N F Y P R E A K V
 gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
 ! Q W K V D N A L Q S G N S Q E
 cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
 ! S V T E Q D S K D S T Y S L S
 agt gtc aca gag cag gac agc aag gac agc acc tac agc ctc agc

EP 1 578 903 B2

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195

! S T L T L S K A D Y E K H K V

agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa gtc

5

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! Y A C E V T H Q G L S S P V T

tac gcc tgc gaa gtc acc cat cag ggc ctg agc tgc cct gtc aca

10

! 211 212 213 214 215 216 217 218 219 220 221 222 223

! K S F N K G E C K G E F A

aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc.....

15

20

25

30

35

40

45

50

55

Table 26: h3401-d8 KAPPA captured with CJ and *BsmAI*

5
 ! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! S A Q D I Q M T Q S P A T L S
 aGT GCA Caa gac atc cag atg acc cag tct cct gcc acc ctg tct
 ! ApaLI...Extender.....g gcc acc ! L25,L6,L20,L2,L16,A11
 ! A GCC ACC CTG TCT ! L2

10
 ! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
 ! V S P G E R A T L S C R A S Q
 gtg tct cca ggt gaa aga gcc acc ctc tcc tgc agg gcc agt cag
 ! GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC ! L2

15
 ! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
 ! N L L S N L A W Y Q Q K P G Q
 aat ctt ctc agc aac tta gcc tgg tac cag cag aaa cct ggc cag

20
 ! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
 ! A P R L L I Y G A S T G A I G
 gct ccc agg ctc ctc atc tat ggt gct tcc acc ggg gcc att ggt

25
 ! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
 ! I P A R F S G S G S G T E F T
 atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gag ttc act

30
 ! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
 ! L T I S S L Q S E D F A V Y F
 ctc acc atc agc agc ctg cag tct gaa gat ttt gca gtg tat ttc

35
 ! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
 ! C Q Q Y G T S P P T F G G G T
 tgt cag cag tat ggt acc tca ccg ccc act ttc ggc gga ggg acc

40
 ! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
 ! K V E I K R T V A A P S V F I
 aag gtg gag atc aaa cga act gtg gct gca cca tct gtc ttc atc

45
 ! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
 ! F P P S D E Q L K S G T A S V
 ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt

50
 ! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
 ! V C P L N N F Y P R E A K V Q
 gtg tgc ccg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag

55
 ! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
 ! W K V D N A L Q S G N S Q E S
 tgg aag gtg gat aac gcc ctc caa tgc ggt aac tcc cag gag agt

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
 ! V T E Q D N K D S T Y S L S S
 gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc

EP 1 578 903 B2

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! T L T L S K V D Y E K H E V Y
acc ctg acg ctg agc aaa gta gac tac gag aaa cac gaa gtc tac

5

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! A C E V T H Q G L S S P V T K
gcc tgc gaa gtc acc cat cag ggc ctt agc tcg ccc gtc acg aag

10

! 211 212 213 214 215 216 217 218 219 220 221 222 223
! S F N R G E C K K E F V
agc ttc aac agg gga gag tgt aag aaa gaa ttc gtt t

15

20

25

30

35

40

45

50

55

Table 27: V3-23 VH framework with variegated codons shown

```

!
!           17 18 19 20 21 22
!           A Q P A M A
!
5  5'-ctg tct gaa cG GCC cag ccG GCC atg gcc 29
   3'-gac aga ctt gc cgg gtc ggc cgg tac cgg
   Scab.....SfiI.....
   NgoMI...
   NcoI....
!
!
10  FR1(DP47/V3-23)-----
   23 24 25 26 27 28 29 30
   E V Q L L E S G
   ga|gtt|CAA|TTG|tta|gag|tct|ggt| 53
   ctt|caalgtt|aac|aat|ctc|aga|cca|
   | MfeI |
!
!
! -----FR1-----
! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
! G G L V Q P G G S L R L S C A
! |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct| 98
20 |ccg|cca|gaa|caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|
!
! Sites to be varied--> *** *** ***
! ---FR1----->|...CDR1.....|---FR2-----
! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
! A S G F T F S S Y A M S W V R
25 |gct|TCC|GGA|ttc|act|ttc|tct|tCG|TAC|Gct|atg|tct|tgg|gtt|cgC| 143
! |cga|agg|cct|aag|tga|aag|aga|agc|atg|cga|tac|aga|acc|caa|gcg|
! | BspEI | | BsiWI | | BstXI.
!
! Sites to be varies--> *** *** ***
! ---FR2----->|...CDR2.....
! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
! Q A P G K G L E W V S A I S G
! |CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|gtt|tct|gct|atc|tct|ggt| 188
! |gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|cga|tag|aga|cca|
! ...BstXI |
35
!
! *** ***
! .....CDR2.....|---FR3---
! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
! S G G S T Y Y A D S V K G R F
! |tct|ggt|ggc|agt|act|tac|tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc| 233
40 |aga|cca|ccg|tca|tga|atg|ata|cga|ctg|agg|caa|ttt|cca|gcg|aag|
!
! ---FR3-----
! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! T I S R D N S K N T L Y L Q M
! |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| 278
45 |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|
! | XbaI |
!
! ---FR3----->|
! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
! N S L R A E D T A V Y Y C A K
! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 323
50 |ttg|tcg|aat|tcc|cga|ctc|ctg|tga|cgt|cag|atg|ata|acg|cga|ttt|
!
!
55

```

```

!      |AflII|      |PstI|
!
!      .....CDR3.....|---FR4-----
!      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!      D Y E G T G Y A F D I W G Q G
!      |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|caa|ggg| 368
!      |ctg|ata|ctt|cca|tga|cca|ata|ga|aag|ctg|tat|acc|cca|ggt|cca|
!      |NdeI|
!
!      -----FR4----->|
!      136 137 138 139 140 141 142
!      T M V T V S S
!      |act|atG|GTC|ACC|gtc|tct|agt- 389
!      |tga|tac|cag|tgg|cag|aga|tca-
!      |BstEII|
!
!      143 144 145 146 147 148 149 150 151 152
!      A S T K G P S V F P
!      gcc tcc acc aaG GGC CCa tgc GTC TTC ccc-3' 419
!      cgg agg tgg ttc ccg ggt agc cag aag ggg-5'
!      Bsp120I. BbsI...(2/2)
!      ApaI....

(SFPRMET) 5'-ctg tct gaa cG GCC cag ccG-3'
(TOPFR1A) 5'-ctg tct gaa cG GCC cag ccG GCC atg gcc-
          gaa|ggt|CAA|TTG|tta|gag|tct|ggg|
          |ggc|ggg|ctt|gtt|cag|cct|ggg|ggg|tct|tta-3'
(BOTFR1B) 3'-caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|-
          |cga|agg|cct|aag|tga|aag-5' ! bottom strand
(BOTFR2) 3'-acc|caa|gcg|-
          |ggt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga-5' ! bottom strand
(BOTFR3) 3'- a|cga|ctg|agg|caa|ttt|cca|gca|aag|-
          |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|-
          |ttg|tcg|aat|tcc|cga|ctc|ctg|tga-5'
(F06) 5'-gC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|-
          |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|c-3'
(BOTFR4) 3'-cga|aag|ctg|tat|acc|cca|ggt|cca|-
          |tga|tac|cag|tgg|cag|aga|tca-
          cgg agg tgg ttc ccg ggt agc cag aag ggg-5' ! bottom strand
(BOTPRCPRIM) 3'-gg ttc ccg ggt agc cag aag ggg-5'
!
! CDR1 diversity
!
! (ON-vgC1) 5'-lgct|TCC|GGA|ttc|act|ttc|tct|<1>|TAC|<1>|atg|<1>
!              CDR1.....6859
!              |tgg|gtt|cgc|CAa|gct|ccT|GG-3'
!
! <1> stands for an equimolar mix of {ADEFHGHIKLMNPQRSTVWY}; no C
! (this is not a sequence)
!
! CDR2 diversity
!
! (ON-vgC2) 5'-ggg|ttg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|-
!              CDR2.....
!              |tct|ggg|ggc|<1>|act|<1>|tat|gct|gac|tcc|gtt|aaa|gg-3'
!              CDR2.....
! <1> is an equimolar mixture of {ADEFHGHIKLMNPQRSTVWY}; no C
! <2> is an equimolar mixture of {YRWVGS}; no ACDEFHGHIKLMNPQT
!
! <3> is an equimolar mixture of {PS}; no ACDEFHGHIKLMNPQRTVWY

```

Table 28: Stuffer used in VH

1 TCCGGAGCTT CAGATCTGTT TGCCTTTTGT TGGGGTGGTG CAGATCGCGT TACGGAGATC
 61 GACCGACTGC TTGAGCAAAA GCCACGCTTA ACTGCTGATC AGGCATGGGA TGTTATTGCG
 121 CAAACCAATC GTCAGGATCT TAACCTGAGG CTTTTTTTAC CTACTCTGCA AGCAGCGACA
 181 TCTGGTTTGA CACAGAGCGA TCCGCGTCGT CAGTTGGTAG AACATTAAAC ACGTTGGGAT
 241 GGCATCAATT TGCTTAA TGA TGATGGTAA ACCTGGCAGC AGCCAGGCTC TGCCATCCTG
 301 AACGTTTGGC TGACCAAGTAT GTTGAAGCGT ACCGTAGTGG CTGCCGTACC TATGCCATTT
 361 GATAAGTGGT ACAGCGCCAG TGGCTACGAA ACAACCCAGG ACGGCCCAAC TGGTTCGCTG
 421 AATATAAGTG TTGGAGCAAA AATTTGTAT GAGGCGGTGC AGGAGAGCAA ATCACCATC
 481 CCACAGGCGG TTGATCTGTT TGCTGGGAAA CCACAGCAGG AGTTGTGTT GGCTGCGCTG
 541 GAAGATACCT GGGAGACTCT TTCCAAACGC TATGGCAATA ATGTAGTAA CTGGAAAAACA
 601 CCTGCAATGG CCTTAACGTT CCGGGCAAAT AATTCTTTG GTGTACCGCA GGCCGCAGCG
 661 GAAGAAACGC GTCATCAGGC GGAGTATCAA AACCGTGAA CAGAAAAACA TATGATTGTT
 721 TTCTCACCAA CGACAAAGCGA TCGTCCTGTG CTTGCCTGGG ATGTGGTTCG ACCCGGTGAG
 781 AGTGGGTTTA TTGCTCCCGA TGGAACAGTT GATAAGCACT ATGAAGATCA GCTGAAAAATG
 841 TACGAAAAAT TTGGCCGTAA GTCGCTCTGG TTAACGAAGC AGGATGTGGA GGCGCATAAAG
 901 GAGTCGTCTA GA

Table 29: DNA sequence of pCES5

```

! pCES5 6680 bases = pCes4 with stuffers in CDR1-2 and CDR3 2000.12.13
!
! Ngene = 6680
! Useful REs (cut MAAnoLI fewer than 3 times) 2000.06.05
!
! Non-cutters
! Acc65I Ggtacc Afel AGCgct AvrII Cctagg
! BsaBI GATNNnnatc BsiWI Cgtacg BsmFI Nnnnnnnnnnnnnngtccc
! BsrGI Tgtaca BstAPI GCANNNNnlgc BstBI TTcgaa
! BstZ17I GTAtac BtrI CACgtg Ecl136I GAGctc
! EcoRV GATatc FseI GGCCGGcc KpnI GGTACc
! MscI TGGcca NruI TCGcca NsiI ATGCAI
! PacI TTAAItaa PmeI GTTTaaac PmlI CACgtg
! PpuMI RCGwccy PshAI GACNNNngtc SacI GAGCTc
! SacII CCGCgg SbfI CCTGCagg SexAI Accwgg
! SgfI GCGATcgc SnaBI TACgta Spel Actagt
! SphI GCATGc Sse8387I CCTGCagg StuI AGGcct
! SwaI ATTTaat XmaI Ccgggg
!
! cutters
! Enzymes that cut more than 3 times.
! AlwNI CAGNNNctg 5
! BglI cgcac 4
! BsrFI Rccgy 5
! EarI CTCCTCNhnn 4
! FaeI nNNNNNGCGGG 10
!
! Enzymes that cut from 1 to 3 times.
!
! EcoO109I RGnccy 3 7 2636 4208
! BssSI Ctcgtg 1 12
! "- Caccag 1 1703
! BspHI Tcaiga 3 43 148 1156
! AatII GACGTc 1 65

```

5
10
15
20
25
30
35
40
45
50
55

!BciVI GTATCCNNNNNN 2 140 1667
 !Eco57I CTGAAG 1 301
 !"- ctcag 2 1349
 !AvaI CyeGg 3 319 2347 6137
 !BsiHKA I GWGCWc 3 401 2321 4245
 !HgiAI GWGCWc 3 401 2321 4245
 !BglI gcannnnnctg 1 461
 !ScaI AGTact 1 505
 !PvuI CGATeg 3 616 3598 5926
 !FspI TGCgca 2 763 5946
 !BglI GCCNNNNnggc 3 864 2771 5952
 !BpmI CTGGAG 1 898
 !"- cccag 1 4413
 !BsaI GGTCCTCnNNnn 1 916
 !AhdI GACNNNNngtc 1 983
 !EamI I05I GACNNNNngtc 1 983
 !DrdI GACNNNNngtc 3 1768 6197 6579
 !SapI gaagag 1 1998
 !PvuII CACgtg 3 2054 3689 5896
 !PflMI CCANNNNntgg 3 2233 3943 3991
 !HindIII Aagctt 1 2235
 !ApaLI Glgcac 1 2321
 !BspMI Nnnnnnnngcaggt 1 2328
 !"- ACCTGCNNNNn 2 3460
 !PstI CTGCAG 1 2335
 !AccI GTmkac 2 2341 2611
 !HincII GTYrac 2 2341 3730
 !SalI Gcgac 1 2341
 !TliI Ctcgag 1 2347
 !XhoI Ctcgag 1 2347
 !BbsI gcttc 2 2383 4219
 !BpI GCtnagc 1 2580
 !EspI GCtnagc 1 2580
 !SgrAI CRccgByg 1 2648
 !AclI Accggt 2 2649 4302
 !AscI GGcgcc 1 2689
 !BssHII Gcgagc 1 2690

5

10

15

20

25

30

35

40

45

50

55

```

!SfiI GGCCNNNNnggcc 1 2770
!NaeI GCCggc 2 2776 6349
!NgoMIV Gcggc 2 2776 6349
!BglI Ccrygg 3 2781 3553 5712
!Dsal Ccrygg 3 2781 3553 5712
!NcoI Ccatgg 1 2781
!StyI Ccwwgg 3 2781 4205 4472
!MfeI Caatg 1 2795
!BspEI Tcggga 1 2861
!BglII Agatct 1 2872
!BclI Tgata 1 2956
!Bsu36I CCTnagg 3 3004 4143 4373
!XcmI CCANNNNNnnnngg 1 3215
!MluI Acgct 1 3527
!HpaI GTTaac 1 3730
!XbaI Tctaga 1 3767
!
!AflII Cttaag 1 3811
!BsmI NGcatc 1 3821
!-. GAATGCN 1 4695
!RsrII CGgwcg 1 3827
!NheI Gctagc 1 4166
!BstEII Ggtnacc 1 4182
!BsmBI CGTCTCnmmn 2 4188 6625
!-. Nnnnnngagacg 1 6673
!ApaI GGGCCc 1 4209
!BanII GRGCYc 3 4209 4492 6319
!BspI20I Gggccc 1 4209
!PspOMI Gggccc 1 4209
!BseRI NNNnnnnncttc 1 4226
!-. GAGGAGNNNNNNNN 1 4957
!EcoNI CCTNnnnagg 1 4278
!PflFI GACNngtc 1 4308
!TthI I I I GACNngtc 1 4308
!KasI Gggccc 2 4327 5967
!BstXI CCANNNNNnnngg 1 4415
!NotI GCggccgc 1 4507

```

5

10

15

20

25

30

35

40

45

50

55

```

!EagI Cggccg      | 4508
!BamHI Ggaicc     | 5169
!BspDI ATcgat     | 5476
!NdeI CATatg      | 5672
!EcoRI Gaatic     | 5806
!PstI TTATAa      | 6118
!DraIII CACNNNgig | 6243
!BsaAI YACgtr     | 6246
|-----|
| 1 gacgaagg cTCGTGata cgcctatt tataggttaa tgcatagala alaatggtt
|      BssSI.(1/2)
| 61 ctaGACGTC aggtgcact ttccgggaa atg'gcgcgg aaccttatt tgtttatt
|      AatII.
| 121 tctaaata tcaaatatG TATCCgctca tgagacaata acccigataa algcttcaat
|      BciVI.(1 of 2)
| 181 aatatgaaa aaggaagagt
| Base # 201 to 1061 = AprR gene from pUC119 with some RE sites removed
|
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
| M S I Q H F R V A L I P F F A
| 201 atg agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt geg
|
| 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
| A F C L P V F A H P E T L V K
| 246 gca ttt tgc ctt cct gtt ttt gct cac cac cca gaa acg cttg gttg aaa
|
| 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
| V K D A E D Q L G A R V G Y I
| 291 gla aaa gat gct gaa gat cag ttg ggt gcc cga gttg ggt tac atc
|
| 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
| E L D L N S G K I L E S F R P
| 336 gaa cttg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc ccc
|
| 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
| E E R F P M M S T F K V L L C
| 381 gaa gaa cgt ttt cca alg atg agc act ttt aaa gtt cttg cta tgt

```

5

10

15

20

25

30

35

40

45

50

55

```

!   76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
!   G A V L S R I D A G Q E Q L G
!   426 ggc gcg gla tta tcc cgt att gac gcc ggg caa gaG CAa ctc ggT
!           Bgl.....
!
!   91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
!   R R I H Y S Q N D L V E Y S P
!   471 CGc cgc ala cac tat tcl cag aat gac ttg gtt gAG TAC Tca cca
!..Bgl.....
!           Scal.....
!
!   106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!   V T E K H L T D G M T V R E L
!   516 gtc aca gaa aag cat ctt acg gat ggc alg aca gla aga tta
!
!   121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!   C S A A I T M S D N T A A N L
!   561 tgc agt gct gcc ala acc atg agt gat aac act gcg gcc aac tta
!
!   136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
!   L L T T I G G P K E L T A F L
!   606 ctt ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg
!           PvuI.... (1/2)
!
!   151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
!   H N M G D H V T R L D R W E P
!   651 cac aac atg ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg
!
!   166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
!   E L N E A I P N D E R D T T M
!   696 gag ctg aat gaa gcc ala cca aac gac gag cgt gac acc acg atg
!
!   181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
!   P V A M A T T L R K L L T G E
!   741 cct gla GCA ATG gca aca cgt tTG CGC Aaa cta tta act ggc gaa
!           BsrDI..(1/2)   FspI.... (1/2)
!

```


5

10

15

20

25

30

35

40

45

50

55

```

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! L L T L A S R Q Q L I D W M E
786 cta ctt act cta gct tcc cgg caa tta ata gac tgg atg gag
!
! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
! A D K V A G P L L R S A L P A
831 geg gat aaa gtt gca gga cca ctt ctg cgc tgg gcc ctt ccg gct
!
! 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
! G W F I A D K S G A G E R G S
876 geg tgg ttt att gct gat aaa tCT GGA Gcc ggt gag cgt gGG TCT
! BpmI...(1/2) BsaI....
!
! 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
! R G I I A A L G P D G K P S R
921 Cgc ggt atC ATT GCa gca ctg ggg cca gat ggt aag ccc tcc cgt
! BsaI..... BsrDI...(2/2)
!
! 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
! I V V I Y T T G S Q A T M D E
966 atc gta gtt atc tac acG ACg egg aCT Cag gca act atg gat gaa
! AhdI.....
!
! 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
! R N R Q I A E I G A S L I K H
1011 cga aat aga cag atc gct gag ata ggt gcc tca ctg att aag cat
!
! 286 287
! W
!
1056 tgg taa
1062 ctgtcagac caagtttact
1081 calalalact ttatgatgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga
1141 tcttttnga taatctcag accaaaatcc cttaacgtga gttttcgttc cactgagcgt
1201 cagaccctcgt agaaaagatc aaaggatctt ctgagatccc tttttttcgc cgcgtaaact
1261 gcgtgttga aacaaaaaaa ccaccctac cagcgggtgt ttgtttgccc gatcaaggagc
1321 taccaaactt ttttcggaag gtaactgtgt tcaagcagagc gcagatacca aaactgtcc
1381 ttctagtga gccgtagtta ggccaccact tcaagaactc tgtagcaccg cclacalacc

```

5

10

15

20

25

30

35

40

45

50

55

```

1441 tcgctcgt aatccigtta ccagtgctg ctgcagctg ccgaaagctg tgcctacg
1501 gggtggactc aagacgatag ttaccgata aggcgcagcg gtccggctga acgggggggt
1561 cgtgcataca gccacgttg gagcgaaga cctacaccga acigagatac ctacacgtg
1621 agcatgaga aagcgccacg ctccggaag ggagaaaggc ggacagGTAT CCggtaagcg
! BclVI.. (2 of 2)
1681 gcagggtcgg aacagggag cgCACGAGgg agctccagg gggaaacgcc tggatctt
! BssSI..(2/2)
1741 atagtcctgt cgggtttgc caccctgac ttgagctgc atttttga tgcctgcag
1801 gggggcggag cctatgaaa aacccagca acgcggctt ttacggctc ctggccttt
1861 gctggcctt tgcACATG Tctttctg cgtatccc tgattctg gataacgta
! PciI...
1921 ttaccgctt tgagtgcgt gatccgctc gccgcagcg aacgacgag cgcagcgagt
1981 cagtgcgca ggaagcgGAA GAGCgcca tacgcaacc gccctcccc gcgctggc
! SapI....
2041 cgattcatia algCAGCTGg cagcacaggt ttccgactg gaaagcgggc agtgagcgca
! PvuII..(1/3)
2101 acgcaatTAA TGTgagtag ctactcatt aggcacccca ggcTTTACAc ttatgcttc
! ..-35.. Plac ..-10.
2161 cggctcgat gttgttga atttgagcg gatacaatt tcacaCAGGA AACAGCTATG
! M13Rev_seq_primer
2221 ACcatgatta cgCCAAGCTT TGGagcctt ttgttgaga tticaac
! PfiM1.....
! Hind3.
! signal::linker::CLight
!
! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
! fM K L L F A I P L V V P F Y
2269 gtc aaa tta tta ttc gca att cct tta gtt cct ttc tat
!
! Linker..... End of FR4
! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
! S H S A Q V Q L Q V D L E I K
2314 tct cac aGT GCA Cag gtc caa CTG CAG GTC GAC CTC GAG atc aaa
! ApaLI..... PstI... XhoI...
! BspMI...
! SalI...
! AccI...(1/2)

```

123

5

10

15

20

25

30

35

40

45

50

55

```

!      136 137 138 139 140
!      G E C . .
! 2674 gga gag tgt taa taa GG CGCGCCAatt
!      AscI.....
!      BssHII.
!
! 2701 ctatttcaag gagacagtca ta
!
! PelB::3-23(stuffed)::CH1::III fusion gene
!
!      1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
!      M K Y L L P T A A A G L L L L
! 2723 atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
!
!-----
!      16 17 18 19 20 21 22
!      A A Q P A M A
! 2768 gcG GCC cag ccG GCC atg gcc
!      SfiI.....
!      NgoMIV..(1/2)
!      NcoI....
!
!      FRI(DP47/V3-23)-----
!      23 24 25 26 27 28 29 30
!      E V Q L L E S G
!      gaalgt|CAA|TTG|ta|gag|ct|gg|
!      |MfeI |
! 2789
!
!-----FRJ-----
!      31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
!      G G L V Q P G G S L R L S C A
! 2813 |ggc|gg|ctt|gtt|cag|cct|ggg|ggg|tct|ta|cgt|ctt|tct|tgc|gct|

```

5
10
15
20
25
30
35
40
45
50
55

```

! ----FR1-----
! 46 47 48
!   A S G
!
! 2858 |gc|TCC|GGA|
!      |BspEI|
!
!
!   Stuffer for CDR1, FR2, and CDR2----->
!   There are no stop codons in this stuffer.
!
! 2867      gctcAGATC Tgtttgctt
!           BglI..
!
! 2887 ttgtggggt ggtgcagatc gcgttacaga gategaccga ctgcttgagc aaaagccacg
! 2947 cttaadgct GATCaggcat gggatgttat tcgccaacc agtcgcagg aictaaact
!           BclI...
!
! 3007 gaggccttt ttacctactc tgcagcagc gacatcgggt ttgacacaga gcgacccgcg
! 3067 tcgtcagttg gtagaacat taacacgttg ggaigggcat aatttgctta atgatgatgg
! 3127 taaaacctgg cagcagccag gcctgcocat ccgaaacgtt tggcigacca gtaigtgaa
! 3187 gcgtacogta gtggcgccg tacctatgCC Attgataag TGGIacagcg ccagtggcta
!           XcmI.....
!
! 3247 cgaacaacc caggcggcc caactggctc gcigaaata agtgtggag caaaaattt
! 3307 gtagaggcg gtcagggag acaaatcacc aaiccacag gcggttgalc tgttgctgg
! 3367 gaaaccacag caggaggttg tgtggctgc gctggaagat accleggaga ctcttccaa
! 3427 acgctatggc aataatgta gtaactggaa aacacctgca atggccttaa cgttcgggc
! 3487 aaataattc ttgtgttac cgcagccgc agcgggaaga ACGCGTcatc aggcggagta
!           MluI..
!
! 3547 tcaaacctg tgaacagaaa acgataatgat tgttttca ccaacgacaa gcgatgctc
! 3607 tgcctgccc tgggatggg tcgcaccggg tcagagtggg ttatgctc ccgatggaac
! 3667 agttgataag cactatgaag atcagctgaa aatgtacgaa aatttggcc gtaagtcgt
!           PvuII.
!
! 3727 ctgGTTAACg aagcaggatg tggagcgca taaggagtcg
!           HpaI..
!           HincII(2/2)
!
!
! -----FR3-----
!   4 5 6 7 8 9 10 11 12 13 14 15 16
!   93 94 95 96 97 98 99 100 101 102 103 104 105
!   S R D N S K N T L Y L Q M
!
! 3767 |TCT|AGA|gac|aac|ct|aag|aat|act|ctc|tac|ttg|cag|atg|

```

5
10
15
20
25
30
35
40
45
50
55

```

! | XbaI |
!
! ---FR3----->|
! 17 18 19 20
! 106 107 108 109
! N S L s l s i r s g
3806 |aac|agC|TTA|AG t ctg agc att CCG TCC G
! |AflII| RsrII..
!
! q h s p t .
3834 gg caa cat tct cca aac tga ccagacga cacaacggc
3872 ttacgctaaa tccgcgcac ggga|tg|taa agag|ggc|g tctt|gtc|gg cc|ggactca
3932 tcagatgaag gccaaaat| ggca|ggag|g|g|gacacagcag gccagcgaac aagcactgac
3992 calcaactcg tactat|ctg|atg|taaacgg caata|tgg|t|atg|t|cata ctg|gtc|t|a
4052 tccagatcgt caatc|aggcc|atg|atc|cgc|g|at|acc|g|t| cc|gg|t|ac|gg|g|g|aaal|gg|ga
4112 ctggaaagg|g|ctat|g|c|ctt|t|g|aaal|g|aa|c|c|ta|a|gg|g|g|tata|a|c|c|c|c|c|c|ag
4164 aa GCTAGC ctgcgcttc
! NheI..
!
4182 G|GTC|ACC| gtc tca agc
! |BstEII|
!
! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
! A S T K G P S V F P L A P S S
4198 gcc tcc acc aag ggc cca tgg gtc ttc ccc ctg gca ccc tcc tcc
!
! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! K S T S G T A A L G C L V K
4243 aag agc acc tct|ggg|ggc|aca|g|c|g|g|c|c|c|ctg|ggc|tgc|ctg|gtc|aag
!
! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! D Y F P E P V T V S W N S G A
4288 gac tac ttc ccc gaa ccg g|g|g|acg|g|g|t|cg|t|gg|aac|tca|ggc|ggc
!

```

5

10

15

20

25

30

35

40

45

50

55

```

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! L T S G V H T F P A V L Q S S
4333 ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tcc tca
!
! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! G L Y S L S S V V T V P S S S
4378 gga ctc tac tcc ctc agc agc gta gtc acc gtc ccc tcc agc agc
!
! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
! L G T Q T Y I C N V N H K P S
4423 ttg ggc acc cag acc tac atc tgc aac gtc aat cac aag ccc agc
!
! 226 227 228 229 230 231 232 233 234 235 236 237 238
! N T K V D K K V E P K S C
4468 aac acc aag gtc gac aaG AAA GTT GAG CCC AAA TCT TGT
! ON-TQHCforw.....
!
! Poly His linker
! 139 140 141 142 143 144 145 146 147 148 149 150
! A A A H H H H G A A
4507 GCG GCC GCa cat cat cac cat ccc ggg gcc gca
! Notl.....
! Eagl....
!
! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! E Q K L I S E D L N G A A
4543 gaa caa aaa ctc atc tca gaa gag gat ctg aat ggg gcc gca tag
!
! Mature III----->...
! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! T V E S C L A K P H T E N S F
4588 act gtt gaa agt tgt tta gca aaa cct cat aca gaa aat tca ttt
!
! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! T N V W K D K T L D R Y A N
4633 act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac
!

```

5

10

15

20

25

30

35

40

45

50

55

```

!   196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
!   Y E G C L W N A T G V V C T
!   4678 tat gag ggc tgt ctg tgG AAT GCt aca ggc gtt glg gtt tgt act
!       BsmI....
!
!   211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
!   G D E T Q C Y G T W V P I G L
!   4723 ggt gac gaa act cag tgt tac ggt aca tgg gtt cct att ggg cit
!
!   226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
!   A I P E N E G G S E G G S
!   4768 gct atc cct gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct
!
!   241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
!   E G G S E G G T K P P E Y
!   4813 gag ggt ggc ggt tct gag ggt ggc ggt act aaa cct cct gag tac
!
!   256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
!   G D T P I P G Y T Y I N P L D
!   4858 ggt gat aca cct att ccg ggc tat act tat atc aac cct ctc gac
!
!   271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
!   G T Y P P G T E Q N P A N P N
!   4903 ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct aat
!
!   286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
!   P S L E E S Q P L N T F M F Q
!   4948 cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg tti cag
!       BseRI..(2/2)
!
!   301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
!   N N R F R N R Q G A L T V Y T
!   4993 aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg
!
!   316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
!   G T V T Q G T D P V K T Y Y Q
!   5038 ggc act gtt act caa ggc act gac ccc gtt aaa act tat tac cag

```


5

10

15

20

25

30

35

40

45

50

55

```

!      331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
!      Y T P V S S K A M Y D A Y W N
! 5083  tac act cct gta tca tca aaa gcc atg tat gac gct tac tgg aac
!
!      346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
!      G K F R D C A F H S G F N E D
! 5128  ggt aaa ttc aga gac tgc gct ttc cat tct ggc tt aat gaG GAT
!      BamHI..
!
!      361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
!      P F V C E Y Q G Q S S D L P Q
! 5173  Cca ttc gtt tgt gaa tat caa ggc caa tgc tct gAC CTG Cct caa
!      BamHI...
!      BspMI...(2/2)
!
!      376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
!      P P V N A G G S G G S G G
! 5218  cct cct gtc aat gct ggc ggc tct ggt ggt tct ggt ggc
!
!      391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
!      G S E G G S E G G S E G G
! 5263  ggc tct gag ggt ggc tct gag ggt ggc tct gag ggt ggc
!
!      406 407 408 409 410 411 412 413 414 415 416 417 418 419 420
!      G S E G G S G G S G S G D
! 5308  ggc tct gag ggt ggc tcc ggt ggc tcc ggt tcc ggt gat
!
!      421 422 423 424 425 426 427 428 429 430 431 432 433 434 435
!      F D Y E K M A N A N K G A M T
! 5353  tt gat tat gaa aaa atg gca aac gct aat aag ggg gct atg acc
!
!      436 437 438 439 440 441 442 443 444 445 446 447 448 449 450
!      E N A D E N A L Q S D A K G K
! 5398  gaa aat gcc gat gaa aac gcg cia cag tct gac gct aaa ggc aaa
!

```

5

10

15

20

25

30

35

40

45

50

55

```

! 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465
! L D S V A T D Y G A A I D G F
5443 ctt gat tct gtc gct act gat tac ggt gct gct ATC GAT ggt ttc
!
! BspDI..
!
! 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480
! I G D V S G L A N G N G A T G
5488 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt
!
! 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495
! D F A G S N S Q M A Q V G D G
5533 gat ttt gct ggc tct aat tcc caa alg gct caa gtc ggt gac ggt
!
! 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510
! D N S P L M N N F R Q Y L P S
5578 gat aat tca cct tta atg aat aat ttc cgt caa tat tta cct tct
!
! 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525
! L P Q S V E C R P Y V F G A G
5623 ttg cct cag tcg gtt gaa tgt cgc cct tat gtc ttt ggc gct ggt
!
! 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540
! K P Y E F S I D C D K I N L F
5668 aaa cCA TAT Gaa ttt att gat tgt gac aaa ata aac tta ttc
! NdeI...
!
! 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555
! R G V F A F L L Y V A T F M Y
5713 cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt alg tat
!
! 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570
! V F S T F A N I L R N K E S
5758 gta ttt tcg acg ttt gct aac ata ctg cgt aat aag gag tct taa
!

```

5

10

15

20

25

30

35

40

45

50

55

```

! 571
!
5803 taa GAATTC
! EcoRI.
5812 actgcccgt cgtttacaa cgtcgtgact gggaaaacc lggcgtacc caactaac
5871 gccitgcagc acatcccci ttgccagct ggctgaalag cgaagaggcc cgcacCGATC
! PvuI..
5931 Gcccttccca acagtTGGCG AGccigaatg gcgaatGGCG CCigatgogg tatttctcc
! ...PvuI... (3/3) FspI... (2/2) KsiI... (2/2)
5991 ttacgcact gtgcggta ttacaccgca tataatgt aaacgtaat atttgttaa
6051 aatcgcgtt aaatttgt taaatcagct catttttaa ccaataggcc gaaatcgcca
6111 aaatccTTA TAAatcaaaa gaatagccc agatagggtt gagtgtgt ccagttgga
! PstI...
6171 acaagagtc actattaag aacgtggact ccaacglca agggcgaaaa accgtctatc
6231 agggc-gatgg ccCACTacGT Gaacalcac ccaatcaag tttttggg lcgagglgcc
! DraIII...
6291 gtaagcact aaatcggaac cclaaaggga gcccgcgatt tagagctga cggggaaaaGC
! NgoMIV..
6351 CGGCgaact ggcgagaag gaagggaaga agcgaaagg agcgggcgt agggcgcgtgg
! ..NgoMIV (2/2)
6411 caagltagc ggltacgtcg cgcgtaacca ccacaccgc cgcgcctaac ggcgcgtac
6471 agggcgcta ctatgttgc ttgacgggt gacgtctcag tacaatgc tctgatgccg
6531 catagtaag ccagcccca caccggcca caccgcctga cgggctgtgc
6591 tgcctccggc atccgttac agacaagcig taccgctc cgggagcgc atgtgtcaga
6651 ggittcacc gtcacaccg aaacgcgga

```

Table 30: Oligonucleotides used to clone CDR1/2 diversity

All sequences are 5' to 3'.

1) ON_CDIBsp, 30 bases

5
A c c T c A c T g g c T T c c g g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

T T c A c T T T c T c T
19 20 21 22 23 24 25 26 27 28 29 30

2) ON_Br12, 42 bases

10
A g A A A c c c A c T c c A A A c c
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

T T T A c c A g g A g c T T g g c g
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

A A c c c A
37 38 39 40 41 42

3) ON_CD2Xba, 51 bases

20
g g A A g g c A g T g A T c T A g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

g A T A g T g A A g c g A c c T T T
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

A A c g g A g T c A g c A T A
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

4) ON_BotXba, 23 bases

30
g g A A g g c A g T g A T c T A g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

g A T A g
19 20 21 22 23

Table 31: Bridge/Extender Oligonucleotides

35
ON_Lam1aB7(rc)GTGCTGACTCAGCCACCCTC. 20
ON_Lam2aB7(rc)GCCCTGACTCAGCCTGCCTC. 20
ON_Lam31B7(rc)GAGCTGACTCAGG.ACCCTGC 20
ON_Lam3rB7(rc)GAGCTGACTCAGCCACCCTC. 20
ON_LamHf1cBrg(rc) CCTCGACAGCGAAGTGCACAGAGCGTCTTGACTCAGCC..... 38
ON_LamHf1cExt CCTCGACAGCGAAGTGCACAGAGCGTCTTG..... 30
ON_LamHf2b2Brg(rc) CCTCGACAGCGAAGTGCACAGAGCGCTTTGACTCAGCC..... 38
ON_LamHf2b2Ext CCTCGACAGCGAAGTGCACAGAGCGCTTTG..... 30
ON_LamHf2dBrg(rc) CCTCGACAGCTAAGTGCACAGAGCGCTTTGACTCAGCC..... 38
ON_LamHf2dExt CCTCGACAGCGAAGTGCACAGAGCGCTTTG..... 30
ON_LamHf31Brg(rc) CCTCGACAGCGAAGTGCACAGAGCGAATTGACTCAGCC..... 38
ON_LamHf31Ext CCTCGACAGCGAAGTGCACAGAGCGAATTG..... 30
ON_LamHf3rBrg(rc) CCTCGACAGCGAAGTGCACAGTACGAATTGACTCAGCC..... 38
ON_LamHf3rExt CCTCGACAGCGAAGTGCACAGTACGAATTG..... 30
ON_lamPlePCR CCTCGACAGCGAAGTGCACAG..... 21
Consensus

Table 32: Oligonucleotides used to make SSDNA locally double-stranded

Adapters (8)

H43HF3.1?02#1 5'-cc gtg tat tac tgt gcg aga g-3'
H43.77.97.1-03#2 5'-ct gtg tat tac tgt gcg aga g-3'
H43.77.97.323#22 5'-cc gta tat tac tgt gcg aaa g-3'
H43.77.97.330#23 5'-ct gtg tat tac tgt gcg aaa g-3'
H43.77.97.439#44 5'-ct gtg tat tac tgt gcg aga c-3'
H43.77.97.551#48 5'-cc atg tat tac tgt gcg aga c-3'

Table 33: Bridge/extender pairs

Bridges (2)

H43.XABr1

5'ggtgtagtgaTCTAGtgacaactctaagaatactcttacttgcagatgaacagCTTtAGgc
ctgaggacaCTGCAGtctactattgtgcgaga-3'

H43.XABr2

5'ggtgtagtgaTCTAGtgacaactctaagaatactcttacttgcagatgaacagCTTtAGgc
ctgaggacaCTGCAGtctactattgtgcgaaa-3'

Extender

H43.XAExt

5'ATAgTAGAcTgcAgTgTccTcAgccccTTAAgcTgTTcATcTgcAAgTAGAgAgTATTcTTAg
AgTTgTcTcTAGATcActTAcAcc-3'

Table 34: PCR primers

Primers

H43.XAPCR2 gactgggTgTAgTgATcTAg
Hucmnest ctttcttgttgccgtggggtg

Table 35: PCR program for amplification of heavy chain CDR3 DNA

95 degrees C	5 minutes	
95 degrees C	20 seconds	
60 degrees C	30 seconds	repeat 20x
72 degrees C	1 minute	
72 degrees C	7 minutes	
4 degrees C	hold	

Reagents (100 ul reaction):

Template	5ul ligation mix
10x PCR buffer	1x
Taq	5U
dNTPs	200 uM each
MgCl2	2mM
H43.XAPCR2-biotin	400 nM
Hucmnest	200 nM

! Table 36: Annotated sequence of CJR DY3F7 (CJR-A05) 10251 bases

! Non-cutters

!BclI Tgatca	BsiWI Cgtacg	BssSI Caccgag
!BstZ17I GTAtac	BtrI CACgtg	EcoRV GATatc
!FseI GGCCGGcc	HpaI GTTaaC	MluI Acgcgt
!PmeI GTTTaaac	PmlI CACgtg	PpuMI RGgwccy
!RsrII CGgwccg	SapI GCTCTTC	SexAI Accwgtt
!SgfI GCGATcgC	SgrAI CRccggyg	SphI GCATGc
!StuI AGGcct	XmaI Cccggg	

! cutters

! Enzymes that cut from 1 to 4 times and other features

!End of genes II and X		829		
!Start gene V		843		
!BsrGI Tgtaca	1	1021		
!BspMI Nnnnnnnnnngcaggt	3	1104	5997	9183
!-"- ACCTGCNNNNn	1	2281		
!End of gene V		1106		
!Start gene VII		1108		
!BsaBI GATNNnnatc	2	1149	3967	
!Start gene IX		1208		
!End gene VII		1211		
!SnaBI TACgta	2	1268	7133	
!BspHI Tcatga	3	1299	6085	7093
!Start gene VIII		1301		
!End gene IX		1304		
!End gene VIII		1522		
!Start gene III		1578		
!EagI Cggccg	2	1630	8905	
!XbaI Tctaga	2	1643	8436	
!KasI Ggcgcc	4	1650	8724	9039 9120
!BsmI GAATGCN	2	1769	9065	
!BseRI GAGGAGNNNNNNNNNN	2	2031	8516	
!-"- NNNnnnnnnnctcctc	2	7603	8623	
!AlwNI CAGNNNctg	3	2210	8072	8182
!BspDI ATcgat	2	2520	9883	
!NdeI CATatg	3	2716	3796	9847
!End gene III		2846		
!Start gene VI		2848		
!AfeI AGCgct	1	3032		
!End gene VI		3187		
!Start gene I		3189		
!EarI CTCTTCNnnn	2	4067	9274	
!-"- Nnnnngaagag	2	6126	8953	
!PacI TTAATtaa	1	4125		
!Start gene IV		4213		
!End gene I		4235		
!BsmFI Nnnnnnnnnnnnnnnngtccc	2	5068	9515	
!MscI TGGcca	3	5073	7597	9160
!PsiI TTAtaa	2	5349	5837	
!End gene IV		5493		
!Start ori		5494		
!NgoMIV Gccggc	3	5606	8213	9315
!BanII GRGCYc	4	5636	8080	8606 8889
!DraIII CACNNNgtg	1	5709		
!DrdI GACNNNNnnngtc	1	5752		
!AvaI Cycgrg	2	5818	7240	

EP 1 578 903 B2

	!PvuII CAGctg	1	5953		
	!BsmBI CGTCTCNnnnn	3	5964	8585	9271
	!End ori region		5993		
	!BamHI Ggatcc	1	5994		
5	!HindIII Aagctt	3	6000	7147	7384
	!BciVI GTATCCNNNNNN	1	6077		
	!Start bla		6138		
	!Eco57I CTGAAG	2	6238	7716	
	!SpeI Actagt	1	6257		
10	!BcgI gcannnnnntcg	1	6398		
	!ScaI AGTact	1	6442		
	!PvuI CGATcg	1	6553		
	!FspI TGCgca	1	6700		
	!BglI GCCNNNNnggc	3	6801	8208	8976
	!BsaI GGTCTCNnnnn	1	6853		
15	!AhdI GACNNNngtc	1	6920		
	!Eam1105I GACNNNngtc	1	6920		
	!End bla		6998		
	!AccI GTmkac	2	7153	8048	
	!HincII GTYrac	1	7153		
	!SalI Gtcgac	1	7153		
20	!XhoI Ctcgag	1	7240		
	!Start PlacZ region		7246		
	!End PlacZ region		7381		
	!PflMI CCANNNNntgg	1	7382		
	!RBS1		7405		
25	!start M13-iii signal seq for LC		7418		
	!ApaLI Gtgcac	1	7470		
	!end M13-iii signal seq		7471		
	!Start light chain kappa L20:JK1		7472		
	!PflFI GACNngtc	3	7489	8705	9099
	!SbfI CCTGCagg	1	7542		
30	!PstI CTGCag	1	7543		
	!KpnI GGTACc	1	7581		
	!XcmI CCANNNNNnnntgg	2	7585	9215	
	!NsiI ATGCAc	2	7626	9503	
	!BsgI ctgcac	1	7809		
	!BbsI gtcttc	2	7820	8616	
35	!BlpI GCtnagc	1	8017		
	!EspI GCtnagc	1	8017		
	!EcoO109I RGgnccy	2	8073	8605	
	!Ecl136I GAGctc	1	8080		
	!SacI GAGCTc	1	8080		
	!End light chain		8122		
40	!AscI GGcgcgcc	1	8126		
	!BssHII Gcgcgcc	1	8127		
	!RBS2		8147		
	!SfiI GGCCNNNNnggcc	1	8207		
	!NcoI Ccatgg	1	8218		
45	!Start 3-23, FR1		8226		
	!MfeI Caattg	1	8232		
	!BspEI Tccgga	1	8298		
	!Start CDR1		8316		
	!Start FR2		8331		
	!BstXI CCANNNNNntgg	2	8339	8812	
50	!EcoNI CCTNNnnnagg	2	8346	8675	
	!Start FR3		8373		
	!XbaI Tctaga	2	8436	1643	
	!AflII Cttaag	1	8480		
	!Start CDR3		8520		
55	!AatII GACGTc	1	8556		

```

!Start FR4                                8562
!PshAI GACNNnngtc                        2   8573   9231
!BstEII Ggtnacc                          1   8579
!Start CH1                                8595
5  !ApaI GGGCCc                            1   8606
!Bsp120I Gggccc                          1   8606
!PspOMI Gggccc                           1   8606
!AgeI Accggt                             1   8699
!Bsu36I CCtnagg                          2   8770   9509
10 !End of CH1                             8903
!NotI GCggccgc                           1   8904
!Start His6 tag                           8913
!Start cMyc tag                           8931
!Amber codon                             8982
!NheI Gctagc                             1   8985
15 !Start M13 III Domain 3                 8997
!NruI TCGcga                             1   9106
!BstBI TTcgaa                            1   9197
!EcoRI Gaattc                             1   9200
!XcmI CCANNNNNnnntgg                     1   9215
!BstAPI GCANNNNntgc                       1   9337
20 !SacII CCGCgg                          1   9365
!End IIIstump anchor                     9455
!AvrII Cctagg                             1   9462
!trp terminator                           9470
!SwaI ATTTaaat                           1   9784
25 !Start gene II                         9850
!BglII Agatct                             1   9936
!-----
1 aat gct act act att agt aga att gat gcc acc ttt tca gct cgc gcc
! gene ii continued
49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta
30 97 tct aat ggt caa act aaa tct act cgt tcg cag aat tgg gaa tca act
145 gtt aTa tgg aat gaa act tcc aga cac cgt act tta gtt gca tat tta
193 aaa cat gtt gag cta cag caT TaT att cag caa tta agc tct aag cca
241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc tct
289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgt ttt gaa gct
337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt
35 385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac
433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa gca
481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg gac
! Start gene x, ii continues
529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct
40 577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt cgt gta aac
625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg
673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg
721 atg aat ctt tct acc tgt aat aat gtt gtt ccg tta gtt cgt ttt att
769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt
817 ctt aaa atc gca TAA
45 ! End X & II
832 ggtaattca ca
!
! M1 E5 Q10 T15
843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt
! Start gene V
50 !
! S17 S20 P25 E30
891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cag ctt
!
! V35 E40 V45
55 939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att act

```



```

!
!           D50           A55           L60
!   987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cat
!                                     BsrGI...
5 !           L65           V70           S75           R80
!   1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gac cgt
!
!           P85           K87 end of V
!   1083 ctg cgc ctc gtt ccg gct aag TAA C
!
10 !   1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg
!       Start gene VII
!
!   1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc
!
!           VII and IX overlap.
15 !           ..... S2 V3 L4 V5           S10
!   1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tct ttT gcc tct ttc gtt
!       End VII
!       |start IX
!           L13           W15           G20           T25           E29
20 !   1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta atg gaa
!
!   1293 act tcc tc
!
!       .... stop of IX, IX and VIII overlap by four bases
!   1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc
25 !       Start signal sequence of viii.
!
!   1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg
!       mature VIII --->
!   1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg
!   1445 tgg gcg atg gtt gtt gtc att
30 !   1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
!
! bases 1499-1539 are probable promoter for iii
!   1499 aaa ttc acc tcg aaa gca ! 1515
!       ..... -35 ..
!
35 !   1517 agc tga taaaccgat acaattaaag gctccttttg
!       ..... -10 ...
!
!   1552 gagccttttt ttt GGAGAt ttt ! S.D. uppercase, there may be 9 Ts
!
!       <----- III signal sequence ----->
40 !       M K K L L F A I P L V V P F
!   1574 caac GTG aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc ! 1620
!
!       Y S G A A E S H L D G A
!   1620 tat tct ggc gCG GCC Gaa tca caT CTA GAc ggc gcc
45 !       EagI.... XbaI....
!
! Domain 1 -----
!       A E T V E S C L A
!   1656 gct gaa act gtt gaa agt tgt tta gca
!
!       K S H T E I S F T N V W K D D K T
50 !   1683 aaA Tcc cat aca gaa aat tca ttt aCT AAC GTC TGG AAA GAC GAC AAA ACT
!
!       L D R Y A N Y E G S L W N A T G V
!   1734 tta gat cgt tac gct aac tat gag ggC tgt ctg tgG AAT GcT aca ggc gtt
55

```

BsmI....

```

!
!
!      V   V   C   T   G   D   E   T   Q   C   Y   G   T   W   V   P   I
1785 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att
5
!
!      G   L   A   I   P   E   N
1836 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
!      E   G   G   G   S   E   G   G   G   S
10 1857 gag ggt ggt ggc tct gag ggt ggc ggt tct
!
!      E   G   G   G   S   E   G   G   G   T
1887 gag ggt ggc ggt tct gag ggt ggc ggt act
!
! Domain 2 -----
15 1917 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac
1968 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct
2019 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat
!
!      BseRI..
2070 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act
20 2118 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct
2166 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA
!
!      AlwNI
2214 GAC TGc gct ttc cat tct ggc ttt aat gaG gat TTa ttT gtt tgt gaa
!
!      AlwNI
2262 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
25
!
2307 ggc ggc ggc tct
! start L2 -----
2319 ggt ggt ggt tct
2331 ggt ggc ggc tct
30 2343 gag ggt ggt ggc tct gag gga ggc ggt tcc
2373 ggt ggt ggc tct ggt ! end L2
!
! Many published sequences of M13-derived phage have a longer linker
! than shown here by repeats of the EGGGS motif two more times.
!
! Domain 3 -----
35
!      S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
2388 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct
!
!      M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
2436 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc
40
!
!      K   L   D   S   V   A   T   D   Y   G   A   A   M   D   G   F
2484 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc
!
!      I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
2532 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat
45
!
!      F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
2580 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat
!
!      S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
50 2628 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa
!
!      S   V   E   C   R   P   F   V   F   G   A   G   K   P   Y   E
2676 tcg gtt gaa tgt cgc cct ttt gtc ttt Ggc gct ggt aaa cca tat gaa
!
!      F   S   I   D   C   D   K   I   N   L   F   R
55

```

```

2724 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
                                     End Domain 3
!
!
!
5  !   G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F140
! 2760 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt
!   start transmembrane segment
!
!   S   T   F   A   N   I   L
! 2808 tct acg ttt gct aac ata ctg
!
!
10 !   R   N   K   E   S
! 2829 cgt aat aag gag tct TAA ! stop of iii
!   Intracellular anchor.
!
!
!
15 !   M1 P2 V   L L5   G   I   P   L L10 L   R   F   L   G15
! 2847 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt
!   Start VI
!
!
!
20 ! 2894 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag
! 2942 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt att
! 2990 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct
! 3038 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct
! 3086 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct att
! 3134 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat
!
!
!
25 !   M1 A2 V3   F5   L10   G13
! 3182 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!   end VI   Start gene I
!
!
!
!   K   T   L   V   S   V   G   K   I   Q   D   K   I   V   A
! 3228 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!
30 !   G   C   K   I   A   T   N   L   D   L   R   L   Q   N   L
! 3273 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!
!   P   Q   V   G   R   F   A   K   T   P   R   V   L   R   I
! 3318 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!
35 !   P   D   K   P   S   I   S   D   L   L   A   I   G   R   G
! 3363 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
!
!
!   N   D   S   Y   D   E   N   K   N   G   L   L   V   L   D
! 3408 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
!
40 !   E   C   G   T   W   F   N   T   R   S   W   N   D   K   E
! 3453 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!
!
!   R   Q   P   I   I   D   W   F   L   H   A   R   K   L   G
! 3498 aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga
!
!
45 !   W   D   I   I   F   L   V   Q   D   L   S   I   V   D   K
! 3543 tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa
!
!
!   Q   A   R   S   A   L   A   E   H   V   V   Y   C   R   R
! 3588 cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt
!
!
50 !   L   D   R   I   T   L   P   F   V   G   T   L   Y   S   L
! 3633 ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt
!
!
!   I   T   G   S   K   M   P   L   P   K   L   H   V   G   V
! 3678 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt
!
55

```

```

!
!   V   K   Y   G   D   S   Q   L   S   P   T   V   E   R   W
3723 gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg
!
!   L   Y   T   G   K   N   L   Y   N   A   Y   D   T   K   Q
5 3768 ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag
!
!   A   F   S   S   N   Y   D   S   G   V   Y   S   Y   L   T
!   3813 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg
!
!   P   Y   L   S   H   G   R   Y   F   K   P   L   N   L   G
10 3858 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt
!
!   Q   K   M   K   L   T   K   I   Y   L   K   K   F   S   R
!   3903 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc
!
!   V   L   C   L   A   I   G   F   A   S   A   F   T   Y   S
15 3948 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt
!
!   Y   I   T   Q   P   K   P   E   V   K   K   V   V   S   Q
!   3993 tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct cag
!
!   T   Y   D   F   D   K   F   T   I   D   S   S   Q   R   L
20 4038 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt
!
!   N   L   S   Y   R   Y   V   F   K   D   S   K   G   K   L
!   4083 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA
25                                     PacI
!
!   I   N   S   D   D   L   Q   K   Q   G   Y   S   L   T   Y
!   4128 ATT AAT agc gac gat tta cag aag caa ggt tat tca ctc aca tat
!   PacI
!
!   i   I   D   L   C   T   V   S   I   K   K   G   N   S   N   E
30 iv                                     M1 K
!   4173 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
!                                       Start IV
!
!   i   I   V   K   C   N   .End of I
!   iv  L3 L  N5 V  I7 N  F  V10
!   4218 att gtt aaa tgt aat TAA T TTT GTT
!   IV continued.....
!   4243 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg
!   4291 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca
40 4339 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta
!   4387 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct
!   4435 gtt tta cgt gcA aat aat ttt gat atg gtA ggt tcT aAC cct tcc atT
!   4483 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca
!   4531 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt
45 4579 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat
!   4627 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag
!   4675 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat
!   4723 cta tta gtt gtt agt gcT cct aaa gat att tta gat aac ctt cct caa
!   4771 ttc ctt tcA act gtt gat ttg cca act gac cag ata ttg att gag ggt
!   4819 ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct
50 4867 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc
!   4915 ctc acc tct gtt tta tct tct gct ggt ggt tcg ttc ggt att ttt aat
!   4963 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat
!   5011 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag
!   5059 ggt tct atc tct gtT GGC CAg aat gtc cct ttt att act ggt cgt gtg
!
!   MscI....
55

```

```

5107 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt
5155 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc
5203 ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct
5251 tct act cag gca agt gat gtt att act aat caa aga agt att gct aca
5299 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act
5347 gat tat aaa aac act tct caG gat tct ggc gta ccg ttc ctg tct aaa
5395 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tct aac gag
5443 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg
5491 TAG cggcgcatt
! End IV
10 5503 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccttagc
5563 gcccgctcct ttcgctttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca
! NgoMI.
5623 agctctaaat cgggggctcc ctttaggggtt ccgatttagt gctttacggc acctcgaccc
5683 caaaaaactt gatttggttg atgggtCACG TAGTGggcca tgcacctgat agacgggttt
! DraIII....
15 5743 tgcacctttG ACGTTGGAGT Ccactgtctt taatagtga ctcttggtcc aaactggaac
! DrdI.....
5803 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga
5863 accaccatca aacaggattt tgcctgctg gggcaaacca gcgtggaccg cttgctgcaa
5923 ctctctcagg gccaggcggg gaagggaat CAGCTGttgc cCGTCTCact ggtgaaaaga
! PvuII. BsmBI.
20 5983 aaaaccaccc tGGATCC AAGCTT
! BamHI HindIII (1/2)
! Insert carrying bla gene
6006 gcagggtg gcacttttcg gggaaatgtg cgcggaaccc
6043 ctatttggtt atttttctaa atacattcaa atatGTATCC gctcatgaga caataaccct
! BciVI
25 6103 gataaatgct tcaataatat tgaaaaAGGA AGAgT
! RBS.?...
! Start bla gene
6138 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt
6189 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct
30 6240 gaa gat cag ttg ggC gCA CTA GTg ggt tac atc gaa ctg gat ctc aac agc
! SpeI....
! ApaLI & BssSI Removed
6291 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc
6342 act ttt aaa gtt ctg cta tgt GGC GcG Gta tta tcc cgt att gac gcc ggg
6393 caa gaG CAA CTC GGT CGc cgC ATA cAC tat tct cag aat gac ttg gtt gAG
35 ! BcgI..... ScaI
6444 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa
! ScaI.
6495 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt
6546 ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg cac aac atg
! PvuI....
40 6597 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc
6648 ata cca aac gac gag cgt gac acc acg atg cct gta gca atg Gca aca acg
6699 tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa
! FspI....
!
45 6750 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tgc
6801 GCC ctt ccG GcT ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt
! BglI.....
6852 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt
! BsaI....
6903 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa cga aat
! AhdI.....
50 6954 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt
! stop
7003 cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa
7063 ggatctaggt gaagatcctt ttgataatc tcatgaccaa aatcccttaa cgtgagtttt

```

7123 cgttccactg tacgtaagac cccc
 7147 AAGCTT GTCGAC tgaa tggcgaatgg cgctttgcct
 ! HindIII SalI..
 ! (2/2) HincII

5 7183 ggtttccggc accagaagcg gtgccggaaa gctggctgga gtgcgatctt

! Start of Fab-display cassette, the Fab DSR-A05, selected for
 ! binding to a protein antigen.

10 7233 CCTGAcG CTCGAG
 ! xBsu36I XhoI..

! PlacZ promoter is in the following block

7246 cgcaacgc aattaatgtg agttagctca
 7274 ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg
 15 7324 tgttgaattg tgagcggata acaatttcac acaggaaaca gctatgacca
 7374 tgattacgCC AagcttTGGA gccttttttt tggagatttt caac

PflMI.....

Hind3. (there are 3)

! Gene iii signal sequence:

20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! M K K L L F A I P L V V P F Y
 7418 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat

16 17 18 Start light chain (L20:JK1)

25 S H S A Q D I Q M T Q S P A
 7463 tct cac aGT GCA Caa gac atc caq atg acc caq tct cca gcc

ApaLI...

Sequence supplied by extender.....

30 T L S L
 7505 acc ctg tct ttg

S P G E R A T L S C R A S Q G
 7517 tct cca ggg gaa aga gcc acc ctc tcc tgc agg gcc agt cag Ggt

V S S Y L A W Y Q Q K P G Q A
 35 7562 gtt agc agc tac tta gcc tgg tac cag cag aaa cct ggc cag gct

P R L L I Y D A S S R A T G I
 7607 ccc agg ctc ctc atc tat gAt gca tcc aAc agg gcc act ggc atc

P A R F S G S G P G T D F T L
 40 7652 cca gCc agg ttc agt ggc agt ggg Cct ggg aca gac ttc act ctc

T I S S L E P E D F A V Y Y C
 7697 acc atc agc agC ctA gag cct gaa gat ttt gca gtT tat tac tgt

45 Q Q R S W H P W T F G Q G T R
 7742 cag cag CGT aAc tgg cat ccg tgg ACG TTC GGC CAA GGG ACC AAG

V E I K R T V A A P S V F I F
 7787 gtg gaa atc aaa cga act gtg gCT GCA Cca tct gtc ttc atc ttc
 ! BsgI....

50 P P S D E Q L K S G T A S V V
 7832 ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg

C L L N N F Y P R E A K V Q W
 7877 tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg

```

!
!      K   V   D   N   A   L   Q   S   G   N   S   Q   E   S   V
7922  aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc
!
!      T   E   R   D   S   K   D   S   T   Y   S   L   S   S   T
5 7967  aca gag cgg gac agc aag gac agc acc tac agc ctc agc agc acc
!
!      L   T   L   S   K   A   D   Y   E   K   H   K   V   Y   A
8012  ctg acG CTG AGC aaa gca gac tac gag aaa cac aaa gtc tac gcc
!      EspI.....
!
!      C   E   V   T   H   Q   G   L   S   S   P   V   T   K   S
10 8057  tgc gaa gtc acc cat cag ggc ctG AGC TCg ccc gtc aca aag agc
!      SacI....
!
!      F   N   R   G   E   C   .   .
15 8102  ttc aac agg gga gag tgt taa taa
!
!      GGCGCG CCaattctat ttcaaGGAGA cagtcata
8126  AscI..... RBS2.
!
!      PelB signal sequence----- (22 codons)----->
20      1   2   3   4   5   6   7   8   9  10  11  12  13  14  15
!      M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L
8160  atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
!
!      ...PelB signal-----> Start VH, FR1----->
25      16  17  18  19  20  21  22  23  24  25  26  27  28  29  30
!      A   A   Q   P   A   M   A   E   V   Q   L   L   E   S   G
8205  gcG GCC cag ccG GCC atg gcc gaa gtt CAA TTG tta gag tct ggt
!      SfiI..... MfeI...
!      NcoI....
!
!      31  32  33  34  35  36  37  38  39  40  41  42  43  44  45
30 8250  G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A
!      ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct
!
!      ...FR1-----> CDR1-----> FR2----->
35      46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
!      A   S   G   F   T   F   S   T   Y   E   M   R   W   V   R
8295  gct TCC GGA ttc act ttc tct act tac gag atg cgt tgg gtt cgC
!      BspEI... BstXI...
!
!      FR2-----> CDR2 ----->
40      61  62  63  64  65  66  67  68  69  70  71  72  73  74  75
!      Q   A   P   G   K   G   L   E   W   V   S   Y   I   A   P
8340  CAa gct ccT GGt aaa ggt ttg gag tgg gtt tct tat atc gct cct
!      BstXI.....
!
!      ...CDR2-----> FR3----->
45      76  77  78  79  80  81  82  83  84  85  86  87  88  89  90
!      S   G   G   D   T   A   Y   A   D   S   V   K   G   R   F
8385  tct ggt ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc
!
!      91  92  93  94  95  96  97  98  99 100 101 102 103 104 105
!      T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M
50 8430  act atc TCT AGA gac aac tct aaq aat act ctc tac ttq caq atq
!      XbaI...
!      Supplied by extender-----
!
!      -----FR3----->

```

```

!      106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!      N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R
8475   aac aqC TTA AGg gct qag qac act qca qtc tac tat tgt gcg agg
!      AflIII...
5   from extender----->

!      CDR3-----> FR4-->
!      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!      R   L   D   G   Y   I   S   Y   Y   Y   G   M   D   V   W
10  8520   agg ctc gat ggc tat att tcc tac tac tac ggt atg GAC GTC tgg
!      AatII..

!      136 137 138 139 140 141 142 143 144 145
!      G   Q   G   T   T   V   T   V   S   S
15  8565   ggc caa ggg acc acG GTC ACC gtc tca agc
!      BstEII...

!      CH1 of IgG1----->
!      A   S   T   K   G   P   S   V   F   P   L   A   P   S   S
20  8595   gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc
!      K   S   T   S   G   G   T   A   A   L   G   C   L   V   K
!      aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag
!      D   Y   F   P   E   P   V   T   V   S   W   N   S   G   A
25  8685   gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc
!      L   T   S   G   V   H   T   F   P   A   V   L   Q   S   S
!      ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tCC TCA
30  8730   Bsu36I....
!      G   L   Y   S   L   S   S   V   V   T   V   P   S   S   S
!      GGa ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc
!      Bsu36I....

!      L   G   T   Q   T   Y   I   C   N   V   N   H   K   P   S
35  8820   ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc
!      N   T   K   V   D   K   K   V   E   P   K   S   C   A   A
!      aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt GCG GCC
!      NotI.....

!      A   H   H   H   H   H   H   G   A   A   E   Q   K   L   I
40  8910   GCa cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc
!      ..NotI.... H6 tag..... Myc-Tag.....

!      S   E   E   D   L   N   G   A   A   q   A   S   S   A
!      tca gaa gag gat ctg aat ggg gcc gca tag GCT AGC tct gct
!      Myc-Tag..... NheI...
!      Amber

45  III'stump

!      Domain 3 of III -----
!      S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
50  8997   agt ggc gac ttc gac tac gag aaa atg gct aat gcc aac aaa GGC GCC
!      tcc   t   t   t   t   t   a   g           a   c   t   t   g   g   t   !W.T.
!      KasI...(2/4)

!      M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
55

```



```

9045 atG ACT GAG AAC GCT GAC GAG aat gct ttg caa agc gat gcc aag ggt
      c a t c t a c g c a g t c t c t a c !W.T.
5
      K L D S V A T D Y G A A I D G F
9093 aag tta gac agc gTC GCG Acc gac tat GGC GCC gcc ATC GAc ggc ttt
      a c t t t c t t t c t t t c !W.T.
      NruI.... KasI...(3/4)
      I G D V S G L A N G N G A T G D
9141 atc ggc gat gtc agt ggt tTG GCC Aac ggc aac gga gcc acc gga gac
      t t c t t c c c t t t t t t t t !W.T.
      MscI....(3/3)
      F A G S N S Q M A Q V G D G D N
9189 ttc GCA GGT tcG AAT TCt cag atg gcC CAG GTT GGA GAT GGg gac aac
      t t c t c a t a c t c t t t !W.T.
      BspMI.. (2/2) XcmI.....
      EcoRI....
      S P L M N N F R Q Y L P S L P Q
9237 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg cag
      tca t t a t t c c t a t t a t c c t a !W.T.
      S V E C R P F V F S A G K P Y E
9285 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gag
      tcg t a t c t t c t agc t t a a t a !W.T.
25
      F S I D C D K I N L F R
9333 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC
      t t c t t t c a a c t a c t !W.T.
      BstAPI..... SacII...
      End Domain 3
      G V F A F L L Y V A T F M Y V F
9369 GGc gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc
      t c t g t c t t a t t c c t t a t !W.T.
      start transmembrane segment
      S T F A N I L R N K E S
9417 aGC ACT TTC GCC AAT ATT TTA Cgc aac aaa gaa agc
      t c t g t t c a c g t t g g t c t !W.T.
      Intracellular anchor.
      tag tga tct CCT AGG
9453
      AvrII..
9468 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt
      | Trp terminator |
End Fab cassette
9503 ATGCAT CCTGAGG ccgat actgtcgtcg tcccctcaaa ctggcagatg
      NsiI.. Bsu36I.(3/3)
9551 cacggttacg atgcgcccac ctacaccaac gtgacctatc ccattacggt caatccgccg
9611 tttgttccca cggagaatcc gacgggttgt tactcgctca catttaatgt tgatgaaagc
9671 tggctacagg aaggccagac gcgaattatt ttgatggcg ttcctattgg ttaaaaaatg
9731 agctgattta acaaaaattt aaTgcgaatt ttaacaaaat attaacgttt acaATTATAA
      SwaI...
9791 Tatttgctta tacaatcttc ctgttttttg ggctttttctg attatcaacc GGGGTAcac
9850 ATG att gac atg cta gtt tta cga tta ccg ttc atc gat tct ctt gtt tgc

```

EP 1 578 903 B2

```

!      Start gene II
 9901 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata
!
 9952 gct acc ctc tcc ggc atT aat tta tca gct aga acg gtt gaa tat cat att
10003 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct tta cct
10054 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt
10105 tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat
10156 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt
10207 aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt !
! gene II continues
!----- End of Table -----

```

Table 37: DNA seq of w.t. M13 gene iii

```

1      1  2  3  4  5  6  7  8  9 10 11 12 13 14 15
fM    K  K  L  L  F  A  I  P  L  V  V  P  F  Y
5      1579 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat
Signal sequence.....

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
S  H  S  A  E  T  V  E  S  C  L  A  K  P  H
10      1624 tct cac tcc gct gaa act gtt gaa agt tgt tta gca aaa ccc cat
Signal sequence> Domain 1-----

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
T  E  N  S  F  T  N  V  W  K  D  D  K  T  L
15      1669 aca gaa aat tca ttt act aac gtc tgg aaa gac gac aaa act tta
Domain 1-----

46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
D  R  Y  A  N  Y  E  G  C  L  W  N  A  T  G
20      1714 gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GcT aca ggc
BsmI....
Domain 1-----

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
V  V  V  C  T  G  D  E  T  Q  C  Y  G  T  W
25      1759 gtt gta gtt tgt act ggt gac gaa act cag tgt tac ggt aca tgg
Domain 1-----

76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
V  P  I  G  L  A  I  P  E  N  E  G  G  G  S
30      1804 gtt cct att ggg ctt gct atc cct gaa aat gag ggt ggt ggc tct
Domain 1-----> Linker 1-----

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
E  G  G  G  S  E  G  G  G  S  E  G  G  G  T
35      1849 gag ggt ggc ggt tct gag ggt ggc ggt tct gag ggt ggc ggt act
Linker 1----->

106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
K  P  P  E  Y  G  D  T  P  I  P  G  Y  T  Y
40      1894 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat
Domain 2-----

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
I  N  P  L  D  G  T  Y  P  P  G  T  E  Q  N
45      1939 atc aac cct ctc gac ggc act taT CCG CCt ggt act gag caa aac
EciI....
Domain 2-----

136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
P  A  N  P  N  P  S  L  E  E  S  Q  P  L  N
50      1984 ccc gct aat cct aat cct tct ctt GAG GAG tct cag cct ctt aat
BseRI..
Domain 2-----

151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
T  F  M  F  Q  N  N  R  F  R  N  R  Q  G  A
55      2029 act ttc atg ttt cag aat aat agg ttc cga aat agg cag ggg gca
Domain 2-----

166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

```

EP 1 578 903 B2

```

!      L   T   V   Y   T   G   T   V   T   Q   G   T   D   P   V
2074 tta act gtt tat acg ggc act gtt act caa ggc act gac ccc gtt
!      Domain 2-----
5      !
!      181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
!      K   T   Y   Y   Q   Y   T   P   V   S   S   K   A   M   Y
2119 aaa act tat tac cag tac act cct gta tca tca aaa gcc atg tat
!      Domain 2-----
10     !
!      196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
!      D   A   Y   W   N   G   K   F   R   D   C   A   F   H   S
2164 gac gct tac tgg aac ggt aaa ttC AGa gaC TGc gct ttc cat tct
!      AlwNI.....
!      Domain 2-----
15     !
!      211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
!      G   F   N   E   D   P   F   V   C   E   Y   Q   G   Q   S
2209 ggc ttt aat gaG GAT CCa ttc gtt tgt gaa tat caa ggc caa tcg
!      BamHI...
!      Domain 2-----
20     !
!      226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
!      S   D   L   P   Q   P   P   V   N   A   G   G   G   S   G
2254 tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt
!      Domain 2-----> Linker 2-----
25     !
!      241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
!      G   G   S   G   G   G   S   E   G   G   G   S   E   G   G
2299 ggt ggt tct ggt ggc ggc tct gag ggt ggt ggc tct gag ggt ggc
!      Linker 2-----
30     !
!      256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
!      G   S   E   G   G   G   S   E   G   G   G   S   G   G   G
2344 ggt tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc
!      Linker 2-----
35     !
!      271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
!      S   G   S   G   D   F   D   Y   E   K   M   A   N   A   N
2389 tct ggt tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat
! Linker 2> Domain 3-----
40     !
!      286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
!      K   G   A   M   T   E   N   A   D   E   N   A   L   Q   S
2434 aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta cag tct
!      Domain 3-----
45     !
!      301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
!      D   A   K   G   K   L   D   S   V   A   T   D   Y   G   A
2479 gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct
!      Domain 3-----
50     !
!      316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
!      A   I   D   G   F   I   G   D   V   S   G   L   A   N   G
2524 gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt
!      Domain 3-----
55     !
!      331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
!      N   G   A   T   G   D   F   A   G   S   N   S   Q   M   A
2569 aat ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct
!      Domain 3-----

```

EP 1 578 903 B2

```

!      346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
!      Q   V   G   D   G   D   N   S   P   L   M   N   N   F   R
2614  caa gtc ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt
!      Domain 3-----
5
!      361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
!      Q   Y   L   P   S   L   P   Q   S   V   E   C   R   P   F
2659  caa tat tta cct tcc ctc cct caa tcg gtt gaa tgt cgc cct ttt
!      Domain 3-----
10
!      376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
!      V   F   S   A   G   K   P   Y   E   F   S   I   D   C   D
2704  gtc ttt agc gct ggt aaa cca tat gaa ttt tct att gat tgt gac
!      Domain 3-----
15
!      391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
!      K   I   N   L   F   R   G   V   F   A   F   L   L   Y   V
2749  aaa ata aac tta ttc cgt ggt gtc ttt gcg ttt ctt tta tat gtt
!      Domain 3-----> Transmembrane segment-----
!
!      406 407 408 409 410 411 412 413 414 415 416 417 418 419 420
!      A   T   F   M   Y   V   F   S   T   F   A   N   I   L   R
2794  gcc acc ttt atg tat gta ttt tct acg ttt gct aac ata ctg cgt
!      Transmembrane segment-----> ICA--
!
!      421 422 423 424 425
!      N   K   E   S   .
2839  aat aag gag tct taa ! 2853
!      ICA-----> ICA = intracellular anchor
!
!----- End of Table -----

```

Table 38: Whole mature III anchor M13-III
derived anchor with recoded DNA

```

!
!      1   2   3
!      A   A   A
5      1   GCG gcc gca
!      NotI.....
!
!      4   5   6   7   8   9  10  11  12  13  14  15  16  17
!      H   H   H   H   H   H   G   A   A   E   Q   K   L   I
10     10   cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc
!
!      18  19  20  21  22  23  24  25  26  27  28  29
!      S   E   E   D   L   N   G   A   A   .   A   S
!      52   tca gaa gag gat ctg aat ggg gcc gca Tag GCT AGC
15     NheI...
!
!      30  31  32  33  34  35  36      37  38  39
!      D   I   N   D   D   R   M      A   S   T
!      88   GAT ATC aac gat gat cgt atg gct tct act
! (ON_G37bot) [RC] 5'-c aac gat gat cgt atg gcG CAt Gct gcc gag aca g-3'
20     EcoRV..
!     Enterokinase cleavage site.
!
! Start mature III (recoded) Domain 1 ---->
!      40  41  42  43
!      A   E   T   V
25     118   |gcC|gaG|acA|gtC|
!           t   a   t   t ! W.T.
!
!      44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
!      E   S   C   L   A   K   P   H   T   E   N   S   F   T   N
30     130   |gaa|TCC|tgC|CTG|GCC|AaG|ccT|caC|acT|gaG|aat|AGT|ttC|aCA|Aat|
!           agt   t t a   a   a   c   t   a   a   tca   t   t   c ! W.T.
!           MscI....
!
!      59  60  61  62  63  64  65  66  67  68  69  70  71  72  73
!      V   W   K   D   D   K   T   L   D   R   Y   A   N   Y   E
35     175   |gtg|TGG|aaG|gaT|gaT|aaG|acC|CtT|gAT|CGA|TaT|gcC|aaT|taC|gaA|
!           c           a   c   c   a   t t a           t   c   t   c   t   g ! W.T.
!           BspDI...
!
!      74  75  76  77  78  79  80  81  82  83  84  85  86  87  88
!      G   C   L   W   N   A   T   G   V   V   V   C   T   G   D
40     220   |ggC|tgC|TtA|tgg|aat|gcC|ACC|GGC|GtC|gtT|gtC|TGC|ACG|ggC|gaT|
!           t   t c g           t   a           t   t   t   t   c ! W.T.
!           SgrAI..... BsgI....
!
!      89  90  91  92  93  94  95  96  97  98  99  100 101 102 103
!      E   T   Q   C   Y   G   T   W   V   P   I   G   L   A   I
45     265   |gaG|acA|caA|tgC|taT|ggC|ACG|TGg|gtG|ccG|atA|gGC|TTA|GCC|atA|
!           a   t   g   t   c   t   a           t   t   t   g c t   t   c ! W.T.
!           PmlI..... BlpI.....
!
! Domain 1-----> Linker 1----->
!      104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
!      P   E   N   E   G   G   G   S   E   G   G   G   S   E   G
50     310   |ccG|gaG|aaC|gaA|ggC|ggC|ggT|AGC|gaA|ggC|ggT|ggC|AGC|gaA|ggC|
!           t   a   t   g   t   t   c tct   g   t   c   t tct   g   t ! W.T.
!
! Linker 1-----> Domain 2----->

```

55

```

!      HincII.
!
!      Linker 2-----> Domain 3-->
!      269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
5      E   G   G   G   S   E   G   G   G   S   G   G   G   S   G
!      805 |gaA|ggC|ggA|ggT|AGC|gaA|ggA|ggT|ggC|AGC|ggA|ggC|ggT|AGC|ggC|
!           g   t   t   c tct   g   t   c   t tct   g   t   c tct   t   ! W.T.
!
!      -----Domain 3----->
!      284 285 286 287 288 289 290 291 292 293 294 295 296 297 298
10     S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G
!      850 |AGT|ggC|gac|ttc|gac|tac|gag|aaa|atg|gct|aat|gcc|aac|aaa|GGC|
!           tcc   t   t   t   t   t   t   a   g           a   c   t   t   g   g   ! W.T.
!                                     KasI....
!
!      299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
15     A   M   T   E   N   A   D   E   N   A   L   Q   S   D   A
!      895 |GCC|atg|act|gag|aac|gct|gac|gaG|AAT|GCA|ctg|caa|agt|gat|gCC|
!           t           c   a   t   c   t   a   c   g   a   g tct   c   t   ! W.T.
!      KasI....                      BsmI....                      StyI...
!
!      314 315 316 317 318 319 320 321 322 323 324 325 326 327 328
20     K   G   K   L   D   S   V   A   T   D   Y   G   A   A   I
!      940 |AAG|GGt|aag|tta|gac|agc|gTC|GCc|Aca|gac|tat|ggT|Gct|gcc|atc|
!           a   c   a c t   t tct           t   t   t   c           t           ! W.T.
!      StyI.....                      PflFI.....
!
!      329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
25     D   G   F   I   G   D   V   S   G   L   A   N   G   N   G
!      985 |gac|ggc|ttt|atc|ggc|gat|gtc|agt|ggt|ctg|gct|aac|ggc|aac|gga|
!           t   t   c   t   t   c   t tcc   c c t           t   t   t   t   ! W.T.
!
!      344 345 346 347 348 349 350 351 352 353
30     A   T   G   D   F   A   G   S   N   S
!      1030 |gcc|acc|gga|gac|ttc|GCA|GGT|tcG|AAT|TCt|
!           t   t   t   t   t   t   c   t           c   ! W.T.
!                                     BstBI...
!                                     EcoRI...
!                                     BspMI..
!
!      354 355 356 357 358 359 360 361 362 363
35     Q   M   A   Q   V   G   D   G   D   N
!      1060 cag atg gcC CAG GTT GGA GAT GGg gac aac
!           a           t   a   c   t   c   t   t   t   ! W.T.
!                                     XcmI.....
!
!      364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379
40     S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
!      1090 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg cag
!           tca   t t a           t   t   c c t   a   t t a   t   c   c   t   a   ! W.T.
!
!      380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395
45     S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
!      1138 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gag
!           tcg   t   a   t   c   t   t   c   t   agc   t   t   a   a   t   a   ! W.T.
!
!      Domain 3----->
!      396 397 398 399 400 401 402 403 404 405 406 407
50     F   S   I   D   C   D   K   I   N   L   F   R
!      1186 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC
!           t tct   t   t   t   c   a   a   c t a           t

```



```

!           BstAPI.....                      SacII...
!
!           transmembrane segment----->
!           408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423
5 !           G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F
! 1222 GGC gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc
!           t   c   t   g   t   c   t   a   t   t   c   c   t           t   a   t   ! W.T.
!
!           424 425 426 427 428 429 430           431 432 433 434 435
!           S   T   F   A   N   I   L           R   N   K   E   S
10 ! 1270 aGC ACT TTC GCC AAT ATT TTA           Cgc aac aaa gaa agc
!           tct   g   t   t   c   a   c   g           t   t   g   g   tct ! W.T.
!
!           Intracellular anchor.
!
!
! 1306           tag tga tct CCT AGG
15 !
!           AvrII..
!
! 1321 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt
!           | Trp terminator |
!
! End Fab cassette
20 !----- End of Table -----

```

Table 39: ONs to make deletions in III

```

! ONs for use with NheI
!
25 N
! (ON_G29bot)           5'-c gTT gAT ATc gCT Agc cTA Tgc-3' !
22
! this is the reverse complement of 5'-gca tag gct agc gat atc aac g-3'
!                               NheI... scab.....
30 ! (ON_G104top) 5'-g|ata|ggc|tta|gCT|aGC|ccg|gag|aac|gaa|gg-3' !
30
!           Scab.....NheI... 104 105 106 107 108
! (ON_G236top) 5'-c|ttt|cac|agc|ggg|ttc|GCT|AGC|gac|cct|ttt|gtc|tgc-3' !
37
!           NheI... 236 237 238 239 240
35 ! (ON_G236tCS) 5'-c|ttt|cac|agc|ggg|ttc|GCT|AGC|gac|cct|ttt|gtc|Agc-
!           NheI... 236 237 238 239 240
!           gag|tac|cag|ggg|c-3' !
50
!
40 ! ONs for use with SphI G CAT Gc
! (ON_X37bot)           5'-gAc TgT cTc ggc Agc ATg cgc cAT Acg ATc ATc gTT g-3' !
37
!           N   D   D   R   M   A   H   A
! (ON_X37bot)=[RC] 5'-c aac gat gat cgt atg gcG CAT Gct gcc gag aca gtc-3'
!                               SphI....Scab.....
45 ! (ON_X104top) 5'-g|gtG ccg|ata|ggc|ttG|CAT|GCa|ccg|gag|aac|gaa|gg-3' !
36
!           Scab.....SphI.... 104 105 106 107 108
! (ON_X236top) 5'-c|ttt|cac|agc|ggg|ttG|CaT|gCa|gac|cct|ttt|gtc|tgc-3' !
37
!           SphI.... 236 237 238 239 240
50 ! (ON_X236tCS) 5'-c|ttt|cac|agc|ggg|ttG|CaT|gCa|gac|cct|ttt|gtc|Agc-
!           NheI... 236 237 238 239 240
!           gag|tac|cag|ggg|c-3' !
50

```

55

Table 40: Phage titers and enrichments of a selections with a DY3F31-based human Fab library

	Input (total cfu)	Output (total cfu)	Output/input ratio
R1-ox selected on phOx-BSA	4,5 x 10 ¹²	3,4 x 10 ⁵	7,5 x 10 ⁻⁸
R2-Strep selected on Strep-beads	9,2 x 10 ¹²	3 x 10 ⁸	3,3 x 10 ⁻⁵

Table 41: Frequency of ELISA positives in DY3F31-based Fab libraries

	Anti-M13 HRP	9E10/RAM-HRP	Anti-CK/CL Gar-HRP
R2-ox (with IPTG induction)	18/44	10/44	10/44
R2-ox (without IPTG)	13/44	ND	ND
R3-strep (with IPTG)	39/44	38/44	36/44
R3-strep (without IPTG)	33/44	ND	ND

SEQUENCE LISTING

[0200]

<110> LADNER, ROBERT C.
 COHEN, EDWARD H.
 NASTRI, HORACIO G.
 ROOKEY, KRISTIN L.
 HOET, RENE
 HOOGENBOOM, HENDRICUS R. J. M.

<120> NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES

<130> DYAX/002 CIP2

<140> 10/045,674
 <141> 2001-10-25

<150> 06/198,069
 <151> 2000-04-17

<150> 09/837,306
 <151> 2001-04-17

<160> 635

<170> PatentIn Ver. 2.1

<210> 1
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 1
 catgtgtatt actgtgc 17

<210> 2
 <211> 44
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 2
 10 cacatccgtg ctcttgac ggatgtggca cagtaataca catg 44
 <210> 3
 <211> 18
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 3
 gtgtattaga ctgctgcc 18
 <210> 4
 <211> 43
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 4
 ggcagcagtc taatacacca catccgtgtt cttcacggat gtg 43
 <210> 5
 35 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 5
 cacatccgtg ttgttacac ggatgtggtg tcttacagtc cattctg 47
 45 <210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 6
 55 cagaatggac tgtaagacac 20
 <210> 7
 <211> 43
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 5
 <400> 7
 atcgagtctc actgagccac atccgtggtt ttccacggat gtg 43
 <210> 8
 10 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 8
 gctcagtgag actcgat 17
 20 <210> 9
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 30 <222> (10)..(24)
 <223> A, T, C, G, other or unknown
 <400> 9
 cacgaggagn nnnnnnnnnn nnnn 24
 35 <210> 10
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 10
 45 atgaccgaat tgctacaag 19
 <210> 11
 <211> 46
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 55 <400> 11
 gactcctcag ctcttgctg aggagtcctt gtagcaattc ggtcat 46
 <210> 12

EP 1 578 903 B2

<211>> 6
 <212> PRT
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: 6 His tag

<400> 12

10 His His His His His His
 1 5

<210> 13
 <211> 10
 15 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

20 <220>
 <221> modified_base
 <222> (6)..(10)
 <223> A, T, C, G, other or unknown

25 <400> 13
 gtctcnnnnn 10

<210> 14
 30 <211> 11
 <212> DNA
 <213> Artificial Sequence

<220>
 35 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (1)..(6)
 40 <223> A, T, C, G, other or unknown

<400> 14
 nnnnnngaga c 11

45 <210> 15
 <211> 24
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 55 <222> (11)..(24)
 <223> A, T, C, G, other or unknown

<400> 15

5 cacggatgtg nnnnnnnnnn nnnn 24
 <210> 16
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (1)..(14)
 <223> A, T, C, G, other or unknown
 15 <400> 16
 nnnnnnnnnn nnnncacatc cgtg 24
 <210> 17
 20 <211> 14
 <212> DNA
 <213> Artificial Sequence
 <220>
 25 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 17
 gtgtattact gtgc 14
 30 <210> 18
 <211> 34
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 18
 40 cacatccgtg cacggatgtg gcacagtaat acac 34
 <210> 19
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 19
 50 gtgtattaga ctgc 14
 <210> 20
 <211> 34
 <212> DNA
 55 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

EP 1 578 903 B2

<400> 20
 gcagtcta acaccacatc cgtgcacgga tgtg 34

5 <210> 21
 <211> 34
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 21
 cacatccgtg cacggatgtg gtgtcttaca gtcc 34

15 <210> 22
 <211> 14
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

25 <400> 22
 ggactgtaag acac 14

30 <210> 23
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <400> 23
 gagtctcact gagccacatc cgtgcacgga tgtg 34

40 <210> 24
 <211> 14
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

45 <400> 24
 gctcagtgag actc 14

50 <210> 25
 <211> 14
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 25
 gtgtattact gtgc 14

<210> 26
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 26
 10 gtatattact gtgc 14
 <210> 27
 <211> 14
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 27
 gtgtattact gtaa 14
 <210> 28
 <211> 14
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 28
 gtgtattact gtac 14
 <210> 29
 <211> 14
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 29
 ttgtattact gtgc 14
 45 <210> 30
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 30
 55 ttgtatcact gtgc 14
 <210> 31
 <211> 14
 <212> DNA

EP 1 578 903 B2

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 31

acatattact gtgc 14

<210> 32

10

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 32

acgtattact gtgc 14

<210> 33

20

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

25

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 33

atgtattact gtgc 14

30

<210> 34

<211> 101

<212> DNA

<213> Homo sapiens

35

<400> 34

agggtcacca tgaccagga cagtcctac agcacagcct acatgabcga gctgagcagg 60
ctgagatctg acgacacggc cgtgtattac tgtgcgagag a 101

40

<210> 35

<211> 98

<212> DNA

<213> Homo sapiens

45

<400> 35

agagtcacca ttaccagga cacatccgcg agcacagcct acatggagct gagcagcctg 60
agatctgaag acacggctgt gtattactgt gcgagaga 98

50

<210> 36

<211> 98

<212> DNA

<213> Homo sapiens

55

<400> 36

EP 1 578 903 B2

agagtcacca tgaccaggaa cacctccata agcacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagaga 98

5 <210> 37
<211> 98
<212> DNA
<213> Homo sapiens

10 <400> 37

agagtcacca tgaccacaga cacatccacg agcacagcct acatggagct gaggagcctg 60
agatctgacg acacggccgt gtattactgt gcgagaga 98

15 <210> 38
<211> 98
<212> DNA
<213> Homo sapiens

20 <400> 38

agagtcacca tgaccgagga cacatctaca gacacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcaacaga 98

25 <210> 39
<211> 98
<212> DNA
<213> Homo sapiens

30 <400> 39

agagtcacca ttaccagga caggtctatg agcacagcct acatggagct gagcagcctg 60
agatctgagg acacagccat gtattactgt gcaagata 98

35 <210> 40
<211> 98
<212> DNA
<213> Homo sapiens

40 <400> 40

agagtcacca tgaccagga caggtccacg agcacagtct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagaga 98

45 <210> 41
<211> 98
<212> DNA
<213> Homo sapiens

50 <400> 41

agagtcacca ttaccagga catgtccaca agcacagcct acatggagct gagcagcctg 60
agatccgagg acacggccgt gtattactgt gcggcaga 98

55

EP 1 578 903 B2

<210> 42
 <211> 98
 <212> DNA
 <213> Homo sapiens
 5
 <400> 42
 agagtcacga ttaccgcgga cgaatccacg agcacagcct acatggagct gagcagcctg 60
 agatctgagg acacggccgt gtattactgt gcgagaga 98
 10
 <210> 43
 <211> 98
 <212> DNA
 <213> Homo sapiens
 15
 <400> 43
 agagtcacga ttaccgcgga caaatccacg agcacagcct acatggagct gagcagcctg 60
 agatctgagg acacggccgt gtattactgt gcgagaga 98
 20
 <210> 44
 <211> 98
 <212> DNA
 <213> Homo sapiens
 25
 <400> 44
 agagtcacca taaccgcgga cacgtctaca gacacagcct acatggagct gagcagcctg 60
 agatctgagg acacggccgt gtattactgt gcaacaga 98
 30
 <210> 45
 <211> 100
 <212> DNA
 <213> Homo sapiens
 35
 <400> 45
 aggctcacca tcaccaagga cacctccaaa aaccaggtgg tccttacaat gaccaacatg 60
 gaccctgtgg acacagccac atattactgt gcacacagac 100
 40
 <210> 46
 <211> 100
 <212> DNA
 <213> Homo sapiens
 45
 <400> 46
 aggctcacca tctccaagga cacctccaaa agccaggtgg tccttaccat gaccaacatg 60
 gaccctgtgg acacagccac atattactgt gcacggatac 100
 50
 <210> 47
 <211> 100
 <212> DNA
 <213> Homo sapiens
 55
 <400> 47

EP 1 578 903 B2

aggctcacca tctccaagga cacctccaaa aaccaggtgg tccttacaat gaccaacatg 60
gacctgtgg acacagccac gtattactgt gcacggatac 100

5 <210> 48
<211> 98
<212> DNA
<213> Homo sapiens

10 <400> 48

cgattcacca tctccagaga caacgccaaag aactcactgt atctgcaaata gaacagcctg 60
agagccgagg acacggctgt gtattactgt gcgagaga 98

15 <210> 49
<211> 100
<212> DNA
<213> Homo sapiens

20 <400> 49

cgattcacca tctccagaga caacgccaaag aactccctgt atctgcaaata gaacagtctg 60
agagctgagg acacggcctt gtattactgt gcaaaagata 100

25 <210> 50
<211> 98
<212> DNA
<213> Homo sapiens

30 <400> 50

cgattcacca tctccaggga caacgccaaag aactcactgt atctgcaaata gaacagcctg 60
agagccgagg acacggccgt gtattactgt gcgagaga 98

35 <210> 51
<211> 98
<212> DNA
<213> Homo sapiens

40 <400> 51

cgattcacca tctccagaga aaatgccaaag aactccttgt atcttcaaata gaacagcctg 60
agagccgggg acacggctgt gtattactgt gcaagaga 98

45 <210> 52
<211> 98
<212> DNA
<213> Homo sapiens

50 <400> 52

agattcacca tctcaagaga tgattcaaaa aacacgctgt atctgcaaata gaacagcctg 60
aaaaccgagg acacagccgt gtattactgt accacaga 98

55 <210> 53
<211> 98
<212> DNA

EP 1 578 903 B2

<213> Homo sapiens

<400> 53

5 **cgattcacca tctccagaga caacgccaaag aactccctgt atctgcaa at gaacagtctg 60**
 agagccgagg acacggcctt gtattactgt gcgagaga 98

<210> 54

<211> 98

10 <212> DNA

<213> Homo sapiens

<400> 54

15 **cgattcacca tctccagaga caacgccaaag aactcactgt atctgcaa at gaacagcctg 60**
 agagccgagg acacggctgt gtattactgt gcgagaga 98

<210> 55

<211> 98

20 <212> DNA

<213> Homo sapiens

<400> 55

25 **cggttcacca tctccagaga caattccaag aacacgctgt atctgcaa at gaacagcctg 60**
 agagccgagg acacggcctt atattactgt gcgaaaga 98

<210> 56

<211> 98

30 <212> DNA

<213> Homo sapiens

<400> 56

35 **cgattcacca tctccagaga caattccaag aacacgctgt atctgcaa at gaacagcctg 60**
 agagctgagg acacggctgt gtattactgt gcgaaaga 98

<210> 57

<211> 98

40 <212> DNA

<213> Homo sapiens

<400> 57

45 **cgattcacca tctccagaga caattccaag aacacgctgt atctgcaa at gaacagcctg 60**
 agagctgagg acacggctgt gtattactgt gcgagaga 98

<210> 58

<211> 98

50 <212> DNA

<213> Homo sapiens

<400> 58

55 **cgattcacca tctccagaga caattccaag aacacgctgt atctgcaa at gaacagcctg 60**
 agagctgagg acacggctgt gtattactgt gcgaaaga 98

<210> 59

EP 1 578 903 B2

<211> 98
 <212> DNA
 <213> Homo sapiens

5 <400> 59

cgattcacca tctccagaga caattccaag aacacgctgt atctgcaa at gaacagcctg 60
 agagccgagg acacggctgt gtattactgt gcgagaga 98

10 <210> 60
 <211> 100
 <212> DNA
 <213> Homo sapiens

15 <400> 60

cgattcacca tctccagaga caacagcaaa aactccctgt atctgcaa at gaacagtctg 60
 agaactgagg acaccgcctt gtattactgt gcaaaagata 100

20 <210> 61
 <211> 98
 <212> DNA
 <213> Homo sapiens

25 <400> 61

cgattcacca tctccagaga caatgccaa aactcactgt atctgcaa at gaacagcctg 60
 agagacgagg acacggctgt gtattactgt gcgagaga 98

30 <210> 62
 <211> 98
 <212> DNA
 <213> Homo sapiens

<400> 62

agattcacca tctcaagaga tggttccaaa agcatcgcct atctgcaa at gaacagcctg 60
 aaaaccgagg acacagccgt gtattactgt actagaga 98

40 <210> 63
 <211> 98
 <212> DNA
 <213> Homo sapiens

<400> 63

cgattcacca tctccagaga caattccaag aacacgctgt atcttcaa at gaacagcctg 60
 agagccgagg acacggccgt gtattactgt gcgagaga 98

50 <210> 64
 <211> 98
 <212> DNA
 <213> Homo sapiens

<400> 64

EP 1 578 903 B2

agattcacca tctccagaga caattccaag aacacgctgt atcttcaa at ggcagcctg 60
agagctgagg acatggctgt gtattactgt gcgagaga 98

<210> 65
<211> 98
<212> DNA
<213> Homo sapiens

<400> 65

agattcacca tctccagaga caattccaag aacacgctgt atcttcaa at gaacagcctg 60
agagctgagg acacggctgt gtattactgt gcgagaga 98

<210> 66
<211> 98
<212> DNA
<213> Homo sapiens

<400> 66

agattcacca tctcaagaga tgattcaa ag aactcactgt atctgcaa at gaacagcctg 60
aaaaccgagg acacggccgt gtattactgt gctagaga 98

<210> 67
<211> 98
<212> DNA
<213> Homo sapiens

<400> 67

aggttcacca tctccagaga tgattcaa ag aacacggcgt atctgcaa at gaacagcctg 60
aaaaccgagg acacggccgt gtattactgt actagaga 98

<210> 68
<211> 98
<212> DNA
<213> Homo sapiens

<400> 68

cgattcacca tctccagaga caacgccaa g aacacgctgt atctgcaa at gaacagtctg 60
agagccgagg acacggctgt gtattactgt gcaagaga 98

<210> 69
<211> 98
<212> DNA
<213> Homo sapiens

<400> 69

agattcacca tctccagaga caattccaag aacacgctgc atcttcaa at gaacagcctg 60
agagctgagg acacggctgt gtattactgt aagaaaga 98

<210> 70
<211> 98

EP 1 578 903 B2

<212> DNA
<213> Homo sapiens

<400> 70

5

cgagtcacca tatcagtaga caagtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcgg acacggccgt gtattactgt gcgagaga 98

10

<210> 71
<211> 98
<212> DNA
<213> Homo sapiens

15

<400> 71

cgagtcacca tgtcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgtgg acacggccgt gtattactgt gcgagaaa 98

20

<210> 72
<211> 98
<212> DNA
<213> Homo sapiens

25

<400> 72

cgagttacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcgg acacggccgt gtattactgt gcgagaga 98

30

<210> 73
<211> 98
<212> DNA
<213> Homo sapiens

35

<400> 73

cgagtcacca tatcagtaga caggtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcgg acacggccgt gtattactgt gccagaga 98

40

<210> 74
<211> 98
<212> DNA
<213> Homo sapiens

45

<400> 74

cgagttacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcag acacggccgt gtattactgt gccagaga 98

50

<210> 75
<211> 98
<212> DNA
<213> Homo sapiens

55

<400> 75

cgagttacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcgg acacggccgt gtattactgt gcgagaga 98

EP 1 578 903 B2

<210> 76
 <211> 98
 <212> DNA
 <213> Homo sapiens
 5
 <400> 76
 cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
 accgccgcgg acacggctgt gtattactgt gcgagaga 98
 10
 <210> 77
 <211> 98
 <212> DNA
 <213> Homo sapiens
 15
 <400> 77
 cgagtcacca tatccgtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
 accgccgcag acacggctgt gtattactgt gcgagaga 98
 20
 <210> 78
 <211> 98
 <212> DNA
 <213> Homo sapiens
 25
 <400> 78
 cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
 accgctgcgg acacggccgt gtattactgt gcgagaga 98
 30
 <210> 79
 <211> 98
 <212> DNA
 <213> Homo sapiens
 35
 <400> 79
 cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
 accgctgcgg acacggccgt gtattactgt gcgagaga 98
 40
 <210> 80
 <211> 98
 <212> DNA
 <213> Homo sapiens
 45
 <400> 80
 cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
 accgccgcag acacggccgt gtattactgt gcgagaga 98
 50
 <210> 81
 <211> 98
 <212> DNA
 <213> Homo sapiens
 55
 <400> 81

EP 1 578 903 B2

caggtcacca tctcagccga caagtccatc agcaccgcct acctgcagtg gagcagcctg 60
aaggcctcgg acaccgccat gtattactgt gcgagaca 98

<210> 82

<211> 96

<212> DNA

<213> Homo sapiens

<400> 82

cacgtcacca tctcagctga caagtccatc agcactgcct acctgcagtg gagcagcctg 60
aaggcctcgg acaccgccat gtattactgt gcgagaca 96

<210> 83

<211> 98

<212> DNA

<213> Homo sapiens

<400> 83

cgaataacca tcaaccaga cacatccaag aaccagttct ccctgcagct gaactctgtg 60
actcccaggg acacggctgt gtattactgt gcaagaga 98

<210> 84

<211> 98

<212> DNA

<213> Homo sapiens

<400> 84

cggtttgtct tctccttggg cacctctgtc agcacggcat atctgcagat ctgcagccta 60
aaggctgagg acactgccgt gtattactgt gcgagaga 98

<210> 85

<211> 11

<212> DNA

<213> Artificial Sequence

<220> <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (3)..(9)

<223> A, T, C, G, other or unknown

<400> 85

gcnnnnnnng c 11

<210> 86

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (4)..(7)
 <223> A, T, C, G, other or unknown
 5
 <400> 86
 caynnnnrtg 10
 <210> 87
 10 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (6)..(11)
 20 <223> A, T, C, G, other or unknown
 <400> 87
 gagtcnnnnn n 11
 25 <210> 88
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (1)..(6)
 <223> A, T, C, G, other or unknown
 <400> 88
 nnnnnngaga c 11
 40 <210> 89
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 50 <221> modified base
 <222> (4)..(7)
 <223> A, T, C, G, other or unknown
 <400> 89
 55 gaannnttc 10
 <210> 90
 <211> 90

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 3-23 FR3 nucleotide sequence

<220>

<221> CDS

<222> (1)..(90)

<220>

<221> modified_base

<222> (3)

<223> A, T, C or G

<220>

<221> modified_base

<222> (9)

<223> A, T, C or G

<220>

<221> modified_base

<222> (12)

<223> A, T, C or G

<220>

<221> modified_base

<222> (21)

<223> A, T, C or G

<220>

<221> modified_base

<222> (30)

<223> A, T, C or G

<220>

<221> modified_base

<222> (36)

<223> A, T, C or G

<220>

<221> modified_base

<222> (51)

<223> A, T, C or G

<220>

<221> modified_base

<222> (57)

<223> A, T, C or G

<220>

<221> modified_base

<222> (60)

<223> A, T, C or G

<220>

<221> modified_base

<222> (69)

EP 1 578 903 B2

<223> A, T, C or G

<220>

<221> modified base

$\langle 222 \rangle$ (72)

<223> A, T, C or G

 $\langle 220 \rangle$

<221> modified_base

$\langle 222 \rangle$ (75)

<223> A, T, C or G

<220>

<221> modified_base

$\langle 222 \rangle$ (78)

<223> A, T, C or G

<220>

<221> modified base

$\langle 222 \rangle$ (87)

<223> A, T, C or G

<400> 90

acn ath wsn mgn gay aay wsn aar aay acn ytn tay ttn car atg aay 48
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
1 5 10 15

wsn ttr mgn gcn gar gay acn gcn gtn tay tay tgy gcn aar 90
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
20 25 30

<210> 91

$\langle 211 \rangle$ 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 3-23 FR3 protein sequence

<400> 91

Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
1 5 10 15

Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
20 25 30

<210> 92

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 92

agttctccct gcagctgaac tc 22

<210> 93
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 <400> 93
 10 cactgtatct gcaaatgaac ag 22
 <210> 94
 <211> 22
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 20 <400> 94
 ccctgtatct gcaaatgaac ag 22
 <210> 95
 <211> 22
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 30 <400> 95
 ccgcctacct gcagtggagc ag 22
 <210> 96
 <211> 22
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 40 <400> 96
 cgctgtatct gcaaatgaac ag 22
 <210> 97
 <211> 22
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 50 <400> 97
 55 cggcataatct gcagatctgc ag 22
 <210> 98
 <211> 22
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

5

<400> 98

cggcgtatct gcaaatgaac ag 22

<210> 99

10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Synthetic probe

<400> 99

ctgcctacct gcagtggagc ag 22

20

<210> 100

<211> 22

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 100

tcgcctatct gcaaatgaac ag 22

30

<210> 101

<211> 63

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 101

40

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agg 63

45

<210> 102

<211> 45

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 102

caagtagaga gtattcttag agttgtctct agacttagtg aagcg 45

55

<210> 103

<211> 54

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 103
 cgcttcacta agtctagaga caactctaag aatactctct actgcagct gaac 54

<210> 104
 <211> 54
 <212> DNA
 <213> Artificial Sequence

10

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

15

<400> 104
 cgcttcacta agtctagaga caactctaag aatactctct acttgcaaat gaac 54

20

<210> 105
 <211> 54
 <212> DNA
 <213> Artificial Sequence

25

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

30

<400> 105
 cgcttcacta agtctagaga caactctaag aatactctct acttgcaagt gagc 54

<210> 106
 <211> 21
 <212> DNA
 <213> Artificial Sequence

35

<220>
 <223> Description of Artificial Sequence: Primer

40

<400> 106
 cgcttcacta agtctagaga c 21

<210> 107
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> Description of Artificial Sequence: Synthetic probe

50

<400> 107
 acatggagct gagcagcctg ag 22

<210> 108
 <211> 22
 <212> DNA
 <213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 108
 acatggagct gagcaggctg ag 22

<210> 109
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 109
 acatggagct gaggagcctg ag 22

<210> 110
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 110
 acctgcagtg gagcagcctg aa 22

<210> 111
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 111
 atctgcaaat gaacagcctg aa 22

<210> 112
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 112
 atctgcaaat gaacagcctg ag 22

<210> 113
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 113

EP 1 578 903 B2

atctgcaaat gaacagtctg ag 22

<210> 114
 <211> 22
 5 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

10 <400> 114
 atctgcagat ctgcagccta aa 22

<210> 115
 15 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 20 <223> Description of Artificial Sequence: Synthetic probe

<400> 115
 atcttcaaat gaacagcctg ag 22

25 <210> 116
 <211> 22
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 116
 35 atcttcaaat ggcagcctg ag 22

<210> 117
 <211> 22
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 117
 45 ccctgaagct gagctctgtg ac 22

<210> 118
 <211> 22
 <212> DNA
 50 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

55 <400> 118
 ccctgcagct gaactctgtg ac 22

<210> 119

<211> 22
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 119
 tccttacaat gaccaacatg ga 22

10 <210> 120
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 120
 20 tccttaccat gaccaacatg ga 22

<210> 121
 <211> 22
 <212> DNA
 25 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

30 <400> 121
 acatggagct gagcagcctg ag 22

<210> 122
 <211> 22
 35 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

40 <400> 122
 ccctgaagct gagctctgtg ac 22

<210> 123
 45 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 50 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 123
 cgcttcacta agcttagaga caactctaag aatactctct acttgcagat gaac 54

55 <210> 124
 <211> 60
 <212> DNA
 <213> Artificial Sequence

EP 1 578 903 B2

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 124 cgcttcactc agtctagaga taacagtaaa aatactttgt acttcagct gagcagcctg 60
 5
 <210> 125
 <211> 60
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 125
 15 cgcttcactc agtctagaga taacagtaaa aatactttgt acttcagct gagctctgtg 60
 <210> 126
 <211> 52
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 25 <400> 126
 tcagctgcaa gtacaaagta ttttactgt tatctctaga ctgagtgaag cg 52
 <210> 127
 <211> 24
 30 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 35 <400> 127
 cgcttcactc agtctagaga taac 24
 <210> 128
 40 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 45 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 128
 ccgtgtatta ctgtgcgaga ga 22
 50 <210> 129
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 55 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 129

ctgtgtatta ctgtgcgaga ga 22

<210> 130
 <211> 22
 5 <212> DNA
 <213> Artificial Sequence

<220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 130
 ccgtgtatta ctgtgcgaga gg 22

<210> 131
 15 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 20 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 131
 ccgtgtatta ctgtgcaaca ga 22

<210> 132
 25 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 30 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 132
 35 ccatgtatta ctgtgcaaga ta 22

<210> 133
 <211> 22
 <212> DNA
 40 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 133
 45 ccgtgtatta ctgtgcggca ga 22

<210> 134
 <211> 22
 <212> DNA
 50 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 134
 55 ccacatatta ctgtgcacac ag 22

<210> 135

<211> 22
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 135
 ccacatatta ctgtgcacgg at 22

10

<210> 136
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 136
 ccacgtatta ctgtgcacgg at 22

20

<210> 137
 <211> 22
 <212> DNA
 <213> Artificial Sequence

25

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 137
 cctgttatta ctgtgcaaaa ga 22

30

<210> 138
 <211> 22
 <212> DNA
 <213> Artificial Sequence

35

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

40

<400> 138
 ctgtgtatta ctgtgcaaga ga 22

<210> 139
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

50

<400> 139
 ccgtgtatta ctgtaccaca ga 22

55

<210> 140
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5 <400> 140
 ccttgatca ctgtgcgaga ga 22

10 <210> 141
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

20 <400> 141
 ccgtatatta ctgtgcgaaa ga 22

25 <210> 142
 <211> 22
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <400> 142
 ctgtgtatta ctgtgcgaaa ga 22

40 <210> 143
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

50 <400> 143
 ccgtgtatta ctgtactaga ga 22

55 <210> 144
 <211> 22
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

65 <400> 144
 ccgtgtatta ctgtgctaga ga 22

70 <210> 145
 <211> 22
 <212> DNA
 <213> Artificial Sequence

75 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 145
 ccgtgtatta ctgtactaga ca 22

 <210> 146
 5 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 146
 ctgtgtatta ctgtaagaaa ga 22

 15 <210> 147
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 147
 25 ccgtgtatta ctgtgcgaga aa 22

 <210> 148
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 148
 35 ccgtgtatta ctgtgccaga ga 22

 <210> 149
 <211> 22
 <212> DNA
 40 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 45 <400> 149
 ctgtgtatta ctgtgcgaga ca 22

 <210> 150
 <211> 22
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 55
 <400> 150
 ccatgtatta ctgtgcgaga ca 22

<210> 151
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 151
 10 ccatgtatta ctgtgcgaga 20
 <210> 152
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 152
 ccgtgtatta ctgtgcgaga g 21
 <210> 153
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 153
 ctgtgtatta ctgtgcgaga g 21
 <210> 154
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 154
 ccgtgtatta ctgtgcgaga g 21
 45 <210> 155
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 155
 55 ccgtatatta ctgtgcgaaa g 21
 <210> 156
 <211> 21
 <212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 156
ctgtgtatta ctgtgcgaaa g 21

10

<210> 157
<211> 21
<212> DNA
<213> Artificial Sequence

15

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 157
ctgtgtatta ctgtgcgaga c 21

20

<210> 158
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 158
ccatgtatta ctgtgcgaga c 21

30

<210> 159
<211> 20
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 159
ccatgtatta ctgtgcgaga 20

40

<210> 160
<211> 94
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

50

<400> 160

gggtgtagtga tctagtgaca actctaagaa tactctctac ttgcagatga acagcttttag 60
ggctgaggac actgcagtct actattgtgc gaga 94

55

<210> 161
<211> 94
<212> DNA
<213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 161

5

ggtgtagtga tctagtgaca actctaagaa tactctctac ttgcagatga acagctttag 60
ggctgaggac actgcagtct actattgtgc gaaa 94

<210> 162

10

<211> 85

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 162

20

atagtagact gcagtgtcct cagcccttaa gctgttcac tgcaagtaga gagtattctt 60
agagttgtct ctatgcact acacc 85

<210> 163

<211> 22

<212> DNA

25

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

30

<400> 163

ggtgtagtga tctagagaca ac 22

<210> 164

<211> 55

35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

40

<400> 164

ggtgtagtga aacagcttta gggctgagga cactgcagtc tactattgtg cgaga 55

<210> 165

45

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

50

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 165

ggtgtagtga aacagcttta gggctgagga cactgcagtc tactattgtg cgaaa 55

55

<210> 166

<211> 46

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5 <400> 166
 atagtagact gcagtgctct cagcccttaa gctgtttcac tacacc 46

<210> 167
 <211> 46
 <212> DNA
 10 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

15 <400> 167
 ggtgtagtga aacagcttaa gggctgagga cactgcagtc tactat 46

<210> 168
 <211> 26
 20 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

25 <400> 168
 ggtgtagtga aacagcttaa gggctg 26

<210> 169
 <211> 22
 30 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic probe

35 <400> 169
 agttctccct gcagctgaac tc 22

40 <210> 170
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic probe

50 <400> 170
 cactgtatct gcaaatgaac ag 22

<210> 171
 <211> 22
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence: Synthetic probe

<400> 171
 ccctgtatct gcaaatgaac ag 22

 <210> 172
 5 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 10 <223> Description of Artificial Sequence: Synthetic probe

 <400> 172
 ccgcctacct gcagtggagc ag 22

 15 <210> 173
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 <400> 173
 25 cgctgtatct gcaaatgaac ag 22

 <210> 174
 <211> 22
 <212> DNA
 30 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 <400> 174
 35 cggcatact gcagatctgc ag 22

 <210> 175
 <211> 22
 <212> DNA
 40 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 <400> 175
 45 cggcgtatct gcaaatgaac ag 22

 <210> 176
 <211> 22
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 55

 <400> 176
 ctgcctacct gcagtggagc ag 22

<210> 177
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic probe
 <400> 177
 10 tcgcctatct gcaaatgaac ag 22
 <210> 178
 <211> 22
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 178
 acatggagct gagcagcctg ag 22
 <210> 179
 <211> 22
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 179
 acatggagct gagcaggctg ag 22
 <210> 180
 <211> 22
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 180
 acatggagct gaggagcctg ag 22
 <210> 181
 <211> 22
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 181
 55 acctgcagtg gagcagcctg aa 22
 <210> 182
 <211> 22
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 182
atctgcaaat gaacagcctg aa 22

<210> 183

10 <211> 22
<212> DNA
<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 183
atctgcaaat gaacagcctg ag 22

20 <210> 184
<211> 22
<212> DNA
<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 184
atctgcaaat gaacagtctg ag 22

30 <210> 185
<211> 22
<212> DNA
<213> Artificial Sequence

35 <220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 185
40 atctgcagat ctgcagccta aa 22

<210> 186
<211> 22
<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

50 <400> 186
atcttcaaat gaacagcctg ag 22

<210> 187
<211> 22
<212> DNA

55 <213> Artificial Sequence

<220>

EP 1 578 903 B2

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 187

atcttcaaat gggcagcctg ag 22

<210> 188

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 188

ccctgaagct gagctctgtg ac 22

<210> 189

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 189

ccctgcagct gaactctgtg ac 22

<210> 190

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 190

tccttacaat gaccaacatg ga 22

<210> 191

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 191

tccttaccat gaccaacatg ga 22

<210> 192

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 192

ccgtgtatta ctgtgcgaga ga 22

<210> 193
 <211> 22
 5 <212> DNA
 <213> Artificial Sequence

<220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 193
 ctgtgtatta ctgtgcgaga ga 22

<210> 194
 15 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 20 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 194
 ccgtgtatta ctgtgcgaga gg 22

<210> 195
 25 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 30 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 195
 35 ccgtgtatta ctgtgcaaca ga 22

<210> 196
 <211> 22
 <212> DNA
 40 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 196
 45 ccatgtatta ctgtgcaaga ta 22

<210> 197
 <211> 22
 <212> DNA
 50 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 197
 55 ccgtgtatta ctgtgcggca ga 22

<210> 198

<211> 22
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 198
 ccacatatta ctgtgcacac ag 22

10 <210> 199
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 199
 ccacatatta ctgtgcacgg at 22

20 <210> 200
 <211> 22
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 200
 ccacgtatta ctgtgcacgg at 22

30 <210> 201
 <211> 22
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 201
 cctgtatta ctgtgcaaaa ga 22

40 <210> 202
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 202
 ctgtgtatta ctgtgcaaga ga 22

50 <210> 203
 <211> 22
 <212> DNA
 <213> Artificial Sequence

55 <210> 203
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5 <400> 203
 ccgtgtatta ctgtaccaca ga 22

10 <210> 204
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

20 <400> 204
 cctgtatca ctgtgcgaga ga 22

25 <210> 205
 <211> 22
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <400> 205
 ccgtatatta ctgtgcgaaa ga 22

40 <210> 206
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

50 <400> 206
 ctgtgtatta ctgtgcgaaa ga 22

55 <210> 207
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 207
 ccgtgtatta ctgtactaga ga 22

 <210> 208
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 208
 ccgtgtatta ctgtgctaga ga 22

 <210> 209
 5 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 209
 ccgtgtatta ctgtactaga ca 22

 15 <210> 210
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 210
 25 ctgtgtatta ctgtaagaaa ga 22

 <210> 211
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 211
 35 ccgtgtatta ctgtgcgaga aa 22

 <210> 212
 <211> 22
 <212> DNA
 40 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 45 <400> 212
 ccgtgtatta ctgtgccaga ga 22

 <210> 213
 <211> 22
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 55
 <400> 213
 ctgtgtatta ctgtgcgaga ca 22

EP 1 578 903 B2

<210> 214
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 214
 10 ccatgtatta ctgtgcgaga ca 22
 <210> 215
 <211> 22
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 215
 ccatgtatta ctgtgcgaga aa 22
 <210> 216
 <211> 90
 25 <212> DNA
 <213> Homo sapiens
 <400> 216
 30 caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc 90
 <210> 217
 35 <211> 90
 <212> DNA
 <213> Homo sapiens
 <400> 217
 40 caggtccagc ttgtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtt 60
 tcctgcaagg cttctggata caccttcact 90
 <210> 218
 45 <211> 90
 <212> DNA
 <213> Homo sapiens
 <400> 218
 50 caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc 90
 <210> 219
 55 <211> 90
 <212> DNA
 <213> Homo sapiens

EP 1 578 903 B2

<400> 219

cagggttcagc tgggtgcagtc tgggagctgag gtgaagaagc ctggggcctc agtgaagggtc 60
tcctgcaagg cttctgggta cacctttacc 90

5

<210> 220

<211> 90

<212> DNA

<213> Homo sapiens

10

<400> 220

cagggtccagc tgggtacagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtc 60
tcctgcaagg tttccggata caccctcact 90

15

<210> 221

<211> 90

<212> DNA

<213> Homo sapiens

20

<400> 221

cagatgcagc tgggtgcagtc tggggctgag gtgaagaaga ctgggtcctc agtgaagggtt 60
tcctgcaagg cttccggata caccctcacc 90

25

<210> 222

<211> 90

<212> DNA

<213> Homo sapiens

30

<400> 222

cagggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtt 60
tcctgcaagg catctggata caccctcacc 90

35

<210> 223

<211> 90

<212> DNA

<213> Homo sapiens

40

<400> 223

caaatgcagc tgggtgcagtc tgggcctgag gtgaagaagc ctggggacctc agtgaagggtc 60
tcctgcaagg cttctggatt cacctttact 90

45

<210> 224

<211> 90

<212> DNA

<213> Homo sapiens

50

<400> 224

cagggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaagggtc 60
tcctgcaagg cttctggagg caccttcagc 90

55

<210> 225

<211> 90

<212> DNA

EP 1 578 903 B2

<213> Homo sapiens

<400> 225

5 caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggagg caccttcagc 90

<210> 226

<211> 90

10 <212> DNA

<213> Homo sapiens

<400> 226

15 gaggtccagc tgggtacagtc tggggctgag gtgaagaagc ctggggctac agtgaaaatc 60
tcctgcaagg tttctggata caccttcacc 90

<210> 227

<211> 90

20 <212> DNA

<213> Homo sapiens

<400> 227

25 cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc 90

<210> 228

<211> 90

30 <212> DNA

<213> Homo sapiens

<400> 228

35 caggtcacct tgaaggagtc tggtcctgtg ctggtgaaac ccacagagac cctcacgctg 60
acctgcaccg tctctgggtt ctcactcagc 90

<210> 229

<211> 90

40 <212> DNA

<213> Homo sapiens

<400> 229

45 caggtcacct tgaaggagtc tggtcctgcg ctggtgaaac ccacacagac cctcacactg 60
acctgcacct tctctgggtt ctcactcagc 90

<210> 230

<211> 90

50 <212> DNA

<213> Homo sapiens

<400> 230

55 gaggtgcagc tgggtggagtc tgggggaggc ttgggtccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttttagt 90

EP 1 578 903 B2

<210> 231
<211> 90
<212> DNA
<213> Homo sapiens

5

<400> 231

gaagtgcagc tgggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat 90

10

<210> 232
<211> 90
<212> DNA
<213> Homo sapiens

15

<400> 232

caggtgcagc tgggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

20

<210> 233
<211> 90
<212> DNA
<213> Homo sapiens

25

<400> 233

gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

30

<210> 234
<211> 90
<212> DNA
<213> Homo sapiens

35

<400> 234

gaggtgcagc tgggtggagtc tgggggaggc ttggtaaagc ctgggggggc ccttagactc 60
tcctgtgcag cctctggatt caccttcagt 90

40

<210> 235
<211> 90
<212> DNA
<213> Homo sapiens

45

<400> 235

gaggtgcagc tgggtggagtc tgggggaggt gtggtacggc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat 90

50

<210> 236
<211> 90
<212> DNA
<213> Homo sapiens

55

<400> 236

EP 1 578 903 B2

gaggtgcagc tggtaggagtc tgggggaggc ctggtcaagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

5 <210> 237
 <211> 90
 <212> DNA
 <213> Homo sapiens

10 <400> 237

gaggtgcagc tggtaggagtc tgggggaggc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttttagc 90

15 <210> 238
 <211> 90
 <212> DNA
 <213> Homo sapiens

20 <400> 238

caggtgcagc tggtaggagtc tgggggaggc gtggtccagc ctgggagggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

25 <210> 239
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 239

caggtgcagc tggtaggagtc tgggggaggc gtggtccagc ctgggagggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

35 <210> 240
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 240

caggtgcagc tggtaggagtc tgggggaggc gtggtccagc ctgggagggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

45 <210> 241
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 241

caggtgcagc tggtaggagtc tgggggaggc gtggtccagc ctgggagggc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt 90

EP 1 578 903 B2

<210> 242
<211> 90
<212> DNA
<213> Homo sapiens

5

<400> 242

gaagtgcagc tggaggagtc tgggggagtc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

10

<210> 243
<211> 90
<212> DNA
<213> Homo sapiens

15

<400> 243

gaggtgcagc tggaggagtc tgggggagtc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

20

<210> 244
<211> 90
<212> DNA
<213> Homo sapiens

25

<400> 244

gaggtgcagc tggaggagtc tgggggagtc ttggtacagc cagggcggtc cctgagactc 60
tcctgtacag cttctggatt caccttcagt 90

30

<210> 245
<211> 90
<212> DNA
<213> Homo sapiens

35

<400> 245

gaggtgcagc tggaggagtc tggaggagtc ttgatccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctgggtt caccgtcagt 90

40

<210> 246
<211> 90
<212> DNA
<213> Homo sapiens

45

<400> 246

gaggtgcagc tggaggagtc tgggggagtc ttggtccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

50

<210> 247
<211> 90
<212> DNA
<213> Homo sapiens

55

<400> 247

EP 1 578 903 B2

gaggtgcagc tggtaggagtc tgggggaggc ttggtccagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccgtcagt 90

<210> 248
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 248

gaggtgcagc tggtaggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccctcagt 90

<210> 249
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 249

gaggtgcagc tggtaggagtc tgggggaggc ttggtccagc ctgggggggtc cctgaaactc 60
tcctgtgcag cctctgggtt caccctcagt 90

<210> 250
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 250

gaggtgcagc tggtaggagtc cgggggaggc ttagttcagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccctcagt 90

<210> 251
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 251

gaggtgcagc tggtaggagtc tcggggagtc ttggtacagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccgtcagt 90

<210> 252
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 252

caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcgggggac cctgtccctc 60
acctgcgctg tctctggtgg ctccatcagc 90

<210> 253
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 253

5 **caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60**
 acctgcgctg tctctggtta ctccatcagc 90

<210> 254

<211> 90

<212> DNA

10 <213> Homo sapiens

<400> 254

15 **caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60**
 acctgcactg tctctggtgg ctccatcagc 90

<210> 255

<211> 90

<212> DNA

20 <213> Homo sapiens

<400> 255

25 **cagctgcagc tgcaggagtc cggctcagga ctggtgaagc cttcacagac cctgtccctc 60**
 acctgcgctg tctctggtgg ctccatcagc 90

<210> 256

<211> 90

<212> DNA

30 <213> Homo sapiens

<400> 256

35 **caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60**
 acctgcactg tctctggtgg ctccatcagc 90

<210> 257

<211> 90

<212> DNA

40 <213> Homo sapiens

<400> 257

45 **caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60**
 acctgcactg tctctggtgg ctccatcagc 90

<210> 258

<211> 90

<212> DNA

50 <213> Homo sapiens

<400> 258

55 **caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60**
 acctgcgctg tctatggtgg gtccttcagt 90

<210> 259

EP 1 578 903 B2

<211> 90
 <212> DNA
 <213> Homo sapiens

5 <400> 259

cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

10 <210> 260
 <211> 90
 <212> DNA
 <213> Homo sapiens

15 <400> 260

caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

20 <210> 261
 <211> 90
 <212> DNA
 <213> Homo sapiens

25 <400> 261

caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccgtcagc 90

30 <210> 262
 <211> 90
 <212> DNA
 <213> Homo sapiens

35 <400> 262

caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcgctg tctctggtta ctccatcagc 90

40 <210> 263
 <211> 90
 <212> DNA
 <213> Homo sapiens

45 <400> 263

gaggtgcagc tgggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60
tcctgtaagg gttctggata cagctttacc 90

50 <210> 264
 <211> 90
 <212> DNA
 <213> Homo sapiens

55 <400> 264

EP 1 578 903 B2

gaagtgcagc tgggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaggatc 60
tcctgtaagg gttctggata cagctttacc 90

5 <210> 265
<211> 90
<212> DNA
<213> Homo sapiens

10 <400> 265

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60
acctgtgcca tctccgggga cagtgtctct 90

15 <210> 266
<211> 90
<212> DNA
<213> Homo sapiens

20 <400> 266

caggtgcagc tgggtgcaatc tgggtctgag ttgaagaagc ctggggcctc agtgaagggtt 60
tcctgcaagg cttctggata caccttcact 90

25 <210> 267
<211> 22
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 267
ccgtgtatta ctgtgcgaga ga 22

35 <210> 268
<211> 22
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 268
ctgtgtatta ctgtgcgaga ga 22

45 <210> 269
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

55 <400> 269
ccgtgtatta ctgtgcgaga gg 22

<210> 270

<211> 22
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 270
 ccgtatatta ctgtgcgaaa ga 22

10 <210> 271
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 271
 ctgtgtatta ctgtgcgaaa ga 22

20 <210> 272
 <211> 22
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 272
 ctgtgtatta ctgtgcgaga ca 22

30 <210> 273
 <211> 22
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 273
 ccatgtatta ctgtgcgaga ca 22

40 <210> 274
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 274
 ccatgtatta ctgtgcgaga aa 22

50 <210> 275
 <211> 69
 <212> DNA
 <213> Homo sapiens

55

EP 1 578 903 B2

<400> 275

5

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 276

<211> 69

<212> DNA

<213> Homo sapiens

10

<400> 276

15

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 277

<211> 69

<212> DNA

<213> Homo sapiens

20

<400> 277

25

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 278

<211> 69

<212> DNA

<213> Homo sapiens

30

<400> 278

35

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 279

<211> 69

<212> DNA

<213> Homo sapiens

40

<400> 279

45

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 280

<211> 69

<212> DNA

<213> Homo sapiens

50

<400> 280

55

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

EP 1 578 903 B2

<210> 281
 <211> 69
 <212> DNA
 <213> Homo sapiens
 5
 <400> 281
 aacatccaga tgaccagtc tccatctgcc atgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgt 69
 10
 <210> 282
 <211> 69
 <212> DNA
 <213> Homo sapiens
 15
 <400> 282
 gacatccaga tgaccagtc tccatcctca ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgt 69
 20
 <210> 283
 <211> 69
 <212> DNA
 <213> Homo sapiens
 25
 <400> 283
 gacatccaga tgaccagtc tccatcctca ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgt 69
 30
 <210> 284
 <211> 69
 <212> DNA
 <213> Homo sapiens
 35
 <400> 284
 gccatccagt tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgc 69
 40
 <210> 285
 <211> 69
 <212> DNA
 <213> Homo sapiens
 45
 <400> 285
 gccatccagt tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgc 69
 50
 <210> 286
 <211> 69
 <212> DNA
 <213> Homo sapiens
 55
 <400> 286

EP 1 578 903 B2

```

    gacatccaga tgaccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
    atcacttgt                                     69

<210> 287
5  <211> 69
    <212> DNA
    <213> Homo sapiens

<400> 287
10

    gacatccaga tgaccagtc tccatcttct gtgtctgcat ctgtaggaga cagagtcacc 60
    atcacttgt                                     69

<210> 288
15 <211> 69
    <212> DNA
    <213> Homo sapiens

<400> 288
20

    gacatccagt tgaccagtc tccatcttcc ctgtctgcat ctgtaggaga cagagtcacc 60
    atcacttgc                                     69

<210> 289
25 <211> 69
    <212> DNA
    <213> Homo sapiens

<400> 289
30

    gccatccgga tgaccagtc tccatcttcc ctgtctgcat ctgtaggaga cagagtcacc 60
    atcacttgc                                     69

<210> 290
35 <211> 69
    <212> DNA
    <213> Homo sapiens

<400> 290
40

    gccatccgga tgaccagtc tccatcttca ttctctgcat ctacaggaga cagagtcacc 60
    atcacttgt                                     69

<210> 291
45 <211> 69
    <212> DNA
    <213> Homo sapiens

<400> 291
50

    gtcacttgga tgaccagtc tccatcttta ctctctgcat ctacaggaga cagagtcacc 60
    atcagttgt                                     69

<210> 292
55 <211> 69
    <212> DNA

```

EP 1 578 903 B2

<213> Homo sapiens

<400> 292

5 **gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60**
 atcacttgc 69

<210> 293

10 <211> 69

<212> DNA

<213> Homo sapiens

<400> 293

15 **gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60**
 atcacttgc 69

<210> 294

20 <211> 69

<212> DNA

<213> Homo sapiens

<400> 294

25 **gatattgtga tgacccagac tccactctcc ctgcccgta cccctggaga gccggcctcc 60**
 atctcctgc 69

<210> 295

30 <211> 69

<212> DNA

<213> Homo sapiens

<400> 295

35 **gatattgtga tgacccagac tccactctcc ctgcccgta cccctggaga gccggcctcc 60**
 atctcctgc 69

<210> 296

40 <211> 69

<212> DNA

<213> Homo sapiens

<400> 296

45 **gatgttgtga tgactcagtc tccactctcc ctgcccgta cccttggaga gccggcctcc 60**
 atctcctgc 69

<210> 297

50 <211> 69

<212> DNA

<213> Homo sapiens

<400> 297

EP 1 578 903 B2

gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttgagaca gccggcctcc 60
atctcctgc 69

<210> 298
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 298

gatattgtga tgaccagac tccactctct ctgtccgtca cccctggaca gccggcctcc 60
atctcctgc 69

<210> 299
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 299

gatattgtga tgaccagac tccactctct ctgtccgtca cccctggaca gccggcctcc 60
atctcctgc 69

<210> 300
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 300

gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgc 69

<210> 301
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 301

gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgc 69

<210> 302
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 302

gatattgtga tgaccagac tccactctcc tcacctgtca cccttgagaca gccggcctcc 60
atctcctgc 69

<210> 303
 <211> 69
 <212> DNA
 <213> Homo sapiens

EP 1 578 903 B2

<400> 303

5

gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 304

<211> 69

<212> DNA

<213> Homo sapiens

10

<400> 304

15

gaaattgtgt tgacgcagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc . 69

<210> 305

<211> 69

<212> DNA

<213> Homo sapiens

20

<400> 305

25

gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 306

<211> 69

<212> DNA

<213> Homo sapiens

30

<400> 306

35

gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 307

<211> 69

<212> DNA

<213> Homo sapiens

40

<400> 307

45

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 308

<211> 69

<212> DNA

<213> Homo sapiens

50

<400> 308

55

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 309

<211> 69

<212> DNA

<213> Homo sapiens

<400> 309

5 **gaaattgtaa** **tgacacagtc** **tccagccacc** **ctgtctttgt** **ctccagggga** **aagagccacc** 60
 ctctcctgc 69

<210> 310

<211> 69

10 <212> DNA

<213> Homo sapiens

<400> 310

15 **gacatcgtga** **tgaccagtc** **tccagactcc** **ctggctgtgt** **ctctggggga** **gagggccacc** 60
 atcaactgc 69

<210> 311

<211> 69

20 <212> DNA

<213> Homo sapiens

<400> 311

25 **gaaacgacac** **tcacgcagtc** **tccagacttc** **atgtcagcga** **ctccaggaga** **caaagtcacc** 60
 atctcctgc 69

<210> 312

<211> 69

30 <212> DNA

<213> Homo sapiens

<400> 312

35 **gaaattgtgc** **tgactcagtc** **tccagacttt** **cagtctgtga** **ctccaaagga** **gaaagtcacc** 60
 atcacctgc 69

<210> 313

<211> 69

40 <212> DNA

<213> Homo sapiens

<400> 313

45 **gaaattgtgc** **tgactcagtc** **tccagacttt** **cagtctgtga** **ctccaaagga** **gaaagtcacc** 60
 atcacctgc 69

<210> 314

<211> 69

50 <212> DNA

<213> Homo sapiens

<400> 314

55 **gatgttgtga** **tgacacagtc** **tccagctttc** **ctctctgtga** **ctccagggga** **gaaagtcacc** 60
 atcacctgc 69

<210> 315

EP 1 578 903 B2

<211> 66
 <212> DNA
 <213> Homo sapiens

5 <400> 315

cagtcctgtgc tgactcagcc accctcgggtg tctgaagccc ccaggcagag ggtcaccatc 60
tctctgt 66

10 <210> 316
 <211> 66
 <212> DNA
 <213> Homo sapiens

15 <400> 316

cagtcctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60
tctctgc 66

20 <210> 317
 <211> 66
 <212> DNA
 <213> Homo sapiens

25 <400> 317

cagtcctgtgc tgactcagcc accctcagcg tctggggaccc ccgggcagag ggtcaccatc 60
tcttgt 66

30 <210> 318
 <211> 66
 <212> DNA
 <213> Homo sapiens

35 <400> 318

cagtcctgtgc tgactcagcc accctcagcg tctggggaccc ccgggcagag ggtcaccatc 60
tcttgt 66

40 <210> 319
 <211> 66
 <212> DNA
 <213> Homo sapiens

45 <400> 319

cagtcctgtgt tgacgcagcc gccctcagtg tctggggccc caggacagaa ggtcaccatc 60
tctctgc 66

50 <210> 320
 <211> 66
 <212> DNA
 <213> Homo sapiens

55 <400> 320

EP 1 578 903 B2

cagtctgccc tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 321
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 321

cagtctgccc tgactcagcc tcgctcagtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 322
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 322

cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60
tcctgc 66

<210> 323
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 323

cagtctgccc tgactcagcc tccctccgtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 324
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 324

cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60
tcctgc 66

<210> 325
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 325

tcctatgagc tgactcagcc accctcagtg tccgtgtccc caggacagac agccagcatc 60
acctgc 66

<210> 326
 <211> 66
 <212> DNA

EP 1 578 903 B2

<213> Homo sapiens

<400> 326

5 **tcctatgagc tgactcagcc actctcagtg tcagtggccc tgggacagac ggccaggatt 60**
 acctgt 66

<210> 327

10 <211> 66

<212> DNA

<213> Homo sapiens

<400> 327

15

tcctatgagc tgacacagcc accctcgggtg tcagtgtccc caggacaaac ggccaggatc 60
acctgc 66

20 <210> 328

<211> 66

<212> DNA

<213> Homo sapiens

25 <400> 328

```
tcttatgagc tgacacagcc accctcggtg tcaagtgtccc taggacagat ggccaggatc 60
acctgc                                           66
```

30 <210> 329

<211> 66

<212> DNA

<213> Homo sapiens

35 <400> 329

```
tcttctgagc tgactcagga cctgtctgtg tctgtggcct tgggacagac agtcaggatc 60
acatgc 66
```

40 $\langle 210 \rangle$ 330

<211> 66

<212> DNA

<213> Homo sapiens

45 <400> 330

```
tcctatgtgc tgactcagcc accctcagtg tcagtggccc caggaaagac ggccaggatt 60
acctgt                                           66
```

<210> 331

<211> 66

<212> DNA

55 <213> Homo sapiens

<400> 331

EP 1 578 903 B2

tcctatgagc tgacacagct accctcgggtg tcagtgtccc caggacagac agccaggatc 60
acctgc 66

5 <210> 332
<211> 66
<212> DNA
<213> Homo sapiens

10 <400> 332

tcctatgagc tgatgcagcc accctcgggtg tcagtgtccc caggacagac ggccaggatc 60
acctgc 66

15 <210> 333
<211> 66
<212> DNA
<213> Homo sapiens

20 <400> 333

tcctatgagc tgacacagcc atcctcagtg tcagtgtctc cgggacagac agccaggatc 60
acctgc 66

25 <210> 334
<211> 66
<212> DNA
<213> Homo sapiens

30 <400> 334

ctgcctgtgc tgactcagcc cccgtctgca tctgccttgc tgggagcctc gatcaagctc 60
acctgc 66

35 <210> 335
<211> 66
<212> DNA
<213> Homo sapiens

40 <400> 335

cagcctgtgc tgactcaatc atcctctgcc tctgcttccc tgggagcctc ggtcaagctc 60
acctgc 66

45 <210> 336
<211> 66
<212> DNA
<213> Homo sapiens

50 <400> 336

cagcttgtgc tgactcaatc gccctctgcc tctgcctccc tgggagcctc ggtcaagctc 60
acctgc 66

55 <210> 337
<211> 66
<212> DNA
<213> Homo sapiens

EP 1 578 903 B2

<400> 337

5

cagcctgtgc tgactcagcc accttcctcc tccgcatctc ctggagaatc cgccagactc 60
acctgc 66

<210> 338

<211> 66

<212> DNA

<213> Homo sapiens

10

<400> 338

15

caggctgtgc tgactcagcc ggcttcctcc tctgcatctc ctggagcatc agccagtctc 60
acctgc 66

<210> 339

<211> 66

<212> DNA

<213> Homo sapiens

20

<400> 339

25

cagcctgtgc tgactcagcc atcttcccat tctgcatctt ctggagcatc agtcagactc 60
acctgc 66

<210> 340

<211> 66

<212> DNA

<213> Homo sapiens

30

<400> 340

35

aattttatgc tgactcagcc ccactctgtg tcggagtctc cggggaagac ggtaaccatc 60
tcctgc 66

<210> 341

<211> 66

<212> DNA

<213> Homo sapiens

40

<400> 341

45

cagactgtgg tgactcagga gccctcactg actgtgtccc caggagggac agtcactctc 60
acctgt 66

<210> 342

<211> 66

<212> DNA

<213> Homo sapiens

50

<400> 342

55

caggctgtgg tgactcagga gccctcactg actgtgtccc caggagggac agtcactctc 60
acctgt 66

<210> 343

<211> 66

EP 1 578 903 B2

<212> DNA
<213> Homo sapiens

<400> 343

5

cagactgtgg tgaccagga gccatcggtc tcagtgtccc ctggagggac agtcacactc 60
acttgt 66

10 <210> 344
<211> 66
<212> DNA
<213> Homo sapiens

15 <400> 344

cagcctgtgc tgactcagcc accctctgca tcagcctccc tgggagcctc ggtcacactc 60
acctgc 66

20 <210> 345
<211> 66
<212> DNA
<213> Homo sapiens

25 <400> 345

caggcagggc tgactcagcc accctcggtg tccaagggct tgagacagac cgccacactc 60
acctgc 66

30 <210> 346
<211> 11
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

40 <220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

45 <400> 346
nnnnngact c 11

<210> 347
<211> 11
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

55 <220>
<221> modified_base
<222> (6)..(11)
<223> A, T, C, G, other or unknown

<400> 347
 gagtcnnnnn n 11

 <210> 348
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (3)..(9)
 <223> A, T, C, G, other or unknown

 <400> 348
 gcnnnnnnng c 11

 <210> 349
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (7)..(11)
 <223> A, T, C, G, other or unknown

 <400> 349
 acctgcnnnn n 11

 <210> 350
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 350
 cacatccgtg ttgtcacgg atgtg 25

 <210> 351
 <211> 88
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 351

EP 1 578 903 B2

aatagtagac tgcagtgtcc tcagccctta agctgttcat ctgcaagtag agagtattct 60
tagagttgtc tctagactta gtgaagcg 88

5 <210> 352
<211> 88
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 352

15 cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg acactgcagt ctactatt 88

20 <210> 353
<211> 95
<212> DNA
<213> Artificial Sequence

<220>
25 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 353

30 cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg acactgcagt ctactattgt gcgag 95

<210> 354
<211> 95
<212> DNA
35 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

40 <400> 354

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg acactgcagt ctactattgt acgag 95

45 <210> 355
<211> 24
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 355

55 cgcttcacta agtctagaga caac 24

<210> 356
<211> 15

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (8)..(15)
 10 <223> A, T, C, G, other or unknown

 <400> 356 cacctgcnnn nnnnn 15

 <210> 357
 15 <211> 17
 <212> DNA
 <213> Artificial Sequence

 <220>
 20 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (7)..(17)
 25 <223> A, T, C, G, other or unknown

 <400> 357
 cagctcnnnn nnnnnnn 17

 30 <210> 358
 <211> 17
 <212> DNA
 <213> Artificial Sequence

 35 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 40 <222> (7)..(17)
 <223> A, T, C, G, other or unknown

 <400> 358
 gaagacnnnn nnnnnnn 17
 45
 <210> 359
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 55 <221> modified_base
 <222> (6)..(17)
 <223> A, T, C, G, other or unknown

<400> 359
 gcagcnnnnn nnnnnnn 17

5 <210> 360
 <211> 12
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

15 <220>
 <221> modified_base
 <222> (7)..(12)
 <223> A, T, C, G, other or unknown

20 <400> 360
 gaagacnnnn nn 12

25 <210> 361
 <211> 22
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <220>
 <221> modified_base
 <222> (7)..(22)
 <223> A, T, C, G, other or unknown

40 <400> 361
 cttgagnnnn nnnnnnnnnn nn 22

45 <210> 362
 <211> 19
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

55 <220>
 <221> modified_base
 <222> (6)..(19)
 <223> A, T, C, G, other or unknown

<400> 362
 acggcnnnnn nnnnnnnnn 19

<210> 363
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (6)..(18)
 <223> A, T, C, G, other or unknown
 5
 <400> 363
 acggcnnnnn nnnnnnnn 18
 <210> 364
 10 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (7)..(12)
 20 <223> A, T, C, G, other or unknown
 <400> 364
 gtatccnnnn nn 12
 25 <210> 365
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (7)..(11)
 <223> A, T, C, G, other or unknown
 <400> 365
 actgggnnnn n 11
 40 <210> 366
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 50 <221> modified_base
 <222> (6) ..(10)
 <223> A, T, C, G, other or unknown
 <400> 366
 55 ggatcnnnnn 10
 <210> 367
 <211> 11

<212> DNA
 <213> Artificial Sequence

<220>
 5 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (6) ..(11)
 10 <223> A, T, C, G, other or unknown

<400> 367
 gcatcnnnnn n 11

15 <210> 368
 <211> 16
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 25 <222> (7) ..(16)
 <223> A, T, C, G, other or unknown

<400> 368
 gaggagnnnn nnnnnn 16

30 <210> 369
 <211> 19
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 40 <221> modified_base
 <222> (6) .. (19)
 <223> A, T, C, G, other or unknown

<400> 369
 45 gggacnnnnn nnnnnnnn 19

<210> 370
 <211> 14
 <212> DNA
 50 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

55 <220>
 <221> modified_base
 <222> (7) .. (14)
 <223> A, T, C, G, other or unknown

<400> 370
 acctgcnnnn nnnn 14

 <210> 371
 5 <211> 17
 <212> DNA
 <213> Artificial Sequence

 <220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified base
 <222> (7) ..(17)
 15 <223> A, T, C, G, other or unknown

 <400> 371
 ggcggannnn nnnnnnn 17

 20 <210> 372
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 25 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 30 <222> (7) ..(22)
 <223> A, T, C, G, other or unknown

 <400> 372
 ctgaagnnnn nnnnnnnnnn nn 22
 35
 <210> 373
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 45 <221> modified_base
 <222> (6) .. (11)
 <223> A, T, C, G, other or unknown

 <400> 373
 50 cccgcnnnnn n 11

 <210> 374
 <211> 18
 <212> DNA
 55 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5 <220>
 <221> modified_base
 <222> (6) ..(18)
 <223> A, T, C, G, other or unknown

 <400> 374
 ggatgnnnnn nnnnnnnn 18

 10 <210> 375
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 20 <220>
 <221> modified_base
 <222> (7)..(22)
 <223> A, T, C, G, other or unknown

 <400> 375
 ctggagnnnn nnnnnnnnnn nn 22

 25 <210> 376
 <211> 15
 <212> DNA
 <213> Artificial Sequence

 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 35 <220>
 <221> modified_base
 <222> (6)..(15)
 <223> A, T, C, G, other or unknown

 40 <400> 376
 gacgcnnnnn nnnnn 15

 45 <210> 377
 <211> 13
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 50 <220>
 <221> modified_base
 <222> (6) .. (13)
 <223> A, T, C, G, other or unknown

 55 <400> 377
 ggtgannnnn nnn 13

 <210> 378
 <211> 13

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (6)..(13)
 10 <223> A, T, C, G, other or unknown

 <400> 378
 gaagannnnn nnn 13

 15 <210> 379
 <211> 10
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 25 <222> (6) ..(10)
 <223> A, T, C, G, other or unknown

 <400> 379
 gagtcnnnnn 10
 30
 <210> 380
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 40 <221> modified_base
 <222> (7) ..(26)
 <223> A, T, C, G, other or unknown

 <400> 380
 45 tccracnnnn nnnnnnnnnn nnnnnn 26

 <210> 381
 <211> 11
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 55 <220>
 <221> modified_base
 <222> (5) .. (11)
 <223> A, T, C, G, other or unknown

<400> 381
 cctcnnnnnn n 11

 <210> 382
 <211> 10
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (6)..(10)
 <223> A, T, C, G, other or unknown

 <400> 382
 gagtcnnnnn 10

 <210> 383
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (7)..(18)
 <223> A, T, C, G, other or unknown

 <400> 383
 cccacannnn nnnnnnnn 18

 <210> 384
 <211> 14
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (6)..(14)
 <223> A, T, C, G, other or unknown

 <400> 384
 gcatcnnnnn nnnn 14

 <210> 385
 <211> 13
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (6) .. (13)
 <223> A, T, C, G, other or unknown
 5
 <400> 385
 ggtgannnnn nnn 13
 <210> 386
 10 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (5) ..(12)
 20 <223> A, T, C, G, other or unknown
 <400> 386
 cccgnnnnnn nn 12
 25 <210> 387
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (6) ..(19)
 <223> A, T, C, G, other or unknown
 <400> 387
 40 ggatgnnnnn nnnnnnnnn 19
 <210> 388
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 50 <221> modified_base
 <222> (7) ..(17)
 <223> A, T, C, G, other or unknown
 <400> 388
 55 gaccgannnn nnnnnnn 17
 <210> 389
 <211> 17

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (7) ..(17)
 10 <223> A, T, C, G, other or unknown

 <400> 389
 cacccannnn nnnnnnn 17

 15 <210> 390
 <211> 17
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified base
 25 <222> (7)..(17)
 <223> A, T, C, G, other or unknown

 <400> 390
 caarcannnn nnnnnnn 17
 30
 <210> 391
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 <400> 391
 40 gctgtgtatt actgtgcgag 20

 <210> 392
 <211> 20
 <212> DNA
 45 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 50 <400> 392
 gccgtgtatt actgtgcgag 20

 <210> 393
 <211> 20
 55 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 393

gccgtatatt actgtgag 20

<210> 394

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 394

gccgtgtatt actgtacgag 20

<210> 395

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 395

gccatgtatt actgtgag 20

<210> 396

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 396

cacatccgtg ttgtcacgg atgtg 25

<210> 397

<211> 88

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 397

aatagtagac tgcagtgtcc tcagccctta agctgttcat ctgcaagtag agagtattct 60
tagagttgtc tctagactta gtgaagcg 88

<210> 398

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 398

5 **cgcttcacta agtctagaga caactctaag aatactctct acttgagat gaacagctta 60**
 agggtgagg acactgcagt ctactattgt gcgag 95

<210> 399

<211> 24

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

15 <400> 399

cgcttcacta agtctagaga caac 24

<210> 400

<211> 44

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

25

<400> 400

cacatccgtg ttgtcacgg atgtgggagg atggagactg ggtc 44

<210> 401

<211> 44

30

<212> DNA

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 401

cacatccgtg ttgtcacgg atgtgggaga gtggagactg agtc 44

<210> 402

<211> 44

40

<212> DNA

<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 402

cacatccgtg ttgtcacgg atgtgggtgc ctggagactg cgtc 44

50

<210> 403

<211> 44

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 403
 cacatccgtg ttgtcacgg atgtgggtgg ctggagactg cgtc 44

 <210> 404
 <211> 34
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 404
 cctctactct tgcacagtg cacaagacat ccag 34

 <210> 405
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 405
 cctctactct tgcacagtg 20

 <210> 406
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 406
 ggagatgga ctggatgtct tgtgcactgt gacaagagta gagg 44

 <210> 407
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 407
 ggagatgga ctggatgtct tgtgcactgt gacaagagta gagg 44

 <210> 408
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 408
 ggtgcctgga ctggatgtct tgtgcactgt gacaagagta gagg 44

<210> 409
 <211> 44
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 409
 10 ggtggctgga ctggatgtct tgtgcactgt gacaagagta gagg 44
 <210> 410
 <211> 44
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 410
 cacatccgtg ttgttcacgg atgtggatcg actgtccagg agac 44
 <210> 411
 <211> 44
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 411
 cacatccgtg ttgttcacgg atgtggactg tctgtcccaa ggcc 44
 <210> 412
 <211> 44
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 412
 cacatccgtg ttgttcacgg atgtggactg actgtccagg agac 44
 <210> 413
 <211> 44
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 413
 55 cacatccgtg ttgttcacgg atgtggaccc tctgccctgg ggcc 44
 <210> 414
 <211> 59
 <212> DNA

EP 1 578 903 B2

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 414

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccgg 59

10

<210> 415

<211> 69

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 415

20

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagtcgat 69

<210> 416

<211> 69

<212> DNA

25

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

30

<400> 416

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagacagt 69

35

<210> 417

<211> 69

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 417

45

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagtcagt 69

<210> 418

<211> 70

50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

55

<400> 418

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gtstccccgg 60
ggcagagggt 70

5 <210> 419
<211> 24
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 419
cctctgactg agtgcacaga gtgc 24

15 <210> 420
<211> 13
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
25 <222> (5)..(9)
<223> A, T, C, G, other or unknown

<400> 420
ggccnnnnng gcc 13

30 <210> 421
<211> 15
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
40 <222> (4)..(12)
<223> A, T, C, G, other or unknown

<400> 421
45 ccannnnnnn nntgg 15

<210> 422
<211> 12
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

55 <220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 422
 cgannnnnnt gc 12

 <210> 423
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (4) ..(8)
 <223> A, T, C, G, other or unknown

 <400> 423
 gccnnnnngg c 11

 <210> 424
 <211> 10
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (4) ..(7)
 <223> A, T, C, G, other or unknown

 <400> 424
 gatnnnnatc 10

 <210> 425
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (4) ..(8)
 <223> A, T, C, G, other or unknown

 <400> 425
 gacnnnnngt c 11

 <210> 426
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (4) .. (8)
 <223> A, T, C, G, other or unknown
 5
 <400> 426
 gcannnnntg c 11
 <210> 427
 10 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (7)..(12)
 20 <223> A, T, C, G, other or unknown
 <400> 427
 gtatccnnnn nn 12
 25 <210> 428
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (4)..(9)
 <223> A, T, C, G, other or unknown
 <400> 428
 gacnnnnnng tc 12
 40 <210> 429
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 50 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 <400> 429
 55 ccannnnntg g 11
 <210> 430
 <211> 12

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (1)..(6)
 10 <223> A, T, C, G, other or unknown

 <400> 430
 nnnnnngaga cg 12

 15 <210> 431
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 25 <222> (4)..(9)
 <223> A, T, C, G, other or unknown

 <400> 431
 ccannnnnttg 12
 30
 <210> 432
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 40 <221> modified_base
 <222> (4)..(7)
 <223> A, T, C, G, other or unknown

 <400> 432
 45 gaannnttc 10

 <210> 433
 <211> 11
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 55 <220>
 <221> modified_base
 <222> (7)..(11)
 <223> A, T, C, G, other or unknown

<400> 433
 ggtctcnnnn n 11

 <210> 434
 <211> 16
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (1)..(10)
 <223> A, T, C, G, other or unknown

 <400> 434
 nnnnnnnnnn ctctc 16

 <210> 435
 <211> 15
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (1)..(9)
 <223> A, T, C, G, other or unknown

 <400> 435
 nnnnnnnnnt ccgcc 15

 <210> 436
 <211> 13
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (5)..(9)
 <223> A, T, C, G, other or unknown

 <400> 436
 ggccnnnnng gcc 13

 <210> 437
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (4)..(9)
 <223> A, T, C, G, other or unknown
 5
 <400> 437
 ccannnnnnt gg 12
 <210> 438
 10 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 <222> (4)..(9)
 20 <223> A, T, C, G, other or unknown
 <400> 438
 gacnnnnnng tc 12
 25 <210> 439
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (4)..(9)
 <223> A, T, C, G, other or unknown
 <400> 439
 cgannnnnnt gc 12
 40 <210> 440
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 50 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 <400> 440
 55 gcannnnntg c 11
 <210> 441
 <211> 11

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 441
ccannnnntg g 11

<210> 442
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 442
gaannnnnttc 10

<210> 443
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 443
nnnnnngaga cg 12

<210> 444
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 444
 gtatccnnnn nn 12

 5 <210> 445
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 10 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (4)..(8)
 15 <223> A, C, G, other or unknown

 <400> 445
 gacnnnnngt c 11

 20 <210> 446
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 25 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 30 <222> (7)..(11)
 <223> A, T, C, G, other or unknown

 <400> 446
 ggtctcnnnn n 11
 35 <210> 447
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 45 <222> (4)..(8)
 <223> A, T, C, G, other or unknown

 <400> 447
 50 gccnnnnngg c 11

 <210> 448
 <211> 15
 <212> DNA
 55 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (4)..(12)
 <223> A, T, C, G, other or unknown
 5
 <400> 448
 ccannnnnnn nntgg 15
 <210> 449
 10 <211> 16
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified base
 <222> (1)..(10)
 20 <223> A, T, C, G, other or unknown
 <400> 449
 nnnnnnnnnn ctctc 16
 25 <210> 450
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 35 <222> (1)..(9)
 <223> A, T, C, G, other or unknown
 <400> 450
 nnnnnnnnnt ccgcc 15
 40 <210> 451
 <211> 9532
 <212> DNA
 <213> Unknown Organism
 45 <220>
 <223> Description of Unknown Organism: MALIA3 nucleotide sequence
 <220>
 50 <221> CDS
 <222> (1579)..(1638)
 <220>
 <221> CDS
 55 <222> (2343)..(3443)
 <220>
 <221> CDS

<222> (3945)..(4400)

<220>

<221> CDS

5 <222> (4406)..(4450)

<220>

<221> CDS

10 <222> (4746)..(5789)

<400> 451

15

20

25

30

35

40

45

50

55

EP 1 578 903 B2

aatgctacta ctattagtag aattgatgcc accttttcag ctcgcgcccc aaatgaaaat 60
 atagctaaac aggttattga ccatttgcca aatgtatcta atgggtcaaac taaatctact 120
 5 cgttcgcaga attgggaatc aactgttaca tggaatgaaa cttccagaca ccgtacttta 180
 gttgcatatt taaaacatgt tgagctacag caccagattc agcaattaag ctctaagcca 240
 tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcctgacctg 300
 10 ttggagtttg cttccgggtc ggttcgcttt gaagctcgaa ttaaaacgcg atatttgaag 360
 tctttcgggc ttcctcttaa tctttttgat gcaatccgct ttgcttctga ctataatagt 420
 cagggtaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca 480
 15 tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct 540
 aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt 600
 ggtttttacc gtcgtctggg aaacgagggt tatgatagtg ttgctcttac tatgcctcgt 660
 20 aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg 720
 atgaatcttt ctacctgtaa taatgttgtt ccgttagttc gttttattaa cgtagatttt 780
 tcttcccaac gtcctgactg gtataatgag ccagttctta aaatcgcata aggtaattca 840
 caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctggtgttt 900
 25 ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg 960
 aatatccggt tcttgtcaag attactcttg atgaagggtca gccagcctat gcgcctgggtc 1020
 tgtacaccgt tcatctgtcc tctttcaaag ttggtcagtt cggttccctt atgattgacc 1080
 30 gtctgcgcct cgttcgggtc aagtaacatg gagcaggtcg cggatttcga cacaatttat 1140
 caggcgatga tacaatctc cgttgtactt tgtttcgcgc ttggtataat cgctgggggt 1200
 caaagatgag tgtttttagtg tattctttcg cctctttcgt tttagggttg tgccctcgta 1260
 35 gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct 1320
 caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgctg ctgaggggtga 1380
 cgatcccgca aaagcggcct ttaactccct gcaagcctca gcgaccgaat atatcggtta 1440
 40 tgcgtgggcg atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa 1500
 attcacctcg aaagcaagct gataaaccga tacaattaaa ggctcctttt ggagcctttt 1560
 tttttggaga ttttcaac gtg aaa aaa tta tta ttc gca att cct tta gtt 1611
 45 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val
 1 5 10
 gtt cct ttc tat tct cac agt gca cag tctgtcgtga cgcagccgcc 1658
 Val Pro Phe Tyr Ser His Ser Ala Gln

EP 1 578 903 B2

	15	20	
	ctcagtgtct ggggccccag ggcagagggg caccatctcc tgcactggga gcagctccaa	1718	
5	catcggggca gggtatgatg tacactggta ccagcagctt ccaggaacag cccccaaact	1778	
	cctcatctat ggtaacagca atcggccctc aggggtccct gaccgattct ctggctccaa	1838	
	gtctggcacc tcagcctccc tggccatcac tgggctccag gctgaggatg aggctgatta	1898	
10	ttactgccag tcctatgaca gcagcctgag tggcctttat gtcttcggaa ctgggaccaa	1958	
	ggtcaccgtc ctaggctcagc ccaaggccaa cccactgtc actctgttcc cgccctcctc	2018	
	tgaggagctc caagccaaca aggccacact agtgtgtctg atcagtgact tctacccggg	2078	
15	agctgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac	2138	
	cacaccctcc aaacaaagca acaacaagta cgcggccagc agctatctga gcctgacgcc	2198	
	tgagcagtgga aagtcaccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt	2258	
20	ggagaagaca gtggccccta cagaatgttc ataataaacc gcctccaccg ggcgcgccaa	2318	
	ttctatttca aggagacagt cata atg aaa tac cta ttg cct acg gca gcc	2369	
	Met Lys Tyr Leu Leu Pro Thr Ala Ala	25	
25	gct gga ttg tta tta ctc gcg gcc cag ccg gcc atg gcc gaa gtt caa	2417	
	Ala Gly Leu Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Val Gln	30 35 40 45	
	ttg tta gag tct ggt ggc ggt ctt gtt cag cct ggt ggt tct tta cgt	2465	
	Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg	50 55 60	
30	ctt tct tgc gct gct tcc gga ttc act ttc tct tcg tac gct atg tct	2513	
	Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser	65 70 75	
35	tgg gtt cgc caa gct cct ggt aaa ggt ttg gag tgg gtt tct gct atc	2561	
	Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile	80 85 90	
	tct ggt tct ggt ggc agt act tac tat gct gac tcc gtt aaa ggt cgc	2609	
	Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg	95 100 105	
40	ttc act atc tct aga gac aac tct aag aat act ctc tac ttg cag atg	2657	
	Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met	110 115 120 125	
45	aac agc tta agg gct gag gac act gca gtc tac tat tgc gct aaa gac	2705	
	Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp	130 135 140	
50	tat gaa ggt act ggt tat gct ttc gac ata tgg ggt caa ggt act atg	2753	
	Tyr Glu Gly Thr Gly Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met		

EP 1 578 903 B2

	145	150	155	
5	gtc acc gtc tct agt gcc tcc acc Val Thr Val Ser Ser Ala Ser Thr	aag ggc cca tcg gtc ttc ccc ctg Lys Gly Pro Ser Val Phe Pro Leu	2801	
	160	165	170	
	gca ccc tcc tcc aag agc acc tct Ala Pro Ser Ser Lys Ser Thr Ser	ggg ggc aca gcg gcc ctg ggc tgc Gly Gly Thr Ala Ala Leu Gly Cys	2849	
	175	180	185	
10	ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser		2897	
	190	195	200	205
	ggc gcc ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tct Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser		2945	
15		210	215	220
	agc gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tct tct agc Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser		2993	
	225	230	235	
20	ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc aac Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn		3041	
	240	245	250	
	acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt gcg gcc gct cat Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His		3089	
25		255	260	265
	cac cac cat cat cac tct gct gaa caa aaa ctc atc tca gaa gag gat His His His His His Ser Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp		3137	
	270	275	280	285
30	ctg aat ggt gcc gca gat atc aac gat gat cgt atg gct ggc gcc gct Leu Asn Gly Ala Ala Asp Ile Asn Asp Asp Arg Met Ala Gly Ala Ala		3185	
	290	295	300	
	gaa act gtt gaa agt tgt tta gca aaa ccc cat aca gaa aat tca ttt Glu Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu Asn Ser Phe		3233	
35		305	310	315
	act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac tat Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr		3281	
	320	325	330	
40	gag ggt tgt ctg tgg aat gct aca ggc gtt gta gtt tgt act ggt gac Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp		3329	
	335	340	345	
	gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt gct atc cct Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro		3377	
45		350	355	360
	gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct gag ggt ggc ggt Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly		3425	
	370	375	380	

tct gag ggt ggc ggt act aaacctcctg agtacgggtga tacacctatt 3473
 Ser Glu Gly Gly Gly Thr
 385

5 cccgggtata cttatatcaa ccctctcgac ggcacttata cgcctgggtac tgagcaaaac 3533
 cccgctaata ctaatccttc tcttgaggag tctcagcctc ttaatacttt catgtttcag 3593
 aataataggt tccgaaatag gcagggggca ttaactgttt atacgggcac tgttactcaa 3653

10 ggcactgacc ccgttaaaac ttattaccag tacactcctg tatcatcaaa agccatgtat 3713
 gacgcttact ggaacggtaa attcagagac tgcgctttcc attctggctt taatgaagat 3773
 ccattcggtt gtgaatatca aggccaatcg tctgacctgc ctcaacctcc tgtcaatgct 3833

15 ggcgggcggt ctgggtgggtg ttctgggtggc ggctctgagg gtgggtggctc tgaggggtggc 3893
 gggtctgagg gtggcggtc tgagggaggc gggtccgggtg gtggctctgg t tcc ggt 3950
 Ser Gly

20 gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct atg acc 3998
 Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr
 390 395 400 405

gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc aaa ctt 4046
 Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu
 410 415 420

25 gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc att ggt 4094
 Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly
 425 430 435

gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat ttt gct 4142
 Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala
 440 445 450

30 ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat tca cct 4190
 Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro
 455 460 465

35 tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa tcg gtt 4238
 Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val
 470 475 480 485

gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa ttt tct 4286
 Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser
 490 495 500

40 att gat tgt gac aaa ata aac tta ttc cgt ggt gtc ttt gcg ttt ctt 4334
 Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu
 505 510 515

45 tta tat gtt gcc acc ttt atg tat gta ttt tct acg ttt gct aac ata 4382
 Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile
 520 525 530

ctg cgt aat aag gag tct taatc atg cca gtt ctt ttg ggt att ccg tta 4432

EP 1 578 903 B2

	Leu Arg Asn Lys Glu Ser	Met Pro Val Leu Leu Gly Ile Pro Leu	
	535	540	545
5	tta ttg cgt ttc ctc ggt ttccttctgg taactttggt cggtatctg		4480
	Leu Leu Arg Phe Leu Gly		
	550		
	cttacttttc ttaaaaaggg cttcggtaag atagctattg ctatttcatt gtttcttgct		4540
10	cttattattg ggcttaactc aattcttctg gggtatctct ctgatattag cgctcaatta		4600
	ccctctgact ttgttcaggg tgttcagtta attctcccggt ctaatgcgct tccctgtttt		4660
	tatgttatctc tctctgtaaa ggctgctatt ttcatttttg acgttaaaca aaaaatcggt		4720
15	tcttatttgg attgggataa ataat atg gct gtt tat ttt gta act ggc aaa		4772
		Met Ala Val Tyr Phe Val Thr Gly Lys	
		555	560
	tta ggc tct gga aag acg ctc gtt agc gtt ggt aag att cag gat aaa		4820
	Leu Gly Ser Gly Lys Thr Leu Val Ser Val Gly Lys Ile Gln Asp Lys		
	565	570	575
20	att gta gct ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa		4868
	Ile Val Ala Gly Cys Lys Ile Ala Thr Asn Leu Asp Leu Arg Leu Gln		
	580	585	590
	aac ctc ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga		4916
25	Asn Leu Pro Gln Val Gly Arg Phe Ala Lys Thr Pro Arg Val Leu Arg		
		600	605
	ata ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt		4964
	Ile Pro Asp Lys Pro Ser Ile Ser Asp Leu Leu Ala Ile Gly Arg Gly		
		615	620
30	aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat gag		5012
	Asn Asp Ser Tyr Asp Glu Asn Lys Asn Gly Leu Leu Val Leu Asp Glu		
		630	635
	tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa aga cag		5060
35	Cys Gly Thr Trp Phe Asn Thr Arg Ser Trp Asn Asp Lys Glu Arg Gln		
		645	650
	ccg att att gat tgg ttt cta cat gct cgt aaa tta gga tgg gat att		5108
	Pro Ile Ile Asp Trp Phe Leu His Ala Arg Lys Leu Gly Trp Asp Ile		
		660	665
40	att ttt ctt gtt cag gac tta tct att gtt gat aaa cag gcg cgt tct		5156
	Ile Phe Leu Val Gln Asp Leu Ser Ile Val Asp Lys Gln Ala Arg Ser		
		680	685
	gca tta gct gaa cat gtt gtt tat tgt cgt cgt ctg gac aga att act		5204
45	Ala Leu Ala Glu His Val Val Tyr Cys Arg Arg Leu Asp Arg Ile Thr		
		695	700
	tta cct ttt gtc ggt act tta tat tct ctt att act ggc tcg aaa atg		5252
	Leu Pro Phe Val Gly Thr Leu Tyr Ser Leu Ile Thr Gly Ser Lys Met		
		710	715
			720

EP 1 578 903 B2

cct ctg cct aaa tta cat gtt ggc gtt gtt aaa tat ggc gat tct caa 5300
 Pro Leu Pro Lys Leu His Val Gly Val Val Lys Tyr Gly Asp Ser Gln
 725 730 735

5 tta agc cct act gtt gag cgt tgg ctt tat act ggt aag aat ttg tat 5348
 Leu Ser Pro Thr Val Glu Arg Trp Leu Tyr Thr Gly Lys Asn Leu Tyr
 740 745 750 755

10 aac gca tat gat act aaa cag gct ttt tct agt aat tat gat tcc ggt 5396
 Asn Ala Tyr Asp Thr Lys Gln Ala Phe Ser Ser Asn Tyr Asp Ser Gly
 760 765 770

gtt tat tct tat tta acg cct tat tta tca cac ggt cgg tat ttc aaa 5444
 Val Tyr Ser Tyr Leu Thr Pro Tyr Leu Ser His Gly Arg Tyr Phe Lys
 775 780 785

15 cca tta aat tta ggt cag aag atg aaa tta act aaa ata tat ttg aaa 5492
 Pro Leu Asn Leu Gly Gln Lys Met Lys Leu Thr Lys Ile Tyr Leu Lys
 790 795 800

20 aag ttt tct cgc gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt 5540
 Lys Phe Ser Arg Val Leu Cys Leu Ala Ile Gly Phe Ala Ser Ala Phe
 805 810 815

aca tat agt tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc 5588
 Thr Tyr Ser Tyr Ile Thr Gln Pro Lys Pro Glu Val Lys Lys Val Val
 820 825 830 835

25 tct cag acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt 5636
 Ser Gln Thr Tyr Asp Phe Asp Lys Phe Thr Ile Asp Ser Ser Gln Arg
 840 845 850

ctt aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa tta 5684
 Leu Asn Leu Ser Tyr Arg Tyr Val Phe Lys Asp Ser Lys Gly Lys Leu
 855 860 865

30 att aat agc gac gat tta cag aag caa ggt tat tca ctc aca tat att 5732
 Ile Asn Ser Asp Asp Leu Gln Lys Gln Gly Tyr Ser Leu Thr Tyr Ile
 870 875 880

35 gat tta tgt act gtt tcc att aaa aaa ggt aat tca aat gaa att gtt 5780
 Asp Leu Cys Thr Val Ser Ile Lys Lys Gly Asn Ser Asn Glu Ile Val
 885 890 895

aaa tgt aat taattttgtt ttcttgatgt ttgtttcatc atctttctttt 5829
 Lys Cys Asn
 900

40 gctcaggtaa ttgaaatgaa taattcgct ctgcgcgatt ttgtaacttg gtattcaaag 5889
 caatcaggcg aatccgttat tgtttctccc gatgtaaaag gtactgttac tgtatattca 5949
 tctgacgtta aacctgaaaa tctacgcaat ttctttatctt ctgttttacg tgctaataat 6009

45 tttgatatgg ttggttcaat tccttcata attcagaagt ataatccaaa caatcaggat 6069
 tatattgatg aattgccatc atctgataat caggaatatg atgataattc cgctccttct 6129

EP 1 578 903 B2

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

ggtgggtttct ttgttccgca aaatgataat gttactcaaa cttttaaaat taataacggt 6189
 cgggcaaagg atttaatacg agttgtcgaa ttgtttgtaa agtctaatac ttctaaatcc 6249
 tcaaattgat tatctattga cggctctaata ctattagttg tttctgcacc taaagatatt 6309
 ttagataacc ttctcaatt cctttctact gttgatttgc caactgacca gatattgatt 6369
 gagggtttga tatttgaggt tcagcaaggt gatgctttag atttttcatt tgctgctggc 6429
 tctcagcgtg gcactgttgc agggggtgtt aatactgacc gcctcacctc tgttttatct 6489
 tctgctggtg gttcgttcgg tatttttaata ggcatgttt tagggctatc agttcgcgca 6549
 ttaaagacta atagccattc aaaaatattg tctgtgccac gtattcttac gctttcaggt 6609
 cagaagggtt ctatctctgt tggccagaat gtccctttta ttactggctg tgtagctggg 6669
 gaactctgcca atgtaaataa tccatttcag acgattgagc gtcaaaatgt aggtatttcc 6729
 atgagcgttt ttctgttgc aatggctggc ggtaatatg tcttgatat taccagcaag 6789
 gccgatagtt tgagttcttc tactcaggca agtgatgta ttactaatca aagaagtatt 6849
 gctacaacgg ttaatttgcg tgatggacag actcttttac tcggtggcct cactgattat 6909
 aaaaacactt ctcaagattc tggcgtaccg ttctgtcta aaatccctt aatcggcctc 6969
 ctgttttagct cccgctctga ttccaacgag gaaagcacgt tatacgtgct cgtcaaagca 7029
 accatagtac gcgccttga gcggcgcat aagcgcggcg ggtgtggtgg ttacgcgcag 7089
 cgtgaccgct acacttgcca gcgccttagc gccgcctcct ttcgctttct tcccttcctt 7149
 tctcgccacg ttcgccggt ttccccgtca agctctaaat cggggggtcc ctttaggggt 7209
 ccgatttagt gctttacggc acctcgacct caaaaaactt gatttgggtg atgggtcacg 7269
 tagtgggcca tcgccctgat agacggtttt tcgccctttg acgttgaggt ccacgttctt 7329
 taatagtga ctctgttcc aaactggaac aacactcaac cctatctcgg gctattcttt 7389
 tgatttataa gggattttgc cgatttcgga accaccatca aacaggattt tcgcctgctg 7449
 gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg gccaggcggg gaagggaat 7509
 cagctgttgc ccgtctcact ggtgaaaaga aaaaccaccc tggatccaag cttgcagggt 7569
 gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa 7629
 atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga 7689
 agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc 7749
 ttctgtttt tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg 7809
 gcgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc 7869

EP 1 578 903 B2

5 gccccgaaga acgttttcca atgatgagca ctttttaaagt tctgctatgt catacactat 7929
 tatcccgtat tgacgccggg caagagcaac tcggtcgccg ggcgcggtat tctcagaatg 7989
 acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag 8049
 aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa 8109
 cgatcggagg accgaaggag ctaaccgctt ttttgacaaa catgggggat catgtaactc 8169
 10 gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca 8229
 cgatgcctgt agcaatgcca acaacgttgc gcaaactatt aactggcgaa ctacttactc 8289
 tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc 8349
 tgcgctcggc ccttccggct ggctggttta ttgctgataa atctggagcc ggtgagcgtg 8409
 15 ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgat atcgtagtta 8469
 tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag 8529
 gtgcctcact gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga 8589
 20 ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc 8649
 tcatgaccaa aatcccttaa cgtgagtttt cgttccactg tacgtaagac cccaagctt 8709
 gtcgactgaa tggcgaatgg cgctttgcct ggtttccggc accagaagcg gtgccggaaa 8769
 25 gctggctgga gtgcgatctt cctgaggccg atactgtcgt cgtcccctca aactggcaga 8829
 tgcacggta cgatgcgcc atctacacca acgtaacctt tcccattacg gtcaatccgc 8889
 cgtttgctcc caccgagaat ccgacgggtt gttactcgt caccattaat gttgatgaaa 8949
 30 gctggctaca ggaaggccag acgcaatta tttttgatgg cgttcctatt ggttaaaaaa 9009
 tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa atattaacgt ttacaattta 9069
 aatatttgct tatacaatct tcctgttttt ggggcttttc tgattatcaa ccggggtaca 9129
 35 tatgattgac atgctagttt tacgattacc gttcatcgat tctcttggtt gctccagact 9189
 ctcaggcaat gacctgatag cctttgtaga tctctcaaaa atagctaccc tctccggcat 9249
 gaatttatca gctagaacgg ttgaatatca tattgatggg gatttgactg tctccggcct 9309
 40 ttctcaccct tttgaatctt tacctacaca ttactcaggc attgcattta aaatatatga 9369
 gggttctaaa aatttttatc cttgcgttga aataaaggct tctcccgcaa aagtattaca 9429
 gggtcataat gtttttggtt caaccgattt agctttatgc tctgaggctt tattgcttaa 9489
 45 ttttgctaatt tctttgcctt gcctglatga tttattggat gtt 9532

<210> 452

<211> 20

<212> PRT

50 <213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 peptide sequence

55 <400> 452

EP 1 578 903 B2

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
1 5 10 15

His Ser Ala Gln
20

<210> 453

<211> 367

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 protein sequence

<400> 453

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
20 25 30

Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
35 40 45

Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr
65 70 75 80

Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
85 90 95

Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
100 105 110

Thr Ala Val Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr Ala
115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser
130 135 140

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
145 150 155 160

Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro

EP 1 578 903 B2

	165	170	175
	Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val		
	180	185	190
5	His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser		
	195	200	205
	Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile		
	210	215	220
10	Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val		
	225	230	235
	Glu Pro Lys Ser Cys Ala Ala Ala His His His His His Ser Ala		
	245	250	255
15	Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Asp Ile		
	260	265	270
	Asn Asp Asp Arg Met Ala Gly Ala Ala Glu Thr Val Glu Ser Cys Leu		
	275	280	285
20	Ala Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp		
	290	295	300
	Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala		
	305	310	315
25	Thr Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr		
	325	330	335
	Trp Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser		
	340	345	350
30	Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr		
	355	360	365

<210> 454

<211> 152

35 <212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 protein sequence

40

<400> 454

	Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala		
	1	5	10
45	Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly		
	20	25	30
	Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe		
	35	40	45
50			
55			

EP 1 578 903 B2

Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
 50 55 60
 Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
 5 65 70 75 80
 Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
 85 90 95
 Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu
 10 100 105 110
 Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
 115 120 125
 Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
 15 130 135 140
 Asn Ile Leu Arg Asn Lys Glu Ser
 145 150

<210> 455
 <211> 15
 <212> PRT
 <213> Unknown Organism
 <220>
 <223> Description of Unknown Organism: MALIA3 peptide sequence
 <400> 455

Met Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly
 30 1 5 10 15

<210> 456
 <211> 34B
 <212> PRT
 <213> Unknown Organism
 <220>
 <223> Description of Unknown Organism: MALIA3 protein sequence
 <400> 456

Met Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu
 1 5 10 15
 Val Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile
 45 20 25 30
 Ala Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg
 35 40 45
 Phe Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile
 50 55 60

55

EP 1 578 903 B2

Ser Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn
 65 70 75 80
 Lys Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr
 85 90 95
 Arg Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu
 100 105 110
 His Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu
 115 120 125
 Ser Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val
 130 135 140
 Tyr Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu
 145 150 155 160
 Tyr Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val
 165 170 175
 Gly Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg
 180 185 190
 Trp Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln
 195 200 205
 Ala Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro
 210 215 220
 Tyr Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys
 225 230 235 240
 Met Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys
 245 250 255
 Leu Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln
 260 265 270
 Pro Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp
 275 280 285
 Lys Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr
 290 295 300
 Val Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln
 305 310 315 320
 Lys Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile
 325 330 335
 Lys Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
 340 345

<210> 457

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 457

tggaagaggc acgttctttt cttt 24

<210> 458

<211> 24

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Description of Artificial Sequence: Primer

 <400> 458
 cttttcttgg ttgccgttgg ggtg 24

 10 <210> 459
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 15 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 459
 20 acactctccc ctgtgaagc tctt 24

 <210> 460
 <211> 51
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 460
 30 accgcctcca ccgggcgcgc ctattaaca ctctcccctg ttgaagctct t 51

 <210> 461
 <211> 23
 <212> DNA
 35 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 40 <400> 461
 tgaacattct gtaggggcca ctg 23

 <210> 462
 <211> 23
 45 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer
 50
 <400> 462
 agagcattct gcaggggcca ctg 23

 <210> 463
 55 <211> 50
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

5 <400> 463
 accgcctcca ccgggcgcgc ctattatga acattctgta ggggccactg 50

10 <210> 464
 <211> 50
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Primer

20 <400> 464
 accgcctcca ccgggcgcgc ctattaaga gcattctgca ggggccactg 50

25 <210> 465
 <211> 23
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Primer

35 <400> 465
 cgactggagc acgaggacac tga 23

40 <210> 466
 <211> 26
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Primer

50 <400> 466
 ggacactgac atggactgaa ggagta 26

55 <210> 467
 <211> 20
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

65 <400> 467
 gggaggatgg agactgggtc 20

70 <210> 468
 <211> 20
 <212> DNA
 <213> Artificial Sequence

75 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

EP 1 578 903 B2

<400> 468
 gggaagatgg agactgggtc 20

 <210> 469
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 469
 gggagagtgg agactgagtc 20

 <210> 470
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 470
 ggggtgcctgg agactgcgtc 20

 <210> 471
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 471
 ggggtggctgg agactgcgtc 20

 <210> 472
 <211> 50
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 472
 gggaggatgg agactgggtc atctggatgt ctgtgcact gtgacagagg 50

 <210> 473
 <211> 50
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 473
 gggaagatgg agactgggtc atctggatgt ctgtgcact gtgacagagg 50

<210> 474
 <211> 50
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 474
 10 gggagagtgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50
 <210> 475
 <211> 50
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 475
 gggtgcttgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50
 <210> 476
 <211> 50
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 476
 gggtgcttgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50
 <210> 477
 <211> 50
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 40 <400> 477
 gggagtctgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50
 <210> 478
 <211> 42
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 478
 55 cctctgtcac agtgacaag acatccagat gacccagtct cc 42
 <210> 479
 <211> 22
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

5

<400> 479

cctctgtcac agtcacaag ac 22

<210> 480

10

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Primer

<400> 480

acactctccc ctgtgaagc tctt 24

20

<210> 481

<211> 668

<212> DNA

<213> Homo sapiens

25

<220>

<221> CDS

<222> (1)..(668)

<400> 481

30

35

40

45

50

55

EP 1 578 903 B2

	agt gca caa gac atc cag atg acc cag tct cca gcc acc ctg tct gtg	48
	Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val	
	1 5 10 15	
5	tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag agt gtt	96
	Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val	
	20 25 30	
10	agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag gtt ccc agg	144
	Ser Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Arg	
	35 40 45	
15	ctc ctc atc tat ggt gca tcc acc agg gcc act gat atc cca gcc agg	192
	Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Asp Ile Pro Ala Arg	
	50 55 60	
20	ttc agt ggc agt ggg tct ggg aca gac ttc act ctc acc atc agc aga	240
	Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg	
	65 70 75 80	
25	ctg gag cct gaa gat ttt gca gtg tat tac tgt cag cgg tat ggt agc	288
	Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Arg Tyr Gly Ser	
	85 90 95	
30	tca ccg ggg tgg acg ttc ggc caa ggg acc aag gtg gaa atc aaa cga	336
	Ser Pro Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg	
	100 105 110	
35	act gtg gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag cag	384
	Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln	
	115 120 125	
40	ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg aat aac ttc tat	432
	Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr	
	130 135 140	
45	ccc aga gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa tcg	480
	Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser	
	145 150 155 160	
50	ggg aac tcc cag gag agt gtc aca gag cag gac agc aag gac agc acc	528
55	Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr	
	165 170 175	
60	tac agc ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag aaa	576
	Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys	
	180 185 190	
65	cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg cct	624
	His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro	
	195 200 205	
70	gtc aca aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc	668
	Val Thr Lys Ser Phe Asn Lys Gly Glu Cys Lys Gly Glu Phe Ala	
	210 215 220	

<210> 482

<211> 223

<212> PRT

<213> Homo sapiens

<400> 482

EP 1 578 903 B2

Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val
1 5 10 15

Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val
20 25 30

Ser Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Arg
35 40 45

Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Asp Ile Pro Ala Arg
50 55 60

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
65 70 75 80

Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Arg Tyr Gly Ser
85 90 95

Ser Pro Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Lys Gly Glu Cys Lys Gly Glu Phe Ala
210 215 220

<210> 483

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 483

agccaccctg tct 13

<210> 484

<211> 700

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(699)

<400> 484

EP 1 578 903 B2

	agt gca caa gac atc cag atg acc cag tct cct gcc acc ctg tct gtg	48
	Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val	
	1 . 5 10 15	
5	tct cca ggt gaa aga gcc acc ctc tcc tgc agg gcc agt cag gtg tct	96
	Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ser	
	20 25 30	
10	cca ggg gaa aga gcc acc ctc tcc tgc aat ctt ctc agc aac tta gcc	144
	Pro Gly Glu Arg Ala Thr Leu Ser Cys Asn Leu Leu Ser Asn Leu Ala	
	35 40 45	
15	tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc atc tat ggt	192
	Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly	
	50 55 60	
20	gct tcc acc ggg gcc att ggt atc cca gcc agg ttc agt ggc agt ggg	240
	Ala Ser Thr Gly Ala Ile Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly	
	65 70 75 80	
25	tct ggg aca gag ttc act ctc acc atc agc agc ctg cag tct gaa gat	288
	Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp	
	85 90 95	
30	ttt gca gtg tat ttc tgt cag cag tat ggt acc tca ccg ccc act ttc	336
	Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Thr Phe	
	100 105 110	
35	ggc gga ggg acc aag gtg gag atc aaa cga act gtg gct gca cca tct	384
	Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser	
	115 120 125	
40	gtc ttc atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc	432
	Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala	
	130 135 140	
45	tct gtt gtg tgc ccg ctg aat aac ttc tat ccc aga gag gcc aaa gta	480
	Ser Val Val Cys Pro Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val	
	145 150 155 160	
50	cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt	528
	Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser	
	165 170 175	
55	gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc acc	576
	Val Thr Glu Gln Asp Asn Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr	
	180 185 190	
60	ctg acg ctg agc aaa gta gac tac gag aaa cac gaa gtc tac gcc tgc	624
	Leu Thr Leu Ser Lys Val Asp Tyr Glu Lys His Glu Val Tyr Ala Cys	
	195 200 205	
65	gaa gtc acc cat cag ggc ctt agc tcg ccc gtc acg aag agc ttc aac	672
	Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn	
	210 215 220	
70	agg gga gag tgt aag aaa gaa ttc gtt t	700
	Arg Gly Glu Cys Lys Lys Glu Phe Val	
	225 230	

<210> 485

<211> 233

<212> PRT

<213> Homo sapiens

<400> 485

EP 1 578 903 B2

Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val
 1 5 10 15
 Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ser
 20 25 30
 Pro Gly Glu Arg Ala Thr Leu Ser Cys Asn Leu Leu Ser Asn Leu Ala
 35 40 45
 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly
 50 55 60
 Ala Ser Thr Gly Ala Ile Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
 65 70 75 80
 Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp
 85 90 95
 Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Thr Phe
 100 105 110
 Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
 115 120 125
 Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala
 130 135 140
 Ser Val Val Cys Pro Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val
 145 150 155 160
 Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser
 165 170 175
 Val Thr Glu Gln Asp Asn Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr
 180 185 190
 Leu Thr Leu Ser Lys Val Asp Tyr Glu Lys His Glu Val Tyr Ala Cys
 195 200 205
 Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn
 210 215 220
 Arg Gly Glu Cys Lys Lys Glu Phe Val
 225 230

40 <210> 486
 <211> 419
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: Synthetic 3-23 VH nucleotide sequence
 <220>
 <221> CDS
 50 <222> (12)..(419)
 <400> 486

55

EP 1 578 903 B2

	ctgtctgaac g gcc cag ccg gcc atg gcc gaa gtt caa ttg tta gag tct	50
	Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser	
	1 5 10	
5	ggt ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct	98
	Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala	
	15 20 25	
10	gct tcc gga ttc act ttc tct tcg tac gct atg tct tgg gtt cgc caa	146
	Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln	
	30 35 40 45	
15	gct cct ggt aaa ggt ttg gag tgg gtt tct gct atc tct ggt tct ggt	194
	Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly	
	50 55 60	
20	ggc agt act tac tat gct gac tcc gtt aaa ggt cgc ttc act atc tct	242
	Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser	
	65 70 75	
25	aga gac aac tct aag aat act ctc tac ttg cag atg aac agc tta agg	290
	Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg	
	80 85 90	
30	gct gag gac act gca gtc tac tat tgc gct aaa gac tat gaa ggt act	338
	Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr	
	95 100 105	
35	ggt tat gct ttc gac ata tgg ggt caa ggt act atg gtc acc gtc tct	386
	Gly Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser	
	110 115 120 125	
40	agt gcc tcc acc aag ggc cca tcg gtc ttc ccc	419
	Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro	
	130 135	

<210> 487

<211> 136

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 3-23 VH protein sequence

<400> 487

EP 1 578 903 B2

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
1 . 5 10 15
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
5 20 25 30
Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly
35 40 45
Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr
10 50 55 60
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
65 70 75 80
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
15 85 90 95
Thr Ala Val Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr Ala
100 105 110
Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser
20 115 120 125
Thr Lys Gly Pro Ser Val Phe Pro
130 135

<210> 488
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 488
ctgtctgaac ggcccagccg 20

<210> 489
<211> 83
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 489

ctgtctgaac ggcccagccg gccatggccg aagttcaatt gttagagtct ggtggcggtc 60
ttgttcagcc tgggtgttct tta 83

<210> 490
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 490
gaaagtgaat ccggaagcag cgcaagaaag acgtaaagaa ccaccaggct gaac 54

EP 1 578 903 B2

<210> 491
<211> 42
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 491
agaaacccac tccaaacctt taccaggagc ttggcgaacc ca 42

10

<210> 492
<211> 94
<212> DNA
<213> Artificial Sequence

15

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

20

<400> 492

agtgctctca gcccttaagc tgttcattctg caagtagaga gtattcttag agttgtctct 60
agagatagtg aagcgacctt taacggagtc agca 94

25

<210> 493
<211> 81
<212> DNA
<213> Artificial Sequence

30

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 493

35

gcttaagggc tgaggacact gcagtctact attgcgctaa agactatgaa ggtactgggt 60
atgctttcga catatggggt c 81

40

<210> 494
<211> 72
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 494

50

ggggaagacc gatgggccct tggtaggagc actagagacg gtgaccatag taccttgacc 60
tatgtcgaaa gc 72

55

<210> 495
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 495

ggggaagacc gatgggcct tgg 23

5

<210> 496

<211> 56

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

15

<221> modified base

<222> (22)..(24)

<223> A, T, C, G, other or unknown

<220>

20

<221> modified_base

<222> (28)..(30)

<223> A, T, C, G, other or unknown

<220>

25

<221> modified_base

<222> (34)..(36)

<223> A, T, C, G, other or unknown

<220>

30

<223> nnn codes for any amino acid but Cys

<400> 496

gcttcggat tcacttctc tnnntacnnn atgnnntggg ttcgccaagc tcttgg 56

35

<210> 497

<211> 68

<212> DNA

<213> Artificial Sequence

<220>

40

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

45

<222> (19)..(21)

<223> A, T, C or G

<220>

<221> modified_base

50

<222> (25)..(30)

<223> A, T, C or G

<220>

<221> modified_base

55

<222> (40)..(42)

<223> A, T, C or G

<220>

<221> modified_base

<222> (46)..(48)

<223> A, T, C or G

5 <400> 497

```

      ggtttgaggt gggtttctnn nactnnnnnn tctgggtggcn nnactnnnta tgctgactcc 60
      gttaaagg                                     68

```

10

<210> 498

<211> 912

<212> DNA

<213> Escherichia coli

15

<400> 498

20

```

      tccggagcctt cagatctgtt tgcctttttg tggggtggtg cagatcgcgt tacggagatc 60
      gaccgactgc ttgagcaaaa gccacgctta actgctgatac aggcattgga tggtattcgc 120
      caaaccagtc gtcaggatct taacctgagg ctttttttac ctactctgca agcagcgaca 180
      tctggtttga cacagagcga tccgcgtcgt cagttggtag aaacattaac acgttgggat 240
      ggcatacaatt tgcttaatga tgatggtaaa acctggcagc agccaggctc tgccatcctg 300
      aacgtttggc tgaccagtat gttgaagcgt accgtagtgg ctgccgtacc tatgccattt 360
      gataagtggg acagcgccag tggctacgaa acaaccagg acggcccaac tggttcgcgt 420
      aatataagtg ttggagcaaa aattttgtat gaggcggtgc agggagacaa atcaccaatc 480
      ccacaggcgg ttgatctgtt tgctgggaaa ccacagcagg aggttgtgtt ggctgcgctg 540
      gaagatacct gggagactct ttccaaacgc tatggcaata atgtgagtaa ctggaaaaca 600
      cctgcaatgg ccttaacgtt ccgggcaaat aatttctttg gtgtaccgca ggccgcagcg 660
      gaagaaacgc gtcatacaggc ggagtatcaa aaccgtggaa cagaaaaacga tatgattgtt 720
      ttctcaccaa cgacaagcga tcgtcctgtg cttgcctggg atgtggtcgc acccggtcag 780
      agtgggttta ttgctcccga tggaaacagt gataagcact atgaagatca gctgaaaatg 840
      tacgaaaatt ttggccgtaa gtcgctctgg ttaacgaagc aggatgtgga ggcgcataag 900
      gagtcgtcta ga                                     912

```

25

30

<210> 499

<211> 10

35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

40

<220>.

<221> modified_base

<222> (4)..(7)

<223> A, T, C, G, other or unknown

45

<400> 499

gatnnnnatc 10

50

<210> 500

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

55

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (1)..(15)
 <223> A, T, C, G, other or unknown

 <400> 500
 5 nnnnnnnnnn nnnnngtccc 20

 <210> 501
 <211> 11
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 15 <220>
 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown

 20 <400> 501
 gcannnnntg c 11

 <210> 502
 <211> 10
 25 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30
 <220>
 <221> modified_base
 <222> (9)..(7)
 <223> A, T, C, G, other or unknown
 35
 <400> 502
 gacnnnngtc 10

 <210> 503
 40 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 45 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 <221> modified_base
 <222> (1)..(7)
 50 <223> A, T, C, G, other or unknown

 <400> 503
 nnnnnnngcg gg 12

 55 <210> 504
 <211> 12
 <212> DNA
 <213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

5 <221> modified_base

<222> (7)..(12)

<223> A, T, C, G, other or unknown

<400> 504

10 gtatccnnnn nn 12

<210> 505

<211> 12

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

20 <221> modified_base

<222> (4)..(9)

<223> A, T, C, G, other or unknown

<400> 505

25 gcannnnnnt cg 12

<210> 506

<211> 11

30 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 506

40 gccnnnnngg c 11

<210> 507

<211> 11

45 <212> DNA

<213> Artificial Sequence

<220>

50 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (7)..(11)

55 <223> A, T, C, G, other or unknown

<400> 507

ggtctcnnnn n 11

5 <210> 508
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 10 <221> modified_base
 <222> (4)..(11)
 <223> A, T, C, G, other or unknown
 <400> 508
 15 gacnnnnngt c 11
 <210> 509
 <211> 11
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 25 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 <400> 509
 30 gacnnnnngt c 11
 <210>510
 <211> 12
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 40 <220>
 <221> modified_base
 <222> (4)..(9)
 <223> A, T, C, G, other or unknown
 45 <400> 510
 gacnnnnng tc 12
 <210> 511
 50 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 55 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base

<222> (4)..(8)
 <223> A, T, C, G, other or unknown

 <400> 511 ccannnnntg g 11
 5
 <210> 512
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <220>
 15 <221> modified_base
 <222> (1)..(9)
 <223> A, T, C, G, other or unknown

 <400> 512
 20 nnnnnnnnng caggt 15

 <210> 513
 <211> 11
 <212> DNA
 25 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 30 <220>
 <221> modified_base
 <222> (7)..(11)
 <223> A, T, C, G, other or unknown

 35 <400> 513
 acctgcnnnn n 11

 <210> 514
 <211> 13
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 45
 <220>
 <221> modified_base
 <222> (5)..(9)
 <223> A, T, C, G, other or unknown
 50
 <400> 514
 ggccnnnnng gcc 13

 <210> 515
 55 <211> 15
 <212> DNA
 <213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

5 <221> modified_base

<222> (4)..(12)

<223> A, T, C, G, other or unknown

<400> 515

10 ccannnnnnn nntgg 15

<210> 516

<211> 11

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

20 <221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 516

25 cgtctcnnnn n 11

<210> 517

<211> 12

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (1)..(6)

<223> A, T, C, G, other or unknown

<400> 517

40 nnnnnngaga cg 12

<210> 518

<211> 16

<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (1)..(10)

55 <223> A, T, C, G, other or unknown

<400> 518

nnnnnnnnnn ctctc 16

5
 <210> 519
 <211> 16
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 10 <221> modified_base
 <222> (7)..(16)
 <223> A, T, C, G, other or unknown
 <400> 519
 15 gaggagnnnnn nnnnnn 16
 <210> 520
 <211> 11
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 25 <220>
 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 30 <400> 520
 cctnnnnnag g 11
 <210> 521
 <211> 12
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 40 <220>
 <221> modified_base
 <222> (4)..(9)
 <223> A, T, C, G, other or unknown
 45 <400> 521
 ccannnnnnt gg 12
 <210> 522
 50 <211> 6680
 <212> DNA
 <213> Artificial Sequence
 <220>
 55 <223> Description of Artificial Sequence: Vector pCES5 nucleotide sequence
 <220>
 <221> CDS

<222> (201)..(1058)

<220>

<221> CDS

5 <222> (2269)..(2682)

<220>

<221> CDS

10 <222> (2723)..(2866)

<220>

<221> CDS

<222> (3767)..(3850)

15 <220>

<221> CDS

<222> (4198)..(5799)

20 <400> 522

25

30

35

40

45

50

55

EP 1 578 903 B2

gacgaaaggg cctcgtgata cgcctatttt tatagggttaa tgtcatgata ataatggttt 60
 cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aaccctatt tgtttatttt 120
 5 tctaaataca ttcaaatatg taccgctca tgagacaata accctgataa atgcttcaat 180
 aatattgaaa aaggaagagt atg agt att caa cat ttc cgt gtc gcc ctt att 233
 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile
 1 5 10
 10 ccc ttt ttt gcg gca ttt tgc ctt cct gtt ttt gct cac cca gaa acg 281
 Pro Phe Phe Ala Ala Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr
 15 20 25
 ctg gtg aaa gta aaa gat gct gaa gat cag ttg ggt gcc cga gtg ggt 329
 Leu Val Lys Val Lys Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly
 30 35 40
 15 tac atc gaa ctg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc 377
 Tyr Ile Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg
 45 50 55
 20 ccc gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt ctg cta tgt 425
 Pro Glu Glu Arg Phe Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys
 60 65 70 75
 ggc gcg gta tta tcc cgt att gac gcc ggg caa gag caa ctc ggt cgc 473
 Gly Ala Val Leu Ser Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg
 80 85 90
 25 cgc ata cac tat tct cag aat gac ttg gtt gag tac tca cca gtc aca 521
 Arg Ile His Tyr Ser Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr
 95 100 105
 30 gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta tgc agt gct 569
 Glu Lys His Leu Thr Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala
 110 115 120
 gcc ata acc atg agt gat aac act gcg gcc aac tta ctt ctg aca acg 617
 Ala Ile Thr Met Ser Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr
 125 130 135
 35 atc gga gga ccg aag gag cta acc gct ttt ttg cac aac atg ggg gat 665
 Ile Gly Gly Pro Lys Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp
 140 145 150 155
 cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc ata 713
 His Val Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile
 160 165 170
 40 cca aac gac gag cgt gac acc acg atg cct gta gca atg gca aca acg 761
 Pro Asn Asp Glu Arg Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr
 175 180 185
 45 ttg cgc aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa 809

	Leu	Arg	Lys	Leu	Leu	Thr	Gly	Glu	Leu	Leu	Thr	Leu	Ala	Ser	Arg	Gln	
			190					195					200				
5	caa	tta	ata	gac	tgg	atg	gag	gcg	gat	aaa	gtt	gca	gga	cca	ctt	ctg	857
	Gln	Leu	Ile	Asp	Trp	Met	Glu	Ala	Asp	Lys	Val	Ala	Gly	Pro	Leu	Leu	
		205					210					215					
	cgc	tcg	gcc	ctt	ccg	gct	ggc	tgg	ttt	att	gct	gat	aaa	tct	gga	gcc	905
10	Arg	Ser	Ala	Leu	Pro	Ala	Gly	Trp	Phe	Ile	Ala	Asp	Lys	Ser	Gly	Ala	
		220				225					230				235		
	ggt	gag	cgt	ggg	tct	cgc	ggt	atc	att	gca	gca	ctg	ggg	cca	gat	ggt	953
	Gly	Glu	Arg	Gly	Ser	Arg	Gly	Ile	Ile	Ala	Ala	Leu	Gly	Pro	Asp	Gly	
					240					245					250		
15	aag	ccc	tcc	cgt	atc	gta	gtt	atc	tac	acg	acg	ggg	agt	cag	gca	act	1001
	Lys	Pro	Ser	Arg	Ile	Val	Val	Ile	Tyr	Thr	Thr	Gly	Ser	Gln	Ala	Thr	
				255					260					265			
	atg	gat	gaa	cga	aat	aga	cag	atc	gct	gag	ata	ggt	gcc	tca	ctg	att	1049
20	Met	Asp	Glu	Arg	Asn	Arg	Gln	Ile	Ala	Glu	Ile	Gly	Ala	Ser	Leu	Ile	
			270				275					280					
	aag	cat	tgg	taactgtcag	accaagttta	ctcatatata	ctttagattg										1098
	Lys	His	Trp														
			285														
25	atttaaaact	tcatttttaa	tttaaaagga	tctaggtgaa	gatccttttt	gataatctca											1158
	tgacaaaaat	cccttaacgt	gagttttcgt	tccactgagc	gtcagacccc	gtagaaaaga											1218
	tcaaaggatc	ttcttgagat	cctttttttc	tgcgcgtaat	ctgctgcttg	caaacaaaaa											1278
30	aaccaccgct	accagcggtg	gtttgtttgc	cggatcaaga	gctaccaact	ctttttccga											1338
	aggtaactgg	cttcagcaga	gcgcagatac	caaatactgt	ccttctagtg	tagccgtagt											1398
	taggccacca	cttcaagaac	tctgtagcac	cgctacata	cctcgctctg	ctaactcctgt											1458
35	taccagtggc	tgctgccagt	ggcgataagt	cgtgtcttac	cgggttggac	tcaagacgat											1518
	agttaccgga	taaggcgag	cggtcgggct	gaacgggggg	ttcgtgcata	cagcccagct											1578
	tggagcgaac	gacctacacc	gaactgagat	acctacagcg	tgagcattga	gaaagcgcca											1638
40	cgcttcccga	agggagaaaag	gcggacaggt	atccggtaag	cggcaggggc	ggaacaggag											1698
	agcgcacgag	ggagcttcca	gggggaaacg	cctggatatct	ttatagtcct	gtcgggtttc											1758
	gccacctctg	acttgagcgt	cgatttttgt	gatgctcgtc	aggggggagg	agcctatgga											1818
45	aaaacgccag	caacgcggcc	tttttacggt	tcctggcctt	ttgctggcct	tttgcacaca											1878
	tgttctttcc	tgcgttatcc	cctgattctg	tggataaccg	tattaccgcc	tttgagttag											1938
	ctgataccgc	tcgccgcagc	cgaacgaccg	agcgcagcga	gtcagttagc	gaggaagcgg											1998
50	aagagcgccc	aatacgcaaa	ccgcctctcc	ccgcgcgttg	gccgattcat	taatgcagct											2058

EP 1 578 903 B2

ggcaccgacag gtttcccacgac tggaaagcgg gcagtgagcg caacgcaatt aatgtgagtt 2118
agctcactca ttaggcaccc caggctttac actttatgct tccggctcgt atgttggtg 2178
5 gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat tacgccaagc 2238
tttggagcct tttttttgga gattttcaac gtg aaa aaa tta tta ttc gca att 2292
Met Lys Lys Leu Leu Phe Ala Ile
290
10 cct tta gtt gtt cct ttc tat tct cac agt gca cag gtc caa ctg cag 2340
Pro Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln Val Gln Leu Gln
295 300 305 310
gtc gac ctc gag atc aaa cgt gga act gtg gct gca cca tct gtc ttc 2388
Val Asp Leu Glu Ile Lys Arg Gly Thr Val Ala Ala Pro Ser Val Phe
15 315 320 325
atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt 2436
Ile Phe Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
330 335 340
20 gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg 2484
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
345 350 355
aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca 2532
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr
25 360 365 370
gag cag gac agc aag gac agc acc tac agc ctc agc agc acc ctg acg 2580
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr
375 380 385 390
30 ctg agc aaa gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc 2628
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
395 400 405
acc cat cag ggc ctg agt tca ccg gtg aca aag agc ttc aac agg gga 2676
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
410 415 420
35 gag tgt taataaggcg cgccaattct atttcaagga gacagtcata atg aaa tac 2731
Glu Cys Met Lys Tyr
425
40 cta ttg cct acg gca gcc gct gga ttg tta tta ctc gcg gcc cag ccg 2779
Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro
430 435 440
gcc atg gcc gaa gtt caa ttg tta gag tct ggt ggc ggt ctt gtt cag 2827
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
445 450 455
45 cct ggt ggt tct tta cgt ctt tct tgc gct gct tcc gga gcttcagatc 2876
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
460 465 470

EP 1 578 903 B2

	tgtttgccctt tttgtggggt ggtgcagatc gcgttacgga gatcgaccga ctgcttgagc	2936
	aaaagccacg cttaactgct gatcaggcat gggatgttat tcgccaaacc agtcgtcagg	2996
5	atcttaacct gaggettttt ttacctactc tgcaagcagc gacatctggt ttgacacaga	3056
	gcgatccgcg tcgtcagttg gtagaaacat taacacgttg ggatggcatc aatttgctta	3116
	atgatgatgg taaaacctgg cagcagccag gctctgccat cctgaacgtt tggctgacca	3176
10	gtatgttgaa gcgtaccgta gtggctgccg tacctatgcc atttgataag tggtagacgcg	3236
	ccagtggcta cgaaacaacc caggacggcc caactgggtc gctgaatata agtgttggag	3296
	caaaaatttt gtatgaggcg gtgcaggag acaaatcacc aatccacag gcggttgatc	3356
15	tgtttgctgg gaaaccacag caggaggttg tgttggctgc gctggaagat acctgggaga	3416
	ctctttccaa acgctatggc aataatgtga gtaactggaa aacacctgca atggccttaa	3476
	cgttccgggc aaataatttc tttggtgtac cgcaggccgc agcgggaagaa acgcgtcatc	3536
20	aggcggagta tcaaaaccgt ggaacagaaa acgatatgat tgttttctca ccaacgacaa	3596
	gcgatcgtcc tgtgcttgcc tgggatgtgg tcgcacccgg tcagagtggg tttattgctc	3656
	ccgatggaac agttgataag cactatgaag atcagctgaa aatgtacgaa aattttggcc	3716
25	gtaagtcgct ctggttaacg aagcaggatg tggaggcgca taaggagtgc tct aga	3772
		Ser Arg
	gac aac tct aag aat act ctc tac ttg cag atg aac agc tta agt ctg	3820
	Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Ser Leu	
	475 480 485 490	
30	agc att cgg tcc ggg caa cat tct cca aac tgaccagacg acacaaacgg	3870
	Ser Ile Arg Ser Gly Gln His Ser Pro Asn	
	495 500	
	cttacgctaa atcccgcgca tgggatggta aagaggtggc gtctttgctg gcctggactc	3930
35	atcagatgaa ggccaaaaat tggcaggagt ggacacagca ggcagcgaaa caagcactga	3990
	ccatcaactg gtactatgct gatgtaaacg gcaatattgg ttatgttcat actggtgctt	4050
	atccagatcg tcaatcaggc catgatccgc gattaccctg tcctgggtacg ggaaaatggg	4110
40	actggaaagg gctattgcct ttgaaatga accctaaggt gtataacccc cagaagctag	4170
	cctgcggtt cggtcaccgt ctcaagc gcc tcc acc aag ggc cca tcg gtc ttc	4224
		Ala Ser Thr Lys Gly Pro Ser Val Phe
		505
45	ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg gcc ctg	4272
	Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu	
	510 515 520 525	

EP 1 578 903 B2

	ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg	4320
	Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp	
	530 535 540	
5	aac tca ggc gcc ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta	4368
	Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu	
	545 550 555	
10	cag tcc tca gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc	4416
	Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser	
	560 565 570	
	agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc	4464
	Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro	
	575 580 585	
15	agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt gcg gcc	4512
	Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala	
	590 595 600 605	
20	gca cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc tca	4560
	Ala His His His His His His Gly Ala Ala Glu Gln Lys Leu Ile Ser	
	610 615 620	
	gaa gag gat ctg aat ggg gcc gca tag act gtt gaa agt tgt tta gca	4608
	Glu Glu Asp Leu Asn Gly Ala Ala Thr Val Glu Ser Cys Leu Ala	
	625 630 635	
25	aaa cct cat aca gaa aat tca ttt act aac gtc tgg aaa gac gac aaa	4656
	Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys	
	640 645 650	
30	act tta gat cgt tac gct aac tat gag ggc tgt ctg tgg aat gct aca	4704
	Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr	
	655 660 665	
	ggc gtt gtg gtt tgt act ggt gac gaa act cag tgt tac ggt aca tgg	4752
	Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp	
	670 675 680	
35	gtt cct att ggg ctt gct atc cct gaa aat gag ggt ggt ggc tct gag	4800
	Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu	
	685 690 695 700	
40	ggt ggc ggt tct gag ggt ggc ggt tct gag ggt ggc ggt act aaa cct	4848
	Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro	
	705 710 715	
	cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac cct	4896
	Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro	
	720 725 730	
45	ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct	4944
	Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro	
	735 740 745	
50	aat cct tct ctt gag gag tct cag cct ctt aat act ttc atg ttt cag	4992
	Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln	

EP 1 578 903 B2

	750	755	760	
5	aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg ggc Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly 765 770 775 780	5040		
10	act gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr 785 790 795	5088		
15	cct gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttc Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe 800 805 810	5136		
20	aga gac tgc gct ttc cat tct ggc ttt aat gag gat cca ttc gtt tgt Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys 815 820 825	5184		
25	gaa tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala 830 835 840	5232		
30	ggc ggc ggc tct ggt ggt ggt tct ggt ggc ggc tct gag ggt ggc ggc Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly Ser Glu Gly Gly Gly 845 850 855 860	5280		
35	tct gag ggt ggc ggt tct gag ggt ggc ggc tct gag ggt ggc ggt tcc Ser Glu Gly Gly Ser Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser 865 870 875	5328		
40	ggt ggc ggc tcc ggt tcc ggt gat ttt gat tat gaa aaa atg gca aac Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn 880 885 890	5376		
45	gct aat aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta cag Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln 895 900 905	5424		
50	tct gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala 910 915 920	5472		
55	gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt aat Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn 925 930 935 940	5520		
60	ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct caa gtc Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val 945 950 955	5568		
65	ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt caa tat tta Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu 960 965 970	5616		
70	cct tct ttg cct cag tcg gtt gaa tgt cgc cct tat gtc ttt ggc gct Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Tyr Val Phe Gly Ala 975 980 985	5664		

EP 1 578 903 B2

```

5      ggt aaa cca tat gaa ttt tct att gat tgt gac aaa ata aac tta ttc 5712
      Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe
      990                      995                      1000

10     cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta 5760
      Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val
      1005                      1010                      1015                      1020

      ttt tcg acg ttt gct aac ata ctg cgt aat aag gag tct taataagaat 5809
      Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
      1025                      1030

15     tcactggccg tcgttttaca acgtcgtgac tgggaaaacc ctggcgttac ccaacttaat 5869

      cgccttgacg cacatccccc ttctgccagc tggcgtaata gcgaagaggc ccgcaccgat 5929

20     cgcccttccc aacagttgcg cagcctgaat ggcgaatggc gcctgatgcg gtattttctc 5989

      cttacgcacg .tgtgcggtat ttcacaccgc atataaattg taaacgttaa tattttgtta 6049

      aaattcgcgt taaatttttg ttaaatacgc tcatttttta accaataggc cgaaatcggc 6109

25     aaaatccctt ataaatcaaa agaataggcc gagatagggt tgagtgttgt tccagtttgg 6169

      aacaagagtc cactattaaa gaacgtggac tccaacgtca aagggcgaaa aaccgtctat 6229

      cagggcgatg gccactacg tgaaccatca cccaaatcaa gttttttggg gtcgaggtgc 6289

30     cgtaaagcac taaatcggaa ccctaaaggg agccccgat ttagagcttg acggggaaag 6349

      ccggcgaaacg tggcgagaaa ggaagggaag aaagcgaaag gagcggggcg tagggcgctg 6409

      gcaagtgtag cggtcacgct gcgcgtaacc accacacccg ccgcgcttaa tgcgccgcta 6469

      cagggcgcggt actatggttg ctttgacggg tgcagtctca gtacaatctg ctctgatgcc 6529

35     gcatagttaa gccagccccg acaccgcgca acaccgctg acgcgccctg acgggcttgt 6589

      ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 6649

      aggttttcac cgtcatcacc gaaacgcgcg a 6680

40     <210> 523
      <211> 286
      <212> PRT
      <213> Artificial Sequence

45     <220>
      <223> Description of Artificial Sequence: Vector pCES5 protein sequence

50     <400> 523

      Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala
      1          5          10          15

      Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys
      20          25          30

```

EP 1 578 903 B2

	Asp	Ala	Glu	Asp	Gln	Leu	Gly	Ala	Arg	Val	Gly	Tyr	Ile	Glu	Leu	Asp
			35					40					45			
5	Leu	Asn	Ser	Gly	Lys	Ile	Leu	Glu	Ser	Phe	Arg	Pro	Glu	Glu	Arg	Phe
		50					55					60				
	Pro	Met	Met	Ser	Thr	Phe	Lys	Val	Leu	Leu	Cys	Gly	Ala	Val	Leu	Ser
		65				70					75					80
10	Arg	Ile	Asp	Ala	Gly	Gln	Glu	Gln	Leu	Gly	Arg	Arg	Ile	His	Tyr	Ser
					85					90					95	
	Gln	Asn	Asp	Leu	Val	Glu	Tyr	Ser	Pro	Val	Thr	Glu	Lys	His	Leu	Thr
				100					105					110		
15	Asp	Gly	Met	Thr	Val	Arg	Glu	Leu	Cys	Ser	Ala	Ala	Ile	Thr	Met	Ser
			115					120					125			
	Asp	Asn	Thr	Ala	Ala	Asn	Leu	Leu	Leu	Thr	Thr	Ile	Gly	Gly	Pro	Lys
			130				135					140				
20	Glu	Leu	Thr	Ala	Phe	Leu	His	Asn	Met	Gly	Asp	His	Val	Thr	Arg	Leu
		145				150					155					160
	Asp	Arg	Trp	Glu	Pro	Glu	Leu	Asn	Glu	Ala	Ile	Pro	Asn	Asp	Glu	Arg
					165					170					175	
25	Asp	Thr	Thr	Met	Pro	Val	Ala	Met	Ala	Thr	Thr	Leu	Arg	Lys	Leu	Leu
				180				185						190		
	Thr	Gly	Glu	Leu	Leu	Thr	Leu	Ala	Ser	Arg	Gln	Gln	Leu	Ile	Asp	Trp
			195					200					205			
30	Met	Glu	Ala	Asp	Lys	Val	Ala	Gly	Pro	Leu	Leu	Arg	Ser	Ala	Leu	Pro
		210					215					220				
	Ala	Gly	Trp	Phe	Ile	Ala	Asp	Lys	Ser	Gly	Ala	Gly	Glu	Arg	Gly	Ser
		225				230					235					240
35	Arg	Gly	Ile	Ile	Ala	Ala	Leu	Gly	Pro	Asp	Gly	Lys	Pro	Ser	Arg	Ile
					245				250						255	
	Val	Val	Ile	Tyr	Thr	Thr	Gly	Ser	Gln	Ala	Thr	Met	Asp	Glu	Arg	Asn
				260					265					270		
40	Arg	Gln	Ile	Ala	Glu	Ile	Gly	Ala	Ser	Leu	Ile	Lys	His	Trp		
			275				280						285			

<210> 524

<211> 138

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5 protein sequence

<400> 524

EP 1 578 903 B2

5 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15
 5 His Ser Ala Gln Val Gln Leu Gln Val Asp Leu Glu Ile Lys Arg Gly
 20 25 30
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 35 40 45
 10 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 50 55 60
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 65 70 75 80
 15 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 85 90 95
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 100 105 110
 20 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 115 120 125
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 130 135

<210> 525

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5 protein sequence

<400> 525

35 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
 20 25 30
 40 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
 35 40 45

<210> 526

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5 protein sequence

<400> 526

55 Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
 1 5 10 15
 Ser Leu Ser Ile Arg Ser Gly Gln His Ser Pro Asn
 20 25

<210> 527

EP 1 578 903 B2

<211> 533

<212> PRT

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: Vector pCES5 protein sequence

<400> 527

10	Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys	1 5 10 15
	Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr	20 25 30
15	Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser	35 40 45
	Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser	50 55 60
20	Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr	65 70 75 80
	Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys	85 90 95
25	Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His His His His His His	100 105 110
	Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala	115 120 125
30	Ala Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu Asn Ser Phe	130 135 140
	Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr	145 150 155 160
35	Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp	165 170 175
	Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro	180 185 190
40	Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly	195 200 205

45

50

55

EP 1 578 903 B2

	Ser	Glu	Gly	Gly	Gly	Thr	Lys	Pro	Pro	Glu	Tyr	Gly	Asp	Thr	Pro	Ile	
	210						215					220					
5	Pro	Gly	Tyr	Thr	Tyr	Ile	Asn	Pro	Leu	Asp	Gly	Thr	Tyr	Pro	Pro	Gly	
	225					230					235					240	
	Thr	Glu	Gln	Asn	Pro	Ala	Asn	Pro	Asn	Pro	Ser	Leu	Glu	Glu	Ser	Gln	
					245					250					255		
10	Pro	Leu	Asn	Thr	Phe	Met	Phe	Gln	Asn	Asn	Arg	Phe	Arg	Asn	Arg	Gln	
				260					265					270			
	Gly	Ala	Leu	Thr	Val	Tyr	Thr	Gly	Thr	Val	Thr	Gln	Gly	Thr	Asp	Pro	
			275					280					285				
15	Val	Lys	Thr	Tyr	Tyr	Gln	Tyr	Thr	Pro	Val	Ser	Ser	Lys	Ala	Met	Tyr	
		290					295					300					
	Asp	Ala	Tyr	Trp	Asn	Gly	Lys	Phe	Arg	Asp	Cys	Ala	Phe	His	Ser	Gly	
	305					310					315					320	
20	Phe	Asn	Glu	Asp	Pro	Phe	Val	Cys	Glu	Tyr	Gln	Gly	Gln	Ser	Ser	Asp	
					325					330					335		
	Leu	Pro	Gln	Pro	Pro	Val	Asn	Ala	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	
				340					345					350			
25	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly	Ser	Glu	Gly	
			355					360					365				
	Gly	Gly	Ser	Glu	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Gly	Ser	Gly	Asp	
			370				375					380					
30	Phe	Asp	Tyr	Glu	Lys	Met	Ala	Asn	Ala	Asn	Lys	Gly	Ala	Met	Thr	Glu	
	385					390					395					400	
	Asn	Ala	Asp	Glu	Asn	Ala	Leu	Gln	Ser	Asp	Ala	Lys	Gly	Lys	Leu	Asp	
					405					410					415		
35	Ser	Val	Ala	Thr	Asp	Tyr	Gly	Ala	Ala	Ile	Asp	Gly	Phe	Ile	Gly	Asp	
				420				425						430			
	Val	Ser	Gly	Leu	Ala	Asn	Gly	Asn	Gly	Ala	Thr	Gly	Asp	Phe	Ala	Gly	
			435				440						445				
40	Ser	Asn	Ser	Gln	Met	Ala	Gln	Val	Gly	Asp	Gly	Asp	Asn	Ser	Pro	Leu	
		450					455					460					
	Met	Asn	Asn	Phe	Arg	Gln	Tyr	Leu	Pro	Ser	Leu	Pro	Gln	Ser	Val	Glu	
	465					470					475					480	
45	Cys	Arg	Pro	Tyr	Val	Phe	Gly	Ala	Gly	Lys	Pro	Tyr	Glu	Phe	Ser	Ile	
					485					490					495		
	Asp	Cys	Asp	Lys	Ile	Asn	Leu	Phe	Arg	Gly	Val	Phe	Ala	Phe	Leu	Leu	
				500					505					510			
50	Tyr	Val	Ala	Thr	Phe	Met	Tyr	Val	Phe	Ser	Thr	Phe	Ala	Asn	Ile	Leu	
			515					520					525				
	Arg	Asn	Lys	Glu	Ser												
				530													

<210> 528

<211> 30

<212> DNA

<213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 528

5 acctcactgg ctccggatt cactttctct 30

<210> 529

<211> 42

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 529

15 agaaaccac tcaaacctt taccaggagc ttggcgaacc ca 42

<210> 530

<211> 51

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

25

<400> 530

ggaaggcagt gatctagaga tagtgaagcg accttaacg ggtcagcat a 51

<210> 531

30 <211> 23

<212> DNA

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 531

ggaaggcagt gatctagaga tag 23

<210> 532

40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

45

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 532

50 gtgctgactc agccaccctc 20

<210> 533

<211> 20

<212> DNA

55 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 533
 gccctgactc agcctgcctc 20

 <210> 534
 5 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 10 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 534
 gagctgactc aggaccctgc 20

 15 <210> 535
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 535
 gagctgactc agccaccctc 20

 25 <210> 536
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 <400> 536
 35 cctcgacagc gaagtcaca gagcgtcttg actcagcc 38

 <210> 537
 <211> 30
 <212> DNA
 40 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 45 <400> 537
 cctcgacagc gaagtcaca gagcgtcttg 30

 <210> 538
 <211> 38
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

 55 <400> 538
 cctcgacagc gaagtcaca gagcgtcttg actcagcc 38

<210> 539
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 539
 10 cctcgacagc gaagtcaca gagcgcttg 30
 <210> 540
 <211> 38
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 20 <400> 540
 cctcgacagc taagtcaca gagcgcttg actcagcc 38
 <210> 541
 <211> 30
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 30 <400> 541
 cctcgacagc gaagtcaca gagcgcttg 30
 <210> 542
 <211> 38
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 542
 cctcgacagc gaagtcaca gagcgaattg actcagcc 38
 45 <210> 543
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 543
 55 cctcgacagc gaagtcaca gagcgaattg 30
 <210> 544
 <211> 38
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

5

<400> 544

cctcgacagc gaagtcaca gtacgaattg actcagcc 38

<210> 545

10

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 545

cctcgacagc gaagtcaca gtacgaattg 30

20

<210> 546

<211> 21

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 546

cctcgacagc gaagtcaca g 21

30

<210> 547

<211> 21

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 547

ccgtgtatta ctgtgcgaga g 21

40

<210> 548

<211> 21

<212> DNA

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 548

ctgtgtatta ctgtgcgaga g 21

50

<210> 549

<211> 21

<212> DNA

55

<213> Artificial Sequence

<220>

EP 1 578 903 B2

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 549

ccgtatatta ctgtgcgaaa g 21

<210> 550

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 550

ctgtgtatta ctgtgcgaaa g 21

<210> 551

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 551

ctgtgtatta ctgtgcgaga c 21

<210> 552

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 552

ccatgtatta ctgtgcgaga c 21

<210> 553

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 553

ggtgtagtga tctagtgaca actctaagaa tactctctac ttgcagatga acagcttttag 60
ggctgaggac actgcagtct actattgtgc gaga 94

<210> 554

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

EP 1 578 903 B2

<400> 554

5 ggtgtagtga tctagtgaca actctaagaa tactctctac ttgcagatga acagcttttag 60
ggctgaggac actgcagtct actattgtgc gaaa 94

<210> 555

<211> 85

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 555

atagtagact gcagtgtcct cagcccttaa gctgttcacg tgcaagtaga gagtattctt 60
agagttgtct ctatgacact acacc 85

<210> 556

<211> 20

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: Primer

<400> 556

gactgggtgt agtgatctag 20

<210> 557

<211> 24

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Description of Artificial Sequence: Primer

<400> 557

cttttctttg ttgccgttg ggtg 24

<210> 558

<211> 15

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: Synthetic oligonucleotide

$\langle 220 \rangle$

<221> modified base

<222> (1)..(9)

<223> A, T, C, G, other or unknown

<400> 558

nnnnnnnnng caggt 15

<210> 559

<211> 11
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base
 10 <222> (7)..(11)
 <223> A, T, C, G, other or unknown
 <400> 559
 acctgcnnnn n 11
 15 <210> 560
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 20 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 25 <221> modified base
 <222> (4)..(7)
 <223> A, T, C, G, other or unknown
 <400> 560
 30 gatnnnnatc 10
 <210> 561
 <211> 16
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 40 <220>
 <221> modified_base
 <222> (7)..(16)
 <223> A, T, C, G, other or unknown
 45 <400> 561
 gaggagnnnn nnnnnn 16
 <210> 562
 <211> 16
 50 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 55 <220>
 <221> modified_base
 <222> (1)..(10)

<223> A, T, C, G, other or unknown

<400> 562

nnnnnnnnnn ctctc 16

5

<210> 563

<211> 10

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

15

<221> modified_base

<222> (7)..(10)

<223> A, T, C, G, other or unknown

<400> 563

20

ctctcnnnn 10

<210> 564

<211> 11

<212> DNA

25

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

30

<220>

<221> modified_base

<222> (1)..(5)

<223> A, T, C, G, other or unknown

35

<400> 564

nnnnngaaga g 11

<210> 565

<211> 20

40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

45

<220>

<221> modified_base

<222> (1)..(15)

<223> A, T, C, G, other or unknown

50

<400> 565

nnnnnnnnnn nnnngtccc 20

<210> 566

55

<211> 12

<212> DNA

<213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

5 <221> modified_base

<222> (4)..(9)

<223> A, T, C, G, other or unknown

<400> 566

10 gacnnnnng tc 12

<210> 567

<211> 11

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

20 <221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 567

25 cgtctcnnnn n 11

<210> 568

<211> 12

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (7) ..(12)

<223> A, T, C, G, other or unknown

<400> 568

40 gtatccnnnn nn 12

<210> 569

<211> 12

<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (4)..(9)

55 <223> A, T, C, G, other or unknown

<400> 569

gcannnnnt cg 12

<210> 570
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 10 <221> modified_base
 <222> (9)..(8)
 <223> A, T, C, G, other or unknown
 <400> 570
 15 gccnnnnngg c 11
 <210> 571
 <211> 11
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 25 <220>
 <221> modified_base
 <222> (7)..(11)
 <223> A, T, C, G, other or unknown
 30 <400> 571
 ggtctcnnnn n 11
 <210> 572
 <211> 11
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 40 <220>
 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 45 <400> 572
 gacnnnnngt c 11
 <210> 573
 50 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 55 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 <221> modified_base

<222> (4)..(8)
<223> A, T, C, G, other or unknown

5 <400> 573
gacnnnnngt c 11

<210> 574
<211> 11
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

15 <220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

20 <400> 574
ccannnnntg g 11

<210> 575
<211> 15
25 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

30 <220>
<221> modified_base
<222> (4)..(12)
<223> A, T, C, G, other or unknown

35 <400> 575
ccannnnnnn nntgg 15

<210> 576
40 <211> 13
<212> DNA
<213> Artificial Sequence

<220>
45 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (5)..(9)
50 <223> A, T, C, G, other or unknown

<400> 576
ggccnnnnng gcc 13

55 <210> 577
<211> 12
<212> DNA
<213> Artificial Sequence

EP 1 578 903 B2

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

5 <221> modified_base

<222> (4)..(9)

<223> A, T, C, G, other or unknown

<400> 577

10 ccannnnnnt gg 12

<210> 578

<211> 11

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

20 <221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 578

25 cctnnnnnag g 11

<210> 579

<211> 10

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

35 <221> modified_base

<222> (4)..(7)

<223> A, T, C, G, other or unknown

<400> 579

40 gacnnnngtc 10

<210> 580

45 <211> 15

<212> DNA

<213> Artificial Sequence

<220>

50 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (4) ..(12)

55 <223> A, T, C, G, other or unknown

<400> 580

ccannnnnnn nntgg 15

<210> 581
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <220>
 10 <221> modified_base
 <222> (4)..(8)
 <223> A, T, C, G, other or unknown
 <400> 581
 15 gcannnnntg c 11
 <210> 582
 <211> 10251
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: CJRA05 nucleotide sequence
 25 <220>
 <221> CDS
 <222> (1578)..(1916)
 <220>
 30 <221> CDS
 <222> (2388)..(2843)
 <220>
 35 <221> CDS
 <222> (2849)..(2893)
 <220>
 <221> CDS
 40 <222> (3189)..(4232)
 <220>
 <221> CDS
 <222> (7418)..(8119)
 45 <220>
 <221> CDS
 <222> (8160)..(9452)
 <400> 582
 50
 55

EP 1 578 903 B2

aatgctacta ctattagtag aattgatgcc accttttcag ctgcgcgcc aaatgaaaaat 60
atagctaaac aggttattga ccatttgcca aatgtatcta atgggtcaaac taaatctact 120
cgttcgcaga attgggaatc aactgttata tggaatgaaa cttccagaca ccgctacttta 180
gttgcataatt taaaacatgt tgagctacag cattatatc agcaattaag ctctaagcca 240
tccgcacaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcctgacctg 300
ttggagtttg cttccggctt gggttcgctt gaagctcgaa ttaaaacgcg atatttgaag 360
tctttcgggc ttcctcttaa tctttttgat gcaatccgct ttgcttctga ctataatagt 420
cagggttaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca 480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct 540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt 600
ggtttttacc gtcgtctggg aaacgagggt tatgatagtg ttgctcttac tatgcctcgt 660
aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg 720
atgaatcttt ctacctgtaa taatgttggt ccgtagttc gttttattaa cgtagatttt 780
tcttcccaac gtcctgactg gtataatgag ccagttctta aaatcgcata aggtaattca 840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctgggtgtt 900
ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg 960
aatatccggg tcttgtcaag attactcttg atgaaggcca gccagcctat gcgcctgggc 1020
tgtacaccgt tcatctgtcc tctttcaaag ttggtcagtt cggttccctt atgattgacc 1080
gtctgcgcct cgttccggct aagtaacatg gagcaggctg cggatttcga cacaatttat 1140
caggcgatga tacaaatctc cgttgtactt tgtttcgcgc ttggtataat cgctgggggt 1200
caaagatgag tgttttagtg tattcttttg cctctttcgt tttagggttg tgccttcgta 1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct 1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgtg ctgaggggtg 1380
cgatcccga aaagcggcct ttaactccct gcaagcctca gcgaccgaat atatcggtta 1440
tgctggggcg atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa 1500
attcacctcg aaagcaagct gataaaccga tacaattaaa ggctcctttt ggagcctttt 1560
ttttggagat tttcaac gtg aaa aaa tta tta ttc gca att cct tta gtt 1610
Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val
1 5 10
gtt cct ttc tat tct ggc gcg gcc gaa tca cat cta gac ggc gcc gct 1658
Val Pro Phe Tyr Ser Gly Ala Ala Glu Ser His Leu Asp Gly Ala Ala
15 20 25
gaa act gtt gaa agt tgt tta gca aaa tcc cat aca gaa aat tca ttt 1706
Glu Thr Val Glu Ser Cys Leu Ala Lys Ser His Thr Glu Asn Ser Phe
30 35 40

EP 1 578 903 B2

	act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac tat	1754
	Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr	
	45 50 55	
5	gag ggc tgt ctg tgg aat gct aca ggc gtt gta gtt tgt act ggt gac	1802
	Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp	
	60 65 70 75	
	gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt gct atc cct	1850
10	Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro	
	80 85 90	
	gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct gag ggt ggc ggt	1898
	Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly	
	95 100 105	
15	tct gag ggt ggc ggt act aaacctcctg agtacggtga tacacctatt	1946
	Ser Glu Gly Gly Gly Thr	
	110	
	ccgggctata cttatatcaa cccctctcgac ggcacttata cgcctggtac tgagcaaaac	2006
20	cccgcctaata ctaatccttc tcttgaggag tctcagcctc ttaatacttt catgtttcag	2066
	aataataggt tccgaaatag gcagggggca ttaactgttt atacggggcac tgttactcaa	2126
	ggcactgacc ccgttaaaac ttattaccag tacactcctg tatcatcaaa agccatgtat	2186
25	gacgcttact ggaacggtaa attcagagac tgcgctttcc attctggctt taatgaggat	2246
	ttatttgttt gtgaatatca aggccaatcg tctgacctgc ctcaacctcc tgtcaatgct	2306
	ggcggcggct ctggtggtgg ttctggtggc ggctctgagg gtggtggctc tgagggaggc	2366
30	ggttccggtg gtggctctgg t tcc ggt gat ttt gat tat gaa aag atg gca	2417
	Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala	
	115 120	
	aac gct aat aag ggc gct atg acc gaa aat gcc gat gaa aac gcg cta	2465
35	Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu	
	125 130 135	
	cag tct gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt	2513
	Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly	
	140 145 150 155	
40	gct gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt	2561
	Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly	
	160 165 170	
	aat ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct caa	2609
	Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln	
	175 180 185	
45	gtc ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt caa tat	2657
	Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr	
	190 195 200	
50		
55		

EP 1 578 903 B2

	tta cct tcc ctc cct caa tcg gtt gaa tgt cgc cct ttt gtc ttt ggc	2705
	Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly	
	205 210 215	
5	gct ggt aaa cca tat gaa ttt tct att gat tgt gac aaa ata aac tta	2753
	Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu	
	220 225 230 235	
10	ttc cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat	2801
	Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr	
	240 245 250	
	gta ttt tct acg ttt gct aac ata ctg cgt aat aag gag tct taatc atg	2851
	Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser Met	
	255 260 265	
15	cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt	2893
	Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly	
	270 275 280	
20	ttccttctgg taactttggt cggctatctg cttacttttc ttaaaaaggg cttcggttaag	2953
	atagctattg ctatttcatt gtttcttgct cttattattg ggcttaactc aattcttggtg	3013
	ggttatctct ctgatattag cgctcaatta ccctctgact ttgttcaggg tggtcagtta	3073
	attctcccgt ctaatgcgct tccctgtttt tatgttattc tctctgtaaa ggctgctatt	3133
25	ttcatttttg acgttaaaca aaaaatcggt tcttatttggt attgggataa ata atg	3191
	Met	
	gct gtt tat ttt gta act ggc aaa tta ggc tct gga aag acg ctc gtt	3239
	Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu Val	
	285 290 295	
30	agc gtt ggt aag att cag gat aaa att gta gct ggg tgc aaa ata gca	3287
	Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile Ala	
	300 305 310	
35	act aat ctt gat tta agg ctt caa aac ctc ccg caa gtc ggg agg ttc	3335
	Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg Phe	
	315 320 325	
	gct aaa acg cct cgc gtt ctt aga ata ccg gat aag cct tct ata tct	3383
	Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile Ser	
	330 335 340 345	
40	gat ttg ctt gct att ggg cgc ggt aat gat tcc tac gat gaa aat aaa	3431
	Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn Lys	
	350 355 360	
45	aac ggc ttg ctt gtt ctc gat gag tgc ggt act tgg ttt aat acc cgt	3479
	Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr Arg	
	365 370 375	
50	tct tgg aat gat aag gaa aga cag ccg att att gat tgg ttt cta cat	3527
	Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu His	
	380 385 390	

EP 1 578 903 B2

	gct cgt aaa tta gga tgg gat att att ttt ctt gtt cag gac tta tct	3575
	Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu Ser	
	395 400 405	
5	att gtt gat aaa cag gcg cgt tct gca tta gct gaa cat gtt gtt tat	3623
	Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val Tyr	
	410 415 420 425	
10	tgt cgt cgt ctg gac aga att act tta cct ttt gtc ggt act tta tat	3671
	Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu Tyr	
	430 435 440	
15	tct ctt att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc	3719
	Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val Gly	
	445 450 455	
20	gtt gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg	3767
	Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg Trp	
	460 465 470	
25	ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag gct	3815
	Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln Ala	
	475 480 485	
30	ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg cct tat	3863
	Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro Tyr	
	490 495 500 505	
35	tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt cag aag atg	3911
	Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys Met	
	510 515 520	
40	aaa tta act aaa ata tat ttg aaa aag ttt tct cgc gtt ctt tgt ctt	3959
	Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys Leu	
	525 530 535	
45	gcg att gga ttt gca tca gca ttt aca tat agt tat ata acc caa cct	4007
	Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln Pro	
	540 545 550	
50	aag ccg gag gtt aaa aag gta gtc tct cag acc tat gat ttt gat aaa	4055
	Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp Lys	
	555 560 565	
55	ttc act att gac tct tct cag cgt ctt aat cta agc tat cgc tat gtt	4103
	Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr Val	
	570 575 580 585	
60	ttc aag gat tct aag gga aaa tta att aat agc gac gat tta cag aag	4151
	Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln Lys	
	590 595 600	
65	caa ggt tat tca ctc aca tat att gat tta tgt act gtt tcc att aaa	4199
	Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile Lys	
	605 610 615	
70	aaa ggt aat tca aat gaa att gtt aaa tgt aat taattttgtt ttcttgatgt	4252

EP 1 578 903 B2

Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
620 625

5 ttgtttcatc atcttctttt gctcaggtaa ttgaaatgaa taattcgcct ctgcgcgatt 4312
ttgtaacttg gtattcaaag caatcaggcg aatccgttat tgtttctccc gatgtaaaag 4372
gtactgttac tgtatattca tctgacgtta aacctgaaaa tctacgcaat ttctttattt 4432
10 ctgtttttacg tgcaaataat tttgatatgg taggttctaa cccttcatt attcagaagt 4492
ataatccaaa caatcaggat tatattgatg aattgccatc atctgataat caggaatatg 4552
atgataattc cgctccttct ggtggtttct ttgttccgca aaatgataat gttactcaaa 4612
ctttttaaata taataacgtt cgggcaaagg atttaatacg agttgtcgaa ttgtttgtaa 4672
15 agtctaatac ttctaaatcc tcaaagtgtat tatctattga cggctctaata ctattagttg 4732
ttagtgctcc taaagatatt ttagataacc ttcctcaatt cctttcaact gttgatttgc 4792
caactgacca gatattgatt gagggtttga tatttgaggt tcagcaaggt gatgctttag 4852
20 atttttcatt tgctgctggc tctcagcgtg gcactgttgc aggcggtgtt aatactgacc 4912
gcctcacctc tgttttatct tctgctggtg gttcgttcgg tatttttaata ggcgatgttt 4972
tagggctatc agttcgcgca ttaaagacta atagccattc aaaaatattg tctgtgccac 5032
25 gtattcttac gctttcaggt cagaagggtt ctatctctgt tggccagaat gtccctttta 5092
ttactggctg tgtgactggt gaatctgcca atgtaaataa tccatttcag acgattgagc 5152
gtcaaaatgt aggtatttcc atgagcgtt ttcctgttgc aatggctggc ggtaatatgt 5212
30 ttctggatat taccagcaag gccgatagtt tgagttcttc tactcaggca agtgatgtta 5272
ttactaatca aagaagtatt gctacaacgg ttaatttgcg tgatggacag actcttttac 5332
tcggtggcct cactgattat aaaaacactt ctcaggattc tggcgtaccg ttctgtcta 5392
35 aaatcccttt aatcggcctc ctgttttagct cccgctctga ttctaacgag gaaagcacgt 5452
tatacgtgct cgtcaaagca accatagtac gcgccctgta gcggcgcat aagcgcggcg 5512
ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc gcccgctcct 5572
40 ttcgctttct tcccttctt tctcgccacg ttcgccggt tccccgtca agctctaaat 5632
cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgacct caaaaaactt 5692
gatttgggtg atggttcacg tagtgggcca tcgccctgat agacgggttt tcgccctttg 5752
45 acgttggagt ccacgttctt taatagtga ctcttggtcc aaactggaac aacactcaac 5812
cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga accaccatca 5872
aacaggattt tcgctgctg gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg 5932

EP 1 578 903 B2

gccaggcggg gaagggcaat cagctgttgc ccgtctcact ggtgaaaaga aaaaccaccc 5992
 tggatccaag cttgcagggt gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt 6052
 5 atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct 6112
 tcaataatat tgaaaaagga agagtatgag tattcaacat ttccgtgtcg cccttattcc 6172
 cttttttgcg gcattttgcc ttectgtttt tgctcaccga gaaacgctgg tgaaagtaaa 6232
 10 agatgctgaa gatcagttgg gcgcactagt gggttacatc gaactggatc tcaacagcgg 6292
 taagatcctt gagagttttc gccccgaaga acgttttcca atgatgagca cttttaaaagt 6352
 tctgctatgt ggcgcgggtat tatcccgat tgacgccggg caagagcaac tcggtcgccg 6412
 15 catacactat tctcagaatg acttggttga gtactcacca gtcacagaaa agcatcttac 6472
 ggatggcatg acagtaagag aattatgcag tgctgccata accatgagtg ataactctgc 6532
 ggccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt ttttgacaaa 6592
 20 catgggggat catgtaactc gccttgatcg ttgggaaccg gagctgaatg aagccatacc 6652
 aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacggttc gcaaaactatt 6712
 aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga tggaggcgga 6772
 25 taaagttgca ggaccacttc tgcgctcggc ccttcgggt ggctgggtta ttgctgataa 6832
 atctggagcc ggtgagcgtg ggtctcgcgg tatcattgca gcactggggc cagatggtaa 6892
 gccctcccgt atcgtagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa 6952
 tagacagatc gctgagatag gtgcctcact gattaagcat tggtaactgt cagaccaagt 7012
 30 ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatctaggt 7072
 gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt cgttccactg 7132
 tacgtaagac cccaagctt gtcgactgaa tggcgaatgg cgctttgcct ggtttccggc 7192
 35 accagaagcg gtgccggaag gctggctgga gtgcgatctt cctgacgctc gagcgcaacg 7252
 caattaatgt gagttagctc actcattagg caccacggc tttacacttt atgcttccgg 7312
 ctcgtatgtt gtgtggaatt gtgagcggat aacaatttca cacaggaaac agctatgacc 7372
 40 atgattacgc caagctttgg agcctttttt ttggagattt tcaac gtg aaa aaa tta 7429
 Met Lys Lys Leu
 630
 tta ttc gca att cct tta gtt gtt cct ttc tat tct cac agt gca caa 7477
 45 Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln
 635 640 645
 gac atc cag atg acc cag tct cca gcc acc ctg tct ttg tct cca ggg 7525

EP 1 578 903 B2

	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly	
	650						655					660					
5	gaa	aga	gcc	acc	ctc	tcc	tgc	agg	gcc	agt	cag	ggt	gtt	agc	agc	tac	7573
	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Gly	Val	Ser	Ser	Tyr	
	665					670					675					680	
	tta	gcc	tgg	tac	cag	cag	aaa	cct	ggc	cag	gct	ccc	agg	ctc	ctc	atc	7621
	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	
10					685					690					695		
	tat	gat	gca	tcc	aac	agg	gcc	act	ggc	atc	cca	gcc	agg	ttc	agt	ggc	7669
	Tyr	Asp	Ala	Ser	Asn	Arg	Ala	Thr	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly	
				700					705					710			
	agt	ggg	cct	ggg	aca	gac	ttc	act	ctc	acc	atc	agc	agc	cta	gag	cct	7717
15	Ser	Gly	Pro	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro	
			715					720					725				
	gaa	gat	ttt	gca	gtt	tat	tac	tgt	cag	cag	cgt	aac	tgg	cat	ccg	tgg	7765
	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Arg	Asn	Trp	His	Pro	Trp	
		730					735					740					
20	acg	ttc	ggc	caa	ggg	acc	aag	gtg	gaa	atc	aaa	cga	act	gtg	gct	gca	7813
	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	
	745					750					755					760	
	cca	tct	gtc	ttc	atc	ttc	ccg	cca	tct	gat	gag	cag	ttg	aaa	tct	gga	7861
25	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	
					765					770					775		
	act	gcc	tct	gtt	gtg	tgc	ctg	ctg	aat	aac	ttc	tat	ccc	aga	gag	gcc	7909
	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	
				780					785					790			
30	aaa	gta	cag	tgg	aag	gtg	gat	aac	gcc	ctc	caa	tcg	ggt	aac	tcc	cag	7957
	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	
			795					800					805				
	gag	agt	gtc	aca	gag	cgg	gac	agc	aag	gac	agc	acc	tac	agc	ctc	agc	8005
35	Glu	Ser	Val	Thr	Glu	Arg	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	
		810					815					820					
	agc	acc	ctg	acg	ctg	agc	aaa	gca	gac	tac	gag	aaa	cac	aaa	gtc	tac	8053
	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	
	825					830					835					840	
40	gcc	tgc	gaa	gtc	acc	cat	cag	ggc	ctg	agc	tcg	ccc	gtc	aca	aag	agc	8101
	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	
					845					850					855		
	ttc	aac	agg	gga	gag	tgt	taataaggcg	cgccaattct	atttcaagga								8149
45	Phe	Asn	Arg	Gly	Glu	Cys											
				860													
	gacagtcata	atg	aaa	tac	cta	ttg	cct	acg	gca	gcc	gct	gga	ttg	tta			8198
		Met	Lys	Tyr	Leu	Leu	Pro	Thr	Ala	Ala	Ala	Gly	Leu	Leu			
				865					870					875			
50																	
55																	

EP 1 578 903 B2

	tta ctc gcg gcc cag ccg gcc atg gcc gaa gtt caa ttg tta gag tct	8246
	Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser	
	880 885 890	
5	ggt ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct	8294
	Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala	
	895 900 905	
10	gct tcc gga ttc act ttc tct act tac gag atg cgt tgg gtt cgc caa	8342
	Ala Ser Gly Phe Thr Phe Ser Thr Tyr Glu Met Arg Trp Val Arg Gln	
	910 915 920	
	gct cct ggt aaa ggt ttg gag tgg gtt tct tat atc gct cct tct ggt	8390
	Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ala Pro Ser Gly	
	925 930 935	
15	ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc act atc tct	8438
	Gly Asp Thr Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser	
	940 945 950 955	
20	aga gac aac tct aag aat act ctc tac ttg cag atg aac agc tta agg	8486
	Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg	
	960 965 970	
	gct gag gac act gca gtc tac tat tgt gcg agg agg ctc gat ggc tat	8534
	Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Leu Asp Gly Tyr	
	975 980 985	
25	att tcc tac tac tac ggt atg gac gtc tgg ggc caa ggg acc acg gtc	8582
	Ile Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val	
	990 995 1000	
30	acc gtc tca agc gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca	8630
	Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala	
	1005 1010 1015	
	ccc tcc tcc aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg	8678
	Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu	
	1020 1025 1030 1035	
35	gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc	8726
	Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly	
	1040 1045 1050	
	gcc ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tcc tca	8774
	Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser	
	1055 1060 1065	
40	gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc ttg	8822
	Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu	
	1070 1075 1080	
45	ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc aac acc	8870
	Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr	
	1085 1090 1095	
50	aag gtg gac aag aaa gtt gag ccc aaa tct tgt gcg gcc gca cat cat	8918
55		

EP 1 578 903 B2

	Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His His	
	1100 1105 1110 1115	
5	cat cac cat cac ggg gcc gca gaa caa aaa ctc atc tca gaa gag gat	8966
	His His His His Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp	
	1120 1125 1130	
10	ctg aat ggg gcc gca tag gct agc tct gct wsy ggy gay tty gay tay	9014
	Leu Asn Gly Ala Ala Gln Ala Ser Ser Ala Ser Gly Asp Phe Asp Tyr	
	1135 1140 1145	
15	gar aar atg gct aaw gcy aay aar ggs gcy atg acy gar aay gcy gay	9062
	Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp	
	1150 1155 1160	
20	gar aay gck ytr car wsy gay gcy aar ggy aar ytw gay wsy gtc gck	9110
	Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala	
	1165 1170 1175	
25	acy gay tay ggy gcy gcc atc gay ggy tty aty ggy gay gtc wsy ggy	9158
	Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly	
	1180 1185 1190 1195	
30	ytk gcy aay ggy aay ggy gcy acy ggw gay tty gcw ggy tck aat tcy	9206
	Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser	
	1200 1205 1210	
35	car atg gcy car gty ggw gay ggk gay aay wsw cck ytw atg aay aay	9254
	Gln Met Ala Gln Val Gly Asp Gly Asn Ser Pro Leu Met Asn Asn	
	1215 1220 1225	
40	tty mgw car tay ytw cck tcy cty cck car wsk gty gar tgy cgy ccw	9302
	Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro	
	1230 1235 1240	
45	tty gty tty wsy gcy ggy aar ccw tay gar tty wsy aty gay tgy gay	9350
	Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp	
	1245 1250 1255	
50	aar atm aay ytw tty cgy ggy gty tty gck tty ytk yta tay gty gcy	9398
	Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala	
	1260 1265 1270 1275	
55	acy tty atg tay gtw tty wsy ack tty gcy aay atw ytr cgy aay aar	9446
	Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys	
	1280 1285 1290	
60	gar wsy tagtgatctc ctaggagacc cgcctaataga gcgggctttt tttttctggt	9502
	Glu Ser	
65	atgcacacctg aggccgatac tgctcgtcgtc ccctcaaaact ggcagatgca cggttacgat	9562
70	gcgcccattct acaccaacgt gacctatccc attacgggtca atccgccggtt tgttcccacg	9622
75	gagaatccga cgggttggtta ctgcgtcaca tttaatgttg atgaaagctg gctacaggaa	9682
80	ggccagacgc gaattatttt tgatggcggt cctattgggt aaaaaatgag ctgatttaac	9742

aaaaatttaa tgcgaatttt aacaaaatat taacgtttac aatttaaata ttgcttata 9802
 caatcttcct gtttttgggg cttttctgat tatcaaccgg ggtacatatg attgacatgc 9862
 tagttttacg attaccgttc atcgattctc ttgtttgctc cagactctca ggcaatgacc 9922
 tgatagcctt tgtagatctc tcaaaaatag ctaccctctc cggcattaat ttatcagcta 9982
 gaacgggtga atatcatatt gatggtgatt tgactgtctc cggcctttct cacccttttg 10042
 aatctttacc tacacattac tcaggcattg catttaaaat atatgagggt tctaaaaatt 10102
 tttatccttg cgttgaaata aaggcttctc ccgcaaagt attacagggt cataatgttt 10162
 ttggtacaac cgatttagct ttatgctctg aggcctttatt gcttaatttt gctaattctt 10222
 tgccttgctt gtatgattta ttggatggt 10251

<210> 583

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05 protein sequence

<400> 583

Met	Lys	Lys	Leu	Leu	Phe	Ala	Ile	Pro	Leu	Val	Val	Pro	Phe	Tyr	Ser	1	5	10	15
Gly	Ala	Ala	Glu	Ser	His	Leu	Asp	Gly	Ala	Ala	Glu	Thr	Val	Glu	Ser	20	25	30	
Cys	Leu	Ala	Lys	Ser	His	Thr	Glu	Asn	Ser	Phe	Thr	Asn	Val	Trp	Lys	35	40	45	
Asp	Asp	Lys	Thr	Leu	Asp	Arg	Tyr	Ala	Asn	Tyr	Glu	Gly	Cys	Leu	Trp	50	55	60	
Asn	Ala	Thr	Gly	Val	Val	Val	Cys	Thr	Gly	Asp	Glu	Thr	Gln	Cys	Tyr	65	70	75	80
Gly	Thr	Trp	Val	Pro	Ile	Gly	Leu	Ala	Ile	Pro	Glu	Asn	Glu	Gly	Gly	85	90	95	
Gly	Ser	Glu	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly	100	105	110	
Thr																			

<210> 584

<211> 152

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05 protein sequence

<400> 584

EP 1 578 903 B2

Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala
1 5 10 15
Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly
20 25 30
Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe
35 40 45
Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
50 55 60
Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
65 70 75 80
Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
85 90 95
Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala Gly Lys Pro Tyr Glu
100 105 110
Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
115 120 125
Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
130 135 140
Asn Ile Leu Arg Asn Lys Glu Ser
145 150

<210> 585

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05 peptide sequence

<400> 585

Met Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly
1 5 10 15

<210> 586

<211> 348

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05 protein sequence

<400> 586

EP 1 578 903 B2

Met Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu
 1 5 10 15
 Val Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile
 20 25 30
 Ala Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg
 35 40 45
 Phe Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile
 50 55 60
 Ser Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn
 65 70 75 80
 Lys Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr
 85 90 95
 Arg Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu
 100 105 110
 His Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu
 115 120 125
 Ser Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val
 130 135 140
 Tyr Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu
 145 150 155 160
 Tyr Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val
 165 170 175
 Gly Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg
 180 185 190
 Trp Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln
 195 200 205
 Ala Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro
 210 215 220
 Tyr Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys
 225 230 235 240
 Met Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys
 245 250 255
 Leu Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln
 260 265 270
 Pro Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp
 275 280 285
 Lys Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr
 290 295 300
 Val Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln
 305 310 315 320
 Lys Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile
 325 330 335
 Lys Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
 340 345

<210> 587

<211> 234

EP 1 578 903 B2

<212> PRT

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: CJRA05 protein sequence

<400> 587

```

10      Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
        1          5          10          15
      His Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser
        20          25          30
15      Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Gly
        35          40          45
      Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
        50          55          60
20      Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
        65          70          75          80
      Arg Phe Ser Gly Ser Gly Pro Gly Thr Asp Phe Thr Leu Thr Ile Ser
        85          90          95
25      Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn
        100          105          110
      Trp His Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
        115          120          125
30      Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
        130          135          140
      Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
        145          150          155          160
35      Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
        165          170          175
      Gly Asn Ser Gln Glu Ser Val Thr Glu Arg Asp Ser Lys Asp Ser Thr
        180          185          190
40      Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
        195          200          205
      His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
        210          215          220
45      Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
        225          230

```

<210> 588

<211> 431

50 <212> PRT

<213> Artificial Sequence

<220>

55 <223> Description of Artificial Sequence: CJRA05 protein sequence

<400> 588

EP 1 578 903 B2

	Met	Lys	Tyr	Leu	Leu	Pro	Thr	Ala	Ala	Ala	Gly	Leu	Leu	Leu	Leu	Ala	
	1				5					10					15		
5	Ala	Gln	Pro	Ala	Met	Ala	Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	
				20					25					30			
	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	
			35					40					45				
10	Phe	Thr	Phe	Ser	Thr	Tyr	Glu	Met	Arg	Trp	Val	Arg	Gln	Ala	Pro	Gly	
		50					55					60					
	Lys	Gly	Leu	Glu	Trp	Val	Ser	Tyr	Ile	Ala	Pro	Ser	Gly	Gly	Asp	Thr	
	65					70					75					80	
15	Ala	Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	
					85					90					95		
	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	
				100					105					110			
20	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Arg	Leu	Asp	Gly	Tyr	Ile	Ser	Tyr	
			115					120					125				
	Tyr	Tyr	Gly	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	
		130					135					140					
25	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	
	145					150				155						160	
	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	
					165					170					175		
30	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	
				180					185					190			
	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	
			195					200					205				

EP 1 578 903 B2

	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	
	210						215					220					
5	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	
	225				230					235						240	
	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Ala	Ala	Ala	His	His	His	His	His	
					245					250					255		
10	His	Gly	Ala	Ala	Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Asn	Gly	
				260					265					270			
	Ala	Ala	Gln	Ala	Ser	Ser	Ala	Ser	Gly	Asp	Phe	Asp	Tyr	Glu	Lys	Met	
			275					280					285				
15	Ala	Asn	Ala	Asn	Lys	Gly	Ala	Met	Thr	Glu	Asn	Ala	Asp	Glu	Asn	Ala	
		290					295					300					
	Leu	Gln	Ser	Asp	Ala	Lys	Gly	Lys	Leu	Asp	Ser	Val	Ala	Thr	Asp	Tyr	
	305					310					315					320	
20	Gly	Ala	Ala	Ile	Asp	Gly	Phe	Ile	Gly	Asp	Val	Ser	Gly	Leu	Ala	Asn	
				325					330						335		
	Gly	Asn	Gly	Ala	Thr	Gly	Asp	Phe	Ala	Gly	Ser	Asn	Ser	Gln	Met	Ala	
			340						345					350			
25	Gln	Val	Gly	Asp	Gly	Asp	Asn	Ser	Pro	Leu	Met	Asn	Asn	Phe	Arg	Gln	
		355					360						365				
	Tyr	Leu	Pro	Ser	Leu	Pro	Gln	Ser	Val	Glu	Cys	Arg	Pro	Phe	Val	Phe	
	370						375					380					
30	Ser	Ala	Gly	Lys	Pro	Tyr	Glu	Phe	Ser	Ile	Asp	Cys	Asp	Lys	Ile	Asn	
	385					390					395					400	
	Leu	Phe	Arg	Gly	Val	Phe	Ala	Phe	Leu	Leu	Tyr	Val	Ala	Thr	Phe	Met	
				405					410					415			
35	Tyr	Val	Phe	Ser	Thr	Phe	Ala	Asn	Ile	Leu	Arg	Asn	Lys	Glu	Ser		
			420					425						430			

<210> 589

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative peptide

<400> 589

Glu Gly Gly Gly Ser
1 5

<210> 590

<211> 1275

<212> DNA

<213> Unknown Organism

<220>

<221> CDS

<222> (1) .. (1272)

<220>

EP 1 578 903 B2

<223> Description of Unknown Organism: M13 nucleotide sequence

<400> 590

5	gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat tct	48
	Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser	
	1 5 10 15	
10	cac tcc gct gaa act gtt gaa agt tgt tta gca aaa ccc cat aca gaa	96
	His Ser Ala Glu Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu	
	20 25 30	
15	aat tca ttt act aac gtc tgg aaa gac gac aaa act tta gat cgt tac	144
	Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr	
	35 40 45	
20	gct aac tat gag ggt tgt ctg tgg aat gct aca ggc gtt gta gtt tgt	192
	Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys	
	50 55 60	
25	act ggt gac gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt	240
	Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu	
	65 70 75 80	
30	gct atc cct gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct gag	288
	Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu	
	85 90 95	
35	ggt ggc ggt tct gag ggt ggc ggt act aaa cct cct gag tac ggt gat	336
	Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro Glu Tyr Gly Asp	
	100 105 110	
40	aca cct att ccg ggc tat act tat atc aac cct ctc gac ggc act tat	384
	Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu Asp Gly Thr Tyr	
	115 120 125	
45	ccg cct ggt act gag caa aac ccc gct aat cct aat cct tct ctt gag	432
	Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn Pro Ser Leu Glu	
	130 135 140	
50	gag tct cag cct ctt aat act ttc atg ttt cag aat aat agg ttc cga	480
	Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn Asn Arg Phe Arg	
	145 150 155 160	
55	aat agg cag ggg gca tta act gtt tat acg ggc act gtt act caa ggc	528
	Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr Val Thr Gln Gly	
	165 170 175	

EP 1 578 903 B2

	act gac ccc gtt aaa act tat tac cag tac act cct gta tca tca aaa	576
	Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro Val Ser Ser Lys	
	180 185 190	
5	gcc atg tat gac gct tac tgg aac ggt aaa ttc aga gac tgc gct ttc	624
	Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg Asp Cys Ala Phe	
	195 200 205	
10	cat tct ggc ttt aat gag gat cca ttc gtt tgt gaa tat caa ggc caa	672
	His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu Tyr Gln Gly Gln	
	210 215 220	
	tcg tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt	720
	Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly	
	225 230 235 240	
15	ggt ggt tct ggt ggc ggc tct gag ggt ggt ggc tct gag ggt ggc ggt	768
	Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly	
	245 250 255	
20	tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc tct ggt	816
	Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly	
	260 265 270	
	tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct	864
	Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala	
	275 280 285	
25	atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc	912
	Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly	
	290 295 300	
30	aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc	960
	Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe	
	305 310 315 320	
	att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat	1008
	Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp	
	325 330 335	
35	ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat	1056
	Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn	
	340 345 350	
40	tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa	1104
	Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln	
	355 360 365	
	tcg gtt gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa	1152
	Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu	
	370 375 380	
45	ttt tct att gat tgt gac aaa ata aac tta ttc cgt ggt gtc ttt gcg	1200
	Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala	
	385 390 395 400	
	ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt tct acg ttt gct	1248
	Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala	
50		
	405 410 415	
	aac ata ctg cgt aat aag gag tct taa	1275
	Asn Ile Leu Arg Asn Lys Glu Ser	
	420	
55		

<210> 591
<211> 424
<212> PRT

EP 1 578 903 B2

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: M13 protein sequence

<400> 591

5

10

15

20

25

30

35

40

45

50

55

```

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1      5      10      15
His Ser Ala Glu Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu
      20      25      30
Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr
      35      40      45
Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys
      50      55      60
Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu
      65      70      75      80
Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu
      85      90      95
Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro Glu Tyr Gly Asp
      100      105      110
Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu Asp Gly Thr Tyr
      115      120      125
Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn Pro Ser Leu Glu
      130      135      140
Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn Asn Arg Phe Arg
      145      150      155      160
Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr Val Thr Gln Gly
      165      170      175
Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro Val Ser Ser Lys
      180      185      190
Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg Asp Cys Ala Phe
      195      200      205
His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu Tyr Gln Gly Gln
      210      215      220

```

EP 1 578 903 B2

Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly
 225 230 235 240
 Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly
 245 250 255
 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly
 260 265 270
 Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala
 275 280 285
 Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly
 290 295 300
 Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe
 305 310 315 320
 Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
 325 330 335
 Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
 340 345 350
 Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
 355 360 365
 Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu
 370 375 380
 Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
 385 390 395 400
 Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
 405 410 415
 Asn Ile Leu Arg Asn Lys Glu Ser
 420

<210> 592
 <211> 35
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide
 <400> 592
 caacgatgat cgtatggcgc atgctgccga gacag 35
 <210> 593
 <211> 1355
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: M13-III nucleotide sequence
 <220>
 <221> CDS
 <222>(1)..(1305)
 <400> 593

EP 1 578 903 B2

	gcg gcc gca cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc	48
	Ala Ala Ala His His His His His His Gly Ala Ala Glu Gln Lys Leu	
	1 5 10 15	
5	atc tca gaa gag gat ctg aat ggg gcc gca tag gct agc gat atc aac	96
	Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Ala Ser Asp Ile Asn	
	20 25 30	
10	gat gat cgt atg gct tct act gcy gar acw gty gaa wsy tgy ytr gcm	144
	Asp Asp Arg Met Ala Ser Thr Ala Glu Thr Val Glu Ser Cys Leu Ala	
	35 40 45	
15	aar ccy cay acw gar aat wsw tty acw aay gts tgg aar gay gay aar	192
	Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys	
	50 55 60	
20	acy ytw gat cgw tay gcy aay tay gar ggy tgy ytr tgg aat gcy acm	240
	Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr	
	65 70 75	
25	ggc gty gtw gty tgy ack ggy gay gar acw car tgy tay ggy acr tgg	288
	Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp	
	80 85 90 95	
30	gtk cck atw ggs ytw gcy atm cck gar aay gar ggy ggy ggy wsy gar	336
	Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu	
	100 105 110	
35	ggg ggy ggy wsy gar ggy ggy ggy tcy gar ggy ggy ggy acy aar cck	384
	Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro	
	115 120 125	
40	cck gar tay ggy gay acw cck atw cck ggy tay acy tay aty aay cck	432
	Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro	
	130 135 140	
45	ytm gay ggm acy tay cck cck ggy acy gar car aay ccy gcy aay cck	480
	Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro	
	145 150 155	
50	aay ccw wsy ytw gar gar wsy car cck ytw aay acy tty atg tty car	528
	Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln	
	160 165 170 175	
55	aay aay mgk tty mgr aay mgk car ggk gcw ytw acy gtk tay ack ggm	576
	Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly	
	180 185 190	

EP 1 578 903 B2

	acy gty acy car ggy acy gay ccy gty aar acy tay tay car tay acy	624
	Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr	
	195 200 205	
5	cck gtm tcr wsw aar gcy atg tay gay gcy tay tgg aay ggy aar tty	672
	Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe	
	210 215 220	
10	mgw gay tgy gcy tty cay wsy ggy tty aay gar gay ccw tty gty tgy	720
	Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys	
	225 230 235	
15	gar tay car ggy car wsk wsy gay ytr cck car ccw cck gty aay gck	768
	Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala	
	240 245 250 255	
20	ggy ggy ggy wsy ggy ggy ggy wsy ggy ggy ggy wsy gar ggy ggw ggy	816
	Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly	
	260 265 270	
25	wsy gar ggw ggy ggy wsy ggr ggy ggy wsy ggy wsy ggy gay tty gay	864
	Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp	
	275 280 285	
30	tay gar aar atg gcw aay gcy aay aar ggs gcy atg acy gar aay gcy	912
	Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala	
	290 295 300	
35	gay gar aay gcr ctr car wst gay gcy aar ggy aar ytw gay wsy gtc	960
	Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val	
	305 310 315	
40	gcy acw gay tay ggt gct gcy atc gay ggy tty aty ggy gay gty wsy	1008
	Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser	
	320 325 330 335	
45	ggy ctk gct aay ggy aay ggw gcy acy ggw gay tty gcw ggy tck aat	1056
	Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn	
	340 345 350	
50	tcy car atg gcy car gty ggw gay ggk gay aay wsw cck ytw atg aay	1104
	Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn	
	355 360 365	
55	aay tty mgw car tay ytw cck tcy cty cck car wsk gty gar tgy cgy	1152
	Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg	
	370 375 380	
60	ccw tty gty tty wsy gcy ggy aar ccw tay gar tty wsy aty gay tgy	1200
	Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys	
	385 390 395	
65	gay aar atm aay ytw ttc cgy ggy gty tty gck tty ytk yta tay gty	1248
	Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val	
	400 405 410 415	
70	gcy acy tty atg tay gtw tty wsy ack tty gcy aay atw ytr cgy aay	1296
	Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn	
75		
80		
85		
90		
95		
100		
105		
110		
115		
120		
125		
130		
135		
140		
145		
150		
155		
160		
165		
170		
175		
180		
185		
190		
195		
200		
205		
210		
215		
220		
225		
230		
235		
240		
245		
250		
255		
260		
265		
270		
275		
280		
285		
290		
295		
300		
305		
310		
315		
320		
325		
330		
335		
340		
345		
350		
355		
360		
365		
370		
375		
380		
385		
390		
395		
400		
405		
410		
415		
420		
425		
430		
435		
440		
445		
450		
455		
460		
465		
470		
475		
480		
485		
490		
495		
500		
505		
510		
515		
520		
525		
530		
535		
540		
545		
550		
555		
560		
565		
570		
575		
580		
585		
590		
595		
600		
605		
610		
615		
620		
625		
630		
635		
640		
645		
650		
655		
660		
665		
670		
675		
680		
685		
690		
695		
700		
705		
710		
715		
720		
725		
730		
735		
740		
745		
750		
755		
760		
765		
770		
775		
780		
785		
790		
795		
800		
805		
810		
815		
820		
825		
830		
835		
840		
845		
850		
855		
860		
865		
870		
875		
880		
885		
890		
895		
900		
905		
910		
915		
920		
925		
930		
935		
940		
945		
950		
955		
960		
965		
970		
975		
980		
985		
990		
995		
1000		
1005		
1010		
1015		
1020		
1025		
1030		
1035		
1040		
1045		
1050		
1055		
1060		
1065		
1070		
1075		
1080		
1085		
1090		
1095		
1100		
1105		
1110		
1115		
1120		
1125		
1130		
1135		
1140		
1145		
1150		
1155		
1160		
1165		
1170		
1175		
1180		
1185		
1190		
1195		
1200		
1205		
1210		
1215		
1220		
1225		
1230		
1235		
1240		
1245		
1250		
1255		
1260		
1265		
1270		
1275		
1280		
1285		
1290		
1295		
1300		
1305		
1310		
1315		
1320		
1325		
1330		
1335		
1340		
1345		
1350		
1355		
1360		
1365		
1370		
1375		
1380		
1385		
1390		
1395		
1400		
1405		
1410		
1415		
1420		
1425		
1430		
1435		
1440		
1445		
1450		
1455		
1460		
1465		
1470		
1475		
1480		
1485		
1490		
1495		
1500		
1505		
1510		
1515		
1520		
1525		
1530		
1535		
1540		
1545		
1550		
1555		
1560		
1565		
1570		
1575		
1580		
1585		
1590		
1595		
1600		
1605		
1610		
1615		
1620		
1625		
1630		
1635		
1640		
1645		
1650		
1655		
1660		
1665		
1670		
1675		
1680		
1685		
1690		
1695		
1700		
1705		
1710		
1715		
1720		
1725		
1730		
1735		
1740		
1745		
1750		
1755		
1760		
1765		
1770		
1775		
1780		
1785		
1790		
1795		
1800		
1805		
1810		
1815		
1820		
1825		
1830		
1835		
1840		
1845		
1850		
1855		
1860		
1865		
1870		
1875		
1880		
1885		
1890		
1895		
1900		
1905		
1910		
1915		
1920		
1925		
1930		
1935		
1940		
1945		
1950		
1955		
1960		
1965		
1970		
1975		
1980		
1985		
1990		
1995		
2000		

<210> 594

EP 1 578 903 B2

<211> 434

<212> PRT

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: M13-III protein sequence

<400> 594

10

Ala Ala Ala His His His His His His Gly Ala Ala Glu Gln Lys Leu
1 5 10 15

Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Ala Ser Asp Ile Asn Asp
20 25 30

15

Asp Arg Met Ala Ser Thr Ala Glu Thr Val Glu Ser Cys Leu Ala Lys
35 40 45

Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr
50 55 60

20

Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly
65 70 75 80

Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp Val
85 90 95

25

Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly
100 105 110

Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro
115 120 125

30

Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu
130 135 140

Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn
145 150 155 160

35

Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn
165 170 175

Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr
180 185 190

40

Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro
195 200 205

45

50

55

EP 1 578 903 B2

Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg
 210 215 220
 Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu
 225 230 235 240
 Tyr Gln Gly Gln Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly
 245 250 255
 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser
 260 265 270
 Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr
 275 280 285
 Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp
 290 295 300
 Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala
 305 310 315 320
 Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly
 325 330 335
 Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser
 340 345 350
 Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn
 355 360 365
 Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro
 370 375 380
 Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp
 385 390 395 400
 Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala
 405 410 415
 Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys
 420 425 430
 Glu Ser

<210> 595

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 595

cggtgatatc gctagcctat gc 22

<210> 596

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 596

gtaggctta gctagcccg agaacgaagg 30

EP 1 578 903 B2

```

5  <210> 597
    <211> 37
    <212> DNA
    <213> Artificial Sequence

    <220>
    <223> Description of Artificial Sequence: Synthetic oligonucleotide

10  <400> 597
    cttcacagc ggttcgcta gcgaccctt tgtctgc      37

    <210> 598
    <211> 50
    <212> DNA
15  <213> Artificial Sequence

    <220>
    <223> Description of Artificial Sequence: Synthetic oligonucleotide

20  <400> 598
    cttcacagc ggttcgcta gcgaccctt tgcagcgag taccagggtc      50

    <210> 599
    <211> 37
25  <212> DNA
    <213> Artificial Sequence

    <220>
    <223> Description of Artificial Sequence: Synthetic oligonucleotide

30  <400> 599
    gactgtctcg gcagcatgcg ccatacgatc atcgttg      37

    <210> 600
35  <211> 37
    <212> DNA
    <213> Artificial Sequence

    <220>
40  <223> Description of Artificial Sequence: Synthetic oligonucleotide

    <220>
    <221> CDS
    <222> (2)..(25)
45  <400> 600

    c aac gat gat cgt atg gcg cat gct gccgagacag tc      37
      Asn Asp Asp Arg Met Ala His Ala
50      1          5

    <210> 601
    <211> 8
    <212> PRT
55  <213> Artificial Sequence

    <220>
    <223> Description of Artificial Sequence: Synthetic peptide

```


EP 1 578 903 B2

<400> 601

Asn Asp Asp Arg Met Ala His Ala
1 5

5

<210> 602

<211> 37

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 602

15

ctttcacagc ggttgcatg cagaccctt tgtctgc 37

<210> 603

<211> 50

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 603

25

ctttcacagc ggttgcatg cagaccctt tgcagcgag taccagggtc 50

<210> 604

<211> 7

<212> PRT

30

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative peptide

35

<400> 604

Tyr Ala Asp Ser Val Lys Gly
1 5

40

<210> 605

<211> 21

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Description of Artificial Sequence: Primer

<400> 605

50

cctcgacagc gaagtcaca g 21

<210> 606

<211> 38

<212> DNA

55

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

EP 1 578 903 B2

<400> 606
 ggctgagtca agacgctctg tgcacttcgc tgcgagg 38

5 <210> 607
 <211> 7
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence: Illustrative peptide

<400> 607

15 Gln Ser Ala Leu Thr Gln Pro
 1 5

<210> 608
 <211> 22
 <212> DNA
 20 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

25 <400> 608
 cctctgtcac agtgacaag ac 22

<210> 609
 <211> 42
 30 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <400> 609
 cctctgtcac agtgacaag acatccagat gacccagtct cc 42

40 <210> 610
 <211> 50
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 610
 gggaggatgg agactgggtc gtctggatgt cttgtgcact gtgacagagg 50

50 <210> 611
 <211> 11
 <212> PRT
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence: Illustrative peptide

<400> 611

EP 1 578 903 B2

Gln Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
1 5 10

5 <210> 612
<211> 20
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Primer

<400> 612
gactgggtgt agtgatctag 20

15 <210> 613
<211> 28
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 613
ggtgtagtga tctctagtg acaactct 28

25 <210> 614
<211> 6
<212> PRT
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Synthetic peptide

35 <400> 614

Val Ser Ser Arg Asp Asn
1 5

40 <210> 615
<211> 15
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> CDS
<222> (1)..(15)

50 <400> 615

55 tac tat tgt gcg aaa
Tyr Tyr Cys Ala Lys
1 5

15

<210> 616
<211> 5

EP 1 578 903 B2

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 616

Tyr Tyr Cys Ala Lys
1 5

<210> 617
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 617
ggtgccgata ggcttgcag caccggagaa cgaagg 36

<210> 618
<211> 95
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 618

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg acactgcagt ctactattgt acgag 95

<210> 619
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
<221> modified_base
<222> (4) .. (7)
<223> A, T, C, G, other or unknown

<400> 619
gatnnnnatc 10

<210> 620
<211> 10
<212> PRT
<213> Unknown Organism

<220>

EP 1 578 903 B2

<223> Description of Unknown Organism: MALIA3-derived peptide

<400> 620

5 Met Lys Leu Leu Asn Val Ile Asn Phe Val
1 5 10

<210> 621

<211> 29

10 <212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: CJRA05-derived peptide

<400> 621

20 Met Ser Val Leu Val Tyr Ser Phe Ala Ser Phe Val Leu Gly Trp Cys
1 5 10 15
Leu Arg Ser Gly Ile Thr Tyr Phe Thr Arg Leu Met Glu
20 25

<210> 622

25 <211> 15

<212> DNA

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence: Illustrative nucleotide sequence

<400> 622

tttttttt tttt 15

35 <210> 623

<211> 87

<212> PRT

<213> Unknown Organism

40 <220>

<223> Description of Unknown Organism: MALIA3-derived peptide

<400> 623

45 Met Ile Lys Val Glu Ile Lys Pro Ser Gln Ala Gln Phe Thr Thr Arg
1 5 10 15
Ser Gly Val Ser Arg Gln Gly Lys Pro Tyr Ser Leu Asn Glu Gln Leu
20 25 30
50 Cys Tyr Val Asp Leu Gly Asn Glu Tyr Pro Val Leu Val Lys Ile Thr
35 40 45
Leu Asp Glu Gly Gln Pro Ala Tyr Ala Pro Gly Leu Tyr Thr Val His
50 55 60
55 Leu Ser Ser Phe Lys Val Gly Gln Phe Gly Ser Leu Met Ile Asp Arg
65 70 75 80
Leu Arg Leu Val Pro Ala Lys
85

EP 1 578 903 B2

<210> 624
 <211> 29
 <212> PRT
 <213> Unknown Organism

5

<220>
 <223> Description of Unknown Organism: MALIA3-derived peptide

10

Met	Ser	Val	Leu	Val	Tyr	Ser	Phe	Ala	Ser	Phe	Val	Leu	Gly	Trp	Cys
1				5					10					15	
Leu	Arg	Ser	Gly	Ile	Thr	Tyr	Phe	Thr	Arg	Leu	Met	Glu			
			20				25								

15

<210> 625
 <211> 10
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

25

<220>
 <221> modified_base
 <222> (7)..(10)
 <223> A, T, C, G, other or unknown

30

<400> 625
 ctcttcnnnn 10

35

<210> 626
 <211> 87
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: CJRA05-derived peptide

40

<400> 626

45

50

55

EP 1 578 903 B2

Met Ile Lys Val Glu Ile Lys Pro Ser Gln Ala Gln Phe Thr Thr Arg
1 5 10 15
Ser Gly Val Ser Arg Gln Gly Lys Pro Tyr Ser Leu Asn Glu Gln Leu
5 20 25 30
Cys Tyr Val Asp Leu Gly Asn Glu Tyr Pro Val Leu Val Lys Ile Thr
35 40 45
Leu Asp Glu Gly Gln Pro Ala Tyr Ala Pro Gly Leu Tyr Thr Val His
10 50 55 60
Leu Ser Ser Phe Lys Val Gly Gln Phe Gly Ser Leu Met Ile Asp Arg

65 70 75 80
Leu Arg Leu Val Pro Ala Lys
85

<210> 627
20 <211> 10
<212> PRT
<213> Artificial Sequence
<220>
25 <223> Description of Artificial Sequence: CJRA05-derived peptide
<400> 627

Met Lys Leu Leu Asn Val Ile Asn Phe Val
30 1 5 10

<210> 628
<211> 19
35 <212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

40 <400> 628
gaccagtct ccatcctcc 19

<210> 629
45 <211> 19
<212> DNA
<213> Artificial Sequence

<220>
50 <223> Description of Artificial Sequence: Synthetic oligonucleotide
<400> 629
gactcagtct ccactctcc 19

55 <210> 630
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

5 <400> 630
 gacgcagtct ccaggcacc 19

10 <210> 631
 <211> 19
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

20 <400> 631
 gacgcagtct ccagccacc 19

25 <210> 632
 <211> 19
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

35 <400> 632
 gtctcctgga cagtcgatc 19

40 <210> 633
 <211> 19
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

50 <400> 633
 ggccttgga cagacagtc 19

55 <210> 634
 <211> 19
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

65 <400> 634
 gtctcctgga cagtcagtc 19

70 <210> 635
 <211> 19
 <212> DNA
 <213> Artificial Sequence

75 <220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 635

ggccccaggg cagagggtc

19

5 **Claims**

1. A method for producing a population or library of immunoglobulin genes that comprises the steps of:
 - (i) introducing synthetic diversity into at least one of VH CDR1 or VH CDR2 of those genes; and
 - (ii) combining the diversity from step (i) with VH CDR3 natural diversity captured from the VH CDR3 region of immunoglobulin genes from B cells.
2. The method according to claim 1, wherein synthetic diversity is introduced into both VH CDR1 and VH CDR2.
3. The method according to claim 2, wherein the synthetic diversity is provided in a human 3-23 framework and wherein the synthetic diversity comprises:
 - (a) a VH CDR1 having an amino acid sequence according to the formula -X1-Y-X2-M-X3-, wherein X1, X2, and X3 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and
 - (b) a VH CDR2 having an amino acid sequence according to the formula X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G-, wherein X4 and X5 are independently selected from the group consisting of Y, R, W, V, G, and S, X6 is selected from the group consisting of P and S, and X7 and X8 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y.
4. A library comprising a collection of genetic packages that display a member of a diverse family of antibodies and that collectively display at least a portion of the family, the antibodies being encoded by DNA sequences comprising sequences each encoding
 - (a) a VH CDR1 having an amino acid sequence according to the formula -X1-Y-X2-M-X3-, wherein X1, X2, and X3 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y, provided in a human 3-23 framework;
 - (b) a VH CDR2 having an amino acid sequence according to the formula X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G-, wherein X4 and X5 are independently selected from the group consisting of Y, R, W, V, G, and S, X6 is selected from the group consisting of P and S, and X7 and X8 are independently selected from the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y, provided in a human 3-23 framework; and
 - (c) a sequence encoding a VH CDR3, wherein said VH CDR3 is a natural VH CDR3 captured from the VH CDR3 region of an immunoglobulin gene from a B cell;
 wherein the DNA sequences have synthetic diversity in said CDR1 and CDR2.
5. The library according to claim 4, wherein said DNA sequences further comprise a sequence encoding an immunoglobulin light chain.
6. The library according to claim 5, wherein said sequence encoding an immunoglobulin light chain is captured from a B cell.
7. The library according to claim 6, wherein said B cell is isolated from a blood sample from an autoimmune patient.
8. The library according to claim 7, wherein the autoimmune patient is diagnosed with a disorder selected from the group consisting of systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, antiphospholipid syndrome and vasculitis.
9. The library according to any of claims 4 or 5 to 8, wherein said genetic packages are M13 phages.
10. The library according to claim 9, wherein said DNA sequences are in a phage vector.
11. The library according to claim 9 or 10, wherein said phage comprises a wild-type gene iii and a truncated gene iii

for display of peptides, polypeptides or proteins.

12. The library according to any of claims 4 or 5 to 8, wherein said DNA sequences are in a phagemid vector.

13. The library according to any of claims 9 to 12, wherein said displayed antibodies are displayed through a short linker to the final portion of M13 gene III.

Patentansprüche

1. Verfahren zur Herstellung einer Population oder Bibliothek von Immunglobulinen, welches die Schritte umfasst:

- (i) Einführung einer synthetischen Diversität in mindestens eine der VH-CDR1 oder VH-CDR2 dieser Gene; und
- (ii) Kombination der Diversität aus Schritt (i) mit natürlicher VH-CDR3-Diversität, die aus der VH-CDR3-Region von Immunglobulinen von B-Zellen gewonnen wurde.

2. Verfahren gemäß Anspruch 1, wobei synthetische Diversität sowohl in VH-CDR1 als auch in VH-CDR2 eingeführt wird.

3. Verfahren gemäß Anspruch 2, wobei die synthetische Diversität in einem humanen 3-23-Gerüst bereitgestellt wird, und wobei die synthetische Diversität umfasst

- (a) eine VH-CDR1, welche eine Aminosäuresequenz gemäß der Formel -X1-Y-X2-M-X3- hat, wobei X1, X2 und X3 unabhängig ausgewählt sind aus der Gruppe bestehend aus A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W und Y; und
- (b) eine VH-CDR2, welche eine Aminosäuresequenz gemäß der Formel X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G- hat, wobei X4 und X5 unabhängig ausgewählt sind aus der Gruppe bestehend aus Y, R, W, V, G und S, X6 ausgewählt ist aus der Gruppe bestehend aus P und S, und X7 sowie X8 unabhängig ausgewählt sind aus der Gruppe bestehend aus A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W und Y.

4. Bibliothek, umfassend eine Auswahl von genetischen Paketen, die ein Mitglied einer unterschiedlichen Familie von Antikörpern darstellen und die kollektiv mindestens einen Teil der Familie darstellen, wobei die Antikörper durch DNA-Sequenzen codiert werden, die Sequenzen umfassen, die jeweils

- (a) eine VH-CDR1 codieren, die eine Aminosäuresequenz gemäß der Formel -X1-Y-X2-M-X3- hat, wobei X1, X2 und X3 unabhängig ausgewählt sind aus der Gruppe bestehend aus A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W und Y, bereitgestellt in einem humanen 3-23-Gerüst;
- (b) eine VH-CDR2 codieren, die eine Aminosäuresequenz gemäß der Formel X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G- hat, wobei X4 und X5 unabhängig ausgewählt sind aus der Gruppe bestehend aus Y, R, W, V, G und S, X6 ausgewählt ist aus der Gruppe bestehend aus P und S, und X7 sowie X8 unabhängig ausgewählt sind aus der Gruppe bestehend aus A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W und Y, bereitgestellt in einem humanen 3-23-Gerüst; und
- (c) eine Sequenz codieren, die VH-CDR3 codiert, wobei die VH-CDR3 eine natürliche VH-CDR3 ist, die aus der VH-CDR3-Region eines Immunglobulins von einer B-Zelle gewonnen wurde;

wobei die DNA-Sequenzen eine synthetische Diversität in dieser CDR1 und CDR2 aufweisen.

5. Bibliothek gemäß Anspruch 4, wobei die DNA-Sequenzen ferner eine Sequenz umfassen, die eine leichte Kette eines Immunglobulins codiert.

6. Bibliothek gemäß Anspruch 5, wobei die Sequenz, die eine leichte Kette eines Immunglobulins codiert, aus einer B-Zelle gewonnen wurde.

7. Bibliothek gemäß Anspruch 6, wobei die B-Zelle aus einer Blutprobe von einem Autoimmunpatienten isoliert wurde.

8. Bibliothek gemäß Anspruch 7, wobei bei dem Autoimmunpatienten eine Krankheit ausgewählt aus der Gruppe bestehend aus systemischem Lupus erythematoses, systemischer Sklerose, rheumatoider Arthritis, Antiphospholipidsyndrom und Vaskulitis diagnostiziert wurde.

9. Bibliothèque gemäß einem der Ansprüche 4 oder 5 bis 8, wobei die genetischen Pakete M13-Phagen sind.

10. Bibliothèque gemäß Anspruch 9, wobei die DNA-Sequenzen in einem Phagenvektor sind.

5 11. Bibliothèque gemäß Anspruch 9 oder 10, wobei der Phage ein Wildtyp-Gen iii und ein verkürztes Gen iii zur Darstellung von Peptiden, Polypeptiden oder Proteinen umfasst.

12. Bibliothèque gemäß einem der Ansprüche 4 oder 5 bis 8, wobei die DNA-Sequenzen in einem Phagemid-Vektor sind.

10 13. Bibliothèque gemäß einem der Ansprüche 9 bis 12, wobei die gezeigten Antikörper durch einen kurzen Linker zu dem finalen Teil des M13-Gens III gezeigt sind.

Revendications

15 1. Procédé de production d'une population ou d'une banque de gènes d'immunoglobulines qui comprend les étapes consistant à :

(i) introduire une diversité synthétique dans au moins un VH-CDR1 ou VH-CDR2 de ces gènes ; et
20 (ii) combiner la diversité de l'étape (i) à la diversité naturelle des VH-CDR3 capturée à partir de la région VH-CDR3 de gènes d'immunoglobulines de cellules B.

2. Procédé selon la revendication 1, dans lequel la diversité synthétique est introduite à la fois dans VH-CDR1 et VH-CDR2.

25 3. Procédé selon la revendication 2, dans lequel la diversité synthétique est fournie dans une charpente 3-23 humaine et dans lequel la diversité synthétique comprend :

(a) un VH-CDR1 ayant une séquence d'acides aminés selon la formule -X1-Y-X2-M-X3-, dans laquelle X1, X2 et X3 sont choisis indépendamment dans le groupe constitué par A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W et Y ; et
30 (b) un VH-CDR2 ayant une séquence d'acides aminés selon la formule X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G-,

35 dans laquelle X4 et X5 sont choisis indépendamment dans le groupe constitué par Y, R, W, V, G et S, X6 est choisi dans le groupe constitué par P et S, et X7 et X8 sont choisis indépendamment dans le groupe constitué par A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W et Y.

4. Banque comprenant une collection d'ensembles génétiques qui présentent un membre d'une famille diverse d'anticorps et qui présentent collectivement au moins une partie de la famille, les anticorps étant codés par des séquences d'ADN comprenant des séquences codant chacune pour

(a) un VH-CDR1 ayant une séquence d'acides aminés selon la formule -X1-Y-X2-M-X3-, dans laquelle X1, X2 et X3 sont choisis indépendamment dans le groupe constitué par A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W et Y, fournie dans une charpente 3-23 humaine ;
45 (b) un VH-CDR2 ayant une séquence d'acides aminés selon la formule X4-I-X5-X6-S-G-G-X7-T-X8-Y-A-D-S-V-K-G-, dans laquelle X4 et X5 sont choisis indépendamment dans le groupe constitué par Y, R, W, V, G et S, X6 est choisi dans le groupe constitué par P et S, et X7 et X8 sont choisis indépendamment dans le groupe constitué par A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W et Y, fournie dans une charpente 3-23 humaine ; et
50 (c) une séquence codant pour un VH-CDR3, dans laquelle ledit VH-CDR3 est un VH-CDR3 naturel capturé à partir de la région VH-CDR3 d'un gène d'immunoglobuline provenant d'une cellule B ;

dans laquelle les séquences d'ADN ont une diversité synthétique dans lesdits CDR1 et CDR2.

55 5. Banque selon la revendication 4, dans laquelle lesdites séquences d'ADN comprennent en outre une séquence codant pour une chaîne légère d'immunoglobuline.

6. Banque selon la revendication 5, dans laquelle ladite séquence codant pour une chaîne légère d'immunoglobuline

est capturée à partir d'une cellule B.

7. Banque selon la revendication 6, dans laquelle ladite cellule B est isolée à partir d'un échantillon de sang prélevé sur un patient auto-immun.

8. Banque selon la revendication 7, dans laquelle le patient auto-immun est diagnostiqué comme étant atteint d'un trouble choisi dans le groupe constitué par le lupus érythémateux systémique, la sclérose systémique, la polyarthrite rhumatoïde, le syndrome des antiphospholipides et la vasculite.

9. Banque selon l'une quelconque des revendications 4 ou 5 à 8, dans laquelle lesdits ensembles génétiques sont les phages M13.

10. Banque selon la revendication 9, dans laquelle lesdites séquences d'ADN sont dans un vecteur phagique.

11. Banque selon la revendication 9 ou 10, dans laquelle ledit phage comprend un gène iii de type sauvage et un gène iii tronqué pour la présentation de peptides, polypeptides ou protéines.

12. Banque selon l'une quelconque des revendications 4 ou 5 à 8, dans laquelle lesdites séquences d'ADN sont dans un vecteur phagemide.

13. Banque selon l'une quelconque des revendications 9 à 12, dans laquelle lesdits anticorps présentés sont présentés par l'intermédiaire d'un lieu de petite taille à la partie finale du gène III de M13.

AMPLIFY VH GENES WITHOUT USING VH SEQUENCES




FIG. 1

AMPLIFY VL GENES WITHOUT
USING VL SEQUENCES




FIG. 2

RACE non-biased antibody V-gene amplification




FIG. 3




FIG. 4





FIG. 5 Gel analysis of PCR product from extender-kappa amplification
Approx. 75ng/5 μ l $\rightarrow$ 15ng/ μ l

- 1 - 100bp
- 2 - LDM
- 3 - 50ng template
- 4 - 10ng template
- 5 - ssDNA unligated
- 6 - negative control
- 7 - LDM
- 8 - 100bp

FIG. 5




- Gel purified PCR product from extender-kappa amplification
Concentration : $\pm 35\text{ng}/\mu\text{l}$

1 - LDM
2 - $1\mu\text{l}$ purif.

FIG. 6

1 2 3 4 5 6 7



Gel-analysis of digested κ -ssDNA

1 μ l digested ssDNA $\approx$ 8ng ssDNA

Total volume of 50 μ l = 400ng ssDNA

→ 400ng ssDNA available for ligation of the bridge-extenders

1 - 100bp

2 - LDM

3 - 1 μ l ssDNA pure


4 - 4 μ l beads after dig.

5 - 8 μ l beads after dig.

6 - LDM

7 - 100bp

FIG. 7



Gel analysis of extender – cleaved kappa ligation
20ng/5 μ l eluted material $\rightarrow$ 4ng/ μ l

- 1- 100bp
- 2 - LDM
- 3 - Ligationmix, 4 μ l
- 4 - Unligated ssDNA
- 5 - LDM

FIG. 8

Cleavage and ligation Kappa light chains




FIG. 9




FIG. 10




FIG. 11

Cleavage antibody light chain genes




FIG. 12A

Ligation of cleaved light chains




FIG. 12B

Figure 3: Cleavage and ligation lambda light chains




FIG. 13

CJ cleavage heavy chain




FIG.14A

Ligation heavy chain CDR3 diversity





FIG. 14B


Cleavage and ligation Heavy Chain

A) HpyCH4III cleavage



- 1 = Cleaved DNA eluted from PN column
- 2 = Beads after HpyCH4III digestion
- 3 = Supernatant after cleavage
- 4 = MspI digest of pBR322

B) PCR



- 1 = NEB 100bp ladder
- 2 = 5µl/100µl PCR product 20 cycles; sample A
- 3 = 5µl/100µl PCR product 20 cycles; sample B
- 4 = no template

FIG. 15





FIG. 16



Fab Cassette

2263 bp

FIG. 17

1. Annealing

3. PCR

2. Ligation

PCRpr.: 5'CCTCGACAGCGAAGTGCA CAG-3' →

5' - XXX XXX XXX-VL

Ext : 5'CCTCGACAGCGAAGTGCA CAG ACC GTC TTG-3' →
 Bridge : 3'GGAGCTGTCGCTTCACGT GTC TCG CAG AAC TGA GTC GG-5' →

-ApaI-

AA-VL

Q	S	A	L	T	Q	P
+1				+5		+7

FIG. 18

3. PCR

1. Annealing

PCRpr.: 5'-CCTCTGTCACA GTGCA CAA GAC-3'

5'-XXX-XXX X-VL...

2. Ligation

Ext : 5'-CCTCTGTCACA GTGCA CAA GAC ATC CAG ATG ACC CAG TCT CC
 Br1 : 3'-CGG .. GGT AGG ACC G-5'

-ApaI-

AA-VL Q D I Q M T Q S P S S
 +1 +8 +9 +10

FIG. 19

3. PCR

PCRpr.:

5'-GAC TGG GTG TAG TGA TCT AG-3'

+70

+92

1. Annealing

(FR3)

V * *

S R D N S

Y Y C A K

Bridge : 5'-G GTG TAG TGA TCT AGT GAC AAC TCT ... TAC TAT TGT GCG AAA-3'

Ext : 3'-C CAC ATC ACT AGA TCT CTG TTG AGA ... ATG ATA-5'

-XbaI-



2. Ligation

3'-XXX XXX XXX-VH

FIG. 20

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60198069 B [0001]
- US 09837306 B [0001]
- US 0112454 W [0001]
- US 10000516 B [0001]
- US 10045674 B [0001]
- EP 368684 B1 [0011]
- US 5869644 A [0024]

Non-patent literature cited in the description

- **HJ DE HAARD et al.** *Journal of Biological Chemistry*, 1999, vol. 274 (26), 18218-30 [0028]
- **FROHMAN, M.A. ; DUSH, M.K. ; MARTIN, G.R.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 8998-9002 [0037]
- **WANG ; WILKINSON.** *Biotechniques*, 2001, vol. 31 (4), 722-724 [0163]
- **HAARD et al.** *Journal of Biological Chemistry*, 1999, vol. 274 (26), 18218-30 [0164]
- **HAARD ; MARKS.** *Journal of Molecular Biology*, 1991, vol. 222 (3), 581-97 [0169]

专利名称(译)	构建文库的新方法包括多肽，多肽或蛋白质家族的展示和/或表达成员以及新文库		
公开(公告)号	EP1578903B2	公开(公告)日	2016-06-01
申请号	EP2002762148	申请日	2002-04-17
[标]申请(专利权)人(译)	拉德纳ROBERT CHARLES COHEN爱德华^ h NASTRI HORACIO摹 ROOKEY KRISTIN大号 HOET RENE HOOGENBOOM HENDRICUS - [R缩略词]		
申请(专利权)人(译)	拉德纳，ROBERT CHARLES COHEN，EDWARD H. NASTRI奥拉西奥·G. ROOKEY克莉丝汀L. HOET，RENE HOOGENBOOM，HENDRICUS R.J.M.		
当前申请(专利权)人(译)	DYAX CORP.		
[标]发明人	LADNER ROBERT C COHEN EDWARD H NASTRI HORACIO G ROOKEY KRISTIN L HOET RENE HOOGENBOOM HENDRICUS R J M		
发明人	LADNER, ROBERT C. COHEN, EDWARD H. NASTRI, HORACIO G. ROOKEY, KRISTIN L. HOET, RENÉ HOOGENBOOM, HENDRICUS R.J.M.		
IPC分类号	C12N15/00 C12P21/06 C12N15/09 C12N15/63 C12N15/70 C12N15/74 C12P21/04 C12Q3/00 C12Q1/70 G01N33/53 C07K1/04 C07K16/00 C07K17/00 C12N1/00 C12N15/10 C12N15/11 C12N15/13 C12N15/66 C12Q1/44 C12Q1/68 C40B40/02		
CPC分类号	C07K16/005 C07K2317/51 C07K2317/515 C07K2317/55 C07K2317/622 C12N15/10 C12N15/1037 C12N15/1093 C12N15/66 C40B40/02 C40B40/08		
优先权	09/837306 2001-04-17 US		
其他公开文献	EP1578903A4 EP1578903A2 EP1578903B1 EP1578903B8		
外部链接	Espacenet		

摘要(译)

含有遗传包装的集合的文库，其显示多肽家族的肽，多肽或蛋白质的成员并且共同显示该家族的至少一部分，所展示的肽，多肽或蛋白质由包含编码序列的序列的DNA序列编码。描述了重链CDR区。

Table 1: Human GLG FR3 sequences

```

! VH1
! 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac atg
! 81 82 82a 82b 82c 83 84 85 86 87 88 89 90 91 92
gag ctg agc agc ctg aga tct gac gac acg gcc gtg tat tac tgt
! 93 94 95
gcg aga ga ! 1-02# 1
aga gtc acc att acc agg gac aca tcc gcg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gaa gac acg gct gtg tat tac tgt
gcg aga ga ! 1-03# 2
aga gtc acc atg acc agg aac acc tcc ata agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga gg ! 1-08# 3
aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac atg
gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-18# 4
aga gtc acc atg acc gag gac aca tct aca gac aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gca aca ga ! 1-24# 5
aga gtc acc att acc agg gac agg tct atg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac aca gcc atg tat tac tgt
gca aga ta ! 1-45# 6
aga gtc acc atg acc agg gac acg tcc acg agc aca gtc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-46# 7
aga gtc acc att acc agg gac atg tcc aca agc aca gcc tac atg
gag ctg agc agc ctg aga tcc gag gac acg gcc gtg tat tac tgt
gcg gca ga ! 1-58# 8
aga gtc acg att acc gcg gac gaa tcc acg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-69# 9
aga gtc acg att acc gcg gac aaa tcc acg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-e# 10
aga gtc acc ata acc gcg gac acg tct aca gac aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gca aca ga ! 1-f# 11

```